

Funding Opportunities Monthly Edition Feb 2026 Due Dates

<u>Introduction</u>

This funding opportunity packet contains information on funding opportunities with deadlines in Feb 2026.

The opportunities are organized in the following order:

- 1. National Institutes of Health (NIH)
- 2. National Science Foundation (NSF)
- 3. Other Federal
- 4. Non Federal

The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 below for assistance or questions.

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
125423 Paul Calabresi Career Development Trial Optional)	nt Award for Clinical Oncology (K12 Clinical	National Cancer Institute/NIH	/DHHS PAR- 18	3-Feb-2026	Not Specified
Contact Name	Yansong Bian, MD, PhD				
Contact Telephone	240-276-5630				
Contact Email	yansong.bian@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	18-Feb-2026 , 18-Jun-2026 , 18-Feb-2027				
Synopsis	The purpose of the NCI Worta McCaskill-St Research (K12) is to support the training or control, and treatment research. Special elecare and outcomes of minority health populations. This Notice of Funding Opportunity (Ninvestigator of an independent community disparities research questions into clinical intervention, control or treatment trial; or another investigator; or proposing to serve minority health populations and populatio clinical trials, as part of their research and	f clinical scientists in community mphasis is placed on training cludations and populations with late and representation as human NOFO) allows the appointment rebased clinical trial; proposing trials; or proposing a separate proposing to gain research expense as leader of innovative clinicals with health disparities that	ty cancer prevention inical scientists who health disparities that an subjects in cancer of Scholars proposition increase the integrand and the increase the integrand and the increase the integrand in a community of the increase the integrand in a community approaches the increase the increase the increase in a community approaches the increase in a community in the inc	n, screening, intervise career goal is to at are underrepresed clinical trials using to serve as the gration of cancer existing prevention in the serve as the last expand engage at expand engage.	vention, o improve the sented in g an equity lead health on, screening, I trial led by
129319 Integrating Biospecimen Science A Development (U01 Clinical Trial N		National Cancer Institute/NIH	/DHHS PAR- 04	l-Feb-2026	1,250,000 USD
Contact Name	Abhi Rao, Ph.D.				

Contact Telephone 240-276-5715

Contact Email abhi.rao@nih.gov

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 04-Feb-2026, 04-Jun-2026, 10-Sep-2026, 04-Feb-2027, 04-Jun-2027, 10-Sep-2027

Synopsis Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to support extramural



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Amount
		research to investigate and mitigate challed preanalytical variability in tumor tissue bid described in this NOFO. Extramural resear associated with the procurement and studiopsies", tissue swabs, tissue secretions, breast milk and saliva. Investigator-design affect emerging and clinically relevant bio program will improve the understanding of variation in biospecimen collection, proce assay development through evidence-base	opsies, blood biospecimens utilized ch funded under this NOFO may by of small biopsies (core biopsies) pleural and esophageal aspirates ed experiments will explore how markers quantified by a variety of how analytical quantification of ssing, and storage procedures. The	ed as "liquid biops include investigat s, small excision so s, feces, or bodily to different biospec of testing platform f clinically relevan the overall goal is t	ies", or other bios ions of preanalytic amples), blood util fluids like sweat, u imen preanalytica s. The results from t biomarkers is aff	specimens as cal variability lized for "liquid rine, CSF, I conditions n this research fected by
1/11/55	Assay Development and Screening or Immunomodulators (R01 Clinic	g for Discovery of Chemical Probes, Drugs cal Trial Not Allowed)	National Cancer Institute/NIH/D	OHHS PAR- 25-153 0	5-Feb-2026	Not Specified
	Contact Name	Suzanne Forry, Ph.D.				
	Contact Telephone	240-276-5922				
	Contact Email	forryscs@mail.nih.gov				
	Sponsor Website					

Program URL Link to program URL

Deadline Dates (ALL) 05-Feb-2026, 05-Jun-2026

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate research in discovery and development of novel, small molecules for cancer. Molecules discovered through this NOFO may be used to probe cancer biology, to validate cancer targets, or as the basis for optimized drugs. Stages of discovery research covered by this NOFO include: 1) development of the primary screen assay(s) and testing in an initial pilot screen; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set.

Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)

National Cancer Institute/NIH/DHHS

PAR-25-079

05-Feb-2026

2,499,995 USD

Funding

Contact Name Darrell Tata, Ph.D. Contact Telephone 240-276-5894

Contact Email Darrell.Tata@nih.gov

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	05-Feb-2026 , 05-Oct-2026					
	Synopsis	Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate translation of scientific discoveries and engineering developments in imaging, data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, or treatment of cancer. A distinguishing feature of each application to this NOFO will be formation of an academic-industrial partnership: a strategic alliance of academic and industrial investigators who work together as partners to identify and translate a technological solution for mitigation of a cancer (or other disease-related) problem. In this sense, the NOFO acts more as a funding mechanism for driving translational research in imaging than for a specific scientific or clinical research area. These partnerships are expected to solidify pre-existing collaborations or establish new ones that would drive the field of imaging, as a whole, further than if they had not been formed. This NOFO defines innovation as the likelihood to deliver a new capability to end users. This funding announcement will support clinical trials that test functionality or validate performance in the chosen setting. However, this NOFO is not intended to support commercial production, basic research projects, or clinical trials that lack translation as the primary motivation.					
1/11/56	<u> Inderstanding Expectancies in Ca Trial Required)</u>	ancer Symptom Management (R01 Clinical	National Cancer Institute/NIH/I	DHHS PAR- 05 25-254	5-Feb-2026	Not Specified	
	Contact Name	Rebecca Ferrer					
	Contact Telephone	240-276-6914					
	Contact Email	ferrerra@mail.nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	05-Feb-2026					
		This Notice of Funding Opportunity (NOFO) will solicit mechanistic researc	h that aims to unde	erstand how and v	why expectancy	



effects occur in a cancer context, elucidate their role in cancer symptom management, and identify patients, symptoms, cancer sites, and contexts in which expectancy effects can be leveraged to improve cancer outcomes. Expectancies are

Expectancies can be evoked by social, psychological, environmental, and systemic factors. Expectancy effects are the

cognitive, behavioral, and biological outcomes caused by expectancies. Expectancy effects can be generated by expectancies held by patients, clinicians, family members, caregivers, and/or dyadic/social networks. Program is particularly interested in

Synopsis defined in this context as beliefs about future outcomes, including one's response to cancer or cancer treatment.

SPIN ID Program Title		Sponsor Name	Sponsor Numbe	Deadline Date	Funding Amount
	applications that enroll individuals and grand behavioral research.	oups from populations historical	ly underreprese	nted or excluded fro	m biomedical
127772 Mechanisms that Impact Cancer Trial Optional)	Risk after Bariatric Surgery (R01 Clinical	National Cancer Institute/NIH/	DHHS PAR- 25-043	06-Jan-2026 [Optional][LOI/Pre- App]	2,500,000 USD
Contact Nam	e Edward R. Sauter, M.D., Ph.D.				
Contact Telephon	e 240-276-7657				
Contact Ema	il <u>edward.sauter@nih.gov</u>				
Sponsor Websit	re				
Program UF	Link to program URL				
Deadline Dates (AL	06-Jan-2026 [Optional][LOI/Pre-App], 05- L) [Optional][LOI/Pre-App], 05-Oct-2026, 06 App], 05-Jun-2027, 05-Sep-2027 [Optional	5-Jan-2027 [Optional][LOI/Pre-Ap			•
Synops	Through this Funding Opportunity Annous of investigator-initiated studies addressin talented scientists who study bariatric sur weight loss and diabetes.	g mechanisms by which bariatric	surgery impact	s cancer risk, and see	ks to draw in
122281 Assay Validation of High Quality (UH2/UH3 Clinical Trial Not Allow	Markers for Clinical Studies in Cancer wed)	National Cancer Institute/NIH/	DHHS PAR- 25-074	13-Feb-2026	Not Specified
Contact Nam	Tracy G. Lively, Ph.D.				
Contact Telephon	e 240-276-5944				
Contact Ema	il <u>livelyt@mail.nih.gov</u>				
Sponsor Websit	re				
Program UF	RL Link to program URL				
Deadline Dates (AL	13-Feb-2026 , 10-Jun-2026 , 14-Oct-2026				
Synops	Through this Notice of Funding Opportunis validation of molecular/cellular/imaging r	• •			



diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding
SPIN ID	rrogram ritie	Sponsor Name	Sponsor Number	Deadine Date	Amount

prevention and control. This NOFO will support investigator-initiated research for both analytical, and clinical validation of assays to be used in cancer treatment, control, or prevention trials supported by the NCI. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays. As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH2 phase of this NOFO supports analytical validation of assays for these molecular/cellular/imaging markers, which must be achieved within 2 years before assays may undergo clinical validation. The UH3 phase of this NOFO supports clinical validation of analytically validated assays for up to 3 years using well-annotated biospecimens from retrospective or prospective clinical trials or studies. This NOFO may be used to validate existing assays for use in other cancer clinical trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this NOFO will require multi-disciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This NOFO is not intended to support early-stage development of technology or the conduct of clinical trials but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays. Investigators responding to this NOFO must address both UH2 and UH3 phases. Milestones to be accomplished in the UH2 phase for transition to the UH3 phase must be proposed by the investigators.

Revision Applications for Validation of Biomarker Assays Developed Through 121826 NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)

National Cancer Institute/NIH/DHHS

13-Feb-2026 24-304

450,000 USD

Contact Name Sumana Dey, Ph.D.

Contact Telephone 240-276-5748

Contact Email sumana.dey@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 13-Feb-2026, 10-Jul-2026, 14-Oct-2026

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) encourages revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects. The applicants should propose projects that are expected to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as "assays") to the clinic. Specifically, the focus of applications submitted in response to this NOFO should be on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response in treatment, as well as markers for cancer prevention and

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	control. Applications may support the acque observational cohorts/consortia for the puthis NOFO encourage multidisciplinary interand clinical laboratory staff. Clinical laboratory of the application. This NOFO is not inclinical trials, but rather the adaption and was investigational assays/tools/devices.	rpose of clinical validation of the raction among scientific investitory scientist(s) and statistical entended to support early-stage	e assay. Research p gators, assay develo xperts are highly er development of teo	orojects proposed opers, clinicians, so necouraged to come chnology or the co	in response to statisticians, prise integral onduct of
129809 NCI Pathway to Independence Aw	vard (K99/R00 – Clinical Trial Required)	National Cancer Institute/NIH/	DHHS PAR- 17 25-313	7-Feb-2026	Not Specified
Contact Name	Michael Schmidt, Ph.D.				
Contact Telephone	240-276-5630				
Contact Email	mschmidt@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	17-Feb-2026 , 15-Jun-2026 , 14-Oct-2026 ,	17-Feb-2027 , 15-Jun-2027 , 14	-Oct-2027		
Synopsis	The goal of the NCI Pathway to Independent postdoctoral researchers with a research a independent, tenure-track or equivalent faduring this transition in order to help awar Opportunity (NOFO) is designed specifically clinical trial, a clinical trial feasibility study, career development. Applicants not plannic clinical trial led by another investigator, much postdoctory and postdoctory.	nd/or clinical doctorate degree iculty positions. The program widees to launch competitive, industry for applicants proposing to sefor a separate ancillary study tong an independent clinical trial,	from mentored, po ill provide independ ependent research rve as the lead inve an existing trial, as or proposing to ga	ostdoctoral resear dent NIH research careers. This No estigator of an ind part of their rese	ch positions to support tice of Funding ependent earch and
128547 Dissemination and Implementation Optional)	on Research in Health (R21 Clinical Trial	National Cancer Institute/NIH/	DHHS PAR- 07	7-Jan-2026	275,000 USD
Contact Name	Gila Neta, Ph.D.				



Contact Telephone 240-276-6785

Sponsor Website

Contact Email gila.neta@nih.gov

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL Deadline Dates (ALL)	Link to program URL 07-Jan-2026, 16-Feb-2026, 07-May-2026, 2027, 16-Jun-2027, 07-Sep-2027, 16-Oct- The purpose of this Notice of Funding Opp	portunity (NOFO) is to support	studies that will ider	ntify, develop, and	/or test
	strategies for overcoming barriers to the adoption, adaptation, integration, sustainability, scale-up, and spread of based interventions, practices, programs, tools, treatments, guidelines, and policies (herein referred to collective evidence-based interventions). Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understan Synopsis circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unprovalue, or harmful. In addition, studies to advance dissemination and implementation research methods and measurement encouraged. Applications that focus on re-implementation of evidence-based health services that may be disrupt disasters (e.g., pandemics, climate change) remain relevant. All applications must be within the scope of the miss the Institutes/Centers listed above. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diversectives (PEDP).					vely as -based anding proven, low- easures are pted amidst ission of one of
1/85/5	Dissemination and Implementation Not Allowed)	on Research in Health (R03 Clinical Trial	National Cancer Institute/NIH	/DHHS PAR- 07 25-233	'-Jan-2026	100,000 USD
	Contact Name	Gila Neta Ph D				

Contact Name Gila Neta, Ph.D.

Contact Telephone 240-276-6785

Contact Email gila.neta@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

07-Jan-2026, 16-Feb-2026, 07-May-2026, 16-Jun-2026, 07-Sep-2026, 16-Oct-2026, 07-Jan-2027, 16-Feb-2027, 07-May-2027, 16-Jun-2027, 07-Sep-2027, 16-Oct-2027, 07-Jan-2028

The purpose of this Notice of Funding Opportunity (NOFO) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, sustainability, scale-up, and spread of evidencebased interventions, practices, programs, tools, treatments, guidelines, and policies (herein referred to collectively as Synopsis evidence-based interventions). Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unproven, lowvalue, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	encouraged. Applications that focus on redisasters (e.g., pandemics, climate change the Institutes/Centers listed above. This N Perspectives (PEDP).) remain relevant. All applicatio	ns must be within t	he scope of the m	ission of one o
128723 Tobacco, Alcohol, and Cannabis Po Clinical Trial Optional)	olicy Research for Health Equity (R21	National Cancer Institute/NIH/	DHHS PAR- 16 25-241	5-Feb-2026	275,000 USD
Contact Telephone	Margaret Mayer, PhD, MPH 202-815-5515 margaret.mayer@nih.gov				
Sponsor Website					
	<u>Link to program URL</u> 16-Feb-2026, 16-Jun-2026, 16-Oct-2026,	16-Feb-2027 , 16-Jun-2027 , 16	i-Oct-2027		
Synopsis	Deadline Dates (ALL) 16-Feb-2026, 16-Jun-2026, 16-Oct-2026, 16-Feb-2027, 16-Jun-2027, 16-Oct-2027 The purpose of this notice of funding opportunity (NOFO) is to support policy research projects that examine new or ad policies pertaining to tobacco, alcohol, and/or cannabis in the U.S., with a particular focus on how the policy or policies influence tobacco, alcohol, and cannabis use or secondhand exposure among populations experiencing disparities. Funding opportunity (NOFO) reguires a Plan for Enhancing Diverse Perspectives (PEDP).				
128810 Basic Research in Cancer Health D	isparities (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/	DHHS PAR- 16	5-Feb-2026	400,000 USD
Contact Telephone	Anu Sharman, Ph.D. 240-276-6250 sharmananu@nih.gov				

Synops

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 16-Feb-2026, 16-Jun-2026, 16-Oct-2026, 16-Feb-2027, 16-Jun-2027, 16-Oct-2027

Synopsis National Cancer Institute (NCI) invites applications from investigators interested in conducting basic, mechanistic research

SPIN ID Program Title Sponsor Name Sponsor Num	ber Deadline Date Funding Amount
--	----------------------------------

into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities.

Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology 128883 and Early Detection Research (U01 Clinical Trial Not Allowed)

National Cancer Institute/NIH/DHHS

10-Feb-2026 25-248

Not Specified

Contact Name Claire Zhu, Ph.D.

Contact Telephone 240-276-7013

Contact Email zhucla@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 10-Feb-2026, 10-Jun-2026, 09-Oct-2026, 10-Feb-2027, 10-Jun-2027, 08-Oct-2027

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from both the screened and the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and other clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens and may include other resources; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research on non-cancer outcomes, especially those related to aging (e.g., Alzheimer's, depression, hip fracture, osteoporosis and rheumatoid arthritis) may also be supported. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.

NCI Continuing Umbrella of Research Experiences (CURE) Non-Mentored 129027 Research Scientist Career Development Award (K22 Independent Clinical Trial Not Allowed)

National Cancer Institute/NIH/DHHS

PAR-12-Feb-2026 24-317

Not Specified

	SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
--	---------	---------------	--------------	----------------	---------------	-------------------

Contact Name Program Director

Contact Telephone 240-276-7754

Contact Email vahedis@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 12-Feb-2026, 12-Jun-2026, 12-Oct-2026, 12-Feb-2027, 12-Jun-2027, 12-Oct-2027

This Notice of Funding Opportunity Announcement (NOFO), NCI Transition Career Development Award to Promote Diversity (K22) supports senior postdoctoral fellows or individuals in similar mentored roles who have not yet gained independence, helping them transition into assistant professor or equivalent roles. The program's goal is to establish successful careers for these individuals as independent research scientists. This NOFO is specifically designed to support individuals from diverse backgrounds, including those whose life experiences, geographic location, socioeconomic status, academic training, professional experience, disability status, military service, career stage, institutional affiliation, cultural background, and Synopsis other factors contribute to a diverse and inclusive research workforce (NOT-OD-20-031). It provides salary and research

support for up to three years of 'protected time,' dedicated to intensive research and career development during their transition into independent research careers. This Notice of Funding Opportunity (NOFO) is specifically intended to support candidates conducting research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Instead, candidates may propose gaining research experience within a clinical trial led by a mentor or co-mentor. Candidates intending to lead a clinical trial, a clinical trial feasibility study, or an ancillary clinical trial should apply to the companion NOFO. (PAR-24-318).

128848 NCI Pathway to Independence Award (K99/R00 – Clinical Trial Not Allowed) National Cancer Institute/NIH/DHHS

25-135 17-Feb-2026 PAR-

Not Specified

Contact Name Michael Schmidt, Ph.D.

Contact Telephone 240-276-5630

Contact Email mschmidt@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 17-Feb-2026, 15-Jun-2026, 14-Oct-2026, 17-Feb-2027, 15-Jun-2027, 14-Oct-2027

The goal of the NCI Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of talented postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to

SPIN ID Program Title Sponsor Number Deadline Date Sponsor Number Deadline Date Sponsor Number Program Title Sponsor Number Deadline Date Sponsor Number Sponsor Number Deadline Date Sponsor Number Sponsor Number Deadline Date Deadli	unding mount
--	-----------------

independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor.

NCI Pathway to Independence Award for Early-Stage Postdoctoral 122437 Researchers (K99/R00 - Independent Basic Experimental Studies with **Humans Required**)

National Cancer Institute/NIH/DHHS

23-288 17-Feb-2026

Not **Specified**

Contact Name Sergey Radaev, PhD

Contact Telephone 240-276-5630

Contact Email sradaev@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 17-Feb-2026, 15-Jun-2026, 14-Oct-2026

increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply. This Notice of Funding Opportunity Synopsis (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PAR-23-286). This Notice of Funding Opportunity is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or

The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	products in mind. Applicants not planning to gain research experience in a clinical tri to the 'Independent Clinical Trial Not Allov interests of one or more of the participatin	al or basic experimental study w ved' companion NOFO. The prop	vith humans led by a cosed project must	another investigat be related to the	tor, must apply
122436 NCI Pathway to Independence Aw Researchers (K99/R00 - Independ		National Cancer Institute/NIH/	DHHS PAR- 23-287 17	7-Feb-2026	Not Specified
Contact Name	Sergey Radaev, PhD				
Contact Telephone	240-276-5630				
Contact Email	sradaev@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	17-Feb-2026 , 15-Jun-2026 , 14-Oct-2026				
Synopsis	The purpose of the NCI Pathway to Indeperince and maintain a strong cohort of nodesigned for postdoctoral fellows with resumentored research training beyond their of these fellows from their mentored, postdoctoral fellows. The program will provide indepercompetitive, independent research career cancer data sciences are especially encour (NOFO) is designed specifically for candidate clinical trial feasibility study, or a separate planning an independent clinical trial, or pumust apply to companion NOFO (PAR-23-22)	new and talented, NCI-supported earch and/or clinical doctoral dedoctoral degrees. The objective of octoral research positions to independent NCI research support dures. Researchers in the scientific a raged to work with their institutions proposing to serve as the learn ancillary clinical trial, as part of roposing to gain research exper	d, independent investigates who do not a confidence who do not a confidence which the confidence which the confidence was a confidence which and investigator of a their research and	estigators. This pro require an extendo acilitate a timely to rack (or equivalent to help awardees lo rol, cancer preven notice of funding of n independent clin career developme	ogram is ed period of ransition of t) faculty launch ntion and opportunity nical trial, a ent. Those not
122435 NCI Pathway to Independence Aw Researchers (K99/R00 - Independ		National Cancer Institute/NIH/	DHHS PAR- 23-286 17	7-Feb-2026	Not Specified
Contact Name	Sergey Radaev, PhD				



Contact Telephone 240-276-5630

Contact Email <u>sradaev@mail.nih.gov</u>

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Link to program URL 17-Feb-2026, 15-Jun-2026, 14-Oct-2026				
	Synopsis	The purpose of the NCI Pathway to Independent increase and maintain a strong cohort of not designed for postdoctoral fellows with resementored research training beyond their distance fellows from their mentored, postdoctoral fellows from their mentored in designed specifically for candidate clinical trial feasibility study, or an ancillary experience in a clinical trial led by a mentor	ew and talented, NCI-supported arch and/or clinical doctoral coctoral degrees. The objective ctoral research positions to incondent NCI research support doctoral searchers in the scientific aged to work with their institutes proposing research that doctorical trial. Under this NOFO	ed, independent invented, independent invented for this award is to for the dependent tenure-truring this transition to areas of cancer contions to apply. This Notes not involve leading candidates are perrodegrees.	estigators. This pro require an extend acilitate a timely to rack (or equivalent to help awardees trol, cancer prever Notice of Funding ang an independen mitted to propose	ogram is ed period of cransition of t) faculty to launch ntion and Opportunity t clinical trial, a a research

investigator, should apply to the companion NOFOs (PAR-23-287 or PAR-23-288).

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 122288 Clinical Trials Not Allowed)

National Cancer Institute/NIH/DHHS

25-075 13-Feb-2026 PAR-

750,000 USD

Contact Name Sumana Dey, Ph.D.

Contact Telephone 240-276-5748

Contact Email sumana.dev@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 13-Feb-2026, 10-Jun-2026, 14-Oct-2026

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to accelerate the adoption

and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for Synopsis cancer prevention and control. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants to this NOFO must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the marker(s) and assay(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring



SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	multiple markers, including immune mark support the clinical validation of establish clinical trials or studies. This NOFO may be population studies. Efforts to harmonize or reproducibility of assays across multiple of proposed for this NOFO will require multistatisticians, and clinical laboratory scient the conduct of clinical trials but is intendentials/studies as investigational assays.	ed assays for up to 3 years using e used to validate existing assays clinical laboratory tests, including clinical laboratories, are also appr disciplinary interaction and collal cists. This NOFO is not intended to	specimens from refor use in other trigoniestigation into opriate for this fundoration among scips support early-sta	etrospective or pro ials, observational the performance iding opportunity. ientific investigato ge development o	ospective I studies, or and . Projects ors, oncologists, of technology or	
110931 Notice of Special Interest (NOSI): Cannabinoid Action in Cancer	Basic Mechanisms of Cannabis and	National Cancer Institute/NIH/I	NOT- DHHS CA-22- 07 085	7-Jan-2026	Not Specified	
Contact Name	Ron Johnson, Ph.D.					
Contact Telephone	240-276-6250					
Contact Emai	l rjohnso2@mail.nih.gov					
Sponsor Website	e					
Program UR	Link to program URL					
Deadline Dates (ALL	07-Jan-2026, 05-Feb-2026, 12-Feb-2026, 16-Feb-2026, 07-May-2026, 05-Jun-2026, 12-Jun-2026, 16-Jun-2026, 07-Sep- 2026, 05-Oct-2026, 12-Oct-2026, 16-Oct-2026, 07-Jan-2027, 05-Feb-2027, 12-Feb-2027, 16-Feb-2027, 07-May-2027					
Synopsi	The purpose of this Notice of Special Intes cannabis and cannabinoids affect cancer cancer symptoms.	•			•	
117338 Impacts of climate change across Trial Optional)	the cancer control continuum (R21 Clinica	National Cancer Institute/NIH/I	DHHS PAR- 25-152	5-Feb-2026	275,000 USD	
Contact Name	Curt DellaValle, Ph.D., MPH					
Contact Telephone	240-276-7225					
Contact Emai	l curt.dellavalle@nih.gov					
Sponsor Website	e					
Program UR	Link to program URL					



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)					
	Synopsis	This Notice of Funding Opportunity (NOFO the effects of climate change across the casurvivorship, and ways to prevent or mitig knowledge of the impact of climate change	incer control continuum, from a ate negative health effects. Thi	cancer etiology and s includes, but is no	cancer risks throut t limited to, studie	igh es to improve
	Mechanisms that Impact Cancer Firial Not Allowed)	Risk after Bariatric Surgery (R21 Clinical	National Cancer Institute/NIH,	/DHHS PAR- 16	5-Feb-2026	550,000 USD
	Contact Name	Edward R. Sauter, M.D., Ph.D.				
	Contact Telephone	240-276-7657				
	Contact Email	edward.sauter@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026 ,	16-Feb-2027 , 16-Jun-2027 , 16	5-Oct-2027		
	Synopsis	Through this Funding Opportunity Announ of investigator-initiated studies addressing talented scientists who study bariatric surgueight loss and diabetes.	g mechanisms by which bariatri	c surgery impacts ca	ancer risk, and see	eks to draw in
		orch Experiences (CURE) Mentored Clinical Diment Award (K08 Clinical Trial Required)	National Cancer Institute/NIH,	/DHHS PAR- 12 24-319	2-Feb-2026	Not Specified
	Contact Name					
	Contact Telephone	240-276-7360				
	Contact Email	K08CareerProgramDirector@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 ,	12-Feb-2027 , 12-Jun-2027 , 12	2-Oct-2027		
	Synopsis	The goal of the NCI Mentored Clinical Scie careers that have a significant impact on the continuation of a long-standing NIH progra	he health-related research need	ds of the nation. Thi	s program repres	ents the



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding
	r rogram ruic	openser runne			Amount

degree or a health professional doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This NCI-sponsored K08 award is specifically designed to support clinical scientists from diverse backgrounds who bring unique perspectives shaped by their life experiences, geographic location, socioeconomic status, academic training, professional experience, disability status, military service, career stage, institutional affiliation, cultural background, and other factors that contribute to a diverse and inclusive research workforce (NOT-OD-20-031), and who are committed to a career in basic biomedical, clinical, behavioral or translational cancer research, including research on cancer health disparities. The expectation is that through this sustained period of research career development and training, awardees will develop enhanced research capabilities for cancer research careers and be better prepared to compete for research project grants (e.g. R03, R21, or R01) funding. This Funding Opportunity Announcement (NOFO) is designed specifically to support candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Candidates not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must work with their organizations to apply to companion NOFO PAR-24-320 NCI Mentored Research Scientist Development Award to Promote Diversity (K08 Independent Clinical Trial Not Allowed))

NCI Continuing Umbrella of Research Experiences (CURE) Mentored Clinical 129030 Scientist Research Career Development Award (K08 Clinical Trial Not Allowed)

National Cancer Institute/NIH/DHHS

24-320 12-Feb-2026

Not Specified

Contact Name

Contact Telephone 240-276-7360

Contact Email K08CareerProgramDirector@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 12-Feb-2026, 12-Jun-2026, 12-Oct-2026, 12-Feb-2027, 12-Jun-2027, 12-Oct-2027

The goal of the NCI Mentored Clinical Scientist Career Development Award (K08) program is to prepare individuals for

careers that have a significant impact on the health-related research needs of the nation. This program represents the continuation of a long-standing NIH program that provides support and protected time to individuals with a clinical doctoral degree or a health professional doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This NCI-sponsored K08 award is specifically designed to support clinical scientists from diverse backgrounds who bring unique perspectives shaped by their life experiences, geographic location, socioeconomic status, academic training, professional experience, disability status, military service, career stage, institutional affiliation, cultural background, and other factors that contribute to a diverse and inclusive

SPIN ID Program Litle Sponsor Name Sponsor Number Deadline Date	unding Amount
---	------------------

research workforce (NOT-OD-20-031), and who are committed to a career in basic biomedical, clinical, behavioral or translational cancer research, including research on cancer health disparities. The expectation is that through this sustained period of research career development and training, awardees will develop enhanced research capabilities for cancer research careers and be better prepared to compete for research project grants (e.g. R03, R21, or R01) funding. This Notice of Funding Opportunity (NOFO) is designed specifically to support candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Candidates seeking support through this NOFO are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (PAR-24-319).

NCI Continuing Umbrella of Research Experiences (CURE) Non-Mentored Research Scientist Career Development Award (K22 Clinical Trial Required)

National Cancer Institute/NIH/DHHS

24-318 12-Feb-2026

Not Specified

Contact Name Program Director

Contact Telephone 240-276-7754

Contact Email vahedis@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 12-Feb-2026, 12-Jun-2026, 12-Oct-2026, 12-Feb-2027, 12-Jun-2027, 12-Oct-2027

This Notice of Funding Opportunity Announcement (NOFO), NCI Transition Career Development Award to Promote Diversity (K22) supports senior postdoctoral fellows or individuals in similar mentored roles who have not yet gained independence, helping them transition into assistant professor or equivalent roles. The program's goal is to establish successful careers for these individuals as independent research scientists. This NOFO is specifically designed to support individuals from diverse backgrounds, including those whose life experiences, geographic location, socioeconomic status, academic training, professional experience, disability status, military service, career stage, institutional affiliation, cultural background, and Synopsis other factors contribute to a diverse and inclusive research workforce (NOT-OD-20-031). It provides salary and research support for up to three years of 'protected time,' dedicated to intensive research and career development during their transition into independent research careers. This Notice of Funding Opportunity (NOFO) is designed specifically to support candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Candidates not planning to lead an independent clinical trial but intending to gain experience in a trial led by another investigator should apply to the companion NOFO (PAR-24-317).

	8	- pp			
SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
121014 Mechanisms that Impact Cand Clinical Trial Not Allowed)	cer Risk with Use of Incretin Mimetics (R21	National Cancer Institute/NIH/	DHHS PAR- 16	5-Feb-2026	275,000 USD
Contact Na	ame Edward R. Sauter, MD, PhD				
Contact Teleph	one 240-276-7657				
Contact E	mail <u>edward.sauter@nih.gov</u>				
Sponsor Web	site				
Program	URL Link to program URL				
Deadline Dates (A	ALL) 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026				
Syno	psis psis and respondent insulinotropic poly agents is due to their reported effects on and side effect profile compared to other scientists to the cancer biology field who	peptide (GIP)-1 receptor agonists thyroid, prostate and other cancer classes of incretin mimetics. In a	(RAs), impact cand er risks, and the ge addition, this NOFO	er risk. The focus enerally more favo seeks to draw in	on these orable efficacy
1 / 3 (15 3	restigator-Initiated Early Phase Clinical Trials gnosis (R01 Clinical Trial Required)	National Cancer Institute/NIH/	DHHS PAR- 07 25-081	7-Jan-2026	2,499,995 USD
Contact Na	ame Lori A. Henderson, Ph.D.				
Contact Teleph	one 240-276-5930				
Contact E	mail hendersonlori@mail.nih.gov				
Sponsor Web	site				
Program	URL Link to program URL				
Deadline Dates (A	ALL) 07-Jan-2026 , 05-Feb-2026 , 07-May-202	6 , 05-Jun-2026 , 07-Sep-2026 , 05	5-Oct-2026 <i>,</i> 07-Jan	-2027	
Syno	Through this Notice of Funding Opportur implement early phase (Phase 0, I, and II) therapeutic interventions of direct relevant at least 1 clinical trial related to the scient Evaluation Program, Cancer Imaging Program Alternative Medicine Program and/or the) investigator-initiated clinical tria ance to the research mission of Do tific interests of one or more of t gram, Cancer Diagnosis Program,	als focused on cance CTD and OHAM. Th he following resear Radiation Research earch Programs. Ap	er-targeted diagn e proposed proje ch programs: Car n Program, Compl plicants may prop	ostic and ct must involvencer Therapy ementary and cose to conduc



an early phase trial by itself, or in combination with another research aim(s) as appropriate. This NOFO does not accept Phase

SPIN ID Program Title		Sponsor Name	Sponso	or Number	Deadline Date	Funding Amount
	III clinical trials.					
123051 Cancer Prevention and Control Cancer Prevention and Cancer Prevention and Cancer Prevention Cancer Prevention and Cancer Prevention	Clinical Trials Grant Program (R01 Clinical	National Cancer Institute/NIH	/DHHS	PAR- 25-167	7-Jan-2026	Not Specified
Contact Nam	e Jessica Faupel-Badger, Ph.D., M.P.H.					
Contact Telephon	e 240-276-7296					
Contact Ema	il <u>badgerje@mail.nih.gov</u>					
Sponsor Websit	e					
Program UR	L Link to program URL					
Deadline Dates (ALL	.) 07-Jan-2026 , 05-Feb-2026 , 07-May-2026	, 05-Jun-2026 , 07-Sep-2026 , 0)5-Oct-2	.026 , 05-Jan	-2027	
	investigator-initiated clinical trials related NCI Division of Cancer Control and Popula improvements in early detection, screening survivorship related to cancer; with such a practice and/or public health. Application Health (NIH) definition of a clinical trial (see described in this NOFO and the application cancer diagnosis and/or oncologic therapy	tion Sciences that have the poting, prevention and interception attributes, the proposed studies submitted to this NOFO must be NOT-OD-15-015 for details) an instructions. This NOFO does	ential to , health s should include and prov	o reduce the care delivery also have th studies that vide specific	burden of cancer	through nd/or prove clinical al Institutes of mation as for studies of
128654 Modular R01s in Cancer Control Optional)	and Population Sciences (R01 Clinical Trial	National Cancer Institute/NIH	/DHHS	PA-25- 172	5-Feb-2026	1,250,000 USD
Contact Nam	e Scott Rogers, MPH					
Contact Telephon	e 240-276-6932					
Contact Ema	il rogerssc@mail.nih.gov					
Sponsor Websit	е					
Program UR	L Link to program URL					
Deadline Dates (ALL	05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026	, 05-Feb-2027 , 05-Jun-2027 , 0	5-Oct-20	027		
Synopsi	This notice of funding opportunity (NOFO) The overarching goal is to provide suppor					



		3 3				
SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		substantially advance cancer research in state behaviors and behavioral interventions, he	· · · · · · · · · · · · · · · · · · ·		•	
1/2///	obacco, Alcohol, and Cannabis P linical Trial Optional)	olicy Research for Health Equity (R01	National Cancer Institute/NIH/	'DHHS PAR- 05 25-240	5-Feb-2026	2,500,000 USD
	Contact Name	Margaret Mayer Sutherland, PhD, MPH				
	Contact Telephone	202-815-5515				
	Contact Email	margaret.mayer@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 ,	05-Feb-2027 , 05-Jun-2027 , 05	-Oct-2027		
	Synopsis	The purpose of this notice of funding opportunity policies pertaining to tobacco, alcohol, and influence tobacco, alcohol, and cannabis uprojects will involve authentic engagemen cancer prevention by addressing tobacco, alcohol, and cannabis policy research stud Funding Opportunity (NOFO) requires a Planta policy requir	d/or cannabis in the U.S., with a se or secondhand exposure am t with one or more community alcohol, and cannabis use and e ies that will improve health equ	particular focus on ong populations ex organizations with exposure. The long- ity and promote ca	how the policy operiencing dispari the aim of promoterm goal is to su	r policies ities. Funded ting equity in oport tobacco,
128809 <u>Ba</u>	asic Research in Cancer Health D	Disparities (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/	'DHHS PAR- 05 25-243	5-Feb-2026	Not Specified
	Contact Name	Anu Sharman, Ph.D.				
	Contact Telephone	240-276-6250				
	Contact Email	sharmananu@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 ,	05-Feb-2027 , 05-Jun-2027 , 05	-Oct-2027		
	Synopsis	National Cancer Institute (NCI) invites applinto the biological/genetic causes of cancer	G		•	



studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	factors associated with cancer disparities, strategies, (2) the development and testing also designed to aid and facilitate the grow in cancer health disparities research who cancels, and methods that are necessary to Research Project (RO1) award mechanism.	g of new methodologies and mother of a nationwide cohort of some can expand available resources o conduct basic research in can	odels, and (3) seco cientists with a high and tools, such as	ndary data analyse n level of basic rese biospecimens, pation	es. This FOA is earch expertise ent derived
	r Therapy-induced Adverse Sequelae and Strategies (R01 Clinical Trial Optional)	National Cancer Institute/NIH,	/DHHS PAR- [+ 25-145	06-Jan-2026 Optional][LOI/Pre- lpp]	Not Specified
Contact Name	Kelly Filipski PhD, MPH				
Contact Telephone	240-276-6841				
Contact Email	Kelly.Filipski@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	06-Jan-2026 [Optional][LOI/Pre-App], 05-F [Optional][LOI/Pre-App], 05-Oct-2026 , 06- App], 05-Jun-2027 , 05-Sep-2027 [Optional	-Jan-2027 [Optional][LOI/Pre-A			•
Synopsis	The purpose of this Notice of Funding Opp sequelae of cancer therapies that persist a This NOFO supports basic, translational, ar induced adverse sequelae, clinically characteristic approaches to prevent or minimulates mechanistic studies with translatic endpoints (biomarkers, imaging, patient-reevaluate the efficacy of interventions design opportunity (NOFO) requires a Plan for En	and become chronic co-morbiding clinical research projects that cterize the adverse sequelae, are imize the development of longonal endpoints and longitudinal eported outcomes or combined gned to prevent or reduce spec	ties or develop as of t seek to identify the nd translate the me term sequelae. The I clinical phenotypi I elements) for futu ific adverse sequel	delayed posttreatm he mechanisms of techanistic understa e scope of research ing to identify and t ure use in clinical tr	nent effects. therapy- inding into in projects validate clinical ials that will
117334 Impacts of Climate Change Across Clinical Trial Optional)	s the Cancer Control Continuum (R01	National Cancer Institute/NIH,	/DHHS PAR- 0 25-094	5-Feb-2026	Not Specified
Contact Name Contact Telephone	Curt DellaValle, Ph.D., MPH 240-276-7225				



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website Program URL Deadline Dates (ALL)	This notice of funding opportunity (NOFO)	ncer control continuum, from c	ancer etiology and	cancer risks throu	gh
1717/16		knowledge of the impact of climate change Cancer Survivors from Sexual and Gender		on cancer risks, co		
	Contact Telephone Contact Email Sponsor Website	David Dean Jr., Ph.D., M.S. 240-276-8703 chipper.dean@nih.gov Link to program URL				
	Deadline Dates (ALL) Synopsis	05-Feb-2026, 05-Jun-2026, 05-Oct-2026 Through this notice of funding opportunity assessment of barriers to quality cancer tree. This funding opportunity is intended to add survivors. The goal is to address the disease poorer health outcomes. The NCI solicits put to understand barriers and/or improve care orientation and gender identity (SOGI) data	eatment and follow-up care for dress a critical need for improve e burden in an underserved and roposals for observational and/ e and outcomes for SGM peopl	sexual and gender ed care delivery and understudied pop or interventional stewith cancer, using	minority (SGM) ca doutcomes for SG ulation that is at h cudies of SGM surv g interoperable se	ncer survivors M cancer higher risk of vivors designed
170973	Mechanisms that Impact Cancer R Clinical Trial Optional)	tisk with Use of Incretin Mimetics (R01	National Cancer Institute/NIH/	DHHS PAR- 05	5-Feb-2026	Not Specified
	Contact Name	Edward R. Sauter, MD, PhD				



Contact Telephone 240-276-7657

Contact Email edward.sauter@nih.gov

SPIN ID Program Title Sponsor Name Sponsor Number Deadline Date Amount
--

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 05-Feb-2026, 05-Jun-2026, 05-Oct-2026

Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for investigatorinitiated studies addressing mechanisms by which incretin mimetics, specifically glucagon-like peptide (GLP)-1 or dual GLP-1/ glucose?dependent insulinotropic polypepide (GIP)-1 receptor agonists (RAs), impact cancer risk. The focus on these agents is due to their reported effects on thyroid, prostate and other cancer risks, and the generally more favorable efficacy and side Synopsis effect profile compared to other classes of incretin mimetics. In addition, this NOFO seeks to draw in talented scientists to the cancer biology field who may study incretin mimetic effects on diseases other than cancer. Investigators wishing to study incretin mimetics other than GLP-1 RAs or GLP-1/GIP-1 RAs, such as dipeptidyl peptidase (DPP)-4 inhibitors, must justify why the agent(s) they propose to study are more effective and/or have a more favorable side effect profile than GLP-1 or GLP-1/GIP-1 RAs. Route of agent administration (oral vs. other) is, by itself, not an adequate justification.

120897

Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)

National Cancer Institute/NIH/DHHS

24-306 05-Feb-2026

2,495,000 USD

Contact Name Joanna Watson, Ph.D.

Contact Telephone 240-276-6206

Contact Email Joanna. Watson@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 05-Feb-2026, 05-Jun-2026

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. The NCI, through this NOFO, encourages submission of projects devoted to demonstrating that mammalian models, including organoids, tumoroids and cell models, used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patient benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that use mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesistesting, non-clinical research. Among many other possible endeavors, applicants in response to this NOFO could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of

Synopsis



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Pr Deadline Date	Funding Amount
		translational models, test approaches to vaused translationally.	alidate and credential models,	or challenge curr	ent practices for hov	nodels are
178447	Dissemination and Implementation optional)	on Research in Health (R01 Clinical Trial	National Cancer Institute/NIH,	/DHHS PAR- 25-144	07-Jan-2026	Not Specified
	Contact Name	Gila Neta, Ph.D.				
	Contact Telephone	240-276-6785				
	Contact Email	gila.neta@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jan-2026 , 05-Feb-2026 , 07-May-2026 2027 , 05-Jun-2027 , 07-Sep-2027 , 05-Oct-	•	5-Oct-2026 , 07	Jan-2027 , 05-Feb-20	27 , 07-May-
The purpose of this Notice of Funding Opportunity (NOFO) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, sustainability, scale-up, and spread of eviden based interventions, practices, programs, tools, treatments, guidelines, and policies (herein referred to collectively as evidence-based interventions). Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unproven, lovalue, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services that may be disrupted amic disasters (e.g., pandemics, climate change) remain relevant.						
1/8019	Molecular Imaging of Inflammatio	on in Cancer (R01 Clinical Trial Not	National Cancer Institute/NIH,	/DHHS PAR- 24-311	06-Jan-2026 [Optional][LOI/Pre- App]	2,499,995 USD
	Contact Name	Charles Lin , Ph.D.				
	Contact Telephone	240-276-6108				
	Contact Email	linp3@nih.gov				



Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 06-Jan-2026 [Optional][LOI/Pre-App], 05-Feb-2026, 06-May-2026 [Optional][LOI/Pre-App], 05-Jun-2026, 05-Sep-2026

SPIN ID	Program Title	Sponsor Name	Sponsor	· Numbe	r Deadline Date	Funding Amount
	Synopsis	[Optional][LOI/Pre-App], 05-Oct-2026, 06-Jan-2027 [Optional][LOI/Pre-App], 05-Jun-2027, 05-Sep-2027 [Optional][LOI/Pre-App], 05-Oct-2027 Through this Notice of Funding Opportunity (NOFO), the National Cancer (R01) for the development and application of current and emerging mole into cancer inflammation in vivo. The motivation for this initiative is the research on inflammation in cancer relies heavily on in vitro and ex vivor provide significant insights into the dynamic interactions between cancer probes in pre-clinical and clinical investigations allows for precise tempor information is valuable for identifying and characterizing in vivo inflammation molecular changes in response to treatment. This NOFO encourages applications are understanding of cancer inflammation interactions.	Institute ecular imarecognition methods. rand inflateral resolute atory cellications fong cross-	(NCI) in aging me on that mathematic ammatic ammatic ammatic are consedused of the conseduration of th	vites research grant a thods to gain fundan nuch of the current in pproaches have limit n. Utilizing molecula nolecular and cellular siology in cancer and on developing integra ne collaboration betw	applications nental insights maging ed potential to r imaging levels. This for detecting ated imaging
1 /Xh / I	ntegration of Imaging and Fluid-E RO1 Clinical Trial Optional)	Based Tumor Monitoring in Cancer Therapy National Cancer Institute/NIH	/DHHS	PAR- 25-175	06-Jan-2026 [Optional][LOI/Pre- App]	499,999 USD
	Contact Name	Shane Woodward				
	Contact Telephone	240-276-6624				
	Contact Email	woodwars@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	2027, 05-Feb-2027, 06-May-2027 [Optional][LOI/Pre-App], 07-May-202	, 026 , 06-J	an-2027	[Optional][LOI/Pre-/	App], 07-Jan-
		App], 07-Sep-2027, 05-Oct-2027, 07-Jan-2028				



SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Diagnosis and Treatment (R01 - C	ilinical Trial Optional)		25-337		USD
Contact Name	Miguel Ossandon MS				
Contact Telephone	240-276-5714				
Contact Emai	ossandom@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 ,	05-Feb-2027 , 05-Jun-2027 , 0	5-Oct-2027		
Synopsis	partnership should plan to transition a tech to a status useful in the chosen setting. Fur translate technologies that address problem of disease status. This FOA defines "innova clinical trials that test functionality or valid clinical trials that lack translation as the pri cancer research are not sought by and will commercial production or basic research p	r tools that address problems agnose, treat, and/or manage dies and methods relevant to the mestic or foreign, for conditions structure that is expected to be trial, and other investigators. The chart to work in strategic a coblem. They are expected to pould include at least one acade anology, method, assay, device and in biology, pathology, risk attion" as likelihood to deliver a late performance in the chosen mary motivation. Applications not be supported through this	in basic research to disease. The rational disease. The rational diseases with the partners on each lliance to implement lan, design, and validemic and one industrie, and/or system from the capability to end setting. This FOA is that propose phase is FOA. This FOA does	understand disease is to deliver new ch and delivery of nin the missions or nowledge and expapplication should a coherent strate date that the solutinal organization. Emandement, and continued to sufficient of the solution	e, or in applied a capabilities to care in pre- f participating perience by d establish an egy to develoption will be each n of possibility otherwise for monitoring will support upport straight any area of upport
129235 Exploratory/Developmental Bioen Clinical Trial Optional)	ngineering Research Grants (EBRG) (R21	National Cancer Institute/NIH	/DHHS PAR- 16 25-321	5-Feb-2026	275,000 USD

Contact Name Miguel R. Ossandon, Ph.D.

Contact Telephone 240-276-5714

Contact Email ossandom@mail.nih.gov



SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
Sponsor Website						
,						
_	Link to program URL	16 Eab 2027 16 Jun 2027 16	Oct 2027			
·	The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility. This FOA will support clinical trials that test functionality or validate performance in the chosen setting. Applications that propose phase III clinical trials in any area of cancer research are not sought by and will not be supported through this FOA					
129261 Exploratory/Developmental Bioe Clinical Trial Not Allowed)	ngineering Research Grants(EBRG) (R21	National Cancer Institute/NIH/	DHHS PAR- 25-346	5-Feb-2026	275,000 USD	
Contact Name	Miguel R. Ossandon, Ph.D.					
Contact Telephone	240-276-5714					
Contact Emai	l ossandom@mail.nih.gov					
Sponsor Website	e					
Program UR	Link to program URL					
Deadline Dates (ALL) 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026 ,	16-Feb-2027 , 16-Jun-2027 , 16-	-Oct-2027			
The purpose of this engineering-oriented notice of funding opportunity announcement (NOFO) is to encourage submiss of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potentially of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.						
128595 Cancer Prevention and Control C Clinical Trials Optional)	linical Trials Planning Grant Program (U34	National Cancer Institute/NIH/	DHHS PAR- 25-103	5-Feb-2026	Not Specified	
Contact Name	Brandy Heckman-Stoddard, Ph.D., M.P.H.					
Contact Telephone	240-276-7048					
Contact Emai	l <u>heckmanbm@mail.nih.gov</u>					
Sponsor Website	e					
Program UR	Link to program URL					



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	25-Feb-2026 , 25-Jun-2026 , 25-Oct-2026 ,	·			
	Synopsis	Through this Funding Opportunity Annour clinical trials across the cancer prevention health behaviors, screening, early detection care, and the long-term outcomes of cancerationale for conducting a clinical trial, involved challenges, intervention, outcome/endporotocol completely. These information gotherned for additional time and expenses trial designs, which minimize infrastructur intervention, at-risk group, symptom or verinclude a pilot/feasibility clinical trial if near requires a Plan for Enhancing Diverse Personal clinical trial in the control of	and control spectrum aimed at it on, healthcare delivery, manager er survivors. Although the scient estigators often lack critical information, data/statistical challenges caps can result in multiple protocos that may prevent study complete and reduce costs may need to enue. Preparatory studies may fil cessary, improving trial design ar	improving preventinent of treatmentific literature or promation about the properational risks of changes before attion. Further, the substitution in the coll information gaps	ion/ interception, related symptoms eliminary data ma study population, necessary to final and after trial start uitability and feas ontext of a particuland address unkn	cancer-related s, supportive y provide the accrual lize the trial t-up, leading to ibility of new lar
1/254/	Cancer Prevention and Control Cli Clinical Trials Optional)	inical Trials Planning Grant Program (R34	National Cancer Institute/NIH/I	DHHS PAR- 25 25-104	5-Feb-2026	Not Specified
	Contact Name	Brandy Heckman-Stoddard, Ph.D., M.P.H.				
	Contact Telephone	240-276-7048				
	Contact Email	heckmanbm@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	25-Feb-2026 , 25-Jun-2026 , 25-Oct-2026 ,	. 25-Feb-2027 , 25-Jun-2027 , 25-	-Oct-2027		
		Through this Funding Opportunity Annour clinical trials across the cancer prevention	• • •	• •		•

Svnopsis

clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns this can



SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	include a pilot/feasibility clinical trial if ne requires a Plan for Enhancing Diverse Pers		and rigor. This Notic	e of Funding Oppo	ortunity (NOFO
126574 Enhancing Mechanistic Research (Clinical Trial Optional)	on Precision Probiotic Therapies (R61/R33	National Center for Complement and Integrative Health/NIH/D	. (1	2-Feb-2026	1,750,000 USD
Contact Telephone Contact Email	hye-sook.kim@nih.gov				
· ·	Link to program URL 02-Feb-2026 , 01-Oct-2026 , 02-Jun-2027				
Synopsis	The purpose of this notice of funding opports the development of effective precision protocolor identify, understand, and develop strate heterogenicity in humans that often cause applications that will characterize person-responders, which may then help enhance provide 1 or 2 years of support to identify gender, diet, age, genetic background, life effects using observational or secondary of support studies to assess the causality of rigorous mechanistic study designs in animal clinical trials. The combined R61/R33 show by NIH staff and is not guaranteed. Approprieview recommendations, successful compon R61 findings, program priorities, and apphase. Support for a single phased award NOFO, PAR-25-210. This Notice of Funding	obiotic interventions using a midegies to address barriers in preses inconsistent probiotic theraph specific features affecting probe probiotic clinical outcomes. The host biological patterns (e.g., restyle, or health history) that are data analysis studies. The seconthe factors identified in the R61 mal models or human subjects. The uld not exceed 5 years. Transitional of the transition to the R33 pletion of transition milestones vailability of funds. It is not expethat does not need the R61 Expethal	ilestone-driven, bipholicision probiotic interestic responses. Speciotic responses to identify the first phase, fundentive microbiome, is ecorrelated with did phase, funded under phase that impact on to the R33 phase phase will be based of, any proposed characted that all applications.	nasic award mechan rventions to according ecifically, this NOF lentify subgroups and by the R61 mechan mmune system, subject on probio der the R33 mechan probiotic responsions support efficacy of requires administ on the original R6 anges to the R33 relations will continuous	anism. It aims unt for the FO solicits of probiotic hanism, will ex and/or otic clinical anism, will exeness through effectiveness trative review of 1/R33 peer search based up to the R33 apanion (R33)

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Sponsor Website Program URI Deadline Dates (ALL	hye-sook.kim@nih.gov	probiotic interventions. The NOFO probiotic interventions' developments. Specifically, this NOFO tterns affecting probiotic responsion. This NOFO will support studies and/or gender, diet, age, genetican modulate responsiveness to a studies using relevant/innovatial host biological patterns that monstrated with supportive prell not support efficacy or effections that may affect probiotic hear	D aims to identify, upper to account for solicits R33 applicated applications and identify sures that assess whether background, lifesty probiotic intervention and models at are correlated with liminary data, which veness clinical trials alth outcomes should	nderstand, and de or human heteroge tions that will asse bgroups of probio er host biological yle, or health histo ons. Well-suited a or human subjects h probiotic usage n require further m . Applicants pursu d consider the cor	velop eneity resulting ess the tic responders patterns (e.g., ery) that are pplications s. This NOFO is or nechanistic ing early-stage npanion
123858 Natural Product Multi-Site Clinical (Collaborative U24 Clinical Trial R		National Center for Compleme and Integrative Health/NIH/DI	• //	0-Feb-2026	Not Specified
Contact Name	Wendy Weber, N.D., Ph.D, M.P.H.				
Contact Telephone					
	weberwj@mail.nih.gov				
Sponsor Website					
	Link to program URL 20-Feb-2026, 17-Mar-2026, 22-Jun-2026	14 Jul 2026			
Synopsis	This Notice of Funding Opportunity (NOFC	O), utilizing the U24 grant fundi	ng mechanism, enco les an investigator-i	ourages applicatio nitiated multi-site	ns for a clinical trial

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding
	r rogram ruic				Amount

(Phase III and beyond) application submitted under PAR-24-312. The DCC application must be specific to the collaborating Clinical Coordinating Center (CCC) application. The objective of the DCC application is to propose a comprehensive plan that provides overall project coordination and administrative, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for consideration by NCCIH. Trials for which this NOFO applies must be relevant to the research mission of NCCIH and considered a high priority by the Center. For additional information about the mission, strategic vision, and research priorities of NCCIH, applicants are encouraged to consult the NCCIH website: (https://www.nccih.nih.gov). Applicants are strongly encouraged to contact the appropriate Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this NOFO. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).

123791

NCCIH Natural Product Mid Phase Clinical Trial Cooperative Agreement (R01 National Center for Complementary Clinical Trial Required)

and Integrative Health/NIH/DHHS

PAR-25-271

23-Feb-2026

1.750.000 USD

Contact Name Sekai Chideya, M.D., MPH

Contact Telephone 301-827-1916

Contact Email sekai.chideya@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 23-Feb-2026, 17-Mar-2026, 20-Oct-2026, 13-Nov-2026

This Funding Opportunity Announcement (FOA) invites cooperative agreement applications for investigator-initiated midphase clinical trials of natural products. All applications submitted under this FOA must be supported by sufficient preliminary data of bioavailability and documentation that the natural product produces a replicable and measurable impact on a biological signature (i.e., measure of the mechanism of action). Only in cases when it is not possible/practical to measure a biological signature in the patient population of interest or when there is a fundamental understanding of the product's mechanism of action will this preliminary data requirement be waived. Applications submitted to this FOA should propose a Synopsis mid-phase clinical trial to do the following: determine the optimal dose or formulation of a given natural product for use in a future multi-site clinical trial; or determine which patient phenotypes will be responders versus non-responders to the natural product to inform inclusion/exclusion criteria of a future efficacy study. Clinical trials submitted under this FOA are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This FOA will not support single-site or multi-site efficacy or effectiveness trials, nor will it support trials to test natural products for the treatment or prevention of cancer. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research

contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.

SPIN ID	Program Title		Sponsor Name	Sponsor Numbe	r Deadline Date	Funding Amount
						7 tilloune
123155		IH Multi-Site Investigator-Initiated Clinical ions (Collaborative U24 Clinical Trial	National Center for Compleme and Integrative Health/NIH/D	•	20-Feb-2026	500,000 USD
	Contact Name	Elizabeth Ginexi, Ph.D.				
	Contact Telephone	301-827-0160				
	Contact Email	elizabeth.ginexi@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	20-Feb-2026 , 17-Mar-2026 , 22-Jun-2026	5 , 14-Jul-2026			
	Synopsis	This notice of funding opportunity (NOFC collaborating data coordinating center (D (Phase III and beyond) application submit companion clinical coordinating center (C plan that provides overall project coordin proposed clinical trial. Both a DCC applicationsideration by NCCIH. Trials for which considered a high priority by the Center. of NCCIH, applicants are encouraged to contact the appropriate Scientific/Reseapplication prior to submitting to this NO Diverse Perspectives (PEDP).	CC) application that accompanie ted under companion PAR-24-2 (CC) application. The objective of action, and administrative, data action and a corresponding CCC at this NOFO applies must be relevant to additional information about the NCCIH website (https.) earch Contact for the area of science.	es an investigator 75. The DCC appl f the DCC applica management, and pplication need to ant to the resear t the mission, straction the the mission of the mice for which the 75.	-initiated multi-site of ication must be spection is to propose and biostatistical support by the submitted simulating of NCCIH ategic vision, and resulting on the planning to design of the submitted simulating the submitted simulating to design of the submitted simulating simu	clinical trial ific to the comprehensive ort for the Itaneously for and search priorities e encouraged evelop an
128271		CCIH Multi-Site Investigator-Initiated iterventions (Collaborative UG3/UH3	National Center for Compleme and Integrative Health/NIH/D	•	21-Jan-2026 [Optional][LOI/Pre- App]	Not Specified
	Contact Name	Elizabeth Ginexi, Ph.D.				
	Contact Telephone	301-827-0160				
	Contact Email	elizabeth.ginexi@nih.gov				
	Sponsor Website					



Program URL Link to program URL

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Deadline Dates (ALL)	21-Jan-2026 [Optional][LOI/Pre-App], 20-F Jul-2026	Feb-2026 , 17-Mar-2026 , 23-Ma	y-2026 [Optional][I	₋OI/Pre-App], 22-J	un-2026 , 14-
Synopsis	This notice of funding opportunity (NOFO) encourages applications for investigator-initiated multisite clinical trials (e.g., efficacy, effectiveness, or pragmatic trials) to study the effects of complementary and integrative health approaches wit physical and/or psychological therapeutic inputs (often called mind and body interventions), and/or multicomponent interventions that include physical, psychological, and/or nutritional approaches in NCCIH-designated areas of high rese priority. Clinical coordinating centers (CCC) should develop and implement the proposed fully powered multisite clinical (Phase III and beyond). The objective of a CCC application is to present the scientific rationale and a comprehensive scie and operational plan for the clinical trial. CCC applications are expected to describe plans for project management, participant recruitment and retention strategies, performance milestones, scientific conduct, and dissemination of resul CCC applications submitted under this NOFO will utilize a two-phase, milestone-driven cooperative agreement (UG3/UH funding mechanism. In addition, an accompanying data coordinating center (DCC) application (U24), submitted under P. 24-087 and proposing a data analysis and data management plan for the clinical project, is required. Both a CCC application and a corresponding DCC application need to be submitted simultaneously for consideration by NCCIH. For additional information about the mission, strategic vision, and research priorities of NCCIH, applicants are encouraged to consult to NCCIH website (https://nccih.nih.gov/about/plans). Applicants are encouraged to contact the appropriate Scientific/Res Contact for the area of science for which they are planning to develop an application prior to submitting to this NOFO. Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).				
123147 NCCIH Multi-Site Feasibility Clinic (R01 Clinical Trial Required)	al Trials of Mind and Body Interventions	National Center for Compleme and Integrative Health/NIH/DH	• //)-Feb-2026	Not Specified
Contact Name	Pete Murray, Ph.D.				
Contact Telephone	301-496-4054				
Contact Emai	peter.murray@nih.gov				
Sponsor Website					
Program URI	Link to program URL				
Deadline Dates (ALL)	20-Feb-2026 , 17-Mar-2026 , 22-Jun-2026	, 14-Jul-2026 , 20-Oct-2026 , 17-	-Nov-2026		
	This notice of funding opportunity (NOFO)	invites applications for investigations	ator-initiated clinic	al trials of comple	mentary and



integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body Synopsis interventions) in NCCIH-designated areas of high research priority. Applications submitted under this NOFO are expected to

propose a multisite feasibility clinical trial that will provide new information that is scientifically necessary for the planning and conduct of a subsequent clinical efficacy or effectiveness study, pragmatic trial, or dissemination and implementation

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding
	r rogram ruic				Amount

trial within NCCIH's mission. NCCIH expects that applications to this NOFO will describe the planned future clinical trial and in so doing demonstrate that the proposed (R01) research is scientifically necessary to design or plan the subsequent fully powered, full-scale clinical trial. Under this R01, the data collected should be used to fill gaps in scientific knowledge, including, but not limited to the following: assessing whether the intervention can be delivered with fidelity across sites; demonstrating feasibility of recruitment, accrual, and randomization of participants across sites; demonstrating participant adherence to the intervention, as well as retention of participants throughout the study across sites; refining and assessing the feasibility of protocolized multimodal interventions, and/or demonstrating feasibility of data collection across sites in preparation for a future fully powered, multisite efficacy or effectiveness trial. The need for multisite feasibility trials is expected to be justified by sufficient preliminary data from previous single site feasibility or acceptability trial(s) or the published literature. The data collected should be used to fill gaps in scientific knowledge and be necessary to develop a competitive fully powered multisite clinical trial that has the potential to make a significant impact on public health. Prior to submitting to this NOFO, applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact person for the science area of the planned application. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

Investigator Initiated Clinical Trials of Complementary and Integrative 123153 Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)

National Center for Complementary and Integrative Health/NIH/DHHS

PAR-25-268

20-Feb-2026

Not **Specified**

Contact Name Beda Jean-Francois, Ph.D.

Contact Telephone 202-313-2144

Contact Email beda.jean-francois@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 20-Feb-2026, 17-Mar-2026, 22-Jun-2026, 13-Jul-2026, 20-Oct-2026, 17-Nov-2026

This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated fully remotely delivered and conducted clinical trials to assess the efficacy or effectiveness of complementary and integrative health interventions in NCCIH- designated areas of high research priority. Applications submitted under this NOFO are expected to propose a remotely delivered and conducted fully powered clinical trial with no in-person contact between research staff and study participants and may utilize mHealth tools or technologies. Applicants must provide justification for the remotely delivered approach and provide preliminary data on the feasibility and safety of the approach, along with evidence that the

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		intervention has promise of clinical benef Scientific/Research contact for the area of to this NOFO. This NOFO requires a Plan scientific and technical peer review evaluate be withdrawn. Applicants are strongly end guidance material.	f science for which they are pla for Enhancing Diverse Perspect ation. Applications that fail to i	nning to develop an tives (PEDP), which v nclude a PEDP will b	application prior will be assessed as e considered inco	part of the mplete and will
	easibility Clinical Trials of Mind a Priority Research Topics (R34 Clin	and Body Interventions for NCCIH High nical Trial Required)	National Center for Complem and Integrative Health/NIH/D	• //	0-Feb-2026	450,000 USD
	Sponsor Website	jennifer.baumgartner@nih.gov				
	_	Link to program URL	12 Ivl 2020 20 0 th 2020 1	7 Nov. 2026		
		The goal of this notice of funding opportu approaches with physical and/or psycholoc that have been identified by NCCIH as hig clinical trials that provide new information clinical efficacy or effectiveness study, pra NCCIH expects that applications to this NC the proposed (R34) research is scientifical Under this R34, the data collected should scale clinical trial, including, but not limited published data; tailoring or adapting the refining the intervention to determine the retention, and data collection procedures interventions; or examining acceptability have the potential to make a significant in encouraged to contact the appropriate NC application. This NOFO requires a Plan fo scientific and technical peer review evaluates.	nity (NOFO) is to support feasible or gical therapeutic inputs (often h-priority research topics. This is not that are scientifically necessary of the planned for the following: examining for the following: examining for the planned for the following: examining for the planned for the following: examining for the planned and assessing the feat and adherence of control conditions and adherence of control conditions on public health. Prior to CCIH Scientific/Research contact of Enhancing Diverse Perspectives	called mind and bod funding opportunity ry for the planning a and implementation uture clinical trial and the subsequent complements and implements are assibility and accept vention to a specific or duration; determinability of protocolizations. The subsequence of submitting to this at person for the sciences (PEDP), which will	dy interventions) for its intended to support of a suppor	or conditions opport feasibility absequent I's mission. I constrate that clinical trial. I mpetitive fullations lacking ality, or setting; recruitment, ent al trial should are anned art of the

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		be withdrawn. Applicants are strongly enguidance material.	couraged to read the NOFO insti	ructions carefully a	nd view the availa	ble PEDP
11/4119		Development of Innovative Informatics ools, and Methods for Vision Research	National Eye Institute/NIH/DH	NOT- HS EY-23- 0 005	5-Jan-2026	Not Specifie
	Contact Name	James Gao, Ph.D.				
	Contact Telephone	301-594-6074				
	Contact Email	james.gao@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Jan-2026 , 07-Jan-2026 , 16-Feb-2026				
	Synopsis	The purpose of this Notice of Special Interinterested in supporting research to deve improve data acquisition, analysis, visualisinnovation and its potential impact on vistranslational research.	lop innovative informatics and cation, annotation, integration,	lata science metho and interpretation.	ds, algorithms, and The emphasis will	d tools to be on
/4 / - 4 -	NEI Clinical Research Study Planni Allowed)	ng Grant Program (R34 Clinical Trial Not	National Eye Institute/NIH/DH	HS PAR- 0	7-Jan-2026	300,000 USD
	Contact Name	Donald Everett, MA				
	Contact Telephone	301-435-8181				
	Contact Email	everettd@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jan-2026 , 16-Feb-2026 , 07-May-2026 2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct		6-Oct-2026 , 07-Jar	n-2027 , 16-Feb-20	27 , 07-May-
	Synopsis	The NEI supports large-scale clinical vision eye/vision conditions. At the time of subn			•	_



detailed information regarding the study rationale, design, analytic techniques, protocols and procedures, facilities and

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	environment, organizational structure, and Procedures (MOP), the development of wh grant funding opportunity supports application may be used to support the development of document recruitment potential. The gran NEI FOA is applicable to both epidemiologic	nich represents a costly and timents in their planning efforts to of a MOP, as well as to conduct the must not be used to generate	ne-consuming acti conduct collabora preliminary stud data on the effec	vity. This clinical res ative clinical researc es to refine study p	earch planning ch. The grant rocedures or
129611 NEI Research Grant for Vision-Relation Not Allowed)	ated Secondary Data Analysis (R21 Clinical	National Eye Institute/NIH/DH	HS PAR- 25-357	07-Jan-2026	275,000 USD
Contact Name	Donald Everett, M.A.				
Contact Telephone	301-435-8181				
Contact Email	everettd@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct-	•	6-Oct-2026 , 07-Ja	an-2027 , 16-Feb-20	27 , 07-May-
Synopsis	The purpose of this Notice of Funding Opp from humans participating in vision-related clinical and health care database resources statistical methodologies or test hypothese new data. This NOFO encourages applications secondary analyses of data collected from aims of the original data collection. The NE research projects wherein numerous data wealth of data generated by these studies research questions or develop new analyti limited to those collected under NEI suppo	d clinical trials, epidemiologic, as (e.g., electronic health record es using existing data, but this lons from institutions/organizat humans. Applications may be a supports an extensive portfol collection activities are require often provides unique, cost-effical approaches secondary to a	and other clinical s). This NOFO may NOFO must not be ions that propose related to, but mu io of clinical trials d to meet each prective opportunity	research studies or represent the used to develope used to support the to conduct vision-relate be distinct from, and large-scale epiceoject's specific aimsies to investigate advintended purpose.	represented in onew e collection of elated the specific demiologic s. The resultant dditional
125579 RFA-HL-26-002 NHLBI Outstand Trial Optional)	ing Investigator Award (OIA) (R35 Clinical	National Heart, Lung, and Bloo Institute/NIH/DHHS	hL-26-	20-Jan-2026 [Optional][LOI/Pre- App]	4,900,000 USD
Contact Name	Narasimhan Danthi, Ph.D.				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount

Contact Telephone 301-451-5170

Contact Email NHLBI R35@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

20-Jan-2026 [Optional][LOI/Pre-App], 19-Feb-2026, 28-Apr-2026, 20-Jan-2027 [Optional][LOI/Pre-App], 19-Feb-2027, 28-Apr-2027

The purpose of the NHLBI Outstanding Investigator Award (OIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PDs/PIs) who are currently PDs/PIs on at least two NHLBI R01-equivalent awards or an NHLBI R35 award in the 6th or 7th year of funding and whose outstanding record of research demonstrates their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The OIA is intended to support an investigator's research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The OIA will support the research program of NHLBI-funded investigators for up to seven years and will provide investigators with freedom to conduct Synopsis research that breaks new ground or extends previous discoveries in new directions. It will also allow PDs/PIs to take greater risks and to pursue research that requires a longer time frame. Research supported by the OIA must be within the scope of the NHLBI mission. It is anticipated that the OIA will: Provide a stable funding environment, thereby improving productivity and facilitating nimble, ambitious, creative research; Accelerate scientific innovation by enabling flexibility in pursuing new research directions as they arise, since PD/PIs will not be bound to specific aims proposed in advance of the studies; Reduce the time researchers spend writing grant applications and managing multiple grant awards, thereby allowing more time to be devoted to conducting research; Facilitate PD/PIs' commitment to research through increased stability of funding; and Enable

125580

RFA-HL-26-003 -- NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial National Heart, Lung, and Blood Optional)

Institute/NIH/DHHS

PD/PIs to devote more time and energy to mentoring students and junior scientists and providing scientific service.

RFA-20-Jan-2026 HL-26-[Optional][LOI/Pre-003 Appl

4,900,000 USD

Contact Name Narasimhan Danthi, Ph.D.

Contact Telephone 301-451-5170

Contact Email NHLBI R35@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 20-Jan-2026 [Optional] [LOI/Pre-App], 19-Feb-2026, 28-Apr-2026, 20-Jan-2027 [Optional] [LOI/Pre-App], 19-Feb-2027, 28-

SPIN ID	Program Title		Sponsor Name	Sponsor Numbe	r Deadline Date	Funding Amount
	Synopsis	Apr-2027 The purpose of the NHLBI Emerging Invest long-term support and increased flexibility currently PD/PIs on at least two NHLBI R02 ability to make major contributions to heaprogram, rather than a research project, be grant awards. The EIA will support the reseprovide investigators increased freedom to directions. It will also allow PD/PIs to take supported by the EIA must be within the sefunding environment, thereby improving a scientific innovation by enabling flexibility specific aims proposed in advance of the semultiple grant awards, thereby allowing mand junior scientists and providing scientific	to experienced Program Direct L-equivalent awards and whose rt, lung, blood and sleep (HLBS) by providing the primary and more arch program of NHLBI-funded to conduct research that breaks greater risks and to pursue research the NHLBI mission. It is productivity and facilitating nime in pursuing new research direct tudies; Reduce the time research direct time to be devoted to conducting; and Enable PD/PIs to devoted.	tors/Principal Involutions/Principal Involut	estigators (PD/PIs) word of research demonstrated to support of NHLBI funding rup to seven years. Toxtends previous discretes a longer timeframethe EIA will: Provide reative research; Accept, since PD/PIs will not grant applications.	ho are constrate their cort a research on individual the EIA will coveries in new e. Research a stable elerate ot be bound to and managing mmitment to
176441 -	32 Training Program to Promote Allowed)	Broad Participation (T32 Clinical Trial Not	National Heart, Lung, and Bloc Institute/NIH/DHHS	od PAR- 25-356	28-Jan-2026 [Optional][LOI/Pre- App]	Not Specified
	Contact Name	Wayne Wang, PhD				
	Contact Telephone	301-435-0535				
	Contact Email	wayne.wang2@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	28-Jan-2026 [Optional][LOI/Pre-App], 27-F	eb-2026 , 15-Aug-2026 [Option	al][LOI/Pre-App],	14-Sep-2026	
		The purpose of this Notice of Funding Opp documented historical institutional missio	, ,	ed students from	across the career de	velopment



continuum. The NHLBI T32 Training Program for Institutions That Promote Diversity is a Ruth L. Kirschstein National Research

underrepresented students and/or institutions that provide clinical services to populations that experience health disparities,

Service Award Program intended to support training of predoctoral, health professional students, and individuals in

postdoctoral training at institutions with a documented historical institutional mission focused on educating

|--|

with the potential to develop meritorious training programs in cardiovascular, pulmonary, and hematologic diseases, and sleep disorders. These institutions are uniquely positioned to educate and train students from diverse backgrounds, including those from underrepresented groups, in research, translation, and implementation of research advances that impact health outcomes, as well as provide health care for populations experiencing health disparities. Please note that institution eligibility is outlined in Section III, and funding decisions are based on the outcome of the peer review process and scientific priorities of the NHLBI. This Notice of Funding Opportunity (NOFO) does not allow appointed Trainees to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

116586

Notice of Special Interest (NOSI): Integrative Omics Analysis of NHLBI TOPMed Data (Parent R01 Clinical Trial Not Allowed)

National Heart, Lung, and Blood Institute/NIH/DHHS

NOT-HL-23- 07-Jan-2026 067

Not Specified

Contact Name James Luo, Ph.D.

Contact Telephone 301-435-0533

Contact Email luoja@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-Jan-2026, 05-Feb-2026, 07-May-2026

The symptom-based diagnosis and treatment of heart, lung, blood, and sleep (HLBS) diseases has vastly improved in recent years, yet an understanding of the molecular mechanisms underlying many of these diseases has remained elusive. Furthermore, in most cases the impact of genetic variation on severity of disease and treatment outcomes remains unknown. Therefore, the NHLBI has created the Trans-omics for Precision Medicine (TOPMed) program, which aims to utilize genomics data to characterize a variety of HLBS diseases. TOPMed is well on its way to collecting whole genome sequence (WGS) from over 194,270 well-phenotyped individuals and is currently generating multi-omics data (e.g., over 31,852 RNA sequences, over 44,342 DNA methylation profiles, and 26,124 metabolomics profiles) from many of these individuals to complement Synopsis whole genome sequence information. Having produced an unprecedented volume of high-throughput data, TOPMed now seeks to turn its attention to effectively leveraging this resource to uncover biological function and disease pathobiology through novel systems biology analyses and the power of artificial intelligence (AI) and Machine Learning (ML). Although lower costs and technological improvements in sequencing technology have vastly expanded our ability to generate large volumes of omics data, the ability to analyze such large datasets to extract biologically meaningful insights remains challenging. Systems level models incorporating trans-omics analyses will be an important step in uncovering the underlying biological networks and the gene-gene and gene-environment interactions influencing disease and treatment outcomes. Thus, advanced analyses that incorporate genotype and phenotype datasets from thousands to tens of thousands of

SPIN ID Pro	ogram Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		individuals are essential to move TOPMed	d to the next phase of discovery	·.		
		ent Clinical Trial Not Allowed)	National Heart, Lung, and Bloc Institute/NIH/DHHS	od PAR- 24-209	2-Feb-2026	Not Specified
	Contact Name	Kristen Z. Morgan, Ph.D.				
	Contact Telephone	301-827-5163				
	Contact Email	direducation@nhlbi.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026	, 12-Feb-2027 , 12-Jun-2027			
	Synopsis	The purpose of the NHLBI Career Transition doctoral-level researchers currently in tratheir research programs to extramural instransition Award will support two phases phase (three years), for a total of five year extramural phase is not automatic. Approduring the mentored phase as determine be carried out at the extramural institution candidates proposing research that does ancillary study to a clinical trial. Applicant mentor or co-mentor. Those proposing a companion FOA, PAR-24-211 "NHLBI Care (K22- Clinical Trial Required)".	ining in the NHLBI Division of Institutions as junior investigators of research: a mentored intrances of combined support. Transitival of the transition will be based by an NHLBI progress review, on. This Funding Opportunity Annot involve leading an independent to the trial or an ancillary clinical trial or an ancillary clinical	atramural Research of a chieve these of the chieve these of the chieve these of the chieve the chie	with the opportun bjectives, the NHI wo years) and an e ural phase of supp the awardee's re- n evaluation of a r is designed specif linical trial feasibi perience in a clinic tigator, should ap	ity to transition LBI Career extramural cort to the search program research plan to ically for lity study, or an cal trial led by a ply to the
1 / // II u	I Career Transition Award fo arch Trainees (K22 Clinical Tr	r Intramural Postdoctoral Fellows and ial Required)	National Heart, Lung, and Bloc Institute/NIH/DHHS	od PAR- 24-211	2-Feb-2026	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website	Kristen Z. Morgan, Ph.D. 301-827-5163 direducation@nhlbi.nih.gov	,			-1



SPIN ID Program Title Sp	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
--------------------------	--------------	----------------	---------------	-------------------

Deadline Dates (ALL) 12-Feb-2026, 12-Jun-2026, 12-Oct-2026, 12-Feb-2027, 12-Jun-2027

The purpose of the NHLBI Career Transition Award (K22) program is to provide highly qualified postdoctoral fellows and other doctoral-level researchers currently in training in the NHLBI Division of Intramural Research with the opportunity to transition their research programs to extramural institutions as junior investigators. To achieve these objectives, the NHLBI Career Transition Award will support two phases of research: a mentored intramural phase (up to two years) and an extramural phase (three years), for a total of five years of combined support. Transition from the intramural phase of support to the Synopsis extramural phase is not automatic. Approval of the transition will be based on the success of the awardee's research program during the mentored phase as determined by an NHLBI progress review, which will include an evaluation of a research plan to be carried out at the extramural institution. This Notice of Funding Opportunity Announcement (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not proposing to serve as lead investigator of an independent clinical trial must apply to the companion NOFO, PAR-24-209.

122332 NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)

National Heart, Lung, and Blood Institute/NIH/DHHS

PAR-07-Jan-2026 25-032

450,000 USD

Contact Name Patrice Desvigne-Nickens, MD

Contact Telephone 301-435-0504

Contact Email desvignp@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-Jan-2026, 16-Feb-2026, 07-May-2026, 16-Jun-2026, 07-Sep-2026, 16-Oct-2026, 07-Jan-2027

This Notice of Funding Opportunity (NOFO) supports studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI's mission. The NHLBI expects that applications to this NOFO will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. Furthermore, this NOFO will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to Synopsis test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and/or treatment of heart, lung, blood, or sleep disorders. In contrast to the study start up or preparation phase of NHLBI funding opportunities for clinical trials (as described at Clinical Trial Development Continuum | NHLBI, NIH), the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial. Regardless of the results of the R34, support of the

proposed future clinical trial will require a new application. Plan for Enhancing Diverse Perspectives The NIH recognizes that



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding
SF IIV ID	Program rice	Sponsor Name	Sponsor Number	Deadine Date	Amount

diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogeneous teams. There are many benefits that flow from a diverse scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved populations participate in, and benefit from research, and enhancing public trust. To support the best science, the NIH encourages inclusivity in research. Examples of structures that promote diverse perspectives include but are not limited to: -Transdisciplinary research projects and collaborations among neuroscientists and researchers from fields such as computational biology, physics, engineering, mathematics, computer and data sciences, as well as bioethics. - Engagement from different types of institutions and organizations (e.g., research-intensive, undergraduate-focused, minority-serving, community-based). - Individual applications and partnerships that enhance geographic and regional heterogeneity. - Investigators and teams composed of researchers at different career stages. -Participation of individuals from diverse backgrounds, including groups historically underrepresented in the biomedical, behavioral, and clinical research workforce (see NOT-OD-20-031), such as underrepresented racial and ethnic groups, those with disabilities, those from disadvantaged backgrounds, and women. - Opportunities to enhance the research environment to benefit early- and mid-career investigators. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

RFA-HL-25-008 -- Mentored Career Development Award to Promote Faculty National Heart, Lung, and Blood Diversity in Biomedical Research (KO1 Independent Clinical Trial Required)

Institute/NIH/DHHS

RFA-HL-25- 07-Jan-2026 008

Not Specified

Contact Name Karin F. Lidman, Ph.D.

Contact Telephone 301-435-0535

Contact Email karin.fredriksson@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-Jan-2026, 11-Feb-2026, 07-May-2026, 14-Oct-2026, 07-Jan-2027, 11-Feb-2027, 07-May-2027

This Notice of Funding Opportunity (NOFO) invites applications to provide career development opportunities for a diverse pool of highly trained investigators by providing eligible faculty members with the opportunity to undertake special study and Synopsis supervised research under an accomplished investigator in research areas of interest to the NHLBI. The career development will take place under the guidance of an experienced mentor in the biomedical, behavioral or clinical sciences leading to research independence. It is targeted toward individuals whose basic, clinical, and translational research interests are

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		grounded in the advanced methods and e pulmonary, and hematologic diseases and designed to support candidates proposing feasibility study, or a separate ancillary cli independent clinical trial, or proposing to with their institutes to apply to companion	sleep disorders in the general to serve as the lead investigate nical trial, as part of their resea gain research experience in a c	and health disparitor of an independence rch and career dev	cies populations. The ent clinical trial, a cl relopment. Those n	is NOFO is inical trial ot planning an
125805		er Development Award to Promote Faculty K01 Independent Clinical Trial Not	National Heart, Lung, and Bloomstitute/NIH/DHHS	od RFA- HL-25- (009	07-Jan-2026	Not Specified
	Contact Telephone Contact Email Sponsor Website Program URL	karin.fredriksson@nih.gov	D) invites applications to provide reas of interest to the NHLBI. To biomedical, behavioral or clinical clinical, and translational reseased problems related to cardiodisparities populations. This NC leading an independent clinical DFO are permitted to propose research.	e career developm he career developm cal sciences leading rch interests are gr ovascular, pulmona PFO is designed spe trial, a clinical trial esearch experience	ent activities for a ment will take place g to research indep counded in the advance, and hematolog ecifically to support I feasibility study, oe in a clinical trial le	e under the endence. It is anced methods ic diseases and candidates r a separate ed by a mentor
113286 <u>0</u>	Notice of Special Interest (NOSI): Circadian Regulation of Heart, Lur	investigator should apply to the companic Basic and Translational Research on ng, Blood, and Sleep Disorders (R01)		NOT-	77-Jan-2026	Not Specified
	Contact Name Contact Telephone	Ravi Balijepalli, Ph.D. 301-435-0504				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount

Contact Email ravi.balijepalli@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

07-Jan-2026, 05-Feb-2026, 07-May-2026, 05-Jun-2026, 07-Sep-2026, 05-Oct-2026, 07-Jan-2027, 05-Feb-2027, 07-May-2027, 05-Jun-2027, 07-Sep-2027, 05-Oct-2027, 07-Jan-2028

This NOSI aims to stimulate research on understanding how circadian rhythms regulate cell function and metabolism of peripheral tissues, and to find new avenues for the investigation of heart, lung, and blood disease risk, pathogenesis, diagnosis, treatment, and prevention. Basic, translational, and clinical research applications to elucidate circadian-dependent mechanisms contributing to the pathophysiology of HLBS disorders are invited. This NOSI encourages multidisciplinary and multiple investigator teams of experts in heart, lung, and blood research fields to synergistically work with circadian biologists and sleep researchers to provide a comprehensive understanding of the circadian biology in relation to HLBS conditions. The purpose is to facilitate translational research to identify potential applications of circadian science to the diagnosis, prevention and treatment of HLBS conditions. Mechanism-based studies investigating the circadian rhythm dysregulation, clinical markers, and/or therapeutic targets of HLBS conditions are encouraged. Behavioral, physiological, pharmacological, molecular, and genomic studies aimed at elucidating the relationship between circadian-dependent mechanisms and disease are appropriate. Studies to delineate circadian-based mechanisms, therapeutic targets, epidemiological risk and clinical trials to assess therapeutic safety, efficacy, effectiveness, or implementation may be proposed.

Notice of Special Interest (NOSI): Development of Functional Assay Sites to 115585 Evaluate Candidate -Omics Variants Associated with Heart, Lung, Blood, or Sleep Disease (R01, R41, R42, R43, R44)

National Heart, Lung, and Blood Institute/NIH/DHHS

NOT-HL-23- 05-Jan-2026 066

Not Specified

Contact Name Charlene Schramm, Ph.D.

Contact Telephone 301-402-3793

Contact Email schrammc@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 05-Jan-2026, 07-Jan-2026, 05-Feb-2026, 05-Apr-2026, 07-May-2026, 05-Jun-2026, 05-Sep-2026, 07-Sep-2026

The NHLBI is issuing this Notice of Special Interest (NOSI) to highlight interest in receiving grant applications focused on HLBS disorders in the following area(s): Development and/or application of moderate- or high-throughput functional assays to provide biological validation of candidate human variants associated with HLBS disorders Defining causal relationships between genotypes and phenotypes Development and validation of functionally informed risk predictions

	5	• •			
SPIN ID Program Title		Sponsor Name	Sponsor Num	ber Deadline Date	Funding Amount
106202 Cardiometabolic Health in Early): Promoting Cardiovascular and Stages of the Lifecourse: Pre-adolescence	National Heart, Lung, and Bloo Institute/NIH/DHHS	HL-21	- 07-Jan-2026	Not Specified
Through Adolescence to Young	Adulthood	. ,	015		<u> </u>
Contact Nar	ne Alison G.M. Brown, PhD, MS, RDN				
Contact Telepho	ne 301-435-0583				
Contact Em	ail Alison.brown@nih.gov				
Sponsor Webs	ite				
Program U	RL Link to program URL				
Deadline Dates (A	L) 07-Jan-2026 , 05-Feb-2026 , 07-May-2026	6 , 05-Jun-2026			
Synop	This Notice of Special Interest (NOSI) calls during transitionary phases across the life young adulthood (19-39 years). This initial pathogenesis of cardiometabolic health a phases from pre-adolescence into adoles interventions (at the individual and popultransitionary phases.	ecourse, from pre-adolescence (ative would support research to: and cardiovascular disease (CVD) cence and adolescence into you	6-10 years) thre 1) understand risk in vulnera ng adulthood, a	ough adolescence (11- the mechanisms and ble groups throughou and 2) develop precisi	-18 years) to the t transitionary on prevention
125098 NHLBI Early Phase Clinical Trials HLBS Disorders (R61/R33 Clinic	s for Therapeutics and/or Diagnostics for all Trial Required)	National Heart, Lung, and Bloomstitute/NIH/DHHS	od PAR- 25-02	04-Jan-2026 [Optional][LOI/Pre- App]	Not Specified
Contact Nar	ne Sumita Khatri, MD				
Contact Telepho	ne 301-402-9673				
Contact Em	ail sumita.khatri@nih.gov				
Sponsor Webs	ite				
Program U	RL Link to program URL				
Deadline Dates (A	04-lan-2026 [Ontional][[OI/Pre-Ann] 07-				Лау-2026 , 04-
Synop	The objective of this funding opportunity therapeutic interventions for heart, lung,				



clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	for the implementation of the proposed therapeutic/diagnostic in preparation for bi-phasic, milestone-driven mechanism of as stability, shipping studies, and site train	the clinical trial. The proposed t award where the first phase ca	rial can be single o	r multisite. This FC	ted to the OA will utilize a
125065 NHLBI Early Phase Clinical Trials for HLBS Disorders (R33 CT Required	or Therapeutics and/or Diagnostics for	National Heart, Lung, and Bloc Institute/NIH/DHHS	od PAR- 25-025	4-Jan-2026 Optional][LOI/Pre- .pp]	4,545,000 USD
Contact Name	Sumita Khatri, MD				
Contact Telephone	301-402-9673				
Contact Emai	sumita.khatri@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	04-Jan-2026 [Optional][LOI/Pre-App], 07- Jun-2026 , 02-Sep-2026 [Optional][LOI/Pr			_OI/Pre-App], 07-N	lay-2026 , 04-
Synopsis	The objective of this Notice of Funding O diagnostic and therapeutic interventions proposed trial can be single or multi-site. clinical trial within the first quarter of the (FDA, DSMB, IRB) approvals, and establish agreements should be established by the readiness activities are desired, applicant phased approach.	for heart, lung, blood, and sleep Applicants applying for funding project period. Discussion, sub ment of drug (and placebo, if a time of award. If time and supp	(HLBS) disorders in under this NOFO smission, and attain oplicable) supplies, ort for these and o	n adults and childre should be ready to ment of applicable and any necessary ther pre-clinical an	en. The initiate the regulatory third-party d/or trial
RFA-HL-26-019 Catalyze Product 128905 Design/Testing and Disease Target (R61/R33 - Clinical Trial Not Allow		National Heart, Lung, and Bloc Institute/NIH/DHHS	RFA- HL-26- 2 019	2-Dec-2025	900,000 USD
Contact Name Contact Telephone	Mike Pieck, Ph.D. 301-827-7986				



Contact Email nhlbi catalyze@nih.gov

Sponsor Website

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Program URI	Link to program URL					
	Deadline Dates (ALL)	22-Dec-2025 , 11-Feb-2026 , 21-Apr-2026	22-Dec-2025, 11-Feb-2026, 21-Apr-2026, 18-Jun-2026, 21-Aug-2026, 21-Oct-2026, 23-Dec-2026, 11-Feb-2027, 23-Apr-2027, 17-Jun-2027, 23-Aug-2027, 21-Oct-2027, 23-Dec-2027				
	Synopsis	This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to develop and test device prototype designs, identify diagnostic disease targets and develop associated assays, and develop research tools for use in the treatment of heart, lung, blood and sleep (HLBS) diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.					
128906	RFA-HL-26-020 Catalyze: Produce Optimization (R33 - Clinical Trial N	ct Definition – Medical Device Prototype Not Allowed)	National Heart, Lung, and Bloo Institute/NIH/DHHS	od RFA- HL-26- 2 020	2-Dec-2025	600,000 USD	
	Contact Name	Mike Pieck, Ph.D.					
	Contact Telephone	301-827-7986					
	Contact Email	nhlbi catalyze@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	22-Dec-2025 , 11-Feb-2026 , 21-Apr-2026 2027 , 17-Jun-2027 , 23-Aug-2027 , 21-Oct		1-Oct-2026 , 23-De	c-2026 , 11-Feb-20)27 , 23-Apr-	
	Synopsis	This Funding Opportunity Announcement testing/design modification, assay develop the treatment of heart, lung, blood, and signants to advance projects to the point whattract independent development support characterization.	oment for diagnostic disease ta leep (HLBS) diseases and disord nere they can meet the entry cr	rgets, and developr lers. This FOA is par iteria for the NHLBI	nent of research to t of a suite of Cata Catalyze Preclinic	ools for use in lyze innovation al program or	
128901	and Combination Products - Targe	ct Definition for Small Molecules, Biologics et Identification and Validation, and dentification (R61/R33 – Clinical Trials Not	National Heart, Lung, and Bloo Institute/NIH/DHHS	od RFA- HL-26- 2 017	2-Dec-2025	1,200,000 USD	



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Name	Mike Pieck, Ph.D.				
	Contact Telephone					
	Contact Email	nhlbi catalyze@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	22-Dec-2025 , 11-Feb-2026 , 21-Apr-2026 , 2027 , 17-Jun-2027 , 23-Aug-2027 , 21-Oct-		1-Oct-2026 , 23-De	c-2026 , 11-Feb-20	27 , 23-Apr-
	Synopsis	This Funding Opportunity Announcement (characterize potential therapeutic candidated diseases and disorders. This FOA is part of can meet the entry criteria for the NHLBI Cother federal or private partners for preclin	tes (compound and lead series a suite of Catalyze innovation & atalyze Preclinical program or) to treat heart, lun grants to advance p attract independen	g, blood, and sleep rojects to the poin t development sup	(HLBS) t where they
128904	and Combination Products - Prelir	minary Product/Load Sories Identification	National Heart, Lung, and Bloc Institute/NIH/DHHS	od RFA- HL-26- 2 018	2-Dec-2025	800,000 USD
	Contact Name	Mike Pieck, Ph.D.				
	Contact Telephone					
	Contact Email	nhlbi_catalyze@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	22-Dec-2025 , 11-Feb-2026 , 21-Apr-2026 , 2027 , 17-Jun-2027 , 23-Aug-2027 , 21-Oct-		1-Oct-2026 , 23-De	c-2026 , 11-Feb-20	27 , 23-Apr-
	Synopsis	This Catalyze Product Definition Funding O needed to develop and test device prototy develop research tools for use in the treatr	pportunity Announcement (FC pe designs, identify diagnostic ment of heart, lung, blood and advance projects to the point vependent development suppor	disease targets and sleep (HLBS) diseas where they can mee	develop associate es and disorders. T t the entry criteria	ed assays, and This FOA is part for the NHLBI
128899	RFA-HL-26-016 Catalyze: Enabli	ng Technologies and Transformative	National Heart, Lung, and Bloo	od RFA- 2	2-Dec-2025	700,000



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<u> </u>	Platforms for HLBS Research (R33	- Clinical Trials Not Allowed)	Institute/NIH/DHHS	HL-26- 016		USD
	Contact Name	Mike Pieck, Ph.D.				
	Contact Telephone	301-827-7986				
	Contact Email	nhlbi_catalyze@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	22-Dec-2025 , 11-Feb-2026 , 21-Apr-2026 2027 , 17-Jun-2027 , 23-Aug-2027 , 21-Oc		21-Oct-2026 , 23-D	ec-2026 , 11-Feb-20	127 , 23-Apr-
	Synopsis	This Funding Opportunity Announcement transformative platforms to catalyze next blood, and sleep (HLBS)-related disorders enabling technology or transformative pladata, but still requires further developme adoption. Well-suited applications must of screening, model development, clinical diassociated with HLBS-related diseases and novelty resides in the biological or clinical considered nonresponsive to the FOA will advance projects to the point where they FOAs.	-generation predictive, diagnos and diseases. This FOA solicits atform have already been overcent and rigorous validation to enough the potential to accelerate agnosis, treatment, control, prediction disorders. Projects proposing target/question being pursued not be reviewed. This FOA is particular and disorders.	tic and therapeuti R33 applications wome, as demonstracourage downstreand/or transformevention or epidenapplication of existant of a suite of Ca	c products to addrest there major feasibility ated with supportive am demonstration, the areas of early desired the for this solicitation to provide the for this solicitation and the solicitation are solicitati	ity gaps for the re preliminary utilization and etection and essing issues here the on. Applications ants to
1/4454	RFA-HG-25-009 Supporting Tale Genomics (R01 Clinical Trial Optio		National Human Genome Res Institute/NIH/DHHS	earch HG-25-	28-Jan-2026 [Optional][LOI/Pre- App]	400,000 USD
	Contact Name Contact Telephone	Lisa H. Chadwick, Ph.D. 301-435-7275				



Contact Email <u>lisa.chadwick@nih.gov</u>


Program URL Link to program URL

Sponsor Website

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	28-Jan-2026 [Optional][LOI/Pre-App], 27-F				unromicing
	Synopsis	This Funding Opportunity Announcement is intended to identify and support research projects by exceptionally promising Early Stage Investigators with a long-term career interest in pursuing innovative research in genomics. This opportunity is open to research in all areas relevant to the mission of NHGRI, including genomic sciences, genomic medicine, genomic data science, and ethical, legal, and social implications of genomics.				
	RFA-HG-25-005 Enhancing Reus Not Allowed)	e of NHGRI Data Assets (RO3 Clinical Trial	National Human Genome Rese Institute/NIH/DHHS	RFA- HG-25- 13 005	3-Feb-2026	250,000 USD
	Contact Name	Shurjo K. Sen, Ph.D.				
	Contact Telephone	301-827-7028				
	Contact Email	sensh@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	13-Feb-2026				
	Synopsis	The purpose of this concept is to encourage NHGRI's AnVIL platform for innovative resspecified in NOT-HG-24-020, AnVIL makes NHGRI-funded programs and initiatives.	earch and secondary analysis pr	ojects. As the NHG	RI-designated dat	a repository
		thods for Understanding the Genetic raits (R01 Clinical Trial Not Allowed)	National Human Genome Rese Institute/NIH/DHHS	arch PAR- 05 25-255	5-Feb-2026	Not Specified
	Contact Name	Alexander Arguello, Ph.D.				
	Contact Telephone	240-731-3753				
	Contact Email	alexander.arguello@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026				
	Synopsis	The goal of this NOFO is to support application of how genetic and non-genetic factors co	ations for novel theory and methentribute to complex trait variati	nods development on across individua	that enable bette lls, families, and p	understanding opulations.



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Approaches should be interdisciplinary dra scales of biological, social, and ecological of available large-scale datasets. This Notice (PEDP).	organization, and make extensiv	ve use of theory, m	odeling, and valida	tion with
	Notice of Special Interest (NOSI):	Optimizing Vascularized Composite	National Institute of Allergy ar Infectious Diseases/NIH/DHHS	$\Delta I_{-} J J_{-} = I J_{-}$	7-Jan-2026	Not Specified
	Contact Name	Patricia Kehn, Ph.D.				
	Contact Telephone	240-627-3547				
	Contact Email	pkehn@NIAID.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 ,	07-May-2026			
	Synopsis	The National Institute of Allergy and Infect models or human tissue specimens that for rejection and maximize graft survival after immunosuppression required for long-term	ocus on 1) optimizing treatment vascularized composite allotra	and graft monitori	ng to reduce incid	-
129070 <u>N</u>	NIAID Career Transition Award (K.	22 Independent Clinical Trial Not Allowed)	National Institute of Allergy ar Infectious Diseases/NIH/DHHS	(1	7-Jan-2026	Not Specified
	Contact Name	Jyothi Arikkath, PhD				
	Contact Telephone	301-594-5945				
	Contact Email	AlTrainingHelpDesk@niaid.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jan-2026 , 12-Feb-2026 , 07-May-2026 2027 , 12-Jun-2027 , 07-Sep-2027 , 12-Oct	, 12-Jun-2026 , 07-Sep-2026 , 1 -2027 , 07-Jan-2028	2-Oct-2026 , 07-Jar	ı-2027 , 12-Feb-20	27 , 07-May-
	Synopsis	The purpose of the NIAID Career Transitio assistant professor or equivalent and initia				



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		of Funding Opportunity (NOFO) is designed independent clinical trial, a clinical trial fector propose a research experience in a clinical trial fector propose a research experience in a clinical trial fector propose a research experience in a clinical trial fector propose a research experience in a clinical trial fector propose a research experience in a clinical trial fector propose and trial fector propose a research experience in a clinical trial fector propose and trial fector propose a research experience in a clinical trial fector propose and trial fector propose a research experience in a clinical trial fector propose and trial fector propose a research experience in a clinical trial fector propose and trial fector propose a research experience in a clinical trial fector propose and trial fector propose a research experience in a clinical trial fector propose and trial fector propose and trial fector propose and trial fector propose and trial fector propose a research experience in a clinical trial fector propose and trial fector propose a research experience in a clinical trial fector propose and	asibility study, or an ancillary cli	nical trial. Under th		_
	Notice of Special Interest (NOSI): Research Focused on NIAMS Core	Supporting Exploratory/Developmental Mission Areas	National Institute of Arthritis a Musculoskeletal and Skin Diseases/NIH/DHHS		5-Dec-2025	Not Specified
	Contact Name	Jana Eisenstein				
	Contact Telephone	301-594-5032				
	Contact Email	jana.eisenstein@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Dec-2025 , 07-Jan-2026 , 05-Feb-2026 2026 , 16-Oct-2026 , 07-Jan-2027	, 16-Feb-2026 , 07-May-2026 , 0)5-Jun-2026 , 16-Jur	n-2026 , 07-Sep-20)26 , 05-Oct-
	Synopsis	The purpose of this announcement is to no Musculoskeletal and Skin Diseases (NIAM on NIAMS core mission areas. Awards will systems, tools, agents, targets, and techn research within the NIAMS mission. These considerable risk, but have the potential to	S) is interested in receiving Exploration I provide support for innovative ologies that have the potential for estudies often assess the feasible.	oratory/Developme projects that introd or significant impac bility of a novel aven	ntal grant applica luce novel scientif it, and to substant nue of investigatio	tions focused fic ideas, model tially advance on and involve
114740	Notice of Special Interest (NOSI): HIV/AIDS in NIAMS	Promoting Research Opportunities on	National Institute of Arthritis a Musculoskeletal and Skin Diseases/NIH/DHHS		5-Dec-2025	Not Specified
	Contact Name	Heiyoung Park, Ph.D.				
	Contact Telephone	301-594-5032				
	Contact Email	parkh1@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Dec-2025 , 07-Jan-2026 , 05-Feb-2026 2026 , 16-Oct-2026 , 07-Jan-2027 , 05-Feb	, 16-Feb-2026 , 07-May-2026 , 0 0-2027 , 16-Feb-2027 , 07-May-2)5-Jun-2026 , 16-Jur 027 , 05-Jun-2027 ,	n-2026 , 07-Sep-20 16-Jun-2027 , 07-)26 , 05-Oct- ·Sep-2027 , 05-

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Synops	Oct-2027, 16-Oct-2027, 07-Jan-2028 The purpose of this announcement is to ir and Skin Diseases (NIAMS) of an area of springsion.				
128167 Limited Competition: CCRP Inition Chemical Threats to Skin (R34 C	ative: Promoting a Basic Understanding of linical Trial Not Allowed)	National Institute of Arthritis ar Musculoskeletal and Skin Diseases/NIH/DHHS	PΔ-25-	5-Feb-2026	450,000 USD
Contact Telepho	ne Peter J Koch, PhD ne ail <u>Peter.Koch@nih.gov</u>				
_	RL Link to program URL				
Deadline Dates (Al	This Notice of Funding Opportunity (NOFC understanding of skin injuries caused by c investigating the commonalities of such ir for medical countermeasure developments	D) intends to support fundamenta hemicals that have been identific njuries and identifying potential s	al research that wi ed as public health	threats, with an e	emphasis on
129048 Innovative Screening Approache Newborns (R01 - Clinical Trial O	es and Therapies for Screenable Disorders in ptional)	National Institute of Child Healt Human Development/NIH/DHH	()-	5-Feb-2026	Not Specified
Contact Telepho	ail <u>kathleen.huntzicker@nih.gov</u>				
Program U Deadline Dates (Al	Link to program URL 05-Feb-2026, 05-Jun-2026, 05-Oct-2026 This NOFO encourages research relevant to	to the development of novel scre	ening approaches	•	
Synops	for conditions for which newborn screening conditions that could benefit in the near f	, .	•	•	



	_	•			
SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	is especially critical given that accurate scr prerequisites for new conditions to be add	=		tervention are oft	en
128792 NICHD Small Research Grant Programmes Required)	gram (RO3 Basic Experimental Studies with	National Institute of Child Heal Human Development/NIH/DHI	(1)	7-Jan-2026	100,000 USD
Contact Name					
Contact Telephone					
Contact Email	NICHDReferral@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Jan-2026 , 16-Feb-2026 , 07-May-2026 2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct		6-Oct-2026 , 07-Jan	-2027 <i>,</i> 16-Feb-20	27 , 07-May-
Synopsis	The NICHD Small Research Grant Program mission. This funding opportunity annound in NOT-OD-18-212 as "prospective basic so definition of a clinical trial and also meet to include studies that prospectively assign howariables) and that assess biomedical or be aspects of phenomena without specific apapplications toward processes or products	cement is for basic science experience studies involving human placed by the definition of basic research. It is a participants to conditions to ehavioral outcomes in humans for polication towards processes or pro	rimental studies invalues invalues invalues." These Types of studies the side (i.e., experimental for the purpose of uproducts in mind. So	volving humans, restudies fall withing should submit user should submit user independent the tudies conducted	eferred to n the NIH under this FOA ependent fundamental with specific
128791 NICHD Small Research Grant Prog	gram (R03 Clinical Trial Required)	National Institute of Child Heal Human Development/NIH/DHI	() (7-Jan-2026	100,000 USD
Contact Name					
Contact Telephone					
Contact Email	NICHDReferral@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Jan-2026 , 16-Feb-2026 , 07-May-2026 2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct		6-Oct-2026 , 07-Jan	-2027 <i>,</i> 16-Feb-20	27 , 07-May-



SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Synops	The NICHD Small Research Grant Program mission. The R03 activity code supports s resources. The R03 program may be used analysis of existing data; small, self-contanew research technology.	mall research projects that can b I for different types of projects in	e carried out in a sh cluding pilot and fe	hort period of time easibility studies; s	e with limited secondary
129049 Innovative Screening Approache Newborns (R21 - Clinical Trial O	es and Therapies for Screenable Disorders in otional)	National Institute of Child Heal Human Development/NIH/DHI		6-Feb-2026	275,000 USD
Contact Telephor Contact Ema Sponsor Websi	kathleen.huntzicker@nih.gov				
	RL Link to program URL L) 16-Feb-2026, 16-Jun-2026, 16-Oct-2026	16-Feh-2027 16-Jun-2027 16	-Oct-2027		
·	This NOFO encourages research relevant for conditions for which newborn screeni is conditions that could benefit in the near is especially critical given that accurate so prerequisites for new conditions to be ad	to the development of novel scrong has already been implemente future from the early detection recenting tests and demonstrable	eening approachesed, as well as for ponade possible by nebenefits of early in	tentially fatal or d ewborn screening.	isabling genetic This research
113756 NCMRR Early Career Research A	ward (R03 Clinical Trial Optional)	National Institute of Child Heal Human Development/NIH/DHI	16	6-Feb-2026	200,000 USD
Contact Nam	ne Maria Nurminskaya, PhD				
Contact Telephor	ne 240-591-9986				
Contact Ema	nil Maria.nurminskaya@nih.gov				
Sponsor Websi	te				
Program UI	Link to program URL				
Deadline Dates (AL					
Synops	The National Center for Medical Rehabilit support both basic and clinical research for the National Center for Medical Rehabilit				



SPIN ID Program Title		Sponsor Name	Sponsor Numbe	Pr Deadline Date	Funding Amount
	research must be focused on one or more the NIH Research Plan on Rehabilitation for rehab-plan). The NCMRR ECR Award R03 gexisting data; small, self-contained research outcomes research; and development of reward R03 is for the Program Director(s)/subsequent R01 application.	or strategic priorities (https://w grant mechanism supports varion ch projects; development of res new technology. Irrespective of	ww.nichd.nih.gov ous types of proje earch methodolo the type of proje	y/newsroom/news/1 ects including second ogy; translational resect, the intent of the	10121-NIH- ary analysis of earch; NCMRR ECR
128527 Screening and Functional Validation Variants (R01 Clinical Trial Not All	ion of Human Birth Defects Genomic lowed)	National Institute of Child Hea Human Development/NIH/DH		06-Jan-2026 [Optional][LOI/Pre- App]	2,499,995 USD
Contact Name	Reiko Toyama, Ph.D.				
Contact Telephone	301-435-2723				
Contact Emai	ToyamaR@nih.gov				
Sponsor Website	2				
Program URI	Link to program URL				
Deadline Dates (ALL	06-Jan-2026 [Optional][LOI/Pre-App], 05-I [Optional][LOI/Pre-App], 05-Oct-2026 , 06 App], 05-Jun-2027 , 05-Sep-2027 [Optiona	-Jan-2027 [Optional][LOI/Pre-A		••	•
Synopsis	Rapid advances in genotyping and next ge that are associated with a wide variety of developmental disabilities (IDDs) and inbo pediatric congenital anomalies cohorts are Database of Genotypes and Phenotypes (Or Phenome Archive and Clinical Genome Refunctional validation and characterization databases and individual efforts using insapproaches. This initiative addresses a charecognizing which of those variations have	congenital defects including strom errors of metabolism (IEMs) e available to the research combodism, the Gabriella Miller Kid source (ClinGen). The purpose of congenital anomaly-association tools, appropriate animal rallenging gap between identifying	uctural congenita . Large quantities munity through s s First Data Resou of this initiative is ed genetic variar models, in vitro sy ng sequence varia	al anomalies (SCAs), in of genomic data colleveral databases such the Europe to promote the screets identified through stems or multi-pronations of potential in	ntellectual lected from th as the pean Genome- ening, n public facing ged
126762 Advancement and Innovation in I and Predictors (R01 Clinical Trial	Measurement of Language Development	National Institute of Child Hea Human Development/NIH/DH		05-Feb-2026	Not Specified
and Predictors (NOT Cliffical Trial	NOT Allowed)	пишан речеюриненд Мпл/рп	no 25-112		Specified

SPIN ID Program Title			Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Co	ontact Name	Virginia Salo				
		301-402-3682				
C	Contact Email	virginia.salo@nih.gov				
Spor	nsor Website					
ı	Program URL	Link to program URL				
Deadline	e Dates (ALL)	05-Feb-2026 , 05-Mar-2026 , 05-Jun-2026 , 2027 , 05-Jul-2027	, 05-Jul-2026 , 05-Oct-2026 , 05	5-Nov-2026 , 05-Feb	-2027 , 05-Mar-20	27 , 05-Jun-
	Synopsis	The purpose of this notice of funding opportunity conceptualization of qualities of the environment of novel measures of children focused, culturally and linguistically respondevelopment and/or impairment, and prevail be assessed as part of the scientific and be considered incomplete and will be with Diverse Perspectives (PEDP).	onment that can support languan's language development. The hisive, and generalizable tools to dictors thereof. This NOFO requal technical peer review evalua	age development in e overall goal is to bu o further our unders uires a Community E tion. Applications th	children and that uild the number of childre tanding of childre ingagement (CE) Phat fail to include a	focuses on the f strengths- n's language Plan, which a CE Plan will
126760 Advancement and Inc. and Predictors (R21 C		Measurement of Language Development Not Allowed)	National Institute of Child Hea Human Development/NIH/DH	16	5-Feb-2026	275,000 USD
Co	ontact Name	Virginia Salo				
Contac	ct Telephone	301-402-3682				
C	Contact Email	virginia.salo@nih.gov				
Spor	nsor Website					
ı	Program URL	Link to program URL				
Deadline	e Dates (ALL)	16-Feb-2026 , 16-Mar-2026 , 16-Jun-2026 , 2027 , 16-Jul-2027	, 16-Jul-2026 , 16-Oct-2026 , 16	5-Nov-2026 , 16-Feb	-2027 , 16-Mar-20	27 , 16-Jun-
	Synopsis	The purpose of this notice of funding opportunity conceptualization of qualities of the environment of novel measures of childres focused, culturally and linguistically respondevelopment and/or impairment, and predictions.	onment that can support langua n's language development. The nsive, and generalizable tools to	age development in e overall goal is to bu o further our unders	children and that uild the number of standing of childre	focuses on the f strengths- n's language



	•	•			
SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Enhancing Diverse Perspectives (PEDP).				
117230 NIDCR Research Grants for Analyst (Clinical Trial Not Allowed)	ses of Existing Genomics Data (R01)	National Institute of Dental ar Craniofacial Research/NIH/DH	0.4	7-Jan-2026	Not Specified
Contact Name	Noffisat Oki				
Contact Telephone	301-402-6778				
Contact Emai	noffisat.oki@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Jan-2026 , 05-Feb-2026 , 07-May-2026				
Synopsis	The purpose of this NOFO is to announce to human dental, oral, or craniofacial (DOG available genomic data, with or without of Data analysis for each project can be performed proposed project(s), including methods for (AI)/Machine Learning (ML)/Deep Learning silico work is required to validate the resu Projects aimed at understanding oral heal priority. Projects focused on investigating intervention targets or defining the pathog	C) biology, and diseases and conther types of complementary dispressed using existing and/or not data and metadata mining, dig (DL) methods. In addition to a lts of the proposed analysis, or th disparities to inform strategiand/or characterizing human be	nditions, through an ata, using statistical vel methods to be deata integration, and inalysis of existing do validate a newly eas for improving heatiological pathways to	alysis of existing a and computation eveloped in the Artificial Intelliged ata, experimental developed analyticalth for all individu o inform identifica	and publicly al approaches. nce or in c method. uals are a
128813 NIDCR Small Grant Program for N Allowed)	lew Investigators (RO3 Clinical Trial Not	National Institute of Dental ar Craniofacial Research/NIH/DH	07	7-Jan-2026	200,000 USD
Contact Name	Preethi Chander, PhD				
Contact Telephone					
Contact Emai	preethi.chander@nih.gov				
Sponsor Website					
Program URL	Link to program URL				



Deadline Dates (ALL) 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Feb-2027 , 07-May-2027 , 16-Jun-2027 , 07-Sep-2027 , 07-Jan-2028

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	This NIDCR Small Grant Program for New science conducted by scientists who are enthis R03 program supports pilot or feasib sufficient preliminary data for a subseque	establishing an independent rese ility studies and developmental r	arch career in dent esearch projects w	al, oral and cranio ith the intention o	facial research of obtaining
	NIDCR Mentored Career Developr Participation in Research (K01 Ind	ment Award to Promote Broad ependent Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DH	0.7	7-Jan-2026	Not Specified
	Contact Telephone	nidcrtraining@nidcr.nih.gov				
	'	Link to program URL 07-Jan-2026 12-Feb-2026 07-May-2026		2-Oct-2026 , 07-Jan	-2027 , 12-Feb-20	27 , 07-May-
	Synopsis	The purpose of the NIDCR Mentored Care the dental, oral, and craniofacial research career faculty engaged in these areas of r support for a sustained period of protecte experienced mentor. This NOFO is design independent clinical trial, a clinical trial fe permitted to propose research experience	workforce by expanding the poon esearch This Notice of Funding Control of the for intensive research cased specifically for applicants propassibility study, or an ancillary study.	ol of well-trained po opportunity (NOFO) reer development u posing research tha udy to a clinical trial	ostdoctoral fellow provides salary a under the guidanc It does not involve	s and early nd research e of an e leading an
	NIDCR Dentist Scientist Career Tra (K22 Clinical Trial Not Allowed)	ansition Award for Intramural Investigators	National Institute of Dental and Craniofacial Research/NIH/DHI	1).	7-Jan-2026	Not Specified
	Contact Name	Leslie A. Frieden, PhD				
	Contact Telephone	301-496-4263				
	Contact Email	leslie.frieden@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jan-2026 , 12-Feb-2026 , 07-May-2026 2027 , 12-Jun-2027 , 07-Sep-2027 , 12-Oc	5 , 12-Jun-2026 , 07-Sep-2026 , 12 t-2027 , 07-Jan-2028	2-Oct-2026 , 07-Jan	-2027 , 12-Feb-20	27 , 07-May-

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Synop	The purpose of the NIDCR Dentist Scientic transition of highly qualified dentist scient tenure-track or equivalent faculty position mentored postdoctoral research training funding at the extramural institution. This proposing research that does not involve clinical trial. Under this NOFO applicants a co-mentor. Those proposing a clinical trial NOFO (FON).	tists from NIH Intramural postdo ns at eligible U.S. institutions. The in the NIH Intramural Research P is Notice of Funding Opportunity (leading an independent clinical t are permitted to propose a resea	ctoral research pose e award will provid rogram, and three (NOFO) is designed rial, a clinical trial f rch experience in a	sitions to extramu le support for two years of independ specifically for ap feasibility study, o a clinical trial led b	ral, academic years of dent research plicants r an ancillary y a mentor or
117231 NIDCR Small Research Grants f Clinical Trial Not Allowed)	or Analyses of Existing Genomics Data (R03	National Institute of Dental and Craniofacial Research/NIH/DH	0.	7-Jan-2026	200,000 USD
Contact Na	ne Noffisat Oki				
Contact Telepho	ne 301-402-6778				
Contact Em	ail noffisat.oki@nih.gov				
Sponsor Webs	ite				
Program L	RL Link to program URL				
Deadline Dates (A	LL) 07-Jan-2026 , 16-Feb-2026 , 07-May-2026	5			
Synop	The purpose of this NOFO is to announce to human dental, oral, or craniofacial (DO available genomic data, with or without or Data analysis for each project can be perf proposed project(s), including methods f (AI)/Machine Learning (ML)/Deep Learning biological pathways to inform identification are encouraged.	oc) biology, and diseases and con other types of complementary da formed using existing and/or nov or data and metadata mining, da ng (DL) methods. Projects focused	ditions, through ar ta, using statistical el methods to be d ta integration, and d on investigating a	nalysis of existing a and computation leveloped in the Artificial Intellige and/or characteriz	and publicly al approaches. nce ing human
	nd/or Procedure Intervention Clinical Trial Cooperative Agreement (UG3/UH3 Clinical	National Institute of Dental and Craniofacial Research/NIH/DH	()(6-Jan-2026	Not Specified
Contact Na	ne Dena Fischer, DDS, MSD, MS				
Contact Telepho	ne 301-594-4876				

	SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
--	---------	---------------	--------------	----------------	---------------	-------------------

Contact Email dena.fischer@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL

06-Jan-2026, 10-Jan-2026 [Optional][LOI/Pre-App], 09-Feb-2026, 08-May-2026, 09-May-2026 [Optional][LOI/Pre-App], 08-Jun-2026, 08-Sep-2026 [Optional][LOI/Pre-App], 09-Sep-2026, 08-Oct-2026, 08-Jan-2027, 09-Jan-2027 [Optional][LOI/Pre-App], 08-Feb-2027, 06-May-2027, 08-May-2027 [Optional][LOI/Pre-App], 07-Jun-2027, 07-Sep-2027 [Optional][LOI/Pre-App], 08-Sep-2027, 07-Oct-2027, 06-Jan-2028

This Notice of Funding Opportunity (NOFO) will support UG3/UH3 phased, cooperative agreement research applications to plan and implement clinical trials within the mission of the National Institute of Dental and Craniofacial Research (NIDCR). Studies appropriate for this NOFO are those testing a drug, biologic, device, or procedure to improve dental, oral, or craniofacial diseases or conditions, including trials for any phase of testing for a Food and Drug Administration (FDA)regulated product. Awards made under this NOFO will initially support a one-year milestone-driven planning phase (UG3), with possible transition to a clinical trial implementation phase (UH3) of up to five years. Progression to the UH3 phase is based on an administrative review and is dependent on success in meeting UG3 milestones, NIDCR program priorities, and availability of funds. The UG3/UH3 application must be submitted as a single application with the final design of the UH3 clinical trial including detail about the study population, intervention(s), and outcome(s) described in the application, following the instructions described in this NOFO. The UG3 planning phase permits both scientific and operational planning activities, though the planning phase cannot be used to test for intervention safety or efficacy or assess the study's primary outcome. The UH3 phase of the award will support the conduct of one investigator-initiated clinical trial. Applications designed to test behavior change interventions or those used as tools to understand mechanisms of behavior change will not

Synopsis

NIDCR Prospective Observational or Biomarker Validation Study 117461 Cooperative Agreement (U01 Clinical Trial Not Allowed)

National Institute of Dental and Craniofacial Research/NIH/DHHS PAR-07-Jan-2026 23-162

Not Specified

Contact Name Lorena Baccaglini, DDS, MS, PhD

Contact Telephone 301-435-7908

Contact Email lorena.baccaglini@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-Jan-2026, 05-Feb-2026, 07-May-2026

be supported by this NOFO.

Synopsis This NOFO will support, through the cooperative agreement mechanism, investigator-initiated observational studies or



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		biomarker validation studies that require plata/biospecimens.	prospective collection of data/b	oiospecimens or con	tinued analysis of	
1 / (1 / / 1		vention Clinical Trial Planning and eement (UG3/UH3 Clinical Trial Required)	National Institute of Dental ar Craniofacial Research/NIH/DH	()6	5-Jan-2026	Not Specified
	Contact Name	Jill Mattia, Ph.D.				
	Contact Telephone	301-451-7770				
	Contact Email	jill.mattia@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	06-Jan-2026 , 09-Feb-2026 , 08-May-2026 2027 , 08-Jun-2027 , 08-Sep-2027 , 08-Oct		98-Oct-2026 , 08-Jan	-2027 , 08-Feb-20	27 , 06-May-
		The purpose of this Notice of Funding Opp designed, rigorously conducted, behaviora			-	

Synopsis

designed, rigorously conducted, behavioral/biopsychosocial intervention studies relevant to dental, oral, and craniofacial health as well as associated medical and mental health status or comorbidities. A broad range of intervention research projects that meet the NIH Definition of a Clinical Trial are appropriate for this opportunity. Awards made under this NOFO will initially support a milestone-driven planning phase (UG3) for 1 year, with possible transition to a clinical trial implementation phase (UH3) of up to five years. The UG3/UH3 application must be submitted as a single application. Applications that employ traditional methods as well as novel/advanced features (e.g., mobile health, artificial intelligence, telehealth, responsive health system records, multiple assignment randomized trial designs (SMART) or sequential randomization designs), etc., are encouraged. This NOFO will not support the testing of drugs, devices, or biologics regulated by the FDA; the corresponding NOFO for clinical trials in these areas is PAR-25-057.

SPIN ID	Program Title	ISponsor Name	Sponsor Number	Deadline Date	Funding Amount
127807	Notice of Special Interest (NOSI): Availability of Administrative Supplements to Broaden the NIDDK Clinical Research Workforce	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	NOT-DK- 24-031	16-Feb-2026	200,000 USD

Contact Name Katrina Serrano, PhD Contact Telephone 301-480-7855



broaden the clinical researc ds to hire, train and support mmunity engagement of NIC	clinical researc	ch coordinators for up t	
ds to hire, train and support	clinical researc	ch coordinators for up t	
ds to hire, train and support	clinical researc	ch coordinators for up t	
ds to hire, train and support	clinical researc	ch coordinators for up t	
ds to hire, train and support	clinical researc	ch coordinators for up t	
		arch studies, leading to	
ational Institute of Diabetes gestive and Kidney iseases/NIH/DHHS	and RFA-DK- 26-007	06-Feb-2026 [Optional][LOI/Pre- App]	3,600,000 USD
-2026			
es. This opportunity is intendent echanisms leading to improventes Program (https://www.iory-funding-program/about	ded to fund inve ed delay and du niddk.nih.gov/a -special-diabete	estigative teams collaboration of type bout-niddk/researches-program) which functione, innovative, and continuous to the continuous tique, innovative, and continuous tique, and continuous ti	orating to pe 1 diabetes ds research or collaborative
	portunity (NOF0	,	
	es. This opportunity is intendechanisms leading to improvetes Program (https://www.cory-funding-program/about	vites applications for studies of type 1 diabers. This opportunity is intended to fund investigations leading to improved delay and dustes Program (https://www.niddk.nih.gov/actory-funding-program/about-special-diabeted diabetes and its complications, including ur	vites applications for studies of type 1 diabetes etiology and pathores. This opportunity is intended to fund investigative teams collaborations leading to improved delay and durable prevention of typetes Program (https://www.niddk.nih.gov/about-niddk/researchtory-funding-program/about-special-diabetes-program) which fund diabetes and its complications, including unique, innovative, and one of the complications.



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website Program URL	blondelo@nih.gov	1D Research is designed to suppose. In addition to providing suppose Directors/Principal Investigator or of large, ongoing collaborative of these consortia will provideng of key questions in the field, their careers forward. Bringing their the networks by providinam (https://www.niddk.nih.govm/about-special-diabetes-program/about-special-d	ort for preliminary res (PD/PIs) to pursue ve research programe unique opportunite, to network, and to New and Early Staging new ideas and perviabout-niddk/reserram) which funds reserved.	esearch, the Gate estair their studies with as. Embedding awards for New and East establish unique age Investigators interspectives. This Narch-areas/diabetesearch on the present their spectives of the present their spectives.	way program hin the ardees within arly Stage and potentially to existing IOFO is es/type-1- vention,
123308	NIDDK High Risk Multi-Center Clir Cooperative Agreements (U34 Cli	nical Study Implementation Planning nical Trial Optional)	National Institute of Diabetes Digestive and Kidney Diseases/NIH/DHHS	PAR-25-	L-Feb-2026	450,000 USD
	Contact Telephone Contact Email Sponsor Website	rankint@mail.nih.gov				

Deadline Dates (ALL) 11-Feb-2026, 08-Oct-2026, 10-Jun-2027

NIDDK supports investigator-initiated, high-risk multi-center (more than one center) clinical studies through a two-part Synopsis process that may include an implementation planning cooperative agreement (U34). The U34 is designed to: 1) Permit early peer review of the rationale for the proposed clinical study; 2) Permit assessment of the design and protocol of the proposed study; 3) Provide support for the development of documents needed for the conduct of the study, including a manual of



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		operations; and 4) Support the development proposed clinical study should be hypothest scientific staff is strongly encouraged prior Diverse Perspectives (PEDP), which will be evaluation. Applications that fail to include strongly encouraged to read the FOA instru	sis-driven and focus on a diseas to the submission of the U34 a assessed as part of the scientif e a PEDP will be considered inc	e in the mission of I opplication. This NOI ic and technical pee omplete and will be	NIDDK. Consultati FO requires a Plan r review withdrawn. Appli	al study. The on with NIDDK for Enhancing
116589	Small R01s for Clinical Trials Targe (R01 Clinical Trial Required)	eting Diseases within the Mission of NIDDK	National Institute of Diabetes Digestive and Kidney Diseases/NIH/DHHS	νΔς-25-	'-Jan-2026	600,000 USD
	Contact Telephone Contact Email Sponsor Website Program URL	aynur.unalp-arida@nih.gov Link to program URL 07-Jan-2026, 05-Feb-2026, 07-May-2026 This Funding Opportunity Announcement e humans that will lay the foundation for large conditions within the mission of NIDDK. The acquire preliminary data regarding the e	ger clinical trials related to the e program will support small, s iffects of the intervention, as w for clinical trials submitted und the trial findings will lead to me eatment of the diseases studied	prevention and/or the hort-term proof-of- yell as feasibility dath der this FOA should ore definitive, hypotoland have the pote	reatment of disea concept clinical tr a related to recrui have clearly desci thesis-driven trials	ases and rials in humans itment and ribed aims and is to improve
123312	NIDDK High Risk Multi-Center Clin Clinical Trial Required)	nical Study Cooperative Agreement (U01	National Institute of Diabetes Digestive and Kidney Diseases/NIH/DHHS	ΡΔ-25-	-Feb-2026	Not Specified
	Contact Telephone	Tracy Rankin, Ph.D., M.P.H. 301-594-4748 rankint@mail.nih.gov				



SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026				
Synopsis	This NOFO invites applications for investig center. Proposed trials should be hypothes focus on a disease relevant to the mission opermitted under this NOFO. Applicants who cooperative agreement (U34; see PAR-25-0 to the submission of either a U34 or U01 applicanting Diverse Perspectives (PEDP).	sis-driven, have the potential to of NIDDK. Planning activities m o require a planning phase ma 090). Consultation with NIDDK	o change clinical pr ust be completed y first apply for an Scientific/Research	actice and/or publi prior to submissior implementation pl n staff is strongly en	c health, and and are not anning ncouraged prio
123309 NIDDK High Risk Multi-Center Clin Clinical Trial Not Allowed)	nical Study Cooperative Agreement (U01	National Institute of Diabetes Digestive and Kidney Diseases/NIH/DHHS	DAR-25-	95-Feb-2026	Not Specified
Contact Name	Tracy Rankin, Ph.D., M.P.H.				
Contact Telephone	301-594-4748				
Contact Email	rankint@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026				
Synopsis	This NOFO invites applications for investigation of clinical center. Proposed studies should be Planning activities must be completed prior planning phase may first apply for an imple with NIDDK Scientific/Research Staff strong Notice of Funding Opportunity (NOFO) req	hypothesis-driven and focus or to submission and are not permentation planning cooperation planning cooperation to the submission.	n a disease relevar rmitted under this ve agreement (U34 omission of either a	nt to the mission of NOFO. Applicants I; see PAR-25-090) n U34 or U01 applic	NIDDK. who require a Consultation
128623 Stimulating Hematology Investigation Stimulating	ation: New Endeavors (SHINE) (R01 Clinical	National Institute of Diabetes Digestive and Kidney Diseases/NIH/DHHS	PAS-25-	5-Feb-2026	Not Specified
Contact Name	Shilpa Hattangadi, M.D.				



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone	301-594-7726				
	Contact Email	shilpam.hattangadi@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 ,	05-Feb-2027 , 05-Jun-2027 , 0	5-Oct-2027		
	Synopsis	The Stimulating Hematology Investigation: nonmalignant hematology research releval Diseases (NIDDK), National Institute of Agir initiated research project grant application invited to this program that supports grow that are at the leading edge of the field will and Contracts and hyperlinked to this FOA. Perspectives (PEDP).	nt to the missions of the Nationg (NIA), and the National Heas (R01s) in specific areas of bath in the nonmalignant hemath change over time and will be	nal Institute of Diabort, Lung, and Blood I sic and early translate ology research doma	etes and Digestive nstitute (NHLBI). tional hematology ain. Specific emer nrough the NIH Gu	e and Kidney Investigator- y research are rging topics uide to Grants
129704	Small Grants for New Investigator Related Research (R21 Clinical Tri	rs to Broaden Participation in Health- ial Optional)	National Institute of Diabete Digestive and Kidney Diseases/NIH/DHHS	PAR-75-	7-Jan-2026	375,000 USD
	Contact Name	Katrina J. Serrano, Ph.D.				
	Contact Telephone	301-480-7855				
	Contact Email	katrina.serrano@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct-		L6-Oct-2026 , 07-Jan	-2027 , 16-Feb-20	27 , 07-May-
	Synopsis	The purpose of this Funding Opportunity A backgrounds, including from groups nation research, to conduct small research project and Kidney Diseases (NIDDK), the National Imaging and Bioengineering (NIBIB). New is direct costs of combined research funding research projects that can be carried out in	ally underrepresented in biom ts in the scientific mission area Human Genome Research Inst nvestigators at the time of awa (excluding NIH training and NI	nedical, clinical, beha as of the National Ins titute (NHGRI) or the ard under this FOA w H career awards). Th	evioral and social stitute of Diabetes National Institute will have had less this R21 will suppor	sciences s and Digestive e of Biomedical than \$125,000 rt small

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		research independence. The R21 grant med secondary analysis of existing data; small, s development of new research technology.			• .	•
129738	<u>Limited Competition: Small Grant</u> <u>Recipients (R03 Clinical Trial Option</u>	Program for NIDDK K01/K08/K23/K25 onal)	National Institute of Diabetes Digestive and Kidney Diseases/NIH/DHHS	PAR-25-	7-Jan-2026	150,000 USD
	Contact Name	Lisa M. Spain, Ph.D.				
	Contact Telephone	301-451-9871				
	Contact Email	<u>SpainL@niddk.nih.gov</u>				
	Sponsor Website					
	Program URL	<u>Link to program URL</u>				
	Deadline Dates (ALL)	07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct-2		6-Oct-2026 , 07-Jar	n-2027 , 16-Feb-20	27 <i>,</i> 07-May-
	Synopsis	The National Institute of Diabetes and Dige supported K01, K08, K23, and K25 recipient the award period of their K award. Through K01, K08, K23, and K25 award recipients to investigator status. The R03 grant mechanissecondary analysis of existing data; small, s development of new research technology. Out in a short period of time with limited requivalent, application. This Notice of Fund (PEDP).	is the opportunity to apply for a the use of this mechanism, the conduct research as they comes sm supports different types of elf-contained research project. The RO3 is, therefore, intended asources and that may provide	Small Grant (R03) so the NIDDK is seeking plete their transition projects, including so the support research preliminary data to	upport during the to enhance the cap to fully independent and feasibility research methodo ch projects that cap support a subseq	latter years of pability of its dent y studies; logy; and n be carried puent R01, or
113566	Notice of Special Interest (NOSI): of Micro and/or Nanoplastics	Understanding Exposure and Health Effects	National Institute of Environmental Health Sciences/NIH/DHHS	NOT-ES- 23-002	7-Jan-2026	Not Specified
	Contact Name Contact Telephone	Lingamanaidu V. Ravichandran, Ph.D 984-287-3309				



Contact Email lingamanaidu.ravichandran@nih.gov

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding
						Amount
	Sponsor Website	I				
	•	Link to program URL				
		07-Jan-2026, 05-Feb-2026, 16-Feb-2026, 07-May-2026, 05-Jun-2026, 16-Jun-2026, 07-Sep-2026, 05-Oct-2026, 16-Oct- 2026, 07-Jan-2027, 05-Feb-2027, 16-Feb-2027, 07-May-2027, 05-Jun-2027, 16-Jun-2027, 07-Sep-2027, 05-Oct-2027, 16-Oct-2027				
	Synopsis	The purpose of this Notice of Special Intere Environmental Health Sciences (NIEHS), has microplastics (MPs) and nanoplastics (NPs)	s special interest in application	• •		
11/x/4	Maximizing Investigators' Researd Investigators (R35 - Clinical Trial C		National Institute of General Medical Sciences/NIH/DHHS	PAR-23- 145	3-Feb-2026	1,375,000 USD
	Contact Name	Sailaja Koduri, Ph.D.				
	Contact Telephone					
	Contact Email	sailaja.koduri@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
Deadline Dates (ALL)		03-Feb-2026				
	The Maximizing Investigators' Research Award (MIRA) under this FOA is a grant to provide support for a program of rein an early stage investigator's laboratory that falls within the mission of NIGMS. For the purpose of this FOA, a program research is a collection of projects in the investigator's lab that are relevant to the mission of NIGMS. The goal of MIRA increase the efficiency and efficacy of NIGMS funding. It is anticipated that this FOA will: Enable investigators to apply in their independent research careers, allowing them to secure grant funding that will launch and sustain successful recareers. Enhance investigators' ability to move into research areas that are distinct from those of their postdoctoral maximum which could lead to new scientific discoveries. Increase the stability of funding for NIGMS-supported investigators, who could enhance their ability to take on ambitious scientific projects and approach problems more creatively. Increase flator investigators to follow important new research directions as opportunities arise, rather than being bound to specific proposed in advance of the studies. More widely distribute funding among the nation's highly talented and promising investigators to increase overall scientific productivity and the chances for important breakthroughs. Reduce the time by researchers writing and reviewing grant applications, allowing them to spend more time conducting research. Enablinvestigators to devote more time and energy to mentoring trainees in a more stable research environment.					of program of of MIRA is to o apply earlier essful research ctoral mentors, cors, which crease flexibility o specific aims omising the time spent



128746 Technology Development Research for Establishing Feasibility and Proof of

National Institute of General

PAR-25-

07-Jan-2026

275,000

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Concept (R21 - Clinical Trial Not A	ullowed)	Medical Sciences/NIH/DHHS	202		USD
	Contact Name	 				
	Contact Telephone					
	·	NIGMS_techdev@nigms.nih.gov				
	Sponsor Website					
	•	Link to program URL				
	Deadline Dates (ALL)	07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct-		6-Oct-2026 , 07-Jan	n-2027 , 16-Feb-20	27 , 07-May-
	Synopsis	This Funding Opportunity Announcement (technologies for biomedical research that i participating in this FOA. Projects should en potential impact in biomedical research. O the current state of the art, may include, b software, chemical reagents and processes to become research tools. This NOFO does specific biological questions or that re-pury development of new tools that can potenti proposed technology must not have alread focused on technology development to add that provide proof of concept are not respec	s relevant to the NIGMS mission tail a high degree of risk and/outcomes or products of the product are not limited to: laborators, biological molecules or system not support technology developoses existing technologies for ially benefit a broad spectrum of the literal dress specific biological questiculars.	on or that of other Nor novelty, which wo posed project, which wo posed project, which wo posed project, which is nationally that have been ropment that is narrous new uses. Rather, a for biomedical reseas ature or with prelimons and/or include to	NIH Institutes or Cerill be offset by a high character devices, algo modified by human owly focused on a populcations should irch. Moreover, feating data. Applications unpublished or pulling the control of the contro	enters (ICs) igh future intly advance orithms and in intervention ddressing d propose asibility of the ations that are blished data
128806	Advancing Research Careers (ARC Award to Promote Diversity (F99)	C) Predoctoral to Postdoctoral Transition /K00 - Clinical Trial Not Allowed)	National Institute of General Medical Sciences/NIH/DHHS	PAR-25- 084	7-Jan-2026	Not Specified
	Contact Name	Laurie Stepanek, Ph.D.				
	Contact Telephone					
	Contact Email	laurie.stepanek@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jan-2026 , 13-Feb-2026 , 07-May-2026 , 2027 , 11-Jun-2027 , 07-Sep-2027 , 08-Oct-		4-Oct-2026 , 07-Jan	n-2027 , 11-Feb-20	27 , 07-May-



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		•			

The purpose of the Advancing Research Careers (ARC) program is to support cohorts of promising, late-stage graduate students from diverse backgrounds pursuing research training in NIH mission areas. The program has two components: an individual predoctoral-to-postdoctoral transition award (F99/K00) and a research education cooperative agreement (UE5) awarded to organizations to provide F99/K00 fellows with additional mentoring, networking and professional development activities to support their transition to and success in mentored postdoctoral research positions. The ARC program supports NIH's efforts to develop a biomedical research workforce that will benefit from the full range of perspectives, experiences and backgrounds needed to advance discovery. The ARC Predoctoral to Postdoctoral Transition Award to Promote Diversity (F99/K00) is a two-phase award that will provide support for promising late-stage graduate students from diverse Synopsis backgrounds pursuing research related to the mission areas of participating NIH Institutes, Centers and Offices (ICOs), to complete their doctoral research training (F99 phase) and transition into and succeed in postdoctoral biomedical research and career development opportunities (K00 phase). The program also is designed to support predoctoral researchers who have, appropriate to their career stage, demonstrated contributions and propose meaningful plans to promote broad participation in the biomedical research workforce. It is anticipated that completion of this phased award program will position ARC scholars to advance in impactful careers in the biomedical research workforce that typically require postdoctoral training (for example, academic research and teaching at a range of organization types, industry, or government research). This Notice of Funding Opportunity (NOFO) does not allow candidates to propose to lead an independent clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor.

Maximizing Opportunities for Scientific and Academic Independent Careers

127138 (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity

National Institute of General Medical Sciences/NIH/DHHS PAR-24-225

07-Jan-2026

Not Specified

(K99/R00 Independent Clinical Trial Not Allowed)

Contact Name Kenneth D. Gibbs, Jr., Ph.D.

Contact Telephone

Contact Email kenneth.gibbs@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

07-Jan-2026, 12-Feb-2026, 07-May-2026, 12-Jun-2026, 07-Sep-2026, 12-Oct-2026, 07-Jan-2027, 12-Feb-2027, 07-May-2027, 12-Jun-2027, 07-Sep-2027

Synopsis

The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) program is to support a cohort of early career, independent investigators from diverse backgrounds (for example, individuals from underrepresented groups) conducting research in NIH mission areas. The program has two components: an individual career transition award for postdoctoral scholars (K99/R00) and a research education cooperative agreement (UE5) awarded

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount

to organizations to provide these scholars with additional mentoring, networking and professional development activities to support their transition to and success in independent, tenure-track or equivalent research-intensive faculty careers. The MOSAIC program supports NIH's efforts to develop a biomedical research workforce that will benefit from the full range of perspectives, experiences and backgrounds needed to advance discovery. The goal of the MOSAIC Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds from their mentored postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. The program is designed to support postdoctoral researchers who have demonstrated meaningful contributions and proposed compelling future plans to promote broad participation in the biomedical research workforce, such as activities that promote inclusive, supportive, and accessible biomedical research environments that support the success of trainees and scientists from all backgrounds, including individuals from underrepresented groups. This Notice of Funding Opportunity (NOFO) is designed specifically to support candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Candidates seeking support through this NOFO are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Candidates proposing a clinical trial or an ancillary clinical trial as lead investigator, should work with their institutions to apply to the companion NOFO PAR-24-226.

Focused Technology Research and Development (R01 Clinical Trial Not 128748 Allowed)

National Institute of General Medical Sciences/NIH/DHHS

PAR-25-203

07-Jan-2026

Not Specified

Contact Name Alvin T. Yeh

Contact Telephone

Contact Email NIGMS techdev@nigms.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

07-Jan-2026, 05-Feb-2026, 07-May-2026, 05-Jun-2026, 07-Sep-2026, 05-Oct-2026, 07-Jan-2027, 05-Feb-2027, 07-May-2027, 05-Jun-2027, 07-Sep-2027, 05-Oct-2027, 07-Jan-2028

This Funding Opportunity Announcement (FOA) supports projects relevant to the NIGMS mission or those of other NIH institutes or Centers (ICs) participating in the FOA that focus solely on the development of technologies with the potential to enable acquisition of biomedical knowledge. Projects should be justified in terms of technical innovation and utility of such Synopsis technical innovation for impacting future biomedical research. Outcomes or products of the proposed project should significantly advance the current state of the art and be sufficiently characterized for application in addressing a broad range of biomedical research questions. These outcomes may include, but are not limited to: laboratory instruments and other devices, algorithms and software, chemical reagents and processes, biological molecules or systems that have been modified

					1	
SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		by human intervention to become researc demonstrated proof-of-concept that have As such, applications should not propose t questions are not responsive to this FOA a optimization, hardening, or obvious extrap	remaining significant technical to test specific biological question and will be administratively with	challenges to full in ons. Applications pr ndrawn without revi	nplementation an oposing to test spew. Applications w	d broad utility. ecific biological with a focus on
1 / X 6 / X	Research With Activities Related Optional)	to Diversity (ReWARD) (R01 Clinical Trial	National Institute of General Medical Sciences/NIH/DHHS	PAR-25- 117	7-Jan-2026	Not Specified
	Contact Name	Laurie Stepanek, Ph.D.				
	Contact Telephone					
	Contact Email	laurie.stepanek@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jan-2026 , 05-Feb-2026 , 07-May-2026 2027 , 05-Jun-2027 , 07-Sep-2027 , 05-Oct		5-Oct-2026 , 07-Jan	-2027 , 05-Feb-20	27 , 07-May-
	Synopsis	The NIH Research With Activities Related to geographical location of research and research the health-related research of scientist Accessibility (DEIA) and who have no curres both the scientific research and the DEIA at to the programmatic interests of one or material focused on enhancing diversity in the bion Funding Opportunity (NOFO) requires a Planch and the DEIA at the programmatic interests of the programmatic inter	earch-related activities supported is who are making a significant of ent NIH research project grant for activities of investigators. The go lore of the participating NIH Instanting nedical research enterprise with	ed by NIH. The ReW contribution to Dive unding. The ReWAR rant will support scititutes and Centers thin the United State	ARD program program prograity, Equity, Incluing program provice entific research in (ICs) and ongoing	ovides support usion, and des funding for areas related DEIA activities
1/5/65	Academic Research Enhancemen Institutions (R15 Clinical Trial Not	t Award for Undergraduate-Focused : Allowed)	National Institute of General Medical Sciences/NIH/DHHS	PAR-25- 134	7-Jan-2026	375,000 USD
	Contact Telephone	charles.ansong@nih.gov				
	Program URL	Link to program URL				



	O - Pro-					
SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL) Synopsis	The purpose of this Academic Research En small scale research grants at institutions t providing biomedical research experiences applicant institutions. Fligible institutions in	2027, 07-Jan-2028 hancement Award (AREA) for hat do not receive substantial primarily for undergraduate snust award baccalaureate scienth direct and F&A/indirect co, the \$6 million funding limit is	Undergraduate-Foct funding from the NI tudents, and enhand nce degrees and have osts) in 4 of the last s based on the amou	used Institutions is H, with an emphasicing the research elective received no mo Tiscal years. For int of NIH funding	s to support sis on environment at re than \$6 institutions received by all
175769	Academic Research Enhancemen Institutions (R15 Clinical Trial Rec	t Award (AREA) for Undergraduate-Focused puired)	National Institute of General Medical Sciences/NIH/DHHS	() /	7-Jan-2026	375,000 USD
	Contact Name	Mahua Mukhopadhyay, PhD				
	Contact Telephone	301-435-6886				
	Contact Email	mukhopam@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL) 07-Jan-2026 , 25-Feb-2026 , 07-May-2026 , 25-Jun-2026 , 07-Sep-2026 , 25-Oct-2026 , 07-Jan-2027 , 25-Feb-2027 , 07-May-2026 , 07-Jan-2028					
	The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to sup small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate students and enhancing the research environm applicant institutions. Eligible institutions must award baccalaureate science degrees and have received no more than million dollars per year of NIH support (in both direct and F&A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the \$6 million funding limit is based on the amount of NIH funding received the non-health professional schools and colleges within the institution as a whole. See Part II. Section 3.1 Eligible					sis on invironment at re than \$6 institutions received by all



of the participating NIH institutes.

Organizations for more information. This Notice of Funding Opportunity (NOFO) supports investigator-initiated mechanistic and/or minimal risk clinical trials such as those that do not require FDA oversight, do not intend to formally establish efficacy, and have low risks to potentially cause physical or psychological harm, and which address the mission and research interests

Contact Name Contact Email Contact Email Sponsor Website Unik to sponsor website Program URL Deadline Dates (ALL) Deadline Dates (ALL) Deadline Dates (ALL) O3-Jan-2026 [Optional][LOl/Pre-App], 02-Feb-2026 , 16-May-2027 [Optional][LOl/Pre-App], 15-Jun-2027 This Notice of Funding Opportunity (NOFO) from the NIHB Brain Research through Advancing Innovative Neurotechnologie (BRAIN) Initiative is intended to support facilities at Resource-Limited Institutions (RLIs) and Institutional Development Av (IDeA)-eligible institutions for scaled production and distribution of brain cell type-specific access reagents. The reagents' be distributed will first be developed in separately supported reagent design and development projects for brain cell type specific access across vertebrate species in the BRAIN Initiative Armamentarium project. Recipients of awards under this NOFO will then work with these Armamentarium projects to manufacture and distribute the reagents for use throughout neuroscience community. It is envisioned that the recipients will work both with Armamentarium researchers as well as very the neuroscience research community to optimize the new reagents. The types of reagents to be produced and distribute could include but are not limited to viral vectors, nucleic acid constructs, and nanoparticles designed for selective access the brain cell types. Such reagents will enable neuroscientists to probe circuit function with high precision in experimental animals and ex vivo human tissue and cells. Facilities are needed to contribute to the production and distribution of BRAII Initiative Armamentarium project, whose overall goal is to generate tools to specifically access, manipulate, and monitor brain cell types across multiple vertebrate species. This NOFO will foster close interaction between technologists, disseminators, an neurobiologists in a research consortium including investigators funded by other Armamentarium NOFOs. This Notice of Fuding Opportunity (NOFO) requires a Plan for Enhancing Diverse Persp	SPIN ID	Program Title		Sponsor Name	Sponsor Numbe	r Deadline Date	Funding Amount
Contact Telephone Contact Email Contact Emai	128025	Specific Access and Manipulation	to Broaden Distribution of Enabling		RFA-MH- 26-120	[Optional][LOI/Pre-	Not Specified
This Notice of Funding Opportunity (NOFO) from the NIH Brain Research through Advancing Innovative Neurotechnologie (BRAIN) Initiative is intended to support facilities at Resource-Limited Institutions (RLIs) and Institutional Development Av (IDeA)-eligible institutions for scaled production and distribution of brain cell type-specific access reagents. The reagents be distributed will first be developed in separately supported reagent design and development projects for brain cell type specific access across vertebrate species in the BRAIN Initiative Armamentarium project. Recipients of awards under this NOFO will then work with these Armamentarium projects to manufacture and distribute the reagents for use throughout neuroscience community. It is envisioned that the recipients will work both with Armamentarium researchers as well as very the neuroscience community. It is envisioned that the recipients will work both with Armamentarium researchers as well as very the neuroscience research community to optimize the new reagents. The types of reagents to be produced and distribute could include but are not limited to viral vectors, nucleic acid constructs, and nanoparticles designed for selective access to brain cell types. Such reagents will enable neuroscientists to probe circuit function with high precision in experimental animals and ex vivo human tissue and cells. Facilities are needed to contribute to the production and distribution of BRAII Initiative Armamentarium project, whose overall goal is to generate tools to specifically access, manipulate, and monitor brain cell types across multiple vertebrate species. This NOFO will foster close interaction between technologists, disseminators, an neurobiologists in a research consortium including investigators funded by other Armamentarium NOFOs. This Notice of Fuding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP). Accelerating Solutions to Improve Access and Quality of Empirically- Supported Practices for Youth Mental Health (R01		Contact Telephone Contact Email Sponsor Website Program URL	301-827-6463 douglas.kim@nih.gov Link to sponsor website Link to program URL			45.42027	
129095 Accelerating Solutions to Improve Access and Quality of Empirically- National Institute of Mental PAR-25- Supported Practices for Youth Mental Health (R01 Clinical Trial Optional) Health/NIH/DHHS 310 Not Specific	This Notice of Funding Opportunity (NOFO) from the NIH Brain Research through Advancing Innovative Neurote (BRAIN) Initiative is intended to support facilities at Resource-Limited Institutions (RLIs) and Institutional Develo (IDeA)-eligible institutions for scaled production and distribution of brain cell type-specific access reagents. The be distributed will first be developed in separately supported reagent design and development projects for brain specific access across vertebrate species in the BRAIN Initiative Armamentarium project. Recipients of awards un NOFO will then work with these Armamentarium projects to manufacture and distribute the reagents for use the neuroscience community. It is envisioned that the recipients will work both with Armamentarium researchers at the neuroscience research community to optimize the new reagents. The types of reagents to be produced and could include but are not limited to viral vectors, nucleic acid constructs, and nanoparticles designed for selective brain cell types. Such reagents will enable neuroscientists to probe circuit function with high precision in experimanimals and ex vivo human tissue and cells. Facilities are needed to contribute to the production and distribution Initiative Armamentarium project, whose overall goal is to generate tools to specifically access, manipulate, and monitor types across multiple vertebrate species. This NOFO will foster close interaction between technologists, dissemineurobiologists in a research consortium including investigators funded by other Armamentarium NOFOs. This N					opment Award e reagents to in cell type- under this hroughout the as well as with d distributed ive access to imental on of BRAIN ative r brain cell ninators, and	
Appj	129095			National Institute of Mental Health/NIH/DHHS	PAR-25-		Not Specified



Contact Telephone 301-443-9699

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website Program URL	Link to program URL				
Deadline Dates (ALL) 06-Jan-2026 [Optional][LOI/Pre-App], 05-Feb-2026 , 06-May-2026 [Optional][LOI/Pre-App], 05-Sep-202 (Optional][LOI/Pre-App], 05-Oct-2026						ep-2026
	Synopsis	This notice of funding opportunity (NOFO) NIMH seeks applications that will study me youth mental health. Applications may add strategies; overcoming challenges related to preventive interventions into settings when medicine, community organizations, social barriers to access and quality of mental head management).	ethods to increase access to, ar lress research related to: optin to workforce shortages and wa re youth are most likely to be i services, and juvenile justice),	nd quality of, empiri nizing assessment, in hitlists for treatment dentified as needing and service interve	cally-supported pr ntervention and se ; integration of tre g care (e.g., school: ntions that addres:	actices for rvice atment and s, pediatric s systemic
128886	Neuromodulation/Neurostimulat Applications (R01 Clinical Trial No	ion Device Development for Mental Health t Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-25- 287	5-Feb-2026	Not Specified

Contact Name Jessica Tilghman, PhD

Contact Telephone 301-827-0439

Contact Email jessica.tilghman@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 05-Feb-2026, 05-Jun-2026, 05-Oct-2026, 05-Feb-2027, 05-Jun-2027, 05-Oct-2027

The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are encouraged that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the

effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared.

Synopsis Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable

of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience,

SPIN ID Program Title		Sponsor Namo	Spansor Numbo	r Deadline Date	Funding		
SPIN ID Program Title		Sponsor Name	Sponsor Number	r Deadline Date	Amount		
	engineering, clinical, and regulatory affairs or significant enhancement of novel tools should focus on the engineering developm to demonstrate initial proof of concept is a should propose design-directed, developm	(hardware/software) for brain nent and bench top testing of that allowable. Applications to this F	stimulation in hurne tool, animal an	mans.Although the a d limited human tes ted to be hypothesi	pplication ting necessary s-driven, but		
128944 Navigator Emergency Departs Health Concerns (R01 Clinical	ment Diversion Models for Non-Urgent Mental Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-25- 289	06-Jan-2026 [Optional][LOI/Pre- App]	Not Specified		
Contact Na	me Mary Acri, Ph.D.						
Contact Teleph	one 301-910-8230						
Contact E	mail mary.acri@mail.nih.gov						
Sponsor Web	site						
Program	URL Link to program URL						
Deadline Dates (A	ALL) [Optional][LOI/Pre-App], 05-Oct-2026, 06	06-Jan-2026 [Optional][LOI/Pre-App], 05-Feb-2026, 06-May-2026 [Optional][LOI/Pre-App], 05-Jun-2026, 05-Sep-2026 [Optional][LOI/Pre-App], 05-Oct-2026, 06-Jan-2027 [Optional][LOI/Pre-App], 05-Feb-2027, 06-May-2027 [Optional][LOI/Pre-App], 05-Jun-2027, 05-Sep-2027 [Optional][LOI/Pre-App], 05-Oct-2027					
Syno	The purpose of this notice of funding opports research applications that test the effective Department (ED) diversion models for non delay of several hours would not increase NIMH defines a patient navigation model allied provider such as a nurse, or a lay proto identify mental health acuity, (b) provide facilitate linkages to mental health services to help-seeking. This NOFO is for projects to companion NOFO that utilizes the R34 me	reness, implementation, and open- n-urgent youth mental health pathe potential for an adverse out as an evidence-based intervent ovider (e.g., peer, community had be emotional support and build as and additional resources as nather there are preliminary	etimization of pati roblems. A non-un tcome to occur. F ion that is deliver ealth worker) who mental health kno eeded to support data. Support for	rgent ED visit is that for the purposes of t ed by a mental healt ose role is to (a) utili owledge among care the family, and (d) a r pilot studies is prov	in which a his NOFO, th provider, an ze triage tools egivers, (c) address barriers		
128912 Mood and Psychosis Sympton Clinical Trial Optional)	ns During the Menopause Transition (R01	National Institute of Mental Health/NIH/DHHS	PAR-25- 281	05-Feb-2026	Not Specified		
	one 301-480-8335						



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Contact Email	laura.rowland@nih.gov					
	Sponsor Website						
	•	Link to program URL					
	_	05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 ,	05-Feb-2027 , 05-Jun-2027 , 0	5-Oct-2027			
	Synopsis	and translational research on the onset and perimenopause). In particular, NIMH seeks behavioral mechanisms of mood disruption targets for future mental health intervention companion NOFO PAR-25-282 uses the R22 lack preliminary data, or studies that utilize	the purpose of this Funding Opportunity Announcement (FOA) is to encourage applications that will advance mechanistic and translational research on the onset and worsening of mood and psychotic disorders during the menopausal transition (or imenopause). In particular, NIMH seeks research that will advance understanding of the underlying neurobiological and chavioral mechanisms of mood disruption and psychosis during the menopausal transition and that will identify novel regets for future mental health interventions or prevention efforts This NOFO uses the R01 grant mechanism, while the impanion NOFO PAR-25-282 uses the R21 mechanism. Investigators proposing high risk/high reward projects, projects that it is preliminary data, or studies that utilize existing data may wish to apply using the R21 mechanism, while applicants with eliminary data who seek longer-term funding may wish to apply using the R01 mechanism.				
128915		timulating Opportunities in Humans to randing of Mental Health Disorders (R01	National Institute of Mental Health/NIH/DHHS	PAR-25- 290	06-Jan-2026 [Optional][LOI/Pre- App]	Not Specified	
	Contact Name	Jessica Tilghman, Ph.D.					
	Contact Telephone	301-827-0439					
	Contact Email	jessica.tilghman@nih.gov					
	Sponsor Website						
	Program URL	<u>Link to program URL</u>					
	Deadline Dates (ALL)	06-Jan-2026 [Optional][LOI/Pre-App], 05-Feb-2026, 06-May-2026 [Optional][LOI/Pre-App], 05-Jun-2026, 05-Sep-2026 (ALL) [Optional][LOI/Pre-App], 05-Oct-2026, 06-Jan-2027 [Optional][LOI/Pre-App], 05-Feb-2027, 06-May-2027 [Optional][LOI/Pre-App], 05-Jun-2027, 05-Sep-2027 [Optional][LOI/Pre-App], 05-Oct-2027					
The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue invasive neurous recording studies focused on mental health-relevant questions. Invasive neural recordings provide an unparalleled winto the human brain to explore the neural circuitry and neural dynamics underlying complex moods, emotions, cog functions, and behaviors with high spatial and temporal resolution. Additionally, the ability to stimulate, via the same electrodes, allows for direct causal tests by modulating network dynamics. This FOA aims to target a gap in the scient knowledge of neural circuit function related to mental health disorders. Researchers should target specific questions to invasive recording modalities that have high translational potential. Development of new therapies is outside the					eled window s, cognitive e same scientific stions suited		



SPIN ID	Program Title		Sponsor Name	Sponsor Numbe	r Deadline Date	Funding Amount
		this FOA, though development of novel too uses the RO1 grant mechanism, encouraging grant applications encouraging shorter, hig	ng longer-term projects, where	as its companion	R21 NOFO, PAR-25-2	
128987		ogic or Neuromodulatory Device-based of Mental Disorders (R61/R33 Clinical Trial	National Institute of Mental Health/NIH/DHHS	PAR-25- 184	14-Jan-2026 [Optional][LOI/Pre- App]	Not Specified
	Contact Name	Margaret Grabb, Ph.D.				
	Contact Telephone	301-443-3563				
	Contact Email	mgrabb@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	14-Jan-2026 [Optional][LOI/Pre-App], 13-F [Optional][LOI/Pre-App], 15-Oct-2026, 18- App], 15-Jun-2027, 15-Sep-2027 [Optional	Jan-2027 [Optional][LOI/Pre-A			•
	Synopsis	ugh a series of notice of fundir a, early testing of new intervent DFO is to support the early stag device-based interventions for (e.g., schizophrenia, depressions are also encouraged where so liagnostic criteria being met. Undited under the device-based intervent adequately tested, to provide the early tested, to provide the developmental of the clinical trial pipeline show	tions, confirmator ge testing of pharm of the treatment on, autism, obsess ymptoms of a discolor disco	ry efficacy trials, thromacologic intervention of symptoms or domaive compulsive disorder have been idented to supposed design where the mation where target diatric, adult, and gentaliable in the comparailable in the compa	ough to ons with novel ins of altered der, anxiety, atified in oport e presumed modulation itatric-focused olications. nion R33, PAR-	
128988	Effectiveness Trials to Test Menta Clinical Trial Required)	al Health System Interventions (R61/R33	National Institute of Mental Health/NIH/DHHS		14-Jan-2026 [Optional][LOI/Pre-	Not Specified

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
						Amount		
		App]						
	Contact Name	Shahrzad Mavandadi, PhD						
	Contact Telephone	301-827-1167						
	Contact Email	shahrzad.mavandadi@nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	14-Jan-2026 [Optional][LOI/Pre-App], 13-F [Optional][LOI/Pre-App], 15-Oct-2026, 18- App], 15-Jun-2027, 15-Sep-2027 [Optional	Jan-2027 [Optional][LOI/Pre-A		•	•		
	Synopsis	NIMH solicits clinical trial applications through to effectiveness trials. This NOFO milestone-driven feasibility and infrastruct test the effectiveness of system intervention outcomes of mental health care for prioritic policy, and organizational domains - attending attending to the proposed policy, and organizational domains - attending the management, or quality and safety of mental functional, or population level outcomes, related to care delivered within or across and community clinics, schools, and social interventions to facilitate care transitions across systems. Researchers will have up to infrastructure to justify conducting the matesting should refer to companion NOFOs	irst-in-human, early testing of complements NIMH's suite of ture development (R61) resear ons or strategies that improve y populations. System interved to issues about the access, extal health services, with the goal Accordingly, the focus of system avariety of care settings, such welfare or justice systems. Progrand continuity across settings, to two years in the R61 phase to in trial (R33). Applicants pursuite of complements in trial (R33).	new interventions, of clinical trial funding ch followed by well-the organization, dentions - which may squity, engagement/oal of improved care m interventions may shealth systems and jects may test the interventions to demonstrate feasing other stages of	confirmatory effications of the confirmatory effication of the confirmation of the con	acy trials, supporting rials (R33) to on, and structural, cost/financing), nical, factors/levels mental health and practices, s/coordination		
119255	Novel Mechanism Research on No Alzheimer's Dementia (R21 Clinic	europsychiatric Symptoms (NPS) in all Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-25- 064	6-Feb-2026	275,000 USD		
	Contact Telephone	Laura M. Rowland, Ph.D. 301-480-8335 laura.rowland@nih.gov						



Sponsor Website

Applications (R21 Clinical Trial Not Allowed) Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026 , 16-Feb-2027 , 16-Jun-2027 , 16-Oct-2027 The purpose of this notice of funding opportunity (NOFO) is to encourage applications seeking to develop the next generat of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Althouthe application should focus on the engineering development and bench top testing of the tool, animals and limited, non-	SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Applications (R21 Clinical Trial Not Allowed) Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) The purpose of this notice of funding opportunity (NOFO) is to encourage applications seeking to develop the next generat of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Althout the application should focus on the engineering development and bench top testing of the tool, animals and limited, non-		Deadline Dates (ALL)	16-Feb-2026, 16-Jun-2026 The goal of this Notice of Funding Opporturof mechanisms associated with neuropsych disease-related dementias (ADRD). The find and neurobiological pathways leading to Ni advanced into interventions to treat and promechanism, while the companion PAR-25-0 projects that lack preliminary data may be	niatric symptoms (NPS) in persion dings are expected to advance PS. Findings may also provide revent the development of NP 1065 uses the R01 grant mechanger appropriate for the R21	ons with Alzheimer mechanistic unders insight into novel the S in AD and/or ADR nism. Investigators	's disease (AD) or A standing of both b nerapeutic targets D. This NOFO uses proposing high risl	Alzheimer's iobehavioral that can be the R21 k/high reward
Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Deadline Dates (ALL) The purpose of this notice of funding opportunity (NOFO) is to encourage applications seeking to develop the next generat of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Althou the application should focus on the engineering development and bench top testing of the tool, animals and limited, non-	1/2225				11	6-Feb-2026	275,000 USD
clinical trial human testing necessary to demonstrate initial proof of concept is allowable. This NOFO uses the R21 grant mechanism, encouraging shorter, higher-risk applications, whereas its companion funding opportunity PAR-25-287 seeks R grant applications.		Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	iessica.tilghman@nih.gov Link to program URL 16-Feb-2026, 16-Jun-2026, 16-Oct-2026, The purpose of this notice of funding oppor of brain stimulation devices for treating methoral stimulation devices or 2) significantly brain stimulation devices that are currently should move beyond existing electrical/maspatiotemporal precision as well as multi-fesshould focus on significant enhancement of the application should focus on the engineer clinical trial human testing necessary to demechanism, encouraging shorter, higher-rise	rtunity (NOFO) is to encourage ental health disorders. Applicate enhance, by means of hardway U.S. Food and Drug Administry gnetic stimulation and developed, closed-loop approaches. If the spatial resolution, depthering development and benchmonstrate initial proof of concept	e applications seeking tions are sought that are/software improved at the are/software improved at the are/software improved at the area are are are are are are are are a	of will either 1) devivements, the effect red or cleared. Novechniques capable g to develop new of precision of the de bool, animals and ling is NOFO uses the l	velop novel ctiveness of vel devices of increased capabilities evice. Although mited, non- R21 grant

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Health Concerns (R34 Clinical Tria	al Required)	Health/NIH/DHHS	-	Optional][LOI/Pre-	USD
	Contact Name	Mary Acri, Ph.D.				
	Contact Telephone	301-910-8230				
	Contact Email	mary.acri@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	17-Jan-2026 [Optional][LOI/Pre-App], 16-Feb-2026, 17-May-2026 [Optional][LOI/Pre-App], 16-Jun-2026, 16-Sep-2026 [Optional][LOI/Pre-App], 16-Jun-2027 [Optional][LOI/Pre-App], 16-Feb-2027, 17-May-2027 [Optional][LOI/Pre-App], 16-Jun-2027, 16-Sep-2027 [Optional][LOI/Pre-App], 16-Oct-2027				
		The purpose of this notice of funding oppnavigation Emergency Department (ED) department (ED) department (ED) department (ED) department (ED) department (ED) department for which a delay of several hours were this NOFO, NIMH defines a patient navigation provider, an allied provider such as a nurse triage tools to identify mental health acuicaregivers, c) facilitate linkages to mental address barriers to help-seeking. This NOI testing to detect a signal, and (2) develop or fully powered studies is provided throut Trial Required).	iversion models for non-urgent buld not increase the potential stion model as an evidence-base i.e, or a lay provider (e.g., peer, ty, (b) provide emotional support health services and additional FO is for 1) established navigate ment and pilot testing of compagh a companion NOFO that uti	mental health prob for an adverse outco ed intervention that community health w ort and build mental resources as needed or models that have onents of navigator lizes the RO1 mechal	lems. A non-urgen ome to occur. For t is delivered by a n vorker) whose role health knowledge I to support the far limited evidence a models. Support fo	he purposes of he purposes of hental health is to (a) utilize amongst mily, and (d) nd need pilot or larger-scale (RO1 Clinical
128913	Mood and Psychosis Symptoms d Clinical Trial Optional)	uring the Menopause Transition (R21	National Institute of Mental Health/NIH/DHHS	PAR-25- 282	6-Feb-2026	275,000 USD
	Contact Name	Laura M. Rowland, Ph.D.				
	Contact Telephone	301-792-3242				
	Contact Email	laura.rowland@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				



Deadline Dates (ALL) 16-Feb-2026, 16-Jun-2026, 16-Oct-2026, 16-Feb-2027, 16-Jun-2027, 16-Oct-2027

SPIN ID	Program Title		Sponsor Name	Sponsor Numbe	r Deadline Date	Funding Amount
	Synopsis	The purpose of this Funding Opportunity A and translational research on the onset an perimenopause). In particular, NIMH seeks behavioral mechanisms of mood disruption targets for future mental health interventic companion NOFO PAR-25-281 uses the ROS that lack preliminary data, or studies that with preliminary data who seek longer-term	d worsening of mood and psyc s research that will advance un n and psychosis during the med ons or prevention efforts. This 1 grant mechanism. Investigate utilize existing data may wish to	hotic disorders duderstanding of the nopausal transition NOFO uses the Ripers proposing high papers apply using the	uring the menopaus e underlying neurob n and that will ident 21 mechanism, while n risk/high reward pi R21 mechanism, wh	al transition (or iological and cify novel the rojects, projects
128914		timulating Opportunities in Humans to canding of Mental Health Disorders (R21	National Institute of Mental Health/NIH/DHHS	PAR-25- 291	16-Feb-2026	275,000 USD
	Contact Name	Jessica Tilghman, Ph.D.				
	Contact Telephone	301-827-0439				
	Contact Email	jessica.tilghman@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026 ,	16-Feb-2027 , 16-Jun-2027 , 16	5-Oct-2027		
	Synopsis	The purpose of this notice of funding oppostudies focused on mental health-relevant human brain to explore the neural circuitry and behaviors with high spatial and tempo for direct causal tests by modulating networicuit function related to mental health dimodalities that have high translational pot the scope of this NOFO, though development is NOFO uses the R21 grant mechanism, opportunity, PAR-25-290, seeks R01 grant	questions. Invasive neural recoverance and neural dynamics underly ral resolution. Additionally, the ork dynamics. This NOFO aims sorders. Researchers should talential. Intervention-development of novel tools/methods to encouraging shorter, higher-ri	ordings provide and any complex mood ability to stimulate to target a gap in a rget specific questent clinical trials complex and make the complex and the complex and make the complex and make the complex and the	n unparalleled windon ds, emotions, cognit ate, via the same ele the scientific knowle tions suited to invas of therapeutic device mental health studies	ow into the live functions, ctrodes, allows edge of neural sive recording es are outside is encouraged.
128986		ogic or Neuromodulatory Device-based of Mental Disorders (R33 - Clinical Trial	National Institute of Mental Health/NIH/DHHS	PAR-25- 183	14-Jan-2026 [Optional][LOI/Pre- App]	Not Specified



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
	Contact Name	Margaret Grabb, Ph.D.						
	Contact Telephone							
		mgrabb@mail.nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	14-Jan-2026 [Optional][LOI/Pre-App], 13-Feb-2026, 16-May-2026 [Optional][LOI/Pre-App], 15-Jun-2026, 15-Sep-2026 (ALL) [Optional][LOI/Pre-App], 15-Oct-2026, 18-Jan-2027 [Optional][LOI/Pre-App], 17-Feb-2027, 16-May-2027 [Optional][LOI/Pre-App], 15-Jun-2027, 15-Sep-2027 [Optional][LOI/Pre-App], 15-Oct-2027						
	Synopsis	NIMH solicits clinical trial applications thro development pipeline, from first-in-human effectiveness trials. The purpose of this No mechanisms of action or neuromodulatory functions in individuals with mental illness. have been identified in subjects (a prodrom intended to support early-stage testing of design where the presumed mechanism of where target modulation yields a well-contadult, and geriatric-focused interventions a awards. Applicants proposing high-risk pro 184 or PAR-25-180.	n, early testing of new intervent DFO is to support the early-stated device-based interventions for Early intervention studies are mal phase), prior to full diagno pharmacologic or neuromodule action of the intervention is a trolled, dose-dependent neuronere appropriate for this NOFO.	tions, confirmatory ge testing of pharm or the treatment of also encouraged wastic criteria being natory device-based dequately tested to physiological/clinic This R33 NOFO supports of the physiological or the support of the suppor	r efficacy trials, thromacologic interventions or domachere symptoms of net. Ultimately, this interventions using provide meaningful/behavioral effects oports single-phase	ough to ons with novel ains of altered a disorder NOFO is g a protocol ul information at. Pediatric, d clinical trial		
128982		inical Trials of Novel Investigational Drugs ad Interventions for Psychiatric Disorders	National Institute of Mental Health/NIH/DHHS	PAR-25- 180	.4-Jan-2026 Optional][LOI/Pre- App]	Not Specified		
	Contact Name	Enrique Michelotti, Ph.D.						
	Contact Telephone	301-443-5415						
	Contact Email	michelottiel@mail.nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
Deadline Dates (ALL) [Optional][LOI/Pre-App], 13-Feb-2026 , 16-May-2026 [Optional][LOI/Pre-App], 15-Jun-2026 , 15-Sep-								



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount

App], 15-Jun-2027, 15-Sep-2027 [Optional][LOI/Pre-App], 15-Oct-2027

NIMH solicits clinical trial applications through a series of notice of funding opportunities (NOFOs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this NOFO is to encourage cooperative agreement applications to support early stage clinical trials of novel mechanism of action investigational drugs or novel neuromodulatory devices for the treatment of psychiatric disorders in areas of unmet medical need. The NOFO will support milestone-driven early stage trials, including First-in-human (FIH), Phase Ib, Phase II/PoC and early feasibility studies (EFS), in pediatric and adult populations. These studies are designed to objectively and dose dependently assess target engagement in the central nervous system (CNS), along with safety and tolerability. Phase II/PoC studies additionally must evaluate the drug's/device's impact on clinically Synopsis relevant physiological systems (functional measures) and clinical indicators of effect. The overall objective of this NOFO is to facilitate rapid collection of data to "de-risk" novel mechanism of action investigational drugs, novel drugs for use in pediatric populations with psychiatric disorders, and devices or combination treatments in order to attract private or other public funding (when appropriate) for further clinical development as Food and Drug Administration (FDA)-approved treatments. A key aspect of this NOFO is the formation of collaborative partnerships between the biomedical researchers and biotechnology or industry researchers to facilitate psychiatric drug or device development. This NOFO is designed for applicants seeking funding for cooperative agreements supporting early stage clinical trials as outlined above. Applicants pursuing other stages of the clinical trial pipeline or funding for clinical research not involving cooperative agreements should consider one of the companion NOFOs listed above.

Confirmatory Efficacy Clinical Trials of Non-Pharmacological and 128979 Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required)

National Institute of Mental Health/NIH/DHHS

PAR-25-179

14-Jan-2026 [Optional][LOI/Pre-[qqA

Not Specified

Contact Name Joel Sherrill, Ph.D.

Contact Telephone 301-443-2477

Contact Email isherril@mail.nih.gov

Sponsor Website

Program URL Link to program URL

14-Jan-2026 [Optional][LOI/Pre-App], 13-Feb-2026, 16-May-2026 [Optional][LOI/Pre-App], 15-Jun-2026, 15-Sep-2026 Deadline Dates (ALL) [Optional] [LOI/Pre-App], 15-Oct-2026, 18-Jan-2027 [Optional] [LOI/Pre-App], 17-Feb-2027, 16-May-2027 [Optional] [LOI/Pre-App], 17-Feb-2027, 16-May-2027 [Optional] [LOI/Pre-App], 17-Feb-2027, 16-May-2027 [Optional] [LOI/Pre-App], 18-Date [LOI/Pre-App], 1 App], 15-Jun-2027, 15-Sep-2027 [Optional][LOI/Pre-App], 15-Oct-2027

NIMH solicits clinical trial applications through a series of notices of funding opportunities (NOFOs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials,

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding
	r rogium riuc	openser runne			Amount

through to effectiveness trials. The purpose of this NOFO is to support confirmatory efficacy testing of non-pharmacological preventive and therapeutic interventions, and under certain conditions, selected pharmacological interventions for mental disorders in adults and children through an experimental therapeutics approach. Under this NOFO, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development, effectiveness testing, or dissemination of the intervention. Interventions to be studied include, but are not limited to, behavioral, cognitive, interpersonal, and device-based (both invasive/surgically implanted as well as noninvasive/transcranial) approaches, or a combination thereof. Pharmacological interventions to be studied under this grant mechanism are expected to primarily focus on drugs approved for marketing by the FDA (for any indication). These will include medications off-patent which are undergoing development for a new mental health indication. Confirmatory efficacy trials studying monotherapy, combination treatments, and stepped approaches, including multiple treatment modalities, may be supported. Interventions appropriate for efficacy testing must be based on a compelling scientific rationale, previous demonstration that the intervention engages and alters the hypothesized mechanism of action (target), a preliminary efficacy signal, and must address an unmet therapeutic need. Support will be provided for a trial of the intervention's efficacy that includes measurement of the hypothesized mechanism of action and the relationship between change in the target mechanism and change in functional or clinical effects. Ultimately, this NOFO is intended to support a sufficiently-powered efficacy trial to determine the intervention's potential for significant clinical benefit. Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion NOFOs listed above.

Pilot Hybrid Effectiveness-Implementation Trials for Mental Health Interventions (R01 – Clinical Trial Required)

National Institute of Mental Health/NIH/DHHS

PAR-25-178

14-Jan-2026 [Optional][LOI/Pre-[qqA

750,000 **USD**

Contact Name Joel Sherrill, Ph.D.

Contact Telephone 301-443-2477

Contact Email jsherril@mail.nih.gov

Sponsor Website

Program URL Link to program URL

14-Jan-2026 [Optional][LOI/Pre-App], 13-Feb-2026, 16-May-2026 [Optional][LOI/Pre-App], 15-Jun-2026, 15-Sep-2026 Deadline Dates (ALL) Optional I/OI/Pre-App, 15-Oct-2026, 18-Jan-2027 Optional I/OI/Pre-App, 17-Feb-2027, 16-May-2027 Optional I/OI/Pre-App App], 15-Jun-2027, 15-Sep-2027 [Optional][LOI/Pre-App], 15-Oct-2027

NIMH solicits clinical trial applications through a series of notice of funding opportunities (NOFOs) that cover the Synopsis intervention development pipeline, from first-in-human, early testing of interventions, confirmatory efficacy trials, through to effectiveness trials. This NOFO seeks pilot hybrid effectiveness implementation research consistent with NIMH's priorities

SPIN IDProgram TitleSponsor NameSponsor NumberDeadline DateFunding Amount	
---	--

for: 1) refining and optimizing preventive and therapeutic interventions with previously demonstrated efficacy for use with broader target populations or for delivery routine care, school, community, or online settings, and 2) research on implementation strategies that support the delivery and sustainability of evidence supported interventions in accessible settings. This NOFO supports pilot research designed to generate the preliminary data needed as a prerequisite to a well powered clinical trial. This includes research designed to assess the feasibility, acceptability, safety, and fit of approach, and explore the impact of the approach on both the outcomes of interest and at least one hypothesized mechanism of action. Support for well powered hybrid effectiveness implementation studies is provided through separate NOFOs that are described on the NIMH Support for Clinical Trials web page.

128977

Full-Scale Hybrid Effectiveness-Implementation Trials for Mental Health Interventions (R01 - Clinical Trial Required)

National Institute of Mental Health/NIH/DHHS

PAR-25-177

14-Jan-2026 [Optional][LOI/Pre-[qqA

Not Specified

Contact Name Joel Sherrill, Ph.D.

Contact Telephone 301-443-2477

Contact Email jsherril@mail.nih.gov

Sponsor Website

Program URL Link to program URL

14-Jan-2026 [Optional][LOI/Pre-App], 13-Feb-2026, 16-May-2026 [Optional][LOI/Pre-App], 15-Jun-2026, 15-Sep-2026 Deadline Dates (ALL) [Optional] [LOI/Pre-App], 15-Oct-2026, 18-Jan-2027 [Optional] [LOI/Pre-App], 17-Feb-2027, 16-May-2027 [Optional] [LOI/Pre-App], 17-Feb-2027, 16-May-2027 [Optional] [LOI/Pre-App], 17-Feb-2027, 16-May-2027 [Optional] [LOI/Pre-App], 18-Date [LOI/Pre-App], 1 App], 15-Jun-2027, 15-Sep-2027 [Optional][LOI/Pre-App], 15-Oct-2027

> IMH solicits clinical trial applications through a series of notice of funding opportunities (NOFOs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. This NOFO seeks to support well-powered clinical trials consistent with NIMH's priorities for: 1) optimizing preventive and therapeutic interventions with previously demonstrated efficacy for use with broader target populations or for delivery routine care, school, community, or online settings, and 2) research on implementation strategies that support the delivery and sustainability of optimized interventions in accessible settings. Applications responsive to this NOFO are hybrid effectiveness implementation trials that examine the effectiveness and clinical impact of interventions to prevent or treat mental illness, implementation challenges and strategies within the intervention setting, and at least one mechanism of action associated with an intervention and/or implementation strategy. The research covered under this announcement addresses practice-relevant questions and must be conducted within accessible intervention settings where

the typical consumer can be identified as in need of care and be readily connected to an intervention. Applicants pursuing

other stages of the clinical trial pipeline should consider one of the companion NOFOs listed above.

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
117822	Mentored Career Transition Awar Required)	rd for Intramural Fellows (K22 Clinical Trials	National Institute of Mental Health/NIH/DHHS	PA-23- 150	2-Feb-2026	Not Specified
	Contact Name	Ashlee Van't Veer				
	Contact Telephone	301-443-3107				
	Contact Email	dnbbstrainingbranch@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	12-Feb-2026				
	Synopsis	award program that is intended to facilitate Intramural Programs (DIRP) from intramural equivalent faculty positions at eligible U.S. award will provide research support during research programs. This Funding Opportun as the lead investigator of an independent part of their research and career developm research experience in a clinical trial led by	al postdoctoral research positions institutions. Both the intramusthe extramural phase to help ity Announcement (FOA) is declinical trial, a clinical trial feasent. Applicants not planning a	ons to extramural, a ral and extramural awardees launch co signed specifically f sibility study, or a se n independent clini	academic tenure-t phases will be me ompetitive, indepe or applicants prop eparate ancillary cl ical trial, or propos	rack or ntored, and the endent osing to serve inical trial, as
117821	Mentored Career Transition Awar Not Allowed)	rd for Intramural Fellows (K22 Clinical Trials	National Institute of Mental Health/NIH/DHHS	PA-23- 149	2-Feb-2026	Not Specified
			Tiealth/Mill/Dillis	143		Specified
		Ashlee Van't Veer				
	Contact Telephone					
		dnbbstrainingbranch@mail.nih.gov				
	Sponsor Website					
	Deadline Dates (ALL)	Link to program URL				
	Synopsis	The Mentored Career Transition Award for award program that is intended to facilitate Intramural Programs (DIRP) from intramura equivalent faculty positions at eligible U.S.	e a timely transition of qualifie al postdoctoral research position	d postdoctoral fello ons to extramural, a	ows in the NIMH D academic tenure-t	ivision of rack or



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		award will provide research support during research programs. This Funding Opportur that does not involve leading an independ Applicants to this FOA are permitted to pro Applicants proposing a clinical trial or an a 23-150.	nity Announcement (FOA) is de ent clinical trial, a clinical trial f opose research experience in a	signed specifically f easibility study, or a clinical trial led by	or applicants prop an ancillary clinica a mentor or co-mo	osing research I trial. entor.
129181	NIMH Career Transition Award fo (K22 No Independent Clinical Tria	r Tenure-Track Intramural Investigators ls)	National Institute of Mental Health/NIH/DHHS	PAR-24- 286	2-Feb-2026	Not Specified
	Contact Telephone Contact Email Sponsor Website Program URL	dnbbstrainingbranch@mail.nih.gov	sition Award for Tenure-Track In K22 Program) is to provide su Intramural Research Programs ould have a demonstrated reco	ntramural Investiga pport for career int (IRP) to an indeper rd of meritorious re cally for applicants	ramural investigat ndent research fac esearch in mental proposing researc	ors at NIMH ulty position in health-related
119664	Schizophrenia and Related Disorce Trial Optional)	lers During mid- to Late-Life (R21 Clinical	National Institute of Mental Health/NIH/DHHS	PAR-25- 040	6-Feb-2026	275,000 USD
	Contact Telephone Contact Email Sponsor Website Program URL	laura.rowland@nih.gov				



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
						runount
	Synopsis	The purpose of this Notice of Funding Opp research to better understand the emerger mid- to late-life, and to identify targets for the R21 grant mechanism, while the comparisk/high reward projects that lack prelimin preliminary data who seek longer-term fun	nce, trajectory, and outcomes future development of preven anion NOFO (PAR-25-039) uses arry data may be more approp	of schizophrenia and tion and treatment the R01 mechanism riate for the R21 me	l related psychoti interventions. Thi n. Investigators pr	c disorders in is NOFO uses oposing high
114/115		Complex Brain Disorders (R21 Clinical Trial	National Institute of Mental	PAR-25-	-Feb-2026	275,000
	Not Allowed)	1	Health/NIH/DHHS	037		USD
		David Panchision				
	Contact Telephone					
	Contact Email	panchisiond@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Feb-2026 , 16-Jun-2026				
	Synopsis	This Notice of Funding Opportunity (NOFO) with complex brain disorders, with a focus purposes of this NOFO, the term "complex environmental) and/or highly distributed for generating (unbiased discovery) or hypother paradigms, e.g., model organisms or human incorporated into the research design to fathese are neither required nor expected. Stelucidate the neurobiological impact of indicomponents and their relationships within factors, components and processes. The redisseminated with sufficient detail to enrick Ontology, Synaptic Gene Ontology, FAIR Damechanism and therapeutic target identification develop early stage, high-risk, exploratory and data. Applicants proposing to develop lines to the companion R01 NOFO PAR-25-038.	on the intracellular, transcellus, can refer to a multifactorial cunctional features of the brain esis-testing in design and may neell-based assays. While beh cilitate the characterization of tudies should not attempt to "ividual or combined risk factor defined biological process(es) sulting paradigms, component h common and/or federated data Informatics) in order to brick to the cation. The present NOFO (R21 approaches or establish proof-	lar and circuit substice contribution to risk (disorder. Studies mutilize in vivo, in situavioral paradigms are intracellular, transcemodel" disorders but (s), such as the affect pathways and biologicata resources (e.g., dige the gap betweer activity code) can be of-concept where the contribution of the concept where the contribution of the contribution	rates of neural fur e.g., polygenic an ay be either hypo , or in vitro exper nd outcome meas ellular and circuit t instead should a cted molecular an e fundamental bic gical processes sh those contributing n disease risk factor e used for applica- nere is little or no	nction. For the ad/or thesis- imental cures can be mechanisms, aim to ad cellular blogy of these hould be g to the Gene ors, biological ations to preliminary

			•			
SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
119254	Novel Mechanism Research on Notable Alzheimer's Dementia (R01 Clinic	europsychiatric Symptoms (NPS) in al Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-25- 065	05-Feb-2026	Not Specified
	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	laura.rowland@nih.gov	niatric symptoms (NPS) in personiatric symptoms (NPS) in personings are expected to advance PS. Findings may also provide revent the development of NPS cement PAR-25-064 uses the R	ons with Alzheime mechanistic unde insight into novel t S in AD and/or ADI 21 mechanism. Hig	r's disease (AD) or a rstanding of both b herapeutic targets RD. This NOFO uses gh risk/high payoff	Alzheimer's io behavioral that can be s the R01
117750	Assay Development and Screenin for Brain Disorders (R01 Clinical T	g for Discovery of Validated Chemical Hits rial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-25- 063	07-Jan-2026	Not Specified
	Contact Name	Enrique Michelotti, PhD				
	Contact Telephone	301-443-5415				
	Contact Email	michelottiel@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jan-2026 , 05-Feb-2026 , 07-May-2026				
	Synopsis	The overarching goal of this Notice of Functions assays for the discovery of validated hits the potential drug candidates for the treatment that has the desired activity in a compound Stages of discovery research covered by the	nat can be used in future drug out of mental illness. For purposed screen and whose activity is o	discovery/develop es of this initiative confirmed upon re	ment efforts for ide , a "hit" is defined a testing in orthogon	entifying as a compound al assays.

identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); and 3) hit validation

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		using a series of assays and initial medicina	Il chemistry inspection to prior	itize the hit set.		
119663	Schizophrenia and Related Disord Trial Optional)	ders During mid- to Late-Life (R01 Clinical	National Institute of Mental Health/NIH/DHHS	PAR-25- 039	5-Feb-2026	Not Specified
	Contact Name	Laura M. Rowland, Ph.D.				
	Contact Telephone	301-480-8335				
	Contact Email	laura.rowland@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Feb-2026 , 05-Jun-2026				
	Synopsis	research to better understand the emerger mid- to late-life, and to identify targets for the R01 grant mechanism, while the compa risk/high reward projects that lack prelimin	future development of prever anion NOFO (PAR-25-040), use	tion and treatmen s the R21 mechani	t interventions. Th sm. Investigators p	is NOFO uses
119702	<u>Cellular and Molecular Biology of Not Allowed)</u>	Complex Brain Disorders (R01 Clinical Trial	National Institute of Mental Health/NIH/DHHS	PAR-25- 038	5-Feb-2026	Not Specified
	Contact Name	David Panchision				
	Contact Telephone	301-402-3969				
	Contact Email	panchisiond@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Feb-2026 , 05-Jun-2026				
	Synopsis	This Notice of Funding Opportunity (NOFO with complex brain disorders, with a focus purposes of this NOFO, the term "complex environmental) and/or highly distributed for generating (unbiased discovery) or hypother paradigms, e.g., model organisms or huma	on the intracellular, transcellu " can refer to a multifactorial of unctional features of the brain esis-testing in design and may	lar, and circuit sub contribution to risk disorder. Studies r utilize in vivo, in sit	strates of neural fu (e.g., polygenic an nay be either hypo u or in vitro experi	inction. For the d/or ithesis- imental



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		incorporated into the research design to fa these are neither required nor expected. Stelucidate the neurobiological impact of ind components and their relationships within factors, components, and processes. The redisseminated with sufficient detail to enrick Ontology, Synaptic Gene Ontology, FAIR Damechanism and therapeutic target identific further develop lines of inquiry where feasi research at the early and conceptual stages	tudies should not attempt to "lividual or combined risk factor defined biological process(es). esulting paradigms, componen h common and/or federated data Informatics) in order to brickation. The present NOFO (R01 ibility or proof-of-concept has	model" disorders but (s), such as the affe This can include the t pathways, and bio ata resources (e.g., dge the gap between activity code) can be been established. A	at instead should a cted molecular ar e fundamental bio logical processes s those contributing n disease risk fact pe used for applica pplicants proposi	aim to aid cellular blogy of these should be g to the Gene ors, biological ations to ng exploratory
	Notice of Special Interest (NOSI): Studies of Rare Genetic Neurode	NIMH Planning Grants for Natural History velopmental Disorders	National Institute of Mental Health/NIH/DHHS	NOT-MH- 23-235	7-Jan-2026	Not Specified
	Contact Name	Margaret Grabb, Ph.D.				
	Contact Telephone	301-443-3563				
	Contact Email	mgrabb@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jan-2026 , 05-Feb-2026 , 07-May-2026 ,	05-Jun-2026 , 07-Sep-2026			
	Synopsis	The National Institute of Mental Health (NI conduct retrospective natural history studion function in patients (birth to 25 years of these studies is to assess the time of onset establish potential timepoints for intervent quantitative clinical functional measures or future clinical trials. These retrospective national measures or future clinical trials.	es that explore the prevalence age) with rare genetic neurode and severity of these sympton tion. Additionally, the planning biomarkers that could be use attural history studies are expect	of disabling psychia evelopmental disorchs, identify appropri grants should focus d as prognostics and ted to enable future	etric symptoms and ders (NDD). The printer outcome means on identifying poor of of deprospective long	d disruptions rincipal goal of asures, and otential change in
	Notice of Special Interest (NOSI): Rare Genetic Neurodevelopment	Pre-Clinical Research on Gene Therapies for al Disorders	National Institute of Mental Health/NIH/DHHS	NOT-MH- 23-236	7-Jan-2026	Not Specified
	Contact Name					



Contact Telephone 301-443-3563

SPIN ID Program Title		Sponsor Name	Sponsor Numbe	Deadline Date	Funding Amount
Contact Ema	il NIMHgenetherapies@nih.gov			·	
Sponsor Website	e				
Program UR	L Link to program URL				
Deadline Dates (ALL) 07-Jan-2026 , 05-Feb-2026 , 07-May-2020	6 , 05-Jun-2026 , 07-Sep-2026			
Synopsi	The National Institute of Mental Health (s clinical research aimed at developing now disorders with prominent cognitive, social	el approaches for somatic cell g	-		•
128677 Integrating Mental Health Care in Middle-Income Countries (R01 C	nto Health Care Systems in Low- and linical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-25- 201	06-Jan-2026 [Optional][LOI/Pre- App]	Not Specified
Contact Name	e Vidya Vedham, Ph.D.				
Contact Telephone	e				
Contact Emai	il <u>vidya.vedham@nih.gov</u>				
Sponsor Website	e				
Program UR	L <u>Link to program URL</u>				
Deadline Dates (ALL	06-Jan-2026 [Optional][LOI/Pre-App], 05-) [Optional][LOI/Pre-App], 05-Oct-2026 , 0 App], 05-Jun-2027 , 05-Sep-2027 [Option	6-Jan-2027 [Optional][LOI/Pre-A		•	•
Synopsi	This notice of funding opportunity (NOFC services with chronic health care (for bot non-healthcare settings (such as schools, (LMICs). The objective is to develop, refir care with other services. This NOFO aims financial sustainability of integrated men accessibility, utilization, and quality of me addition, this NOFO seeks to strengthen s	h communicable and non-comm places of worship, and commun ne, and evaluate innovative strat to support research geared tow tal health care models, with the ental health care services in both	nunicable condition hity centers) in lovegies to facilitate ards implementing overarching goal healthcare and r	ns) across various he vand middle-income the integration of m g, scaling up, and er of enhancing the ava non-healthcare settin	ealthcare and e countries ental health isuring the ailability,
128661 <u>Laboratories to Optimize Digital</u>	Health (R01 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-25- 136	06-Jan-2026 [Optional][LOI/Pre- App]	Not Specified

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Name Contact Telephone	Adam Haim, Ph.D. 301-435-3593				
	Sponsor Website	Haima@mail.nih.gov Link to program URL				
	Deadline Dates (ALL)	06-Jan-2026 [Optional][LOI/Pre-App], 05-Fe [Optional][LOI/Pre-App], 05-Oct-2026, 06- App], 05-Jun-2027, 05-Sep-2027 [Optional	Jan-2027 [Optional][LOI/Pre-A		·	•
	Synopsis	NIMH seeks applications for innovative res and quality of digital mental health interve serious mental illness. This Funding Opport health test beds that leverage well-establis optimize existing evidence-based digital he interventions that are statistically powered particularly in populations who experience	ntions which may impact menturity Announcement (FOA) is thed digital mental health platfealth interventions and to condition to provide a definitive answer.	tal health outcomes intended to suppor forms and infrastruc luct clinical research r regarding the inte	, including suicide t the development ture to rapidly refi n testing digital me	behaviors and of digital ine and ntal health
		PET and SPECT Imaging Ligands as address of CNS on the control of	National Institute of Mental Health/NIH/DHHS	PAR-25- 036	7-Jan-2026	Not Specified
	Contact Telephone Contact Email Sponsor Website	michelottiel@mail.nih.gov				



This Notice of Funding Opportunity (NOFO) invites research grant applications that propose the development and evaluation of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) for

Synopsis molecular targets (e.g., receptors, intracellular messengers, disease-related proteins) that are implicated in brain disorders as tools to study disease pathophysiology and/or for assessing target engagement of potential therapeutic candidates. The objective of this NOFO is to stimulate research in the identification and development of PET and SPECT probes for disorders

Deadline Dates (ALL) 07-Jan-2026, 05-Feb-2026, 07-May-2026

SPIN ID	Program Title		Sponsor Name	Sponsor Numbe	Deadline Date	Funding Amount
		of primary interest to the NIMH or NIA.				
128553	Pilot Effectiveness Trials for Post- Optimize Longer-term Outcomes	-Acute Interventions and Services to (R01 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-25- 206	06-Jan-2026 [Optional][LOI/Pre- App]	750,000 USD
	Contact Name	Adam Haim, Ph.D.				
	Contact Telephone	301-435-3593				
	Contact Email	haima@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	06-Jan-2026 [Optional][LOI/Pre-App], 05-F [Optional][LOI/Pre-App], 05-Oct-2026 , 06- App], 05-Jun-2027 , 05-Sep-2027 [Optional	Jan-2027 [Optional][LOI/Pre-A		•	•
	Synopsis	NIMH seeks applications for pilot projects interventions for the post-acute managem both their focus (e.g., consolidating and m preventing relapse, promoting adherence effectiveness research, the trial should be effectiveness of the approach; to address underlie the intervention effects; and to ol (e.g., comparative effectiveness study, pra post-acute outcomes. This notice of fundir tolerability, acceptability, safety, and prelingenerate the preliminary data needed as a definitive effectiveness trials. Support for finterventions is provided via the R01 NOFO	ent of mental health condition aintaining gains from initial tre and appropriate service use) at designed to evaluate the feasily whether the intervention engains preliminary data needed ctical trial) designed to definite ag opportunity (NOFO) support minary indications of effective prerequisite to well powered fully-powered, definitive effect	s that are matcher atment, managing and intensity/burdensility, tolerability, ges the target(s)/las a pre-requisite style test the effection pilot research to ness of post-acute effectiveness trial	d to the stage of illng residual symptoms en. In this pilot phase acceptability, safety mechanisms(s) presuto a larger-scale effeveness of intervention evaluate the feasible phase interventions, and to inform the	ess in terms of sympairment, e of sympairment, and potential umed to ectiveness trial ons to improve ility, approaches, to design of
128559	Effectiveness Trials for Post-Acute Longer-term Outcomes (R01 Clini	e Interventions and Services to Optimize ical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-25- 207	06-Jan-2026 [Optional][LOI/Pre- App]	Not Specified
	Contact Name Contact Telephone	Adam Haim, Ph.D. 301-435-3593				



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email Sponsor Website	haima@mail.nih.gov				
	'	Link to program URL				
	_	06-Jan-2026 [Optional][LOI/Pre-App], 05-Fe [Optional][LOI/Pre-App], 05-Oct-2026, 06-J App], 05-Jun-2027, 05-Sep-2027 [Optional]	lan-2027 [Optional][LOI/Pre-A			
	Synopsis	NIMH seeks applications for research projet for the post-acute management of mental hopportunity (NOFO) encourages clinical trial action, mediators, and predictors and mode matched to the stage of illness in terms of homologies i	nealth conditions affecting you als to establish the effectiveness erators of post-acute phase the both their focus (e.g., consolid preventing relapse, promoting ager-term outcomes. This NOF arding the effectiveness of the e initial feasibility, tolerability,	oth, adults, and olders and test hypothe erapeutic and servicating and maintaining adherence and ap O is intended to supe post-acute phase acceptability, safet	er adults. This noti ses regarding med ces interventions t ng gains from initi propriate service u pport trials that are intervention. Supp	ce of funding chanisms of that are al treatment, use) and e statistically port for pilot
129579	Innovative Mental Health Service: Clinical Trials Not Allowed)	s Research Not Involving Clinical Trials (R01	National Institute of Mental Health/NIH/DHHS	PAR-25- 283	5-Feb-2026	Not Specified
	<u> </u>	Jennifer Humensky, PhD				
	Contact Telephone	,				
	·	Jennifer.Humensky@nih.gov				
	Sponsor Website					
	·	Link to program URL				
	_	05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , (05-Feb-2027 , 05-Jun-2027 , 05	5-Oct-2027		
	Synopsis	The purpose of this notice of funding opport the delivery of high-quality, continuously in or at risk for developing, a mental illness. The address NIMH strategic priorities that strent of the NIMH Strategic Plan. This NOFO solic identifying mutable factors that impact according to the strategic plan.	rtunity (NOFO) is to encourage nproving mental health service his announcement invites app gthen the public health impace its research projects including	e innovative researd es to benefit the gre lications for non-cli et of NIMH-supporte , but not limited to	eatest number of i nical trial R01-leve ed research as des the following: (a)	ndividuals with, el projects that cribed in Goal 4 research

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		outcomes, or scalability of mental health sed development, (b) research that develops an approaches to study these issues, and/or (defecting mental health services outcomes possible, projects should leverage existing in	nd tests new research tools, te c) research that integrates and using advanced computational	chnologies, measu analyzes large dat and predictive an	res, or methods an a sets to understan alytic approaches.	d statistical d factors
1 / 45 / 8	<u>Innovative Pilot Mental Health Se</u> (R34 Clinical Trial Not Allowed)	ervices Research Not Involving Clinical Trials	National Institute of Mental Health/NIH/DHHS	PAR-25- 284	L6-Feb-2026	450,000 USD
	Contact Name	Victor Lushin, M.D., Ph.D., M.S.W.				
	Contact Telephone	301-827-6280				
	Contact Email	victor.lushin@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026 ,	16-Feb-2027 , 16-Jun-2027 , 16	5-Oct-2027		
	Synopsis	The purpose of this Funding Opportunity A support the delivery of high-quality, continindividuals with, or at risk for developing, a projects that address NIMH strategic priori described in Goal 4 of the NIMH Strategic Faccess, continuity, utilization, quality, value services, which may serve as targets in fututools, technologies, measures, or methods and analyzing large data sets to understand and predictive analytic approaches; Where goals.	uously improving mental healt mental illness. This announce ties to strengthen the public herlan. Proposed research should and outcomes, including dispute service delivery intervention and statistical approaches to sal factors affecting mental healt	h services to bene ment invites applice ealth impact of NII seek to: Identify rotarities in outcome in development; Dottudy these issues; th services outcome	fit the greatest nuncations for non-clin MH-supported resemutable factors thates, or scalability of revelop and test new Test the feasibility des using advanced	nber of ical trial pilot arch as t impact nental health v research of integrating computation
I /XUX5	Development of Psychosocial The Mental Disorders (R61/R33 Clinic	erapeutic and Preventive Interventions for al Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-25- 182	20-Jan-2026 Optional][LOI/Pre- App]	Not Specified



Contact Telephone 301-827-7614

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding
SPIN ID	Frogram ritie	Sponsor Wante	Sponsor Number	Deadine Date	Amount

Contact Email alexander.talkovsky@nih.gov

Sponsor Website

Program URL Link to program URL

20-Jan-2026 [Optional][LOI/Pre-App], 19-Feb-2026, 16-May-2026 [Optional][LOI/Pre-App], 15-Jun-2026, 15-Sep-2026 Deadline Dates (ALL) [Optional] [LOI/Pre-App], 15-Oct-2026, 18-Jan-2027 [Optional] [LOI/Pre-App], 17-Feb-2027, 16-May-2027 [Optional] [LOI/Pre-App], 17-Feb-2027, 16-May-2027 [Optional] [LOI/Pre-App], 17-Feb-2027, 16-May-2027 [Optional] [LOI/Pre-App], 18-Jan-2027 [Optional] [LOI/Pre-App], 18-Jan-20 App], 15-Jun-2027, 15-Sep-2027 [Optional][LOI/Pre-App], 15-Oct-2027

> NIMH solicits clinical trial applications through a series of notice of funding opportunities (NOFOs) that cover the intervention development pipeline, from first-inhuman, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials The purpose of this NOFO is to encourage pilot research developing and testing innovative psychosocial intervention approaches in which the target and/or intervention strategy is novel. Consistent with NIMH's experimental therapeutics approach, this NOFO is intended to speed the translation of emergent research on mechanisms and processes underlying mental disorders into promising novel psychosocial preventative or therapeutic interventions. Targets may include, but are not limited to, potentially modifiable behavioral, cognitive, affective, and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms. Novel psychosocial interventions may be standalone interventions or novel augmentations to efficacious interventions for which there is an empirical rationale by which the augmentation (and corresponding target) is expected to substantially enhance outcomes. Support will be provided for up to two years (R61 phase) for preliminary milestone-driven testing of a novel intervention's impact on a target process or mechanism associated with mental disorder risk, causation, or maintenance (target engagement). Up to 3 years of additional support (R33 phase) will be provided for studies with findings that meet the "go/no-go" milestones embedded in the R61 phase. The R33 phase is intended to support the replication of target engagement and to test whether engaging the intervention target/mechanism mediates changes in clinical outcomes. Ultimately, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development and/or testing of the intervention. Applicants

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)

National Institute of Mental Health/NIH/DHHS

pursuing other stages of the clinical trial pipeline should consider one of the companion NOFOs listed above.

PAR-25-181

20-Jan-2026 [Optional][LOI/Pre-[qqA

Not Specified

Contact Name Alexander Talkovsky, Ph.D.

Contact Telephone 301-827-7614

Contact Email alexander.talkovsky@nih.gov

Sponsor Website

128983

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount

Program URL Link to program URL

20-Jan-2026 [Optional][LOI/Pre-App], 19-Feb-2026, 16-May-2026 [Optional][LOI/Pre-App], 15-Jun-2026, 15-Sep-2026 Deadline Dates (ALL) [Optional] [LOI/Pre-App], 15-Oct-2026, 18-Jan-2027 [Optional] [LOI/Pre-App], 17-Feb-2027, 16-May-2027 [Optional] [LOI/Pre-App], 17-Feb-2027, 16-May-2027 [Optional] [LOI/Pre-App], 17-Feb-2027, 16-May-2027 [Optional] [LOI/Pre-App], 18-Date [LOI/Pre-App], 1 App], 15-Jun-2027, 15-Sep-2027 [Optional][LOI/Pre-App], 15-Oct-2027

NIMH solicits clinical trial applications through a series of notice of funding opportunities (NOFOs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this NOFO is to encourage pilot research developing and testing innovative psychosocial intervention approaches in which the target and/or intervention strategy is novel. Consistent with NIMH's experimental therapeutics approach, this NOFO is intended to speed the translation of emergent research on mechanisms and processes underlying mental disorders into promising novel psychosocial preventative or therapeutic interventions. Targets may include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or Synopsis processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms. Novel psychosocial interventions may be standalone interventions or novel augmentations to efficacious interventions for which there is an empirical rationale by which the augmentation (and corresponding target) is expected to substantially enhance outcomes. The R33 is intended to support the replication of target engagement and to test whether engaging the intervention target/mechanism mediates changes in clinical outcomes. Ultimately, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development and/or testing of the intervention. Applicants pursuing other stages of the clinical trial

National Cooperative Drug/Device Discovery/Development Groups (NCDDG) National Institute of Mental for the Treatment of Mental Disorders (U01 Clinical Trial Optional)

Health/NIH/DHHS

PAR-25-352

25-Feb-2026

Not Specified

Contact Name Yael Mandelblat-Cerf, Ph.D.

Contact Telephone 301-793-7563

Contact Email vael.mandelblat-cerf@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 25-Feb-2026, 25-Jun-2026, 25-Oct-2026, 25-Feb-2027, 25-Jun-2027, 25-Oct-2027

pipeline should consider one of the companion NOFOs listed above.

The purpose of this notice of funding opportunity (NOFO) is to accelerate innovative drug and device therapies translation Synopsis from discovery to early human studies. Studies appropriate for this NOFO will develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health disorders; develop and validate tools (pharmacologic or

129833

	SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
--	---------	---------------	--------------	----------------	---------------	-------------------

neurostimulation) in support of experimental therapeutic studies of innovative candidates for mental disorders; and support early-stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Investigational Device Exemption (IDE)-ready devices for the treatment of mental disorders. This NOFO encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. This NOFO will also support applications proposing preclinical discovery of biotechnology products and biologics with potential as candidate therapeutics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral vector-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). This NOFO supports a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies. Projects seeking support for a research program of multiple projects directed toward a specific major objective, basic theme, or program goal, requiring a broadly based, multidisciplinary, and often long-term approach should consider the companion NOFO PAR-25-353.

126542

Summer Research Education Experience Program (R25 Clinical Trial Not Allowed)

National Institute of Neurological PAR-24-Disorders and Stroke/NIH/DHHS 204

18-Feb-2026 [Optional][LOI/Pre-Appl

625,000 **USD**

Contact Name Marguerite Matthews, Ph.D.

Contact Telephone 301-496-3272

Contact Email laura.kwako@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

18-Feb-2026 [Optional][LOI/Pre-App], 17-Mar-2026, 07-May-2026, 18-Feb-2027 [Optional][LOI/Pre-App], 17-Mar-2027, 07-May-2027

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a Synopsis workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Research Experiences for high school students, undergraduate students, and/or science teachers during the summer academic break.



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)	National Institute of Neurolo Disorders and Stroke/NIH/DF	gical PAR-25- IHS 050	1-Jan-2026 Optional][LOI/Pre- pp]	Not Specified

Contact Name Carol Taylor-Burds, PhD

Contact Telephone 301-496-1779

Contact Email carol.taylor-burds@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 21-Jan-2026 [Optional] [LOI/Pre-App], 20-Feb-2026, 23-May-2026 [Optional] [LOI/Pre-App], 22-Jun-2026

The purpose of this notice of funding opportunity (NOFO) is to support rigorous analytical validation of method(s) used for measuring biomarkers for neurological and neuromuscular disorders for use in clinical trials or clinical practice. Applicants must justify the unmet need for the biomarker(s) and measurement methods and specify one or two context(s) of use for the biomarker(s). Activities supported include optimizing and evaluating the accuracy, precision, reportable range, and analytical sensitivity and specificity of the detection method across multiple sites and operators and establishing reference intervals and quality control procedures. Multi-site applications are expected but not required. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFOinstructions carefully and view the available PEDP guidance material. The NIH recognizes that diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogeneous teams. There are many benefits that flow from a diverse scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved populations participate in, and benefit from research, and enhancing public trust. To support the best science, the NIH encourages inclusivity in research. Examples of structures that promote diverse perspectives include but are not limited to: Transdisciplinary research projects and collaborations among neuroscientists and researchers from fields such as computational biology, physics, engineering, mathematics, computer and data sciences, as well as bioethics. Engagement from different types of institutions and organizations (e.g., research-intensive, undergraduatefocused, minority-serving, community-based). Individual applications and partnerships that enhance geographic and regional heterogeneity. Investigators and teams composed of researchers at different career stages. Participation of individuals from diverse backgrounds, including groups traditionally underrepresented in the biomedical, behavioral, and clinical research

workforce (see NOT-OD-20-031), such as underrepresented racial and ethnic groups, those with disabilities, those from disadvantaged backgrounds, and women. Opportunities to enhance the research environment to benefit early- and mid-

Synopsis

SPIN ID Program Title		Sponsor Name	Sponsor Numbe	r Deadline Date	Funding Amount
	career investigators.				
123613 Clinical Validation of a Candidate Neuromuscular Disorders (U01 C		National Institute of Neurolo Disorders and Stroke/NIH/DI	~	21-Jan-2026 [Optional][LOI/Pre- App]	Not Specified
Contact Telephone	Carol Taylor-Burds, PhD 301-496-1779 carol.taylor-burds@nih.gov				
_	Link to program URL 21-Jan-2026 [Optional][LOI/Pre-App], 20-Fe	ob 2026 22 May 2026 [Ontio	aall[I OI/Bra_Ann	22_lun_2026	
	The purpose of this notice of funding oppo neurological and neuromuscular disorders validation of biomarker measurements with specificity of the biomarker consistent with identified, 2) detection method technology clinical need and potential context of use h (PEDP), which will be assessed as part of the	rtunity (NOFO) is to enable clin and conditions. Specifically, th hin the clinical population of in FDA guidelines. This PAR assu has already been developed a as been identified. This NOFO	ical validation of e goal of this PAF atterest to establishes that 1) a car and analytically varequires a Plan for	strong candidate bio t is to enable the rigo th the clinical sensitive adidate biomarker ha alidated, and 3) the re or Enhancing Diverse	orous clinical vity and as already been esearch and/or
Digital Health Technology Deriver 128722 Remote Monitoring and Endpoin Optional)	d Biomarkers and Outcome Assessments for t Development (UG3/UH3 - Clinical Trial	National Institute of Neurolo Disorders and Stroke/NIH/DI	•	21-Jan-2026 [Optional][LOI/Pre- App]	Not Specified
	Scott Janis, Ph.D.				
Contact Telephone					
	moyc@ninds.nih.gov				
Sponsor Website					
•	Link to program URL 21-Jan-2026 [Optional][LOI/Pre-App], 20-Fe	ah-2026 23-May-2026 [Ontio	nal][[OI/Dro_Ann]	22-lun-2026	
Synopsis	The nurnose of this notice of funding opno	rtunity (NOFO) is to support ri	gorous developm	ent and validation of	



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		clinical endpoint for interventional clinical propose to develop and evaluate the DHT of must also propose to conduct development advocacy organizations. The first phase of DHTs with PWLE input; the second phase is to validate the DHT. Research outcomes shaderived from the DHT(s) can be statistically	enabled biomarkers or COAs in It studies that are informed by this funding mechanism is to e Is to support a prospective long Iould include demonstrating ho	three or more dise people with lived ex valuate the technica itudinal clinical stud ow a meaningful cha	ases or conditions xperience (PWLE) al performance of ly in representative ange in the bioman	Applicants and patient the proposed e populations
126698 (Izheimer's Disease-Related Dementias al Career Transition Award to Promote Clinical Trial Not Allowed)	National Institute of Neurolo Disorders and Stroke/NIH/DI	~ 1.	2-Feb-2026	Not Specified
	Contact Name	Amelie Gubitz, Ph.D.				
	Contact Telephone					
		ADRDK99@ninds.nih.gov				
	Sponsor Website					
	-	Link to program URL				
	Deadline Dates (ALL)	12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 ,				
	Synopsis	The purpose of the NINDS Alzheimer's Dise Promote Diversity (K99/R00) program is to backgrounds, including those from groups Notice of NIH's Interest in Diversity), conducting the postdoctoral researchers from their equivalent faculty positions. The program whelp recipients establish independent researchers propositival feasibility study, or an ancillary study to experiences in a clinical trial led by a mental	support a cohort of new and to underrepresented in biomedic acting ADRD research. The pro- r mentored, postdoctoral rese will provide independent NIH re- earch programs in the ADRD field ing research that does not invoto to a clinical trial. Applicants to	calented, independe cal and behavioral so gram is designed to arch positions to incresearch support dueld. This Notice of Fullowe leading an indep	nt investigators from tiences (e.g. see Note of the facilitate a timely dependent, tenure of this transition of the facility o	om diverse OT-OD-20-031, transition of e-track or in order to y (NOFO) is ial, a clinical
I /hhuii -	NINDS Faculty Development Awa Research (K01 Independent Clinic	rd to Promote Diversity in Neuroscience cal Trial Required)	National Institute of Neurolo Disorders and Stroke/NIH/DI	· ()	7-Jan-2026	Not Specified
	Contact Name Contact Telephone	Michelle Jones-London 301-451-7966				



						- II
SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email	NINDSDiversityTraining@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 2027 , 12-Jun-2027 , 07-Sep-2027	. 12-Jun-2026 , 07-Sep-2026 , 1	12-Oct-2026 , 07-Jan	-2027 , 12-Feb-20	27 , 07-May-
	Synopsis	The purpose of the NINDS Faculty Develope participation in the independent neuroscie including those from groups underrepreser and career stage-appropriate mentorship a support under this award if they are in the application. This notice of funding opport investigator of an independent clinical trial research and career development. Those n in a clinical trial led by another investigator	ence research workforce by pronted in biomedical research, wand professional development first 3 years of a faculty tenurunity (NOFO) is designed specifical trial feasibility study ot planning an independent cl	roviding junior faculty vith research cost sup in neuroscience rese e track or equivalent ifically for candidates y, or a separate ancil linical trial, or propos	y from diverse bac pport, protected r earch. Individuals position at the til s proposing to ser lary clinical trial, a	ckgrounds, research time, are eligible for me of rve as the lead as part of their
	NINDS Alzheimer's Disease-Relate		National Institute of Neurolo	ngical PAR-24-		Not
126699	Postdoctoral Career Transition Av Not Allowed)	ward (K99/R00 Independent Clinical Trial	Disorders and Stroke/NIH/DI	1)	2-Feb-2026	Specified
		<u></u>				
		Amber McCartney, Ph.D.				
	Contact Telephone					
	Sponsor Website	amber.mccartney@nih.gov				
	•	Link to program URL				
	-	12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 ,	12-Feh-2027 . 12-Jun-2027			
		The purpose of the NINDS Alzheimer's Dise Award (K99/R00) program is to support a continuous The program is designed to facilitate a time postdoctoral research positions to independent NIH research support during to in the ADRD field. This Notice of Funding Odoes not involve leading an independent of	case-Related Dementias (ADRE cohort of new and talented, in ely transition of eligible postdo ident, tenure-track or equivale this transition in order to help pportunity (NOFO) is designed	dependent investiga octoral researchers fr ent faculty positions. recipients establish d specifically for cand	ators conducting A rom their mentore The program will independent rese didates proposing	ADRD research. ed, provide earch programs research that

SPII	N ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Candidatesto this NOFO are permitted to p	propose research experiences in	n a clinical trial lec	l by a mentor or co-	mentor.
127	7141 (Maximizing Opportunities for Scientific and Academic Independent Careers MOSAIC) Postdoctoral Career Transition Award to Promote Diversity K99/R00 - Independent Basic Experimental Studies with Humans Required BESH))	National Institute of Neurolog Disorders and Stroke/NIH/DF	•	07-Jan-2026	Not Specified
		Contact Name Lanay M. Mudd. Ph. D. FACSM				

Contact Name Lanay M. Mudd, Ph.D., FACSM

Contact Telephone 301-594-9346

Contact Email lanay.mudd@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

07-Jan-2026, 12-Feb-2026, 07-May-2026, 12-Jun-2026, 07-Sep-2026, 12-Oct-2026, 07-Jan-2027, 12-Feb-2027, 07-May-2027, 12-Jun-2027, 07-Sep-2027

The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) program is to support a cohort of early career, independent investigators from diverse backgrounds (for example, individuals from underrepresented groups) conducting research in NIH mission areas. The program has two components: an individual career transition award for postdoctoral scholars (K99/R00) and a research education cooperative agreement (UE5) awarded to organizations to provide these scholars with additional mentoring, networking and professional development activities to support their transition to and success in independent, tenure-track or equivalent research-intensive faculty careers. The MOSAIC program supports NIH's efforts to develop a biomedical research workforce that will benefit from the full range of perspectives, experiences and backgrounds needed to advance discovery. The goal of the MOSAIC Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to facilitate a timely transition of promising postdoctoral Synopsis researchers from diverse backgrounds from their mentored postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. The program is designed to support postdoctoral researchers who have demonstrated meaningful contributions and proposed compelling future plans to promote broad participation in the biomedical research workforce, such as activities that promote inclusive, supportive, and accessible biomedical research environments that support the success of trainees and scientists from all backgrounds, including individuals from underrepresented groups. This Notice of Funding Opportunity is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate

independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		fundamental aspects of phenomena without planning an independent clinical trial or basic experimental study was Trial Not Allowed' companion NOFO. The the participating NIH Institutes and Center	asic experimental study with huith huith humans led by another inve proposed project must be relat	umans, or proposing estigator, must apply ed to the programm	to gain research e to the 'Independe	experience in a ent Clinical
126685	NINDS Faculty Development Awa Research (K01 Independent Clinic	rd to Promote Diversity in Neuroscience cal Trial Not Allowed)	National Institute of Neurolo Disorders and Stroke/NIH/DI	- 111	7-Jan-2026	Not Specified
	Contact Name Contact Telephone	Michelle Jones-London, Ph.D. 301-451-7966				
	Contact Email	NINDSDiversityTraining@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jan-2026 , 12-Feb-2026 , 07-May-2026 2027 , 12-Jun-2027 , 07-Sep-2027	, 12-Jun-2026 , 07-Sep-2026 , 1	12-Oct-2026 , 07-Jan	-2027 , 12-Feb-20	27 <i>,</i> 07-May-
	Synopsis	The purpose of the NINDS Faculty Develop participation in the independent neuroscic including those from groups underreprese and career stage-appropriate mentorship support under this award if they are in the application. This notice of funding opport not involve leading an independent clinicathis NOFO candidates are permitted to proposing a clinical trial or an ancillary stunder NOFO (PAR-24-229).	ence research workforce by proented in biomedical research, wand professional development efirst 3 years of a faculty tenurounity (NOFO) is designed specifical trial, a clinical trial feasibility spose a research experience in	oviding junior faculty vith research cost sup in neuroscience reso e track or equivalent fically for candidates study, or an ancillary a clinical trial led by	r from diverse bac oport, protected rearch. Individuals position at the till proposing resear study to a clinica a mentor or co-m	kgrounds, esearch time, are eligible for me of ch that does I trial. Under entor. Those
129033	Career Transition Award for NINE Clinical Trial Required)	OS Intramural Clinician-Scientists (K22	National Institute of Neurolo Disorders and Stroke/NIH/DI	- 1/	2-Feb-2026	Not Specified
	Contact Telephone	Letitia Weigand, Ph.D. letitia.weigand@nih.gov				



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website					
	·	Link to program URL				
	-	12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 ,	12-Feb-2027 , 12-Jun-2027 , 1	2-Oct-2027		
	Synopsis	This NINDS K22 is specifically designed to scientists to independent, academic facult scientific research as well as clinical activit applicants proposing to serve as the lead is separate ancillary study to an existing trial independent clinical trial, or proposing to companion NOFO (PAR-25-215).	y positions that support clinicia ies. This Notice of Funding Opp nvestigator of an independent , as part of their research and o	an-scientists to enga portunity (NOFO) is c clinical trial, a clinica career development	ge in independen designed specifica al trial feasibility s . Applicants not pl	tly funded lly for tudy, or a lanning an
129031	Career Transition Award for NINE Clinical Trial Not Allowed)	OS Intramural Clinician-Scientists (K22	National Institute of Neurolo Disorders and Stroke/NIH/DI	1	2-Feb-2026	Not Specified
	Contact Name	Letitia Weigand, Ph.D.				
	Contact Telephone					
	Contact Email	letitia.weigand@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 ,	12-Feb-2027 , 12-Jun-2027 , 1	2-Oct-2027		
	Synopsis	This NINDS K22 is specifically designed to scientists to independent, academic facult scientific research as well as clinical activit applicants proposing research that does not ancillary clinical trial. Under this NOFO apprentor or co-mentor. Those proposing a companion NOFO (PAR-25-216).	y positions that support clinicia ies. This Notice of Funding Opp ot involve leading an independ plicants are permitted to propo	an-scientists to enga portunity (NOFO) is c ent clinical trial, a cl sse a research exper	ge in independen designed specifica inical trial feasibili ience in a clinical t	tly funded lly for ity study, or ar trial led by a
128868	Research Opportunities for New Workforce Diversity (R01 Clinical	and "At-Risk" Investigators to Promote Trial Optional)	National Institute of Neurolo Disorders and Stroke/NIH/DI	()	5-Feb-2026	Not Specified
	Contact Name	Lauren Ullrich, Ph.D.				
	Contact Telephone	301-451-7966				



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email	NINDSDiversityTraining@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 ,	05-Feb-2027 , 05-Jun-2027 , 05	5-Oct-2027		
	Synopsis	This Notice of Funding Opportunity (NOFO within the scientific mission areas of the parand At-Risk Investigators.		• • •	•	
129401		Gene-based Therapies for Ultra-Rare Disorders (U01 - Clinical Trial Optional)	National Institute of Neurolo Disorders and Stroke/NIH/DI		9-Feb-2026	Not Specified
	Contact Name	Chris Boshoff, Ph.D.				
	Contact Telephone	301-496-1779				
	Contact Email	chris.boshoff@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	09-Feb-2026 , 09-Jun-2026 , 09-Oct-2026 ,	09-Feb-2027 , 09-Jun-2027 , 08	3-Oct-2027		
	Synopsis	The Ultra-Rare Gene-Based Therapy (URGe planning activities for First-in-Human (FIH) oligonucleotides and viral-based gene ther funding opportunity announcement (FOA) biological rationale and demonstrated processpecified patient population towards an IN	clinical testing of gene-based of apies, for ultra-rare neurologic is to accelerate the development of of concept (POC) data for the	or transcript-directer al or neuromuscula ent of a promising cl e intended approac	ed therapeutics, sur disorders. The g linical candidate w	ich as oal of this vith robust
1 12661	NINDS Ruth L. Kirschstein Nationa Training of Postdoctoral Fellows (al Research Service Award (NRSA) for F32 Clinical Trial Not Allowed)	National Institute of Neurolo Disorders and Stroke/NIH/DI	0.	7-Jan-2026	Not Specified
	Contact Name	Tish Weigand, Ph.D.				
	Contact Telephone	301-496-4188				
	Contact Email	letitia.weigand@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-Jan-2026 , 09-Feb-2026 , 07-May-2026 , 2027 , 09-Jun-2027 , 07-Sep-2027 , 08-Oct-		09-Oct-2026 , 07-Jan	-2027 <i>,</i> 09-Feb-20	27 , 07-May-
	Synopsis	The purpose of this award is to support our outstanding mentors. Candidates are eligible proposed postdoctoral position to within 1 postdoctoral position. This NINDS F32 seed and/or innovative projects by the candidate strongly discouraged; rather, this F32 seeks will facilitate the development of the postdincorporate strong training in quantitative Support by this program is limited to the fill environment, so as to further encourage exparticular lab or environment. This Notice independent clinical trial, but does allow casponsor.	ole to apply for support from the 2 months (or 18 months fo rest ks to foster early, goal-directed that have the potential for sits innovative research ideas and doctoral fellow into an outstan reasoning and the quantitative rest 4 years of a candidate's actuarly, thoughtful planning and the funding Opportunity (NOFC)	nis program from ~1 submissions) after st d planning and to en ignificant impact. Inc d thoughtful plans for ding scientist. Applicate principles of experiivity in a specific laborimely completion of 0) does not allow can	2 months prior to arting in the prop courage application of preliminar training and metations are expect imental design an oratory or research "mentored training didates to propose	the start of the losed ons for bold hary data is entorship that ted to d analysis. The lose to lead an secto lead an
123196	NIH StrokeNet Clinical Trials and Recovery, and Prevention (UG3/U	Biomarker Studies for Stroke Treatment, JH3 Clinical Trial Optional)	National Institute of Neurolo Disorders and Stroke/NIH/DI	- 10	9-Feb-2026	Not Specified
	Contact Name	Scott Janis, Ph.D.				
	Contact Telephone	301-496-9135				
	Contact Email	moyc@ninds.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	19-Feb-2026 , 18-Jun-2026 , 19-Oct-2026				
	Synopsis	This NOFO encourages applications for mu interventions; biomarker or outcome measurevention, treatment, and recovery; and a within StrokeNet. Successful applicants will review, NINDS will prioritize studies among StrokeNet National Coordinating Center (Nefficiently and the National Data Management)	sure validation studies that are ancillary studies designed to ac I collaborate and conduct the g the highest scoring to be con ICC) will work with the success	e immediately prepared scientific aims to study within the NIH ducted in the NIH Studia applicant to impl	ratory to trials in sactive studies being StrokeNet. Follow rokeNet infrastrucement the propos	stroke ng conducted wing peer cture. The NIH sed study

StrokeNet Regional Coordinating Centers (RCCs) and their affiliated clinical sites will provide recruitment/retention support as

SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
-----------------------	--------------	----------------	---------------	-------------------

well as on-site implementation of the clinical protocol. The NIH StrokeNet network will also be uniquely poised to collaborate with other US and international consortia necessary to conduct larger, definitive trials of promising interventions for stroke treatment, prevention, and recovery. It is NINDS's intent that all NINDS-supported multi-center clinical trials in stroke treatment, recovery, or prevention will be conducted within the NIH StrokeNet. Only in exceptional circumstances will NINDS consider funding multi-site stroke clinical trials outside of this network. This NOFO uses the bi-phasic, milestone driven UG3/UH3 cooperative agreement activity code. Awards made under this NOFO will initially support a one-year milestonedriven planning and start-up phase, with possible transition to an implementation (UH3) phase of up to 6 additional years. Only UG3 projects that meet the scientific milestones and award requirements of the UG3 phase may transition to the UH3 phase. Applications submitted in response to this FOA must address both the UG3 and UH3 phases and are expected to include plans for project management and performance milestones for each phase. Applicants do not need to be part of the existing NIH StrokeNet infrastructure to apply under this NOFO.

128451

Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)

National Institute of Neurological PAR-25-Disorders and Stroke/NIH/DHHS 024

07-Jan-2026

Not Specified

Contact Name Carol Taylor-Burds Ph.D

Contact Telephone 301-496-1779

Contact Email carol.taylor-burds@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

07-Jan-2026, 21-Jan-2026 [Optional][LOI/Pre-App], 20-Feb-2026, 07-May-2026, 23-May-2026 [Optional][LOI/Pre-App], 22-Jun-2026, 07-Sep-2026, 20-Sep-2026 [Optional][LOI/Pre-App], 20-Oct-2026, 07-Jan-2027, 23-Jan-2027 [Optional][LOI/Pre-App], 22-Feb-2027, 07-May-2027, 22-May-2027 [Optional][LOI/Pre-App], 21-Jun-2027, 07-Sep-2027, 20-Sep-2027 [Optional][LOI/Pre-App], 20-Oct-2027, 07-Jan-2028

The purpose of this Notice of Funding Opportunity (NOFO) is to promote the development of fit-for-purpose candidate biomarkers and composite biomarker that enable more efficient clinical trials advance therapeutic development or clinical practice help guide clinical care decisions. Specifically, the goal of this phased funding mechanism is to first identify or confirm candidate biomarker(s) or biomarker signatures using human samples and/or data, followed by an independent Synopsis retrospective or prospective clinical study to conduct initial clinical validation of the biomarker/signature's clinical utility for one or two defined Context(s) of Use. In the first phase, applicants are expected to demonstrate that the biomarker acceptably identifies or predicts the concept of interest and may include optimization of the detection method using carefully standardized human samples or datasets. The overarching purpose of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies. This Notice of Funding Opportunity

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	(NOFO) requires a Plan for Enhancing Dive	erse Perspectives (PEDP).			
Innovation Grants to Nurture Init 128336 Neurotherapeutic Agent Characte (R61/R33 Clinical Trial Not Allower	erization and In vivo Efficacy Studies	National Institute of Neurolog Disorders and Stroke/NIH/DH	1 1 1 1 1 1	3-Feb-2026	750,000 USD
Contact Telephone Contact Email Sponsor Website Program URL	rebecca.roof@nih.gov	D) provides funding to conduct posed therapeutic agent(s) have sers that fall under the NINDS mis	harmacodynamic, p sufficient biological ssion. Therapeutic a	activity to warrar gents include sma	it further
Innovation Grants to Nurture Init 128339 Development and Validation of M Neurotherapeutic Discovery (R61	<u> 10del Systems to Facilitate</u>	National Institute of Neurolog Disorders and Stroke/NIH/DH	1 18	3-Feb-2026	750,000 USD
Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	rebecca.roof@nih.gov	o) encourages the development e phenotypic and physiologic ch	and validation of ar	efined neurologica	al or



					Funding
SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Amount
	therapeutic intervention. This NOFO is part Program focused on enabling the explorator requires a Plan for Enhancing Diverse Persp	ory and early stages of drug dis			
129691 Joint NINDS/NIMH Exploratory No Trial Optional)	euroscience Research Grant (R21 Clinical	National Institute of Neurolo Disorders and Stroke/NIH/DI	0.	7-Jan-2026	275,000 USD
Contact Name	Karrah Benson				
Contact Telephone	301-496-0838				
Contact Email	Karrah.benson@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct-		L6-Oct-2026 , 07-Jan	-2027 , 16-Feb-20	27 , 07-May-
Synopsis	The Joint NINDS/NIMH Exploratory Neuros projects, which fall within the missions of t stages of projects. These studies often asse but have the potential to bring about break development of novel techniques, agents, this funding opportunity also accepts clinic (studying pathophysiology or mechanism owith humans (BESH) will be supported. For within scope of this funding opportunity ar Opportunity Description, below, respective	the NINDS and NIMH. Awards were the feasibility of a novel awards throughs in the understandin methodologies, or models, of al trials, only applications proportion of an intervention, but information on NIH clinical trianouncement refer to the NIH	will provide support enue of investigation g of important areas high value to the neposing "mechanistic t not safety or efficated al definitions and the	for the early and n and involve constant of neuroscience, uroscience comm clinical trials or stacy) or basic expende types of clinical	conceptual siderable risk, or to the unity. While udies" rimental studies trials that are
Notice of Special Interest to Enco 128004 to Apply for PA-23-189: Research Health-Related Research (Admin		National Institute of Neurolo Disorders and Stroke/NIH/DI	7.	5-Feb-2026	Not Specified
Contact Name	Eric M. Hudak, PhD				
Contact Telephone	301-496-1779				
Contact Email	eric.hudak@nih.gov				
Sponsor Website					



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Feb-2026 , 15-Apr-2026 , 15-Nov-2026 ,	15-Feb-2027 , 15-Apr-2027 , 1	L5-Nov-2027 , 15-Fe	b-2028 , 15-Apr-20)28
	Synopsis	The NIH has a strong interest in the diversity Research shows that diverse teams working outperform homogenous teams. Scientists perspectives, creativity, and individual enterfrom a diverse NIH-supported scientific wo competitiveness, contributing to robust lead likelihood that underserved or health disparable trust. NIH encourages institutions to Participating institutes continue to support This specific notice reiterates this interest a Initiative community to apply for administry Research Supplements to Promote Diversity	g together and capitalizing on and trainees from diverse bace erprise to address complex scientifications, including: fostering scarning environments, improving erity populations participate in ouse legally available means to these efforts through ongoing and encourages eligible grant arative supplements in response	innovative ideas and kgrounds and life exentific problems. The identific innovation, of the quality of the pand benefit from he create a diverse are programs and suppend cooperative agree to PA-23-189 (or a	d distinct perspect eperiences bring di ere are many bene enhancing global research, advancing lealth research, and inclusive scientical plement funding of eement awardees ny subsequent reise	ifferent efits that flow ong the enhancing ific workforce. epportunities. in the HEAL essuances),
126781		cian Training Program (PCTP): Mentored r Development award (K23 - Clinical Trial	National Institute of Neurolo Disorders and Stroke/NIH/DI	~ 1	2-Feb-2026	Not Specified
	Contact Name	Laura D. Wandner				
	Contact Telephone					
	Contact Email	Laura.Wandner@nih.gov				
	Sponsor Website	<u>Link to sponsor website</u>				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	12-Feb-2026 , 12-Mar-2026 , 12-Jun-2026 , 2027 , 12-Jul-2027	12-Jul-2026 , 12-Oct-2026 , 12	2-Nov-2026 , 12-Feb	-2027 , 12-Mar-20	27 , 12-Jun-
	Synopsis	The purpose of the NIH HEAL Initiative Pair Career Development award (K23) (Clinical doctoral degrees to create a group of new program will provide independent NIH reseindependent research programs in areas suprogram. This Notice of Funding Opportunity	Trial Required) is to support th and well-trained, independent earch support during the early upported by the NIH HEAL Initi	e career developme investigators. This career phase to hel ative's Clinical Rese	ent of individuals w supervised career p recipients estab arch in Pain Mana	vith clinical development olish gement



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					_

investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the companion NOFO.

126790

NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored Clinical Scientist Development Awards (K08 - Clinical Trials Not Allowed)

National Institute of Neurological PAR-24-Disorders and Stroke/NIH/DHHS 219

12-Feb-2026

Not Specified

Contact Name Laura D. Wandner

Contact Telephone

Contact Email Laura.Wandner@nih.gov

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL)

12-Feb-2026, 12-Mar-2026, 12-Jun-2026, 12-Jul-2026, 12-Oct-2026, 12-Nov-2026, 12-Feb-2027, 12-Mar-2027, 12-Jun-2027, 12-Jul-2027

The purpose of this NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored Clinical Scientist Development Awards (K08 - Clinical Trials Not Allowed) is to support the career development of individuals with clinical doctoral degrees to create a group of new and well-trained, independent investigators. This supervised career development program will provide independent NIH research support during the early-career phase to help recipients establish independent research programs in areas supported by the NIH HEAL Initiative's Clinical Research in Pain Management program. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO applicants are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator should apply to the companion NOFO. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing

to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply

programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the

Synopsis

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	inician Training Program (PCTP): Mentored Awards (K08 - Clinical Trials Required)	National Institute of Neuro Disorders and Stroke/NIH/I	•	12-Feb-2026	Not Specified
Contact Nar Contact Telepho	ne Laura D. Wandner ne				
	Laura.Wandner@nih.gov te Link to sponsor website				
Program U	RL Link to program URL				
Deadline Dates (Al	12-Feb-2026 , 12-Mar-2026 , 12-Jun-2026 , 2027 , 12-Jul-2027	. 12-Jul-2026 , 12-Oct-2026 ,	12-Nov-2026 , 12-Fe	eb-2027 , 12-Mar-20)27 , 12-Jun-
Synop	The purpose of this NIH HEAL Initiative Pair Awards (K08) (Clinical Trials Required) is to create a group of new and well-trained, individual independent NIH research support during in areas supported by the NIH HEAL Initiati Opportunity (NOFO) is designed specifically clinical trial, a clinical trial feasibility study, career development. Applicants not plannical trial led by another investigator, mit	support the career develops dependent investigators. This the early-career phase to hel ve's Clinical Research in Pain y for applicants proposing to or a separate ancillary study ng an independent clinical tr	ment of individuals of supervised career of precipients establications. Management progreserve as the lead in to an existing trial, ial, or proposing to	with clinical doctoral development progresh independent restram. This Notice of vestigator of an industrance of as part of their resease.	al degrees to am will provide earch programs Funding ependent earch and
1 /118/13	n of Biomarkers for Alzheimer's Disease (AD) RD)?(U01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-23- 258	05-Feb-2026	Not Specified
Contact Nar	ne Yuan Luo, Ph.D.				
Contact Telepho	ne 301-496-9350				
Contact Em	ail <u>Yuan.Luo@nih.gov</u>				
Sponsor Webs	te				
Program U	RL Link to program URL				
Deadline Dates (Al	.L) 05-Feb-2026				
Synop	This notice of funding opportunity (NOFO) biomarkers of Alzheimer's disease (AD) and				



development, clinical trials, and/or clinical practice. Specifically, this NOFO will support analytical and/or clinical validation of

			\			
SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		a biomarker, composite biomarker, or bior and Drug Administration (FDA's) Biomarke pathways.		•	· ·	
126708	Alzheimer's Drug-Development P	rogram (U01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-25- 297	06-Jan-2026 [Optional][LOI/Pre- App]	Not Specified
	Contact Name	Lorenzo M. Refolo, Ph.D.				
	Contact Telephone	301-594-7576				
	Contact Email	refolol@nia.nih.gov				
	Sponsor Website	<u>Link to sponsor website</u>				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	06-Jan-2026 [Optional][LOI/Pre-App], 05-F App], 05-Jun-2026, 05-Jul-2026, 05-Sep-2 05-Nov-2026, 06-Jan-2027 [Optional][LOI/ Sep-2027 [Optional][LOI/Pre-App], 05-Oct-	026 [Optional][LOI/Pre-App], 0 Pre-App], 05-Feb-2027 , 06-Ma	5-Oct-2026 , 06-O ay-2027 [Optional]	ct-2026 [Optional][l [[LOI/Pre-App], 05-J	.OI/Pre-App],
	Synopsis	This Notice of Funding Opportunity (NOFO development of novel small-molecule and progression, or treat its cognitive and beha activities, such as the following:Medicinal of Toxicology (ADMET); Efficacy in animal modevelopment chemical synthesis under Gostudies; Initial Phase I clinical testing.	biologic drug candidates that a avioral symptoms. Grant recipie chemistry; Pharmacokinetics (F dels; Development of biomark	nim to prevent Alzlents will receive fuck.); Absorption, Diers for target enga	neimer's disease (AI unding for therapy d stribution, Metabol agement; Formulation	o), slow its evelopment ism, Excretion
124752	New Approaches for Measuring E (R01 Clinical Trial Optional)	Brain Changes Across Longer Timespans	National Institute on Aging/NIH/DHHS	PAR-25- 279	05-Feb-2026	Not Specified
	Contact Name	Elizabeth Newman, Ph.D.				
	Contact Telephone	301-480-7937				
	Contact Email	elizabeth.newman@nih.gov				
	Sponsor Website					



Program URL Link to program URL

	SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
--	---------	---------------	--------------	----------------	---------------	-------------------

Deadline Dates (ALL) 05-Feb-2026, 05-Jun-2026, 05-Oct-2026, 05-Feb-2027

The purpose of this funding opportunity is to encourage multidisciplinary investigators to develop new approaches or apply existing approaches in novel ways to measure brain activity, connectivity, genomics, or other aspects across the age spectrum of neurodevelopment. The overarching goal is to extend our understanding of brain development and aging, including studies of the neurodevelopmental origins of later health and disease. Research can include healthy human participants of any age; specific clinical groups such as those with cognitive, motor, or affective regulation challenges; and/or animal research on these domains of function. The studies can focus on longitudinal neuroanatomical or functional changes at any level, including genetics/genomics, single cells, connectomics, neural population activity patterns, and others. This funding opportunity is intended to encourage technological and conceptual innovation to improve repeated measures across longer epochs of the lifespan, to better predict outcomes at later ages. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

Synopsis

Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)

National Institute on Aging/NIH/DHHS

PA-25-246

16-Feb-2026

200,000 **USD**

Contact Name Luci Roberts, Ph.D.

Contact Telephone 301-496-9350

Contact Email roberlu@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 16-Feb-2026

This Small Research Grant Program (R03) will support meritorious projects to provide needed scientific insight to improve the prevention, diagnosis, treatment, and/or care for individuals with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Specifically, this NOFO will support projects covering a wide range of topics related to AD/ADRD. The overall goal of this NOFO is (i) to encourage the next generation of researchers to pursue research and academic careers in Synopsis AD/ADRD research; and (ii) to stimulate established researchers who have not had a major award in AD/ADRD research to perform pilot studies to develop new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from diverse backgrounds, including those from underrepresented groups are always encouraged to apply for NIH support. Investigators who have not successfully competed for an award under this or prior versions of this announcement are specifically encouraged to apply.

117878

			•			
SPIN ID Pr	ogram Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		er Transition Awards to Promote Diversity in DRD (K99/R00 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-24- 271	2-Feb-2026	Not Specified
	Contact Name	Yuan Luo, Ph.D.				
	Contact Telephone	301-496-9350				
	Contact Email	yuan.luo@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 ,	12-Feb-2027 , 12-Jun-2027			
	Synopsis	The purpose of this Notice of Funding Opportunity Alzheimer's disease and Alzheimer's disease dementia, and vascular dementia. This path backgrounds, including those from groups skills that they can apply to various aspects treatments and diagnostics, including all ast translational researchers as they transition program is to expand the pool of translation interdisciplinary approach to studies of AD, This NOFO is designed for candidates propertial feasibility study, or an ancillary clinical experience in a clinical trial led by a mento	e-related dementias (AD/ADRI hway to independence award underrepresented in the biom of AD/ADRD research (from p spects of behavioral and social to research independence in t nal researchers who can effect /ADRD treatment, prevention, osing research that does not in trial. Under this NOFO, candid	D), including frontot will support early caredical sciences, to go opulations studies tresearch). This progen the field of AD/ADRI tively participate in early detection, and wolve leading an income.	temporal dementi treer investigators ain critical transla to research that ca gram will support D. The long-term g and/or lead a tead d disease manage dependent clinical	a, Lewy body from diverse tional research an lead to new highly trained goal of this m-science, ment and care. trial, a clinical
1/8615	Academic Leadership Career wed)	Award (K07 Independent Clinical Trial Not	National Institute on Aging/NIH/DHHS	PAR-24- 321	2-Feb-2026	Not Specified
	Contact Name	Maria Carranza, Ph.D.				
	Contact Telephone					
	Contact Email	NIAtraining@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				



Synopsis The purpose of this notice of funding opportunity (NOFO) is to provide support for established investigators who have the

Deadline Dates (ALL) 12-Feb-2026, 12-Jun-2026, 12-Oct-2026, 12-Feb-2027, 12-Jun-2027, 12-Oct-2027

SPIN ID Program Title Sponsor Name Sponsor Number Deadline Date Amount
--

expertise and leadership skills to enhance aging and/or Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) research capacity within their academic institution. Through this award, investigators will endeavor to develop research and educational infrastructure, mentorship, and career development activities in support of new or emerging areas of aging and/or AD/ADRD research. These may include, but are not limited to, courses, curricula, research support, pilot funding, travel awards, visiting scholars, or networks. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO applicants are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (FON).

New Approaches for Measuring Brain Changes Across Longer Timespans 124754 (R21 Clinical Trial Optional)

National Institute on Aging/NIH/DHHS

PAR-25-272

16-Feb-2026

400,000 **USD**

Contact Name Elizabeth Newman, Ph.D.

Contact Telephone 301-480-7937

Contact Email elizabeth.newman@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 16-Feb-2026, 16-Jun-2026, 16-Oct-2026, 16-Feb-2027

The purpose of this funding opportunity is to encourage multidisciplinary investigators to develop exploratory, highly novel new approaches, or innovative applications of existing approaches, to measure brain activity, connectivity, genomics, or other aspects across the age spectrum of neurodevelopment. The overarching goal is to extend our understanding of brain development and aging, including studies of the neurodevelopmental origins of later health and disease, by improving repeated measures across longer epochs of the lifespan to better predict outcomes at later ages. Research can include healthy human participants of any age; specific clinical groups such those with cognitive, motor, or affective regulation challenges; and/or animal research on these domains of function. The studies can focus on longitudinal neuroanatomical or functional changes at any level, including genetics/genomics, single cells, connectomics, neural population activity patterns, and others. This funding opportunity is intended to encourage technological and conceptual innovation through this high risk, high reward funding mechanism to develop highly innovative ideas that either lack preliminary data or need additional preliminary data. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

Synopsis

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
129575		Experimental Approaches to Advance Drug Therapy Development for Alzheimer's R01 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-25- 374	6-Feb-2026	5,000,000 USD
	Contact Name	Jean Yuan, Ph.D.				
	Contact Telephone	301-496-9350				
	Contact Email	yuanx4@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	06-Feb-2026 , 09-Jun-2026 , 06-Oct-2026 ,	08-Feb-2027 , 09-Jun-2027 , 0	8-Oct-2027 , 07-Feb	-2028	
	Synopsis	This Notice of Funding Opportunity (NOFO enable rigorous preclinical testing of drugs investigational drugs at various stages of clap-related dementias (ADRD). This initiative candidates in combination with non-pharm of this NOFO is to establish robust proof of rational drug repositioning and the develop AD/ADRD.	s or drug combinations current linical development, predicted we will also support preclinical nacologic interventions leading f concept in mouse models or	ly used for other co to be efficacious in testing of repurposa to robust translation	nditions, as well as Alzheimer's Disea able or investigatic onal outcomes. Th f AD/ADRD that w	se (AD) and onal drug e central goal ill enable
120970		g Development (Phase 1 to 2a) for Novel rum of Alzheimer's Disease (AD) and AD- 'UH3 Clinical Trial Required)	National Institute on Aging/NIH/DHHS	PAR-25- 226	0-Feb-2026	Not Specified
	Contact Name	Akanni Clarke				
	Contact Telephone	301-496-9350				
	Contact Email	akanni.clarke@nih.gov				
	Sponsor Website					
	•	Link to program URL				
	Deadline Dates (ALL)	20-Feb-2026 , 22-Jun-2026 , 19-Oct-2026				
	Synopsis	The purpose of this notice of funding opposing phase 1 clinical trials with phase 1b/phase pharmacological interventions for Alzheim	2a clinical trials to streamline	the early-stage eval	uation of promisin	g

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		evaluated through this program, which car tau mechanisms and aim to address cognit pre-symptomatic to more severe stages of prespecified, go/no-go safety and tolerabil development.	ive and/or neuropsychiatric syr disease. This NOFO uses a phas	mptoms in individused award activity	uals across the spec code. Applications	ctrum, from must include
	Aging Research Dissertation Awar Not Allowed)	rds to Promote Diversity (R36 Clinical Trial	National Institute on Aging/NIH/DHHS	PAR-24- 130	L6-Feb-2026	Not Specified
	Contact Telephone	Jamie Lahvic, Ph.D. NIATraining@mail.nih.gov				
	Sponsor Website Program URL	Link to program URL				
	Program URL Deadline Dates (ALL)	Link to program URL 16-Feb-2026, 16-Mar-2026, 16-Jun-2026, This Notice of Funding Opportunity (NOFO engaged in research on aging and aging-rel within NIA's strategic priorities.) invites R36 applications to pro	omote diversity in		
1/U/Ih	Program URL Deadline Dates (ALL) Synopsis	16-Feb-2026, 16-Mar-2026, 16-Jun-2026, This Notice of Funding Opportunity (NOFO engaged in research on aging and aging-rel) invites R36 applications to pro	omote diversity in iding dissertation PA-25-		
1/U/1h	Program URL Deadline Dates (ALL) Synopsis Alcohol Treatment, Pharmacothe Trial Required) Contact Name Contact Telephone	16-Feb-2026, 16-Mar-2026, 16-Jun-2026, This Notice of Funding Opportunity (NOFO engaged in research on aging and aging-rewithin NIA's strategic priorities. Tapy, and Recovery Research (R01 Clinical Brett T. Hagman, Ph.D.) invites R36 applications to pro lated health conditions by prov National Institute on Alcohol	omote diversity in iding dissertation PA-25-	awards in all areas	of research 2,500,000
1/U/Ih	Program URL Deadline Dates (ALL) Synopsis Alcohol Treatment, Pharmacothe Trial Required) Contact Name Contact Telephone Contact Email Sponsor Website Program URL	16-Feb-2026, 16-Mar-2026, 16-Jun-2026, This Notice of Funding Opportunity (NOFO engaged in research on aging and aging-rewithin NIA's strategic priorities. Tapy, and Recovery Research (R01 Clinical Brett T. Hagman, Ph.D. 301-443-0638) invites R36 applications to pro lated health conditions by prov National Institute on Alcohol	omote diversity in iding dissertation PA-25-	awards in all areas	of research 2,500,000



		-	1			
SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		AUD treatment and recovery.				
120720 <u>Al</u>	cohol Health Services Research	(R01 Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/D	PA-25- HHS 245	05-Feb-2026	500,000 USD
	Contact Name	Laura E. Kwako, Ph.D.				
	Contact Telephone	301-451-8507				
	Contact Email	laura.kwako@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Feb-2026 , 05-Jun-2026				
	Synopsis	focusing on alcohol health services. This N disorder (AUD); within this focus, there are making treatment for AUD more appealing dissemination and implementation of exist as a means of addressing the treatment ga	e five major areas of emphasis: g, (3) examining cost structures ting evidence-based approache	(1) increasing acce and insurance syst s to treating AUD,	ess to treatment fo tems, (4) conductir	r AUD, (2) ng studies on
11621	evention and Intervention Applisorders (R34 Clinical Trial Optic	roaches for Fetal Alcohol Spectrum onal)	National Institute on Alcohol Abuse and Alcoholism/NIH/D	PAR-25- HHS 159	.6-Feb-2026	450,000 USD
	Contact Name	William Dunty, PhD				
	Contact Telephone	301-443-7351				
	Contact Email	duntyw@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026				
	Synopsis	This Notice of Funding Opportunity (NOFO strategies for fetal alcohol spectrum disord that advances (1) prevention approaches t	ders (FASD) throughout the life	span. The intent of	this NOFO is to su	pport resear



FASD. It is expected that research conducted via this mechanism will consist of studies that are a pre-requisite for preparing and submitting subsequent applications for larger scale FASD prevention or intervention studies. Applicants interested in

					- III	Funding
SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Amount
		exploratory phased projects may consider I	NOFO (PAR-25-158, the R61/R	33 option).		
116584	Notice of Special Interest (NOSI): Understanding and Preventing Al	Advancing mHealth Interventions for cohol-Related Domestic Violence	National Institute on Alcohol Abuse and Alcoholism/NIH/D	NOT-AA- HHS 23-003	7-Jan-2026	Not Specified
	Contact Name	Robert Freeman, Ph.D.				
	Contact Telephone	301-443-8820				
	Contact Email	rfreeman@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jan-2026 , 05-Feb-2026 , 12-Feb-2026 , 2026	16-Feb-2026 , 07-May-2026 , 0	5-Jun-2026 , 12-Ju	n-2026 , 16-Jun-20	26 , 07-Sep-
	Synopsis	In light of the documented increases in bot of the global COVID-19 pandemic and array grant application solicitation is to announce developing, testing, and intervening proximal cohol consumption at levels sufficient to victimization. In particular, this solicitation potential efficacy, and implementation of s (mHealth) that rely on communication tech the term "domestic violence" will extend to partner violence (IPV).	of mandated restrictions enact e NIAAA's interest in addressin hal to drinking occasions, when trigger DV and to provide skills seeks to advance the developr calable, low resource, and rem inologies for reducing and prev	cted to mitigate CC g the critical need risk of DV is eleva shown to reduce ment, feasibility, ac notely delivered int venting alcohol cor	OVID spread, the portion for research related ted, to decrease the risk of DV perpetracter prior to the reventions via more sumption and DV.	urpose of this d to ne likelihood of tion and esting, bile devices For this FOA,
120718	<u>Alcohol Treatment, Pharmacothe</u> <u>Trial required)</u>	rapy, and Recovery Research (R34 Clinical	National Institute on Alcohol Abuse and Alcoholism/NIH/D	PAR-25- HHS 193	6-Feb-2026	450,000 USD
	Contact Name	Brett T. Hagman, Ph.D.				
	Contact Telephone	301-443-0638				
	Contact Email	brett.hagman@nih.gov				



Sponsor Website

Program URL Link to program URL
Deadline Dates (ALL) 16-Feb-2026 , 16-Jun-2026

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The National Institute on Alcohol Abuse and focusing on alcohol treatment and recovery recovery from alcohol use disorder (AUD), mechanisms of behavioral change (MOBC), AUD treatment and recovery.	y research. This NOFO will focu including: medications develop	s broadly on topics ment, precision me	relevant for treat edicine, behaviora	ment of and I therapies and
120721 <u>A</u>	Alcohol Health Services Research	(R01 Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/D	PAR-25- HHS 192	5-Feb-2026	450,000 USD
	Contact Name	Laura E. Kwako, Ph.D.				
	Contact Telephone	301-451-8507				
	Contact Email	laura.kwako@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Feb-2026 , 16-Jun-2026				
	Synopsis	The National Institute on Alcohol Abuse and focusing on alcohol health services. This NO disorder (AUD); within this focus, there are making treatment for AUD more appealing dissemination and implementation of exist as a means of addressing the treatment gallows.	DFO will broadly focus on closing five major areas of emphasis: (3) examining cost structures ing evidence-based approaches	ng the treatment ga (1) increasing acces and insurance syste s to treating AUD, a	up for individuals was to treatment for ems, (4) conductin	vith alcohol use AUD, (2) g studies on
1 / / / / / / -	Prevention and Intervention App Disorders (R61/R33 Clinical Trial (roaches for Fetal Alcohol Spectrum Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/D	PAR-25- HHS 158	3-Feb-2026	Not Specified
	Contact Name	William Dunty, PhD				
	Contact Telephone	301-443-7351				
	Contact Email	duntyw@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	18-Feb-2026 , 17-Jun-2026 , 19-Oct-2026				
	Synopsis	This Notice of Funding Opportunity (NOFO)	focuses on prevention and int	ervention strategie	s for fetal alcohol	spectrum



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		disorders (FASD) throughout the lifespan. Tapproaches to reduce prenatal alcohol expendil be accomplished with the Exploratory/R61 phase will support pilot studies or second testing the hypotheses can be expanded in program staff after evaluation of the achieve to applications with clinical trials. Applicant consider NOFO (PAR-25-159, the R34 options)	osure and the incidence of FAS Developmental Phased Award ondary data analysis for hypoth the R33 phase. The transition wement of specific milestones stainterested in planning clinica	D and (2) intervent (R61/R33) mechani esis development ato the R33 phase wet for the R61 phas	ions for FASD. The ism, clinical trial o and feasibility, and ill be determined se. Highest priority	ese objectives ptional. The d research by NIAAA y will be given
124298	•	ment Award for Postdoctorate Au.D./Ph.D. asic Experimental Studies with Humans	National Institute on Deafnes and Other Communication Disorders/NIH/DHHS	PAR-7/1-	7-Jan-2026	315,000 USD
	Contact Name	Alberto L. Rivera-Rentas, Ph.D.				
	Contact Telephone	301-496-1804				
	Contact Email	riverara@nidcd.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jan-2026 , 13-Feb-2026 , 07-May-2026 , 2027	15-Jun-2026 , 07-Sep-2026 , 14	4-Oct-2026 , 07-Jan	-2027 , 17-Feb-20	027 , 07-May-
	Synopsis	The purpose of the NIDCD Mentored Cared support comprehensive and rigorous postd behavioral, or clinical sciences of promising independent investigators in scientific heal Opportunity (NOFO) is designed specifically clinical trial, a clinical trial feasibility study, career development. Applicants not plannic clinical trial led by another investigator, mu	loctoral research and career de g Au.D./Ph.D. audiologists who th-related research fields relevy for applicants proposing to se or a separate ancillary study to g an independent clinical trial	velopment experie have the potential ant to NIDCD's missive as the lead inverse an existing trial, as , or proposing to ga	nces in the biome to become produ- sion. This Notice o estigator of an ind s part of their rese	edical, ctive, of Funding ependent earch and
1/4/4/	NIDCD Mentored Career Develop Audiologists (K01 Clinical Trial Re	ment Award for Postdoctorate Au.D./Ph.D. quired)	National Institute on Deafnes and Other Communication Disorders/NIH/DHHS	PAR-14-	7-Jan-2026	315,000 USD
	Contact Name	Alberto L. Rivera-Rentas, Ph.D.				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					_

Contact Telephone 301-496-1804

Contact Email riverara@nidcd.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

07-Jan-2026, 13-Feb-2026, 07-May-2026, 15-Jun-2026, 07-Sep-2026, 14-Oct-2026, 07-Jan-2027, 17-Feb-2027, 07-May-2027

The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Funding Opportunity Synopsis Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA PAR-21-085 for Clinical Trial Required or for PAR-21-087 for Independent Basic Experimental Studies with Humans Required.

SPIN ID	Program Title	Chancar Nama	Sponsor Number	Deadline Date	Funding Amount
124299	NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Independent Clinical Trial Not Allowed)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24- 159	07-Jan-2026	315,000 USD

Contact Name Alberto L. Rivera-Rentas, Ph.D.

Contact Telephone 301-496-1804

Contact Email riverara@nidcd.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-Jan-2026 , 13-Feb-2026 , 07-May-2026 , 15-Jun-2026 , 07-Sep-2026 , 14-Oct-2026 , 07-Jan-2027 , 17-Feb-2027 , 07-May-2027

Synopsis The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D.



SPIN ID	Program Title		Sponso	or Name	Sponsor Number	Deadline Date	Funding Amount
			Audiologists (K01) is to sudevelopment experiences Au.D./Ph.D. audiologists vin scientific health-related Opportunity (NOFO) is deleading an independent ctrial. Applicants to this NO a mentor or co-mentor. Tinvestigator, should apply	s in the biomedical, beh who have the potential d research fields releva signed specifically for a linical trial, a clinical tri DFO are permitted to p hose proposing a clinic	navioral, or clinical so to become product int to NIDCD's mission applicants proposing al feasibility study, ropose research exp al trial or an ancilla	cciences of promis cive, independent on. This Notice of I g research that do or an ancillary stud perience in a clinic ry clinical trial as le	ing investigators Funding es not involve dy to a clinical al trial led by
		Notice of Special Interest 117406 Language and Communic Verbal/Non-Speaking Inc	cation in Minimally	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	NOT-DC- 23-009	05-Jan-2026	Not Specified
		Contact Name	Holly L. Storkel, Ph.D.				
		Contact Telephone	301-496-5061				
		Contact Email	holly.storkel@nih.gov				
		Sponsor Website					
		Program URL	Link to program URL				
			05-Jan-2026, 07-Jan-2026 The purpose of this Notice to promote language and speaking. Further researc interventions, develop an identify meaningful outcome	e of Special Interest (No communication in aut h is needed to evaluate d apply new research o	OSI) is to encourage istic individuals who and tailor existing	e applications for r o are minimally ver interventions, dev	esearch rbal/non- relop novel
		RFA-DC-25-004 NIDCD 129385 for New Investigators to Development (R01 Clinic	Promote Workforce	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	RFA-DC- 25-004	06-Feb-2026	2,499,995 USD

Contact Name

SPIN ID	Program Title		Spo	onsor Name	Sponsor Number	Deadline Date	Funding Amount	
		Contact Telephone	301-402-3458					
			NIDCDRFADC25004@	nidcd.nih.gov				
		Sponsor Website		<u> </u>				
		•	Link to program URL					
			06-Feb-2026 , 08-Jun-	-2026 , 06-Oct-2026				
		Synopsis	This Notice of Funding Opportunity (NOFO) solicits R01 grant applications that propose independent research projects that are within the scientific mission areas of the National Institute on Deafness and Other Communication Disorders (NIDCD). This program is intended to support Early Stage and New Investigators from diverse backgrounds, including individuals from groups underrepresented in the health-related sciences. Preliminary data are not required for this NOFO however, the project should be supported by sufficient information to give confidence to the reviewers that the proposed work is feasible.					
		NIDCD Research Career E 123925 Established Investigators Experimental Studies with	(K18 Independent Ba	1)eathess and ()ther	PAR-24- 142)7-Jan-2026	Not Specified	
		Contact Name	Alberto L. Rivera-Ren	tas, Ph.D.				
		Contact Telephone	301-496-1804					
		Contact Email	riverara@nidcd.nih.ge	<u>ov</u>				
		Sponsor Website						
		Program URL	Link to program URL					
		Deadline Dates (ALL)	07-Jan-2026 , 09-Feb- , 08-Feb-2027 , 07-Ma	-2026 , 07-May-2026 , 08-J ay-2027	un-2026 , 07-Sep-20	026 , 08-Oct-2026	, 07-Jan-2027	
		Synopsis	program is to enable programs through the hearing, balance, sme Announcement is for	IDCD Research Career Enh established, proven invest e acquisition of new researell, taste, voice, speech and basic science experimentave basic science studies invested in the stable in	igators to augment rch skills to answer of d language sciences. Il studies involving h	or redirect their re questions relevant This Funding Opp umans, referred t	esearch to the ortunity o in NOT-OD-	



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding
	1.108.4	openior manie			Amount

within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFOs PAR-24-140 and PAR-24-143

NIDCD Research Career Enhancement Award for 123928 Established Investigators (K18 Independent Clinical Trial Not Allowed)

National Institute on Deafness and Other Communication Disorders/NIH/DHHS

PAR-24-07-Jan-2026 143

Not Specified

Contact Name Alberto L. Rivera-Rentas, Ph.D.

Contact Telephone 301-496-1804

Contact Email riverara@nidcd.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

07-Jan-2026, 09-Feb-2026, 07-May-2026, 08-Jun-2026, 07-Sep-2026, 08-Oct-2026, 07-Jan-2027 08-Feb-2027, 07-May-2027

Synopsis

The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Notice of Funding



SPIN ID	Program Title		Sponso	or Name	Sponsor Number	Deadline Date	Funding Amount
			Opportunity (NOFO) is de leading an independent of trial. Applicants to this NO a mentor or co-mentor. Tinvestigator, should apply	linical trial, a clinical tri DFO are permitted to p hose proposing a clinic	al feasibility study, ropose research exp al trial or an ancilla	or an ancillary stud perience in a clinic ry clinical trial as le	dy to a clinical al trial led by ead
		NIDCD Research Career 123922 Established Investigators Required)	Enhancement Award for s (K18 Clinical Trial	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24- 140	07-Jan-2026	Not Specified
		Contact Telephone	Alberto L. Rivera-Rentas, 301-496-1804 I riverara@nidcd.nih.gov	Ph.D.			
		Sponsor Website					
		·	Link to program URL				
		Deadline Dates (ALL)	07-Jan-2026 09-Feb-202	•	un-2026 , 07-Sep-20	26 , 08-Oct-2026 ,	07-Jan-2027
		Synopsis	The purpose of the NIDCI program is to enable esta programs through the acchearing, balance, smell, to Announcement (FOA) is convestigator of an independent clinical transcript investigator, must another investigator, must be a single program of the study to an existing trial, an independent clinical transcript investigator, must be study to an existing trial, an independent clinical transcript investigator, must be study to an existing trial, an independent clinical transcript.	blished, proven investiquisition of new researd aste, voice, speech and lesigned specifically for indent clinical trial, a cli as part of their researchial, or proposing to gai	gators to augment of ch skills to answer of language sciences. applicants proposion nical trial feasibility hand career develor n research experien	or redirect their requestions relevant This Funding Opping to serve as the study, or a separation of the study, or a separation of the study of the	search to the ortunity lead te ancillary s not planning
		124315 NIDCD Early Career Reservation Clinical Trial Optional)	earch (ECR) Award (R21	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-25- 120	8-Feb-2026	375,000 USD



SPIN ID	Program Title		Sponse	or Name	Sponsor Number	Deadline Date	Funding Amount		
		Contact Telephone Contact Email Sponsor Website Program URL	watsonb@nidcd.nih.gov						
		Synopsis	research from scientists who are beginning to establish an independent research can be used for thesis or dissertation research. The research must be focused on one or areas within the biomedical and behavioral scientific mission of the NIDCD: hearing, taste, voice, speech, or language. The NIDCD FCR Award R21 grant mechanism supplies.						
		NIDCD Cooperative Agree 122020 Communication Disorder Required)	ement for Clinical Trials in s (U01 - Clinical Trial	National Institute or Deafness and Other Communication Disorders/NIH/DHH	PAR-25- 343	.8-Feb-2026	Not Specified		
		Contact Name	Trinh T. Ly, M.D.						
		Contact Telephone	301-435-4085						
		Contact Email	trinh.ly@nih.gov						
		Sponsor Website							
		-	Link to program URL	oc. 40 Out 2025, 45 T		7 40 0 : 222			
		Deadline Dates (ALL)	18-Feb-2026 , 18-Jun-202		•	-	ovention of		
		Synopsis	The NIDCD is committed communication disorders opportunity supports a c	by supporting well-de	esigned and well-exe	cuted clinical trial	s. This funding		



SPIN ID	Program Title				Sponsor Name	Spo	onsor Number	Deadline Date	Funding Amount
				Investigator to support a clinical trial that meets ANY of the following criteria: requires FDA oversight, is intended to formally establish efficacy, or has potentially higher risks to participants. Clinical trial applications exceeding the annual direct costs of \$700,000 or more, in certain cases, may also be a criterion for this funding opportunity. These investigator-initiated clinical trials are perceived to benefit from close interaction, oversight, and guidance resulting from a cooperative agreement. Only one clinical trial may be proposed per application submitted to this funding opportunity.					
		117259	Notice of Special Interest Women's Health Researc Mission Areas	_	Deafne Commu	al Institute on ss and Other unication ers/NIH/DHHS	NOT-DC- 23-006)7-Jan-2026	Not Specified
			Contact Name	Christopher Myers	5				
			Contact Telephone	301-435-0713					
			Contact Email	myersc@nidcd.nih	n.gov				
			Sponsor Website						
			Program URL	Link to program U	<u>RL</u>				
			Deadline Dates (ALL)	07-Jan-2026 , 05-F	eb-2026 , 16-Feb	o-2026 , 25-Feb-2	026 , 07-May-20	026	
			Synopsis	The National Instit Notice of Special II within the scope of research training if speech, and langual NIDCD Strategic Platifespan are encoustudies which may traits, societal aspe	nterest (NOSI) to of NIDCD's mission on the normal and age. As noted in an NIDCD), res or incorporate and	stimulate researd n. NIDCD's missing disordered procently issued arch projects to the NIDCD mission tomical, structure	ch in areas regation is to conductesses of hearinged 2023–2027 Nimprove the hearingen areas. These pal, hormonal, or	rding the health of t and support rese g, balance, taste, si IDCD Strategic Pla alth of women cov projects may include genetic aspects, b	f women arch and mell, voice, n (2023-2027 vering the de biological pehavioral
		122887	RFA-DA-25-023 Integra and Molecular Profiling of the Effects of Addictive S Clinical Trial Not Allowed	of Cell Ensembles En Substances in Roder	ncoding Nationa		ug RFA-DA- 25-023	24-Jan-2026 Optional][LOI/Pre- App]	700,000 USD



			0							
SPIN ID	Program Title		Spor	sor Name	Sponsor Number	Deadline Date	Funding Amount			
		Contact Name	Olivier Berton, PhD							
		Contact Telephone	•							
		·	olivier.berton@nih.gov							
		Sponsor Website								
		•	Link to program URL							
		_	-	[LOI/Pre-App], 23-Feb-20	126					
		Synopsis	innovative scalable tech ensembles encoding th chronic, withdrawal, at generated through pop rodents, with other gra such as transcriptomic goal is to inform new m	opportunity (NOFO) aims nologies to inventory, ree effects of addictive substinence, relapse). Emphibility and the measurement of the measurement	egister and molecula ostances, across vari nasis is on approache ents of cellular activ ollected from the sar onnectivity and spat	arly profile distributions stages of exposes capable of integrity dynamics in being cells at single-cial localization. The	ited cell osure (acute, grating data having ell resolution, e overarching			
		127413 NIDA Animal Genomics Partial Not Allowed)	Program (U01 – Clinical	National Institute or Abuse/NIH/DHHS	n Drug PAR-24- 269	l1-Feb-2026	Not Specified			
		Contact Name	Amy C. Lossie, PhD							
		Contact Telephone	•							
		Contact Email	lossieac@mail.nih.gov							
		Sponsor Website	_							
		Program URL	Link to program URL							
		Deadline Dates (ALL)	11-Feb-2026 , 23-Jul-20	026 , 11-Feb-2027						
		Synopsis	The purpose of the National Institute on Drug Abuse (NIDA) Animal Genetics Program is to identification, genomic, and molecular (epi)genetic variants that underlie neural and behavioral processes and phenotypes relevant to SUD risk, the SUD trajectory and SUD comorbidities. This							

SPIN ID Program Title Sponsor Name Sponsor Num	per Deadline Date Funding Amount
--	----------------------------------

nucleotide variants (SNVs), indels, large and small structural variants, and all types of mobile DNA. NIDA encourages applications that take genomics, multi-omics, data-based, and/or artificial intelligence/machine learning approaches that integrate multi-level 'omics data, delineate gene networks, and/or uncover the function of known or newly discovered genetic or epigenetic variants. Other areas of interest include variant identification at the circuit level and the application of neuroscience to variant identification studies in tissues and cells. NIDA expects these studies to uncover novel mechanisms that contribute to various stages across the SUD trajectory and inform future studies about potential targets and therapeutic strategies for addiction. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).

RFA-DA-25-060 -- High Priority HIV and Substance 123537 Use Research (RM1 Clinical Trial Optional)

National Institute on Drug Abuse/NIH/DHHS

RFA-DA-25-060

11-Feb-2026

7,500,000 USD

Contact Name Vasundhara Varthakavi, DVM, PhD

Contact Telephone 301-443-2146

Contact Email vasundhara.varthakavi@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 11-Feb-2026, 14-Feb-2026, 11-Feb-2027

The purpose of this notice of funding opportunity (NOFO) is to support high priority research at the intersection of HIV and substance use. This NOFO invites research projects with the potential to open new areas of basic and clinical HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use addictive substances. This initiative is

open only to research teams of three to six PD/PIs proposing to pursue challenging research questions at the intersection of HIV and substance use. Teams are encouraged to consider far-Synopsis reaching objectives that will produce major advances in high priority HIV research areas for the institute and the NIH (NOT-OD-20-018: UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding). This NOFO addresses basic science, epidemiologic, clinical, intervention, and implementation research related to HIV in people with substance use and substance use disorders (SUDs). This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be

			5				
SPIN ID	Program Title		Spon	sor Name	Sponsor Number	Deadline Date	Funding Amount
			withdrawn. Applicants the available PEDP guid	are strongly encouraged ance material.	I to read the NOFC) instructions carefu	lly and view
		127285 RFA-DA-25-024 High P Use Research (R01 Clinic		e National Institute or Abuse/NIH/DHHS	n Drug RFA-DA- 25-024	12-Jan-2026 [Optional][LOI/Pre App]	Not Specified
		Contact Name	Richard A. Jenkins, Ph.D).			
		Contact Telephone	301-443-1923				
		Contact Email	jenkinsri@nida.nih.gov				
		Sponsor Website					
		Program URL	Link to program URL				
		Deadline Dates (ALL)		[LOI/Pre-App], 11-Feb-20 tional][LOI/Pre-App], 11		Optional][LOI/Pre-A	pp], 13-Aug-
		Synopsis	intersection of HIV and open new areas of HIV/cure of HIV among peopare required to have a cwith substance use. Thi addresses basic science to HIV in people with suareas must align with the HIV/AIDS Research Prio	ice of funding opportunic substance use. This NOF AIDS research and/or leade who use addictive substailed research plan, post initiative is open to boo, epidemiologic, clinical, ubstance use and substance NIH's HIV/AIDS Researities and Guidelines for IOFO) requires a Plan for	O invites research ad to new avenues bstances. Applicat reliminary data, and th individual resea intervention, and nce use disorders rch Priorities: NOT Determining HIV/	projects with the pass for prevention, tresions submitted undend a clear description rchers and research implementation research (SUDs). The propose F-OD-20-018: UPDAT AIDS Funding. This N	otential to atment and er this NOFO n of the nexus teams. It earch related of research TE: NIH
	Notice of Special Interest Pharmacogenomic Apple and Substance Use Disconstructions Strategies, A Jump Into		paches to Enhancing HIV der (SUD) Treatment	National Institute or Abuse/NIH/DHHS	n Drug NOT-DA- 24-001	07-Jan-2026	Not Specified
		Contact Name Contact Telephone	Guifang Lao, Ph.D. 301-827-5931				



CDINI ID	Dua aurana Tiala			Constant Name	Construction National Assets	Danillina Data	Funding
SPIN ID	Program Title			Sponsor Name	Sponsor Number	Deadline Date	Amount
		Sponsor Website Program URL					
			NIDA is interested	eb-2026, 16-Feb-2026, 07 in receiving research props a crucial step in the sciend rug abuse	osals focusing on study		
		Substance Use/Substance 119295 Dissertation Research Av Not Allowed)		rials National Institute Abuse/NIH/DHHS	- (07-Jan-2026	100,000 USD
		Contact Name	Marsha F. Lopez, P	Ph.D., M.H.S.			
		Contact Telephone	301-443-6504				
		Contact Email	marsha.lopez@nih	n.gov			
		Sponsor Website					
		· ·					
		Deadline Dates (ALL)	07-Jan-2026 , 16-F	eb-2026 , 07-May-2026 , 1	6-Jun-2026 , 07-Sep-20	026	
Program URL Deadline Dates (ALL) Or-Jan-2026, 16-Feb-2026, 07-May-2026, 16-Jun-2026, 07-Sep-2026 The goal of this Notice of Funding Opportunity (NOFO) is to support doctoral cand variety of academic disciplines for up to two years for the completion of the doctoresearch project. Research projects should align with the NIDA Strategic Plan (202: Strategic Plan Director's Message National Institute on Drug Abuse (NIDA) (nih.g. will facilitate the entry of promising new investigators into the field of substance use disorder (SU(D) research, enhancing the pool of highly talented SU(D) research are particularly encouraged from individuals from diverse backgrounds, including the underrepresented groups as described in the Notice of NIH's Interest in Diversity (This NOFO is designed specifically for applicants proposing research that does not an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical to this NOFO are permitted to propose research experience in a clinical trial led by mentor.					on of the doctoral tegic Plan (2022-2 e (NIDA) (nih.gov) of substance use, SU(D) researchers ands, including tho st in Diversity (NOn that does not invacillary clinical tria	dissertation 026 NIDA . This award substance s. Applications se from T-OD-20-031) olve leading I. Applicants	

117405 Notice of Special Interest (NOSI): Liveraging Glial

Not

National Institute on Drug NOT-DA- 07-Jan-2026

N ID	Program Title		Sponso	or Name	Sponsor Number	Deadline Date	Funding Amount
		Cells to Treat Addiction		Abuse/NIH/DHHS	24-006		Specified
		Contact Name	Shang-Yi Anne Tsai, Ph.D.				
		Contact Telephone	301-827-5842				
		Contact Email	stsai@nih.gov				
		Sponsor Website					
		Program URL	Link to program URL				
		Deadline Dates (ALL)	07-Jan-2026 , 05-Feb-202 , 12-Jun-2026 , 16-Jun-202		re-App], 16-Feb-20	026 , 07-May-2026 ,	05-Jun-202
		Synopsis	This Notice of Special Inte functions of glial cells and due to acute or chronic ex	develop strategies to	mitigate Central N	ervous System (CN	S) damage
			treatments.				
		127894 Imaging - Science Track A Transition (I/START) (R03	ward for Research	National Institute or Abuse/NIH/DHHS	Drug PAR-24- 297	07-Jan-2026	150,000 USD
		Transition (I/START) (R03	ward for Research		•	07-Jan-2026	
		Transition (I/START) (R03	ward for Research - Clinical Trial Optional) Hoang Le, Ph.D.		•	07-Jan-2026	
		Transition (I/START) (R03 Contact Name Contact Telephone	ward for Research - Clinical Trial Optional) Hoang Le, Ph.D.		•	07-Jan-2026	
		Transition (I/START) (R03 Contact Name Contact Telephone	Hoang Le, Ph.D. 301-451-8849		•	07-Jan-2026	
		Contact Name Contact Telephone Contact Email Sponsor Website	Hoang Le, Ph.D. 301-451-8849		•	07-Jan-2026	
		Contact Name Contact Telephone Contact Email Sponsor Website Program URL	Hoang Le, Ph.D. 301-451-8849 hoang.le@nih.gov	Abuse/NIH/DHHS 6 , 07-May-2026 , 16-J	297 un-2026 , 07-Sep-2	026 , 16-Oct-2026	, 07-Jan-202



IN ID	Program Title		Sponso	r Name	Sponsor Number	Deadline Date	Funding Amount
		Transition (D/START) (DO	2 Clinical Trial Ontional	Abusa/NIII/DUUS	226		USD
		<u>Transition (D/START) (R0</u>	<u> </u>	Abuse/NIH/DHHS	236		บรม
			Susan N. Wright, Ph.D.				
		Contact Telephone					
			susan.wright@nih.gov				
		Sponsor Website					
		Program URL	Link to program URL				
		Deadline Dates (ALL)	07-Jan-2026 , 16-Feb-202 , 16-Feb-2027 , 07-May-20	•)26 , 16-Oct-2026 ,	, 07-Jan-202
		Synopsis	This notice of funding oppositions cutting-edge data science to substance use and/or solutional Institute on Drug applications to support re	techniques to addres ubstance use disorder Abuse (NIDA). This N	s timely and challeng (SUD) in all areas of OFO requests Small	ging research ques f research support Research Grant (R	stions relate ed by the 103)
			limited resources.	searen projects that e	an be carried out in	a short period or t	ime with
		125421 Interventions to Reduce (R01 - Clinical Trials Option	limited resources. Sleep Health Disparities	National Institute or Minority Health and Disparities/NIH/DHF	n PAR-24- Health 330 C	07-Jan-2026	Not Specifie
		(R01 - Clinical Trials Option	limited resources. Sleep Health Disparities	National Institute or Minority Health and Disparities/NIH/DH	n PAR-24- Health 330 C	<u> </u>	Not
		(R01 - Clinical Trials Option	Sleep Health Disparities onal) Arielle S. Gillman, PhD, M	National Institute or Minority Health and Disparities/NIH/DH	n PAR-24- Health 330 C	<u> </u>	Not
		Contact Name Contact Telephone	Sleep Health Disparities onal) Arielle S. Gillman, PhD, M	National Institute or Minority Health and Disparities/NIH/DH	n PAR-24- Health 330 C	<u> </u>	Not
		Contact Name Contact Telephone	Sleep Health Disparities onal) Arielle S. Gillman, PhD, M 301-435-0060 arielle.gillman@nih.gov	National Institute or Minority Health and Disparities/NIH/DH	n PAR-24- Health 330 C	<u> </u>	Not
		Contact Name Contact Telephone Contact Email Sponsor Website	Sleep Health Disparities onal) Arielle S. Gillman, PhD, M 301-435-0060 arielle.gillman@nih.gov	National Institute or Minority Health and Disparities/NIH/DH	n PAR-24- Health 330 C	<u> </u>	Not
		Contact Name Contact Telephone Contact Email Sponsor Website	Arielle S. Gillman, PhD, M 301-435-0060 arielle.gillman@nih.gov Link to program URL	National Institute or Minority Health and Disparities/NIH/DHI PH	n PAR-24- C Health 330 IS 330 un-2026 , 07-Sep-20	07-Jan-2026	Not Specifie
		Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Sleep Health Disparities onal) Arielle S. Gillman, PhD, M 301-435-0060 arielle.gillman@nih.gov Link to program URL 07-Jan-2026, 05-Feb-202	National Institute or Minority Health and Disparities/NIH/DHI PH 5, 07-May-2026, 05-J 27, 05-Jun-2027, 07 ive is to support non-point disparities, and examples	n PAR-24- CHealth 330 Check San State Check San State Check San Sharmacological intermine sleep as a model.	07-Jan-2026 026 , 05-Oct-2026 erventions to prom lifiable factor to re	Not Specifie , 07-Jan-20 note sleep



			5				
SPIN ID	Program Title		Sponso	r Name	Sponsor Number	Deadline Date	Funding Amount
		Populations that Experie - Clinical Trial Optional)	nce Health Disparities (R01	Minority Health and Disparities/NIH/DHH			Specified
		Contact Name Contact Telephone	Yewande Oladeinde, PhD 301-402-4307				
		Sponsor Website		gov			
		Program URL Deadline Dates (ALL)	Link to program URL 07-Jan-2026, 05-Feb-2026, 05-Feb-2027, 07-May-20	•	•		
		Synopsis	The purpose of this initiati level health care research initiative will support rese screening, diagnostic, and decision-making that is ne and care teams with the o care coordination.	for older adults from parch designed to (1) gaclinical care guidelines eded to enhance care	populations that explicing a better underst in a primary care splanning and patien	perience health di anding of appropr setting, (2) explore nt agency betwee	sparities. The riate e shared n clinicians
		128943 The Role of Work in Heal (R01 Clinical Trials Option	·	National Institute on Minority Health and Disparities/NIH/DHH	747)7-Jan-2026	Not Specified
		Contact Name	Rada K. Dagher, PhD, MPH				
		Contact Telephone	301-451-2187				
		Contact Email	rada.dagher@nih.gov				
		Sponsor Website					
		Program URL	Link to program URL				
		Deadline Dates (ALL)	07-Jan-2026 , 05-Feb-2026 , 05-Feb-2027 , 07-May-20	· ·			
			The purpose of this Fundir based research that can continue through which work or occurrence.	ontribute to identifying	g and characterizing	g pathways and mo	echanisms



SPIN ID	Program Title			S	ponsor Name	Sponso	or Number	Deadline Date	Funding Amount
		populations with health and/or health care disparities, and how work functions as a social determinant of health.							
	129148 Dis		Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Trials Optional)		Minority Hea	National Institute on Minority Health and Health Disparities/NIH/DHHS PAR-2 299		05-Feb-2026	Not Specified
			Contact Telephone	olga.herren@nih.go					
			Program URL Link to program URL Deadline Dates (ALL) O5-Feb-2026, O5-Jun-2026, O5-Oct-2026, O5-Feb-2027, O5-Jun-2027 This initiative will support multi-level and/or multi-domain intervention research to reduce disparities in liver diseases and liver cancer among populations who experience health disparities the United States (U.S.).						
		121868	Unveiling Health and Healthcare Disp Communicable and Chronic Diseases 121868 America: Setting the Stage for Better Outcomes Across the Hemisphere (RO Trials Not Allowed)		n Non- National Inst Minority Hea	lth and Health	PAR-25- 377	07-Jan-2026	Not Specified
			Contact Telephone	avilessantal@nih.go					
			Program URL Deadline Dates (ALL)	Link to program URI 07-Jan-2026, 05-Fe	- b-2026 , 07-May-202 ng Opportunity (NOF ect for application d	O) is being reis	ssued in acco	ordance with the s 2025. This Notice o	implified of Funding



SPIN ID	Program Title			S	ponso	r Name	Sponsor Nur	nber	Deadline Date	Funding Amount
				measurements that	t addre CDs) w	evaluation of public an ss health and healthca ith the highest disease	re disparities	relat	ed to non-commun	icable and
		122869	Mobile Health: Technolo and Middle Income Cour Trial Optional)			National Institutes of Health/DHHS	f PAR- 242	25-	20-Feb-2026 [Optional][LOI/Pre- App]	Not Specified
			Contact Name Contact Telephone	Brad Newsome, Ph. 301-480-8389	.D					
			Contact Email	brad.newsome@nil	h.gov					
			Sponsor Website							
			Program URL	Link to program UR	<u>L</u>					
			Deadline Dates (ALL)	20-Feb-2026 [Optio	nal][LC	OI/Pre-App], 20-Mar-20	026			
			Synopsis	exploratory/develor validation, feasibilit tools specifically suitechnology, platform innovation through evidence base for the and strengthen mH (R21 phase) for tech expanded research studies. Transition to	pmenta cy, and ited for ms, sys multid he use realth ru hnolog support to the F	ng Opportunity Annougal research application effectiveness of innover low- and middle-incoutems, or analytics. The disciplinary research the of mHealth technologiesearch capacity in LW y development and feart (R33 phase) for valication availability of fund	as that propositive mobile of the countries overall goal at addresses y to improve IICs. This FOA asibility studication, larger ompletion of a	se to shealth (LMI) of the globa clinica proves, folloscale escale applic	study the developm h (mHealth) interver Cs) that utilize new e program is to cata al health problems, cal and public health rides support for up llowed by a possible feasibility, and effecant-defined milesto	ntions or or emerging lyze develop an outcomes, to two years e transition to ctiveness nes, as well
		128812	Investigator Initiated Res Genomics and Data Scien Allowed)			National Institutes of Health/DHHS	f PAR- 228	-25-	05-Feb-2026	2,500,000 USD



SPIN ID	Program Title		Spons	or Name	Sponsor Number	Deadline Date	Funding Amount
		Contact Name	Jean Gao, Ph.D.				
		Contact Telephone					
		Contact Email	jean.gao@nih.gov				
		Sponsor Website					
		Program URL	Link to program URL				
		Deadline Dates (ALL)	05-Feb-2026 , 05-Jun-20	26 , 05-Feb-2027 , 05-Ju	un-2027		
		Synopsis	The purpose of this fund range of research efforts relevant to one or both of health and disease. This analytical methodologies refinement or hardening community. Work support or broadly applicable acres	in computational genor of basic or clinical genor FOA supports fundame s and approaches, early of software and tools orted under this FOA sh	omics, data science, s mic science, and bro ntal genomics resea r-stage development of high value to the l ould be enabling for	statistics, and bioinally applicable to rch that develops of tools and softwomedical genome	nformatics human innovative vare, and ics
		Investigator Initiated Res 128814 Genomics and Data Scien Allowed)		National Institutes of Health/DHHS	of PAR-25- 229	L6-Feb-2026	275,000 USD
		Contact Name	Daniel Gilchrist, Ph.D.				
		Contact Telephone					
		Contact Email	daniel.gilchrist@nih.gov				
		Sponsor Website					
		Program URL	Link to program URL				
		Deadline Dates (ALL)	16-Feb-2026 , 16-Jun-20	26 , 16-Feb-2027 , 16-Jւ	un-2027		
		Synopsis	The purpose of this fund range of research efforts relevant to one or both the health and disease. This analytical methodologies refinement or hardening	in computational geno of basic or clinical geno FOA supports fundame s and approaches, early	omics, data science, s mic science, and bro ntal genomics resea -stage development	statistics, and bioinadly applicable to rch that develops to fools and softw	nformatics human innovative vare, and

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		community. Work supported under this or broadly applicable across diseases ar	_	genomics and be	generalizable
	123784 NCCIH Natural Product E Award (R33 Clinical Trial		7	23-Feb-2026	1,050,000 USD
	Contact Telephone Contact Email	Sekai Chideya, M.D., MPH 301-827-1916 sekai.chideya@nih.gov Link to sponsor website			
	Deadline Dates (ALL)	23-Feb-2026, 17-Mar-2026, 20-Oct-20 This Funding Opportunity Announceme early phase, clinical trials of natural prowhich have a strong scientific premise the designed so that results, whether poutility and will support decisions about FOA will provide up to 3 years support the biological signature(s) when used between the degree of the impact on the patient population. Applications are eathe impact of the natural product on the	ent (FOA) encourages applicated of the courages applicated of the courages applicated of the courages applicated of the courage of the courag	ry supplements, ar ng. Under this FO de information of ing of the natural mpact of the natur er there is an asso unctional or clinica s to determine how	nd probiotics), A, trials must high scientific product. This al product on ciation v to optimize
		natural product by examining different designed to combine the natural produthe same biological signature; or study that is more responsive. Clinical trials sobased, milestone-driven, and directly reason, mand mechanism is intended to about natural products into early stage research is warranted. This FOA will not trials to test natural products for the treason.	doses or formulations. In addict with another treatment ap the impact of the natural pro- ubmitted under this FOA are elated to the research prioriti accelerate the translation of clinical testing to determine t support efficacy or effective	dition, application pproach that is knoduct in a target percented to be hylics and mission of emerging basic so whether continue eness trials, nor w	s can be own to impace opulation pothesis NCCIH. This ience findings and clinical

		NII	I Funding Opportunities				
SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
		Phased Innovation Award (I	R61/R33 Clinical Trial Health	/DHHS	269		USD
		Contact Telephone 30 Contact Email se Sponsor Website Program URL <u>Lin</u>	kai Chideya, M.D., MPH 1-827-1916 kai.chideya@nih.gov ok to program URL -Feb-2026 , 17-Mar-2026 , 20-0	Oct-2026 , 13-N	Nov-2026		
		ea wi be ut FC ph m ph th wi Synopsis fu st sig fo	is Funding Opportunity Announ- rly phase, clinical trials of natura- nich have a strong scientific prer- designed so that results, wheth dity and will support decisions a part will provide up to three years armacokinetics, bioavailability, a echanism of action) when used to ase are achieved, up to 3 years a impact of the natural product mether there is an association be actional or clinical outcomes in a didies to determine how to opting mature by optimizing the deliver mulation. In addition, applications enatural product in a target pope	al products (i.e mise to justify her positive or about further of (R61 phase) of and assessme by humans on of additional son the biologic etween the dea patient populate the impact on son be despite the impact	e., botanicals, dietar further clinical testi negative, will providevelopment or test of support for milest nt of the natural proabilities a biological signatus support (R33 phase) ical signature(s) who gree of the impact of allation. Applications of the natural proral product by examisigned to combine the same biological signature (s) who will be same si	ry supplements, and ang. Under this FO de information of the natural tone-driven testing oduct's effect (i.e. are(s). If milestone may be awarded an used by human on the biological state are encouraged to duct on the biological so duct on the biologica	nd probiotics), A, trials must high scientific product. This g of , measure of s in the R61 to replicate s and assess ignature and to design R33 gical ses or the with another the impact of

this FOA are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This R61/R33 funding mechanism is intended to accelerate the translation of emerging basic science findings about natural products into early-stage clinical testing to determine whether continued clinical research is warranted. This FOA will not support efficacy or effectiveness trials, nor will it support trials to test natural products for the treatment or prevention of cancer. A maximum of 5 years will be supported by the two phases of

SPIN ID	Program Title		Spo	nsor Name	Sponsor Number	Deadline Date	Funding Amount
				pplicants are encouraged ntact for the area of sciend bmitting to this FOA.		•	elop an
		Clinical Trial Readiness for 133024 Disorders, and Syndrome Allowed)		National Institutes of Health/DHHS	of PAR-25- 450	18-Feb-2026	275,000 USD
		Contact Telephone	alice.chen2@nih.gov).			
		·	Link to program URL 18-Feb-2026, 17-Mar	-2026 , 17-Jun-2026 , 17			17-Jun-2027 ,
			This Notice of Funding of clinical projects tha initiative seeks applicate efficient and effective to increase their likelil rigorous biomarkers a	028, 17-Mar-2028, 20-Jo g Opportunity (NOFO) inval t address critical needs for ations that are intended to movement of candidate mood of success. This cound and clinical outcome assessisease to enable the design	vites researchers to so or clinical trial reading to facilitate rare diseatherapeutics or diagold be through the dessment measures or	ubmit application ess in rare disease ases research by e nostics toward clirulling the propertion of the properties of t	s. The nabling nical trials and sting of
		055435 \$100,000 for Start an SU	D Startup Challenge	National Institutes of Health/DHHS	of (04-Feb-2026	10,000 USD
		Sponsor Website	301-827-9564 NIDAChallenge@nih.g Link to sponsor websit Link to program URL				
		,	I				



SPIN ID	Program Title		Sponso	r Name	Sponsor Number	Deadline Date	Funding Amount
		Synopsis	National Institute on Drug Health (NIH), announces to support research ideas in intended to be the foundat Challenge will enable the fostered into a biotech statch the pool of innovative small	he \$100,000 for Start the areas of drug use, ation for developing suwinning Teams to test artup, and that eventuall business companies	a SUD Startup Challed misuse, and substartupticessful new startupthe premise that the ally the newly creates that can successful	enge. The Challeng nce use disorder (S ps. NIDA expects t eir research idea o ed startups will co ly compete for NI	ge goal is to SUD) that are that the can be ontribute to DA's Small
		Translational Research in 116476 Pharmacology and Thera Optional)		National Institutes o Health/DHHS	f PAR-25- 110	5-Feb-2026	Not Specified
		Contact Name	Katie M. Vance, Ph.D.				
		Contact Telephone	301-435-6640				
		Contact Email	Katie.Vance@nih.gov				
		Sponsor Website					
		Program URL	Link to program URL				
		Deadline Dates (ALL)	05-Feb-2026				
		Synopsis	The purpose of this notice research to (1) advance puthrough the development clinical or health impact; (action, including the role during pregnancy and lact usage of existing drugs or and lactating persons, need precision therapeutics for including those with disable.	recision medicine in proof novel tools, models 2) enhance the unders of pediatric ontogeny attain; and (3) discover drug repurposing for sonates, and children. To pregnant and lactating	regnant persons, lack s, and other technol standing of the under and the dynamic phy r and develop novel safer and more effect the overall goal is to	tating persons, an ogies that could herlying mechanism ysiological change therapeutics or extive medications improve safe and	nd children have a direct his of drug his that occur hance the hin pregnant effective
		116616 Notice of Special Interest Grants in Valvular Heart	t (NOSI): Research Project Disease (CAROL Act)	National Institutes of Health/DHHS	f NOT-HL- 23-079	7-Jan-2026	Not Specified



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Name	Frank Evans, PhD				
	Contact Telephone	301-435-0510				
	Contact Email	evansf@nhlbi.nih.	gov			
	Sponsor Website					
	Program URL	Link to program U	<u>RL</u>			
	Deadline Dates (ALL)	07-Jan-2026 , 05-F	eb-2026 , 07-May-2026			
	Synopsis	Advances in Resea	ional Heart, Lung, and Blood Ir arch and Opportunities Legacy cations that propose research	(CAROL) Act, this No	otice of Special In	
	Secondary Analysis and I	-	National Institutes of	f PAR-25-	E Eab 2026	1,750,000

(R01 Clinical Trial Not Allowed)

Contact Name Melissa Rotunno, Ph.D.

120387 to Elucidate Cancer Risk and Related Outcomes

Contact Telephone 240-276-7245

Contact Email rotunnom@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 05-Feb-2026, 05-Jun-2026

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) along with other participating Institutes encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific Synopsis

Health/DHHS

questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. Applicants are encouraged to leverage and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in cancer research.

USD

05-Feb-2026

095

SPIN ID	Program Title		Sponso	r Name	Sponsor Number	Deadline Date	Funding Amount
		Personal Health Information 120715 Actionable Insights to Inc. Optional)		National Institutes o Health/DHHS	f PAR-25- 235	05-Feb-2026	1,000,000 USD
		Contact Telephone Contact Email Sponsor Website	allison.dennis@nih.gov				
			O5-Feb-2026, O5-Jun-2020 The purpose of this Notice informatics and data scien health through actionable applications that further t actionable insights to indivanalysis, and personalized understanding of how informaterpretation, and limitate encouraged. Applications to inform the design of ge systems, and platforms fo	e of Funding Opportung of Ending Opportung Opp	In help individuals und participating instituted health informatics ative personal health interpretation. Applys, and platforms causessments for the er engaged approach and scalable personal	understand and im tutes listed in this by providing mea th data collection, plications seeking t in best present the benefit of individu ches and real-worl nal health informa	prove their NOFO seek ningful and integration, to advance the results, tals are d evaluation tics tools,
		120817 Population Approaches t related Cancer Risk (R01		National Institutes of Health/DHHS	f PAR-25- 221	05-Feb-2026	Not Specified
		Contact Telephone Contact Email Sponsor Website Program URL	berrigad@mail.nih.gov	5 , 05-Oct-2026			
		• • •	This Notice of Funding Op	•	s to support researd	ch on interdiscipli	nary



SPIN ID	Program Title			9	Sponso	r Name	Sponsor Numbe	Deadline Date	Funding Amount
				risk, understanding evaluating alcohol population-level in multiple levels of cowell as those focus control. Proposals a underrepresented	g and che policy a tervent onsum ing on a address minorit	increasing awareness nanging social norms reapproaches, and the decions to reduce alcohol ption, such as moderate alcohol use disorder (Asing understudied area by (URM) populations explassion Native, and second	elated to alcohol evelopment, testing terms of the and heavy dring the and heavy dring the person are encouraged experiencing cand	consumption, develong, and implementa sk. Applications that king, are of particular pective of cancer plass is attention to er and alcohol-related	oping and/or tion of t address ar interest, as prevention and ed disparities
		124219	Long-Term Effects of Dis Systems in Populations v (R01- Clinical Trial Option	vith Health Dispariti		National Institutes of Health/DHHS	f PAR-24- 109	06-Jan-2026 [Optional][LOI/Pre App]	Not Specified
			Contact Name	Carolina Solis-Sana	bria, M	D, MPH, FACS			
			Contact Telephone	301-827-3460					
			Contact Email	carolina.solissanab	ria@ni	h.gov			
			Sponsor Website						
			Program URL	Link to program UF	<u>RL</u>				
			Deadline Dates (ALL)	[Optional][LOI/Pre-	-App], (01/Pre-App], 07-Jan-202 07-May-2026 , 05-Jun-2 06-Jan-2027 [Optional]	2026 , 06-Sep-202	26 [Optional][LOI/Pr	
			Synopsis	focused on underst	tanding	e of Funding Opportun the long-term effects g populations that exp	of natural and/or	human-made disas	ters on
		129320	Risk and Protective Factor Family Level Intervention Optional)			National Institutes of Health/DHHS	f PAR-25- 317	07-Jan-2026	Not Specified
			Contact Name	Arundhati Goginen	i, PhD				



SPIN ID	Program Title		Sp	onsor Name	Sponsor Number	Deadline Date	Funding Amount
		Sponsor Website	Arundhati.Gogineni@ Link to program URL 07-Jan-2026, 05-Feb , 05-Feb-2027, 07-M	o-2026 , 07-May-2026 , 05- day-2027	•		
		Synopsis	supporting research Framework recognize	nitiative is to advance the son family health and well-les family health, family we decrease disparities and pr	being and resilience. Il-being, and family r	The NIMHD Resea	arch
		Mentored Quantitative F 125485 Award (Parent K25 Indep Experimental Studies with	endent Basic	National Institutes of Health/DHHS	of PA-24- 192	07-Jan-2026	Not Specified
		Contact Name					
		Contact Telephone					
		Contact Email	GrantsInfo@nih.gov				
		Sponsor Website					
		Program URL	Link to program URL				
		Deadline Dates (ALL)	07-Jan-2026 , 12-Feb , 12-Feb-2027 , 07-M	-2026 , 07-May-2026 , 12 lay-2027	Jun-2026 , 07-Sep-20	026 , 12-Oct-2026	, 07-Jan-2027
		Synopsis	to NIH-relevant reseathas thus far not been provide support and professionals with quimaging science, info expertise with NIH-restudies involving hur	Mentored Quantitative Resarch those investigators who focused primarily on que "protected time" for a peruantitative (e.g., mathematics, physics, chemistralevant research. This Paremans, referred to in NOT-Oticipants." These studies factors	hose quantitative sci stions of health and riod of supervised stu tics, statistics, econo y) and engineering b ent Announcement is DD-18-212 as "prospe	ence and engineer disease. The K25 and research for mics, computer scackgrounds to integration basic science of the control of	ring research award will for productive cience, egrate their experimental e studies

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount

meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Mentored Quantitative Research Development 125483 Award (Parent K25 Independent Clinical Trial Not Allowed)

National Institutes of Health/DHHS

PA-24-191

07-Jan-2026

Not Specified

Contact Name

Contact Telephone

Contact Email GrantsInfo@nih.gov

Sponsor Website

Deadline Dates (ALL)

Program URL Link to program URL

07-Jan-2026, 12-Feb-2026, 07-May-2026, 12-Jun-2026, 07-Sep-2026, 12-Oct-2026, 07-Jan-2027 , 12-Feb-2027 , 07-May-2027

The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO applicants are

permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those

Synopsis

			0 11				
SPIN ID	Program Title		Sponso	r Name	Sponsor Number	Deadline Date	Funding Amount
			proposing a clinical trial o companion NOFO (PA-24-	-	ial as lead investiga	tor, should apply t	o the
		125516 Mentored Clinical Scient Development Award (Pa Basic Experimental Studio		National Institutes o Health/DHHS	f PA-24- 183)7-Jan-2026	Not Specified
		Sponsor Website Program URL	301-496-8580 grantinfo@nih.gov Link to program URL 07-Jan-2026 12-Feb-202	6 07-May-2026 12-l	un-2026 07-Sen-20	026 12-Oct-2026	07-lan-2027
		Deadline Dates (ALL) Synopsis	, 12-Feb-2027 , 07-May-2 The primary purpose of t (K08) program is to prepa health-related research n standing NIH program tha doctoral degree for an int of biomedical and behavi is for basic science experi "prospective basic science definition of a clinical tria	he NIH Mentored Clini re qualified individuals eeds of the Nation. The provides support and ensive, supervised respond research, including mental studies involving hund also meet the deer this NOFO include standard mentally manipulate in umans for the purpose ific application toward clinical trial or basic exit a clinical trial or basic of the 'Independent Clief related to the programment of the programment o	cal Scientist Researds for careers that hat is program represend "protected time" tearch career develog translational research participants." The finition of basic research tearch that prospect idependent variable to funderstanding the processes or produce the processes	ch Career Develop ve a significant im its the continuation to individuals with pment experience inch. This Parent A it to in NOT-OD-18- nese studies fall we earch. Types of studively assign human is) and that assess he fundamental assucts in mind. Applith humans, or prody with humans leved' companion No	ment Awards pact on the n of a long- a clinical in the fields nnouncement 212 as ithin the NIH dies that n participants biomedical or spects of icants not oposing to d by another DFO. The

		•	в помень в ор	por turnico			
SPIN ID	Program Title		S	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Mentored Clinical Scient 125512 Development Award (Par Clinical Trial Required)		ent National Institutes o	f PA-24- 181	07-Jan-2026	Not Specified
		Contact Name					
		Contact Telephone	301-496-8580				
		Contact Email	grantinfo@nih.gov				
		Sponsor Website					
		Program URL	Link to program UR	<u>RL</u>			
		Deadline Dates (ALL)	07-Jan-2026 , 12-Fe , 12-Feb-2027 , 07-	eb-2026 , 07-May-2026 , 12-Jı May-2027	un-2026 , 07-Sep-20)26 , 12-Oct-2026	, 07-Jan-2027
		Synopsis	(KO8) program is to health-related resestanding NIH progradoctoral degree for of biomedical and lis for basic science "prospective basic definition of a clinic should be submitted to conditions (i.e., behavioral outcomphenomena without planning an independant research expensive stigator, must aproposed project modern NIH Institutes and Copportunity (NOFC investigator of an intereses and investigator of an interese standard company to the conditions of the co	se of the NIH Mentored Clinical prepare qualified individuals arch needs of the Nation. This am that provides support and an intensive, supervised resolvenavioral research, including experimental studies involving humber and also meet the defend under this NOFO include steeperimentally manipulate in es in humans for the purpose at specific application toward endent clinical trial or basic experimentally to the 'Independent Clinical trial or basic experimentally to the 'Independent Clinical trial or basic expenses in a clinical trial or basic expenses (ICs) based on their second endent clinical trial, a clinical trial, a spart of their research	for careers that hat a program represerd "protected time" to earch career develogs translational research participants." The finition of basic research that prospect dependent variable of understanding to some processes or produced primental study whice experimental study whice in the processes of produced the processes of processes of produced the processes of produced the processes of produced the processes of processes of produced the processes of processes of produced the processes of processes of processes of produced the processes of proce	ve a significant imports the continuation of individuals with appendix Parent A late in NOT-OD-18 these studies fall we earch. Types of studies and that assess the fundamental aucts in mind. Applyith humans, or produced companion Notice of Funding to serve as the lest study, or a separate	pact on the on of a long- a clinical of the fields of the

			Green				
SPIN ID	Program Title		Spo	nsor Name	Sponsor Number	Deadline Date	Funding Amount
			1	al trial, or proposing to ga must apply to companion		nce in a clinical tria	al led by
		Mentored Research Scie 125527 (Parent K01 Independen Studies with Humans Re	t Basic Experimental	National Institutes of Health/DHHS	of PA-24- 177	07-Jan-2026	Not Specified
		Sponsor Website	grantsinfo@nih.gov Link to program URL 07-Jan-2026, 12-Feb-	2026 , 07-May-2026 , 12-J	lun-2026 , 07-Sep-20	026 , 12-Oct-2026	, 07-Jan-2027
		Synopsis	The purpose of the NI support and protected experience in the bion Although all participa career development e for individuals who prospective basic science expe "prospective basic sciedefinition of a clinical should be submitted uto conditions (i.e., expenditude) behavioral outcomes in phenomena without splanning an independing ain research experier investigator, must approprience.	y-2027 H Mentored Research Scientime (three to five years nedical, behavioral, or clirating NIH Institutes and Cexperiences that lead to recopose to train in a new fiese of illness or pressing farimental studies involving ence studies involving hur trial and also meet the definder this NOFO include so rerimentally manipulate in humans for the purpose pecific application toward ent clinical trial or basic ence in a clinical trial or basic to the 'Independent CI to be related to the progra) for an intensive, surical sciences leading enters (ICs) use this sesearch independenced or for individuals amily circumstances, thumans, referred to man participants." The finition of basic resetudies that prospect needependent variable e of understanding the processes or produce experimental study whice experimental study which is the study of the the st	upervised career d g to research inde support mechanisi ce, some ICs use to s who have had a h . This Parent Anno o in NOT-OD-18-2 hese studies fall we earch. Types of stu- tively assign huma es) and that assess the fundamental a lucts in mind. App with humans, or pr dy with humans le wed' companion N	levelopment spendence. In to support the KO1 award niatus in their puncement is 12 as within the NIH addies that an participants is biomedical or ispects of licants not soposing to ed by another OFO. The

		·		, por cumeros			
SPIN ID	Program Title			Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
			NIH Institutes and	Centers (ICs) based on their s	cientific missions.		
		125530 Independent Scientist Av Independent Clinical Tria		National Institutes o Health/DHHS	of PA-24- 178)7-Jan-2026	Not Specified
		Contact Name					
		Contact Telephone					
		Contact Email	grantinfo@nih.gov	<u>L</u>			
		Sponsor Website					
		Program URL	Link to program U				
		Deadline Dates (ALL)	07-Jan-2026 , 12-F , 12-Feb-2027 , 07-	eb-2026 , 07-May-2026 , 12-J -May-2027	un-2026 , 07-Sep-20	26 , 12-Oct-2026 ,	, 07-Jan-2027
		Synopsis	outstanding scient to their field of result to their field of result intensive research scientist career award candidate. This Pareferred to in NOT These studies fall was research. Types of prospectively assignated wariables) and that understanding the processes or product of their scientific intensive in	e NIH Independent Scientist Asists and enable them to expansion and enable them to expansion newly independent scientists focus as a means of enhancing and program must be tailored arent Announcement is for base for January and program must be tailored arent Announcement is for base for January and program must be tailored arent Announcement is for base for January and prospective by within the NIH definition of a studies that should be submitted assess biomedical or behavior fundamental aspects of pherousts in mind. Applicants not play with humans, or proposing by with humans, or proposing by with humans led by another llowed' companion NOFO. The erests of one or more of the particular serve as the lead investing to serve as the lead investing the server as the server as the lead investing the server as the server	nd their potential to es three to five years sts who can demons a their research card to meet the individual sic science experiments as a science studies clinical trial and also tted under this NOF ditions (i.e., experimental outcomes in hur nomena without spelanning an independate gain research experiments are proposed project articipating NIH Insting Opportunity (NOI)	make significant of sof salary support strate the need for eers. Each independent of the ental studies involving human point meet the definition of include studies entally manipulate mans for the purposific application to dent clinical trial of erience in a clinical apply to the 'Independent be related to itutes and Centers FO) is designed sp	contributions t and r a period of ndent ving humans, participants." on of basic that e independent ose of owards r basic al trial or basic pendent o the s (ICs) based pecifically for

							1	
SPIN ID	Program Title			Spons	or Name	Sponsor Number	Deadline Date	Funding Amount
				feasibility study, or a sep career development. Ap research experience in a (PA-24-179).	plicants not planning ar	n independent clinic	al trial, or proposi	ng to gain
		Mentored Clinic 125513 Development A Clinical Trial No	ward (Par		National Institutes of Health/DHHS	of PA-24- 182	07-Jan-2026	Not Specified
			act Name elephone	301-496-8580				
		Cont	act Email	grantinfo@nih.gov				
		Sponsor	Website					
		Prog	gram URL	Link to program URL				
		Deadline Da	ites (ALL)	07-Jan-2026 , 12-Feb-20 , 12-Feb-2027 , 07-May-		Jun-2026 , 07-Sep-20	026 , 12-Oct-2026	, 07-Jan-2027
			Synopsis	The primary purpose of (KO8) program is to prephealth-related research standing NIH program the doctoral degree for an irof biomedical and behave Opportunity (NOFO) is deading an independent trial. Under this NOFO a led by a mentor or cominvestigator, should app	are qualified individual needs of the Nation. The nat provides support an attensive, supervised restioral research, including esigned specifically for clinical trial, a clinical trial, are permitted entor. Those proposing	s for careers that hat hat is program represer d "protected time" to search career develong translational reseat applicants proposing ial feasibility study, to propose a reseat a clinical trial or an	ve a significant im nts the continuation to individuals with opment experience arch. This Notice of gresearch that do or an ancillary clir och experience in a	npact on the on of a long- a clinical e in the fields of Funding bes not involve nical
		1 /55 //		ntist Development Award nt Clinical Trial Required)	National Institutes of Health/DHHS	of PA-24- 175	07-Jan-2026	Not Specified
		Conta	act Name					



Contact Telephone

							Funding
SPIN ID	Program Title		Spor	sor Name	Sponsor Number	Deadline Date	Amount
			<u> </u>				
		Contact Email	grantsinfo@nih.gov				
		Sponsor Website					
		Program URL	Link to program URL				
		Deadline Dates (ALL)	07-Jan-2026 , 12-Feb-2 , 12-Feb-2027 , 07-May	026 , 07-May-2026 , 12-J -2027	un-2026 , 07-Sep-20	026 , 12-Oct-2026 ,	, 07-Jan-2027
		Synopsis	support and "protected experience in the biom Although all of the part support career develop K01 award for individuation hiatus in their research Funding Opportunity (Findestigator of an indestudy to an existing tria an independent clinical	Mentored Research Scientime" (three to five year edical, behavioral, or cliricipating NIH Institutes at the experiences that leads who propose to train career because of illness (OFO) is designed specification and their research trial, or proposing to galaust apply to companion	rs) for an intensive, nical sciences leading and Centers (ICs) use ead to research inde in a new field or for s or pressing family of cally for applicants pinical trial feasibility th and career develoin research experien	supervised career g to research independence, some I individuals who heircumstances. This proposing to serve study, or a separate pment. Applicants	development pendence. hanism to Cs use the ave had a is Notice of e as the lead ate ancillary s not planning
		Mentored Research Scient 125526 (Parent K01 - Independent Allowed)		National Institutes of Health/DHHS	of PA-24- 176)7-Jan-2026	Not Specified
		Contact Name					
		Contact Telephone					
		Contact Email	grantsinfo@nih.gov				
		Sponsor Website					
		Program URL	Link to program URL				
		Deadline Dates (ALL)	07-Jan-2026 , 12-Feb-2 , 12-Feb-2027 , 07-May	026 , 07-May-2026 , 12-J -2027	un-2026 , 07-Sep-20	026 , 12-Oct-2026 ,	, 07-Jan-2027
			support and "protected	Mentored Research Scions of the Mentored Research Scions of the Mentored Research Science (Mentored Research Science Research Science Research Science Research Science Research Science (Mentored Research Science Research Science Research Science Research Science Research Science Research Science (Mentored Research Science Research Research Science Research R	rs) for an intensive,	supervised career	development



SPIN ID	Program Title				Sponso	r Name	Sponsor Numbe	r Deadline Date	Funding Amount
				support career dev K01 award for indi hiatus in their rese the K01 to support (NOFO) is designed independent clinic Applicants to this I mentor or co-men	velopmo viduals earch ca t career d specif cal trial, NOFO a tor. App	pating NIH Institutes a ent experiences that le who propose to train i reer because of illness development in speci- ically for applicants pro a clinical trial feasibility re permitted to propositicants proposing a cli to the companion NO	ad to research in n a new field or f or pressing fami fic fields. This Not oposing research y study, or a sepa se research exper nical trial or an a	dependence, some or individuals who head of the contract of th	ICs use the nave had a cher ICs use prtunity ye leading an fall trial.
		114765	Notice of Special Interestand Mortality Prevention		jury	National Institutes of Health/DHHS	f NOT- OD-23- 039	07-Jan-2026	Not Specified
			Contact Name	Dara R. Blachman,	Ph.D.				
			Contact Telephone						
			Contact Email	Dara.blachman-de	mner@	nih.gov			
			Sponsor Website						
			Program URL						
			Deadline Dates (ALL)	07-Jan-2026 , 05-F	eb-202	õ			
			Synopsis	determinants of fin and other-directed testing of innovati	rearm in d, victim ve inter prove th	e is to highlight interes njury, the identification is and perpetrators, ac ventions to prevent find e implementation of e ty.	n of those at risk ocidental injury), t rearm injury and	of firearm injury (ind he development, pi mortality, and the e	cluding self- loting, and xamination of
		129186	Pilot Health Services and Treatment of Drug, Alcol Disorders (R34 - Clinical	hol, and Tobacco Us		National Institutes o Health/DHHS	f PAR-25- 100	07-Jan-2026	450,000 USD
			Contact Name	Carrie Mulford					



SPIN ID	Program Title	Sponso	r Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	Carrie.Mulford@nih.gov Link to program URL 07-Jan-2026, 16-Feb-202 , 16-Feb-2027, 07-May-2 This Funding Opportunity	027 Announcement (FOA)	encourages pilot ar	nd preliminary rese	, 07-Jan-2027 earch in
	Synopsi	preparation for larger-sca range of approaches, including to, and the quality, effect disorder treatments and it disorder conditions. Relevance commonly used in pra- assessing the feasibility, a preparation activities. This	uding interventions, priveness, affordability a related services, as welf ant approaches may incide but lack an evidence but lack an utility and utility solutions of Funding Open	ractices, and policies and utilization of dru ll as services for compclude both those the conce base. This FOA of these approaches	designed to optir g, tobacco, or alco norbid medical and nat are novel, and provides resource es, in addition to u	nize access ohol use d mental those that s for usual trial
	Maximizing Opportuniti Academic Independent 127139 Postdoctoral Career Tra Diversity (K99/R00 - Independent)	Careers (MOSAIC) nsition Award to Promote	National Institutes o Health/DHHS	f PAR-24- 226	77-Jan-2026	Not Specified
	Contact Telephone Contact Email Sponsor Website	l lanay.mudd@nih.gov e L Link to program URL		un 2026 07 Sen 20	12 Oct 2026	07 Jan 2027
	Deadline Dates (ALL Synopsi	07-Jan-2026 , 12-Feb-202 , 12-Feb-2027 , 07-May-2 s The purpose of the Maxin	027 , 12-Jun-2027 , 07-	Sep-2027		



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding
SPIN ID	rrogram ritie	Sponsor Name	Sponsor Number	Deadine Date	Amount

Careers (MOSAIC) program is to support a cohort of early career, independent investigators from diverse backgrounds (for example, individuals from underrepresented groups) conducting research in NIH mission areas. The program has two components: an individual career transition award for postdoctoral scholars (K99/R00) and a research education cooperative agreement (UE5) awarded to organizations to provide these scholars with additional mentoring, networking and professional development activities to support their transition to and success in independent, tenure-track or equivalent research-intensive faculty careers. The MOSAIC program supports NIH's efforts to develop a biomedical research workforce that will benefit from the full range of perspectives, experiences and backgrounds needed to advance discovery. The goal of the MOSAIC Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds from their mentored postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. The program is designed to support postdoctoral researchers who have demonstrated meaningful contributions and proposed compelling future plans to promote broad participation in the biomedical research workforce, such as activities that promote inclusive, supportive, and accessible biomedical research environments that support the success of trainees and scientists from all backgrounds, including individuals from underrepresented groups. This Notice of Funding Opportunity (NOFO) is designed specifically to support candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Candidates not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must work with their institutions to apply to companion NOFO PAR-24-225.

Notice of Special Interest (NOSI): Research to

Address 'Ending the HIV Epidemic' Initiative Goals Relevant to Substance Using Populations At-Risk for or Living with HIV National Institutes of Health/DHHS

NOT-DA-23-013 07-Jan-2026

Not Specified

Contact Name Vasundhara Varthakavi, PhD

Contact Telephone 301-443-2146

Contact Email vasundhara.varthakavi@nih.gov

Sponsor Website

114589

CDIN ID	Dura mana Titla		Const		Constant Name have	Dan diina Data	Funding
SPIN ID	Program Title		Spo	nsor Name	Sponsor Number	Deadline Date	Amount
		Program URL	Link to program URL				
		Deadline Dates (ALL)	07-Jan-2026 , 05-Feb- , 05-Oct-2026 , 16-Oct	2026 , 16-Feb-2026 , 07-N -2026 , 07-Oct-2027	1ay-2026 , 05-Jun-20	026 , 16-Jun-2026 ,	, 07-Sep-2026
		Synopsis	research to address th the 'Ending the HIV Ep NOSI are required to r	OSI is to support a broad e goals of the four pillars, idemic in the U.S. (EHE)' in the the subng with HIV in the geograp	including Diagnose, nitiative. Projects pr stance using popula	, Treat, Prevent, and roposed in respons tions who are at h	nd Respond of se to this nigh risk for
		NIH Pathway to Independent Bawith Humans Required)		National Institutes of Health/DHHS	of PA-24- 195)7-Jan-2026	Not Specified
		Contact Name					
		Contact Telephone					
		Contact Email	grantinfo@nih.gov				
		Sponsor Website					
		Program URL	Link to program URL				
		Deadline Dates (ALL)	07-Jan-2026 , 12-Feb-: , 12-Feb-2027 , 07-Ma	2026 , 07-May-2026 , 12-J y-2027	un-2026 , 07-Sep-20	026 , 12-Oct-2026 ,	, 07-Jan-2027
		Synopsis	timely transition of oudegree from mentored faculty positions. The in order to help award Announcement is for 18-212 as "prospective within the NIH definitions tudies that should be participants to condition biomedical or behavior	H Pathway to Independent tstanding postdoctoral red, postdoctoral research porogram will provide indentees to launch competitive pasic science experimental basic science studies involved and all submitted under this NO ons (i.e., experimentally rall outcomes in humans facility in the submitted application of a polication of a polication of a clinical trial and all submitted under this NO ons (i.e., experimentally rall outcomes in humans facility in the submitted under the submitted	searchers with a responsitions to independent NIH researche, independent researche, independent researche, independent researche, independent researche, independent researche, independent researche, include studies the manipulate independent researche purpose of un	earch and/or clinident, tenure-track ch support during arch careers. This umans, referred to ipants." These stuton of basic research at prospectively adent variables) and nderstanding the f	cal doctorate cor equivalent this transition Parent o in NOT-OD-udies fall ch. Types of assign human d that assess fundamental

SPIN ID	Program Title		Spon	sor Name	Sponsor Number	Deadline Date	Funding Amount
			led by another investiga	rch experience in a clinicator, must apply to the 'laroject must be related t	cal trial or basic expendent Clinical to the programmation	erimental study w Trial Not Allowed interests of one o	th humans ' companion
		125534 NIH Pathway to Independent Cli		National Institutes of Health/DHHS	of PA-24- 193	07-Jan-2026	Not Specified
		Contact Name Contact Telephone					
		Contact Email	grantinfo@nih.gov				
		Sponsor Website					
		Program URL	Link to program URL				
		Deadline Dates (ALL)	07-Jan-2026 , 12-Feb-20 , 12-Feb-2027 , 07-May	•	un-2026 , 07-Sep-20)26 , 12-Oct-2026	, 07-Jan-2027
		Synopsis	timely transition of outs degree from mentored, faculty positions. The prin order to help awarde Funding Opportunity (Ninvestigator of an indepstudy to an existing trial planning an independent	Pathway to Independer standing postdoctoral research program will provide inderes to launch competitive (OFO) is designed specific endent clinical trial, a clinical trial, a clinical trial, a clinical trial, a clinical trial, or proposition of the companism of	esearchers with a responsitions to independent NIH researe, independent rese ically for candidates inical trial feasibility th and career develosing to gain research	search and/or clinident, tenure-track ch support during arch careers. This proposing to serv study, or a separatement. Candidate experience in a c	cal doctorate or equivalent this transition Notice of e as the lead ate ancillary es not
		125537 NIH Pathway to Independent Cli		National Institutes of Health/DHHS	PA-24- 194)7-Jan-2026	Not Specified
		Contact Name					
		Contact Telephone					
		Contact Email	grantinfo@nih.gov				



			•				
SPIN ID	Program Title		Sponso	r Name	Sponsor Number	Deadline Date	Funding Amount
		Sponsor Website					
		•	Link to program URL				
		Deadline Dates (ALL)	07-Jan-2026 , 12-Feb-2026 , 12-Feb-2027 , 07-May-20		un-2026 , 07-Sep-20	026 , 12-Oct-2026	, 07-Jan-2027
		Synopsis	The purpose of the NIH Patimely transition of outstand degree from mentored, por faculty positions. The program order to help awardees Funding Opportunity (NOI not involve leading an indiclinical trial. Under this NO clinical trial led by a menton as lead investigator, should	nding postdoctoral repostdoctoral repostdoctoral research param will provide inder to launch competitive (FO) is designed specific ependent clinical trial DFO candidates are peopr or co-mentor. Thos	searchers with a responsitions to independent NIH research, independent research, independent research, a clinical trial feasible rmitted to propose e proposing a clinical	earch and/or clinident, tenure-track ch support during arch careers. This proposing research study, or an aresearch experient trial or an ancilla	cal doctorate or equivalent this transition Notice of th that does ancillary ence in a
		Midcareer Investigator A 125559 Research (Parent K24 - Ir Experimental Studies with	The state of the s	National Institutes o Health/DHHS	f PA-24- 189)7-Jan-2026	Not Specified
		Contact Name					
		Contact Telephone					
		Contact Email	grantinfo@nih.gov				
		Sponsor Website					
		Program URL	Link to program URL				
		Deadline Dates (ALL)	07-Jan-2026 , 12-Feb-2026 , 12-Feb-2027 , 07-May-20	•	un-2026 , 07-Sep-20	026 , 12-Oct-2026	, 07-Jan-2027
		Synopsis	The purpose of the NIH N provide support to mid-ca patient-oriented research pursuing POR research, su Announcement is for basic 18-212 as "prospective basics"	reer health-profession (POR) and to act as reach the chas clinical residents c science experimenta	nal doctorates for presearch mentors for sand junior clinical for a studies involving h	otected time to d junior clinical inve faculty. This Paren umans, referred t	evote to estigators it o in NOT-OD-

SPIN ID Program Title Sponsor Name Sponsor Number Deadline Date Amount
--

within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Midcareer Investigator Award in Patient-Oriented 125557 Research (Parent K24 Independent Clinical Trial Required)

National Institutes of Health/DHHS

PA-24-187

07-Jan-2026

Not Specified

Contact Name

Contact Telephone

Contact Email grantinfo@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

07-Jan-2026, 12-Feb-2026, 07-May-2026, 12-Jun-2026, 07-Sep-2026, 12-Oct-2026, 07-Jan-2027 , 12-Feb-2027 , 07-May-2027

The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors for junior clinical investigators pursuing POR research, such as clinical residents. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of

Synopsis

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	-------------------

phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PA-24-188).

125583	Independent Scientist Award (Parent KO2 Independent Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-24- 180	07-Jan-2026	Not Specified
	Humans Required)				

Contact Name

Contact Telephone

Contact Email GrantsInfo@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

07-Jan-2026, 12-Feb-2026, 07-May-2026, 12-Jun-2026, 07-Sep-2026, 12-Oct-2026, 07-Jan-2027 , 12-Feb-2027 , 07-May-2027

The purpose of the NIH Independent Scientist Award (KO2) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The KO2 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of scientist career award program must be tailored to meet the individual needs of the

Synopsis intensive research focus as a means of enhancing their research careers. Each independent candidate. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic



SPIN ID	Program Title		S	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
			prospectively assign variables) and that understanding the processes or produ experimental study experimental study Clinical Trial Not All	studies that should be submit in human participants to cond assess biomedical or behavio fundamental aspects of phen cts in mind. Applicants not play with humans, or proposing to with humans led by another lowed' companion NOFO. The rests of one or more of the partissions.	litions (i.e., experimoral outcomes in humomena without specanning an independence gain research experimores proposed project	entally manipulat mans for the purp cific application to dent clinical trial o perience in a clinical apply to the 'Inde must be related t	e independent ose of owards r basic al trial or basic pendent to the
		Midcareer Investigator A 125558 Research (Parent K24 Inc Allowed)		NISTIONSI INSTITLITAS OF	f PA-24- 188)7-Jan-2026	Not Specified
		Contact Name					
		Contact Telephone					
			grantinfo@nih.gov				
		Sponsor Website					
		Program URL Deadline Dates (ALL)	Link to program UR 07-Jan-2026, 12-Fe , 12-Feb-2027, 07-I	– eb-2026 , 07-May-2026 , 12-Ju	un-2026 , 07-Sep-20	026 , 12-Oct-2026	, 07-Jan-2027
		Synopsis	The purpose of the provide support to patient-oriented re pursuing POR resea Funding Opportuninot involve leading clinical trial. Under clinical trial led by a	NIH Midcareer Investigator A mid-career health-profession search (POR) and to act as reach, such as clinical residents ty (NOFO) is designed specific an independent clinical trial, this NOFO candidates are permented in the company of the company	nal doctorates for prosearch mentors for and/or junior clinic cally for applicants processing a clinical trial feasily mitted to propose proposing a clinical	rotected time to d junior clinical inve- cal faculty. This No proposing research pility study, or an a a research experion	evote to estigators otice of h that does ancillary ence in a
		125532 Independent Scientist Av	ward (Parent K02 -	National Institutes of	f PA-24- (07-Jan-2026	Not

						_	
SPIN ID	Program Title		Spo	nsor Name	Sponsor Number	Deadline Date	Funding Amount
		Independent Clinical Tria	l Not Allowed)	Health/DHHS	179		Specified
		Contact Name					
		Contact Telephone					
		Contact Email	grantinfo@nih.gov				
		Sponsor Website					
		Program URL	Link to program URL				
		Deadline Dates (ALL)	07-Jan-2026 , 12-Feb-2 , 12-Feb-2027 , 07-Ma	026 , 07-May-2026 , 12 /-2027	-Jun-2026 , 07-Sep-20	026 , 12-Oct-2026	, 07-Jan-2027
		Synopsis	outstanding scientists to their field of research protected time" for n intensive research foctscientist career award. This Notice of Funding research that does not or an ancillary clinical experience in a clinical ancillary clinical trial aproposed project must NIH Institutes and Cen Opportunity (NOFO) is investigator of an indestudy to an existing trian independent clinical another investigator, research	H Independent Scientist and enable them to expendent enable them to expendent scientists as a means of enhance program must be tailored Opportunity (NOFO) is convolve leading an independent sciential. Under this NOFO attrial led by another investigator, shout the related to the prograters (ICs) based on their designed specifically for pendent clinical trial, a control of their research, as part of their research trial, or proposing to ground apply to companion	and their potential to des three to five year tists who can demons ing their research car ed to meet the individ designed specifically to pendent clinical trial, pplicants are permitte estigator. Those prop ld apply to the compa ammatic interests of scientific missions. To r applicants proposing clinical trial feasibility rich and career develor ain research experient in NOFO (PA-24-179).	o make significant is of salary suppor strate the need for eers. Each independent of the control	contributions at and ar a period of endent candidate. posing sibility study, esearch al or an experimental are ancillary as not planning and experimental are ancillary as not planning
		Notice of Special Interest 117360 Address Vaccine Uptake among Populations Expe	and Implementation	National Institutes Health/DHHS	of NOT- MD-23- (008	05-Feb-2026	Not Specified
		Contact Name	Deborah E. Linares, Ph	.D., M.A.			



SPIN ID	Program Title			Spon	sor Name	Sponsor Number	Deadline Date	Funding Amount	
			Sponsor Website Program URL Deadline Dates (ALL)	deborah.linares@nih.gov Link to program URL D5-Feb-2026, 16-Feb-2026, 05-Jun-2026 This Notice of Special Interest (NOSI) highlights the need for research on strategies and interventions to increase vaccine uptake and implementation among populations experiencing health disparities in the United States (U.S.) and its territories. Research is needed to understand and address misinformation, uncertainty, distrust, and hesitancy regarding uptake of vaccines (e.g. SARS-CoV-2, pneumococcal, influenza, hepatitis B, human papilloma virus (HPV), varicella, tetanus, diphtheria, and pertussis [Tdap]) among individuals in the U.S. and its territories, especially in populations at increased risk for morbidity and mortality due to long-standing systemic health and social inequities, as well as chronic medical conditions. This NOSI is focused on individuals across the life span (i.e., all ages). The purpose of this NOSI is to solicit research that will: 1) understand and address barriers to increasing reach, access, and uptake of vaccinations among populations experiencing health disparities; 2) evaluate organizational, local, state, and federal policies and initiatives that mitigate or exacerbate disparities in vaccine access, uptake, and series completion, and 3) evaluate community-engaged interventions (e.g., expand reach, address psychosocial barriers, and social determinants of health [SDOH]) to facilitate vaccination uptake in clinical and community contexts.					
		116487	Translational Research in Pharmacology and Thera Optional)		National Institutes of Health/DHHS	of PAR-25- 111	16-Feb-2026	275,000 USD	
			Contact Telephone Contact Email Sponsor Website	Katie.Vance@nih.gov Link to program URL					

SPIN ID	Program Title			S	ponsor Name	Spoi	nsor Number	Deadline Date	Funding Amount
	· · · · · · · · · · · · · · · · · · ·		Synopsis	The purpose of this research to (1) adva through the develop clinical or health impaction, including the during pregnancy are usage of existing druand lactating persor precision therapeut including those with	nce precision med oment of novel to pact; (2) enhance e role of pediatric and lactation; and (ags or drug repurp as, neonates, and ics for pregnant a	dicine in pregna ols, models, and the understand ontogeny and the 3) discover and posing for safer children. The ov	nt persons, lace of the under the dynamic phe develop novel and more effecterall goal is to	tating persons, an ogies that could herlying mechanism ysiological change therapeutics or extive medications improve safe and	d children ave a direct as of drug as that occur anhance the in pregnant effective
			Mentored Quantitative F Award (Parent K25 Indep Required)	•	nt National I Health/DI	nstitutes of IHS	PA-24- 190	77-Jan-2026	Not Specified
			Contact Name						
			Contact Telephone						
			Contact Email	GrantsInfo@nih.gov	<u>′</u>				
			Sponsor Website						
			Program URL	Link to program URI	=				
			Deadline Dates (ALL)	07-Jan-2026 , 12-Fe , 12-Feb-2027 , 07-N	•	2026 , 12-Jun-20)26 , 07-Sep-20	26 , 12-Oct-2026 ,	07-Jan-2027
			Synopsis	The purpose of the Mentored Quantitative Research Career Development Award (K25) is to NIH-relevant research those investigators whose quantitative science and engineering has thus far not been focused primarily on questions of health and disease. The K25 award provide support and "protected time" for a period of supervised study and research for professionals with quantitative (e.g., mathematics, statistics, economics, computer science imaging science, informatics, physics, chemistry) and engineering backgrounds to integrat expertise with NIH-relevant research. This Notice of Funding Opportunity (NOFO) is design specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as par research and career development. Candidates not planning an independent clinical trial, or					



			0 11				
SPIN ID	Program Title		Spons	or Name	Sponsor Number	Deadline Date	Funding Amount
			proposing to gain resear companion NOFO (PA-2		cal trial led by anoth	ner investigator, m	ust apply to
		Mentored Patient-Orient 125230 Development Award (Pa Basic Experimental Studi	rent K23 Independent	National Institutes of Health/DHHS	PA-24- 186	07-Jan-2026	Not Specified
		Contact Name Contact Telephone					
		Contact Email Sponsor Website	grantinfo@nih.gov				
		Program URL Deadline Dates (ALL)	Link to program URL 07-Jan-2026, 12-Feb-20, 12-Feb-2027, 07-May-	•	un-2026 , 07-Sep-20	026 , 12-Oct-2026	, 07-Jan-2027
		Synopsis	The purpose of the NIH to support the career de commitment to focus th Announcement is for ba 18-212 as "prospective I within the NIH definition studies that should be suparticipants to condition biomedical or behavioral aspects of phenomena vapplicants not planning proposing to gain resear led by another investiga NOFO. The proposed proporticipating NIH Institution	Mentored Patient-Orie velopment of individua eir research endeavors sic science experimentates science studies invarianted under this NO is (i.e., experimentally routcomes in humans for independent clinical ch experience in a clinical cor, must apply to the 'I oject must be related to	Is with a clinical doc on patient-oriented al studies involving he colving human partic so meet the definiti FO include studies to manipulate independ for the purpose of un- cion towards process trial or basic experi- cal trial or basic experi- cal trial or basic experi- ndependent Clinical to the programmatic	ttoral degree who I research. This Panumans, referred to the cipants." These study of basic research at prospectively dent variables) and inderstanding the ses or products in mental study with erimental study will Trial Not Allowed interests of one contract.	have made a rent to in NOT-OD- udies fall ch. Types of assign human d that assess fundamental mind. In humans, or eith humans d' companion
		Mentored Patient-Orient 125228 Development Award (Pa Clinical Trial Not Allowed	rent K23 – Independent	National Institutes on Health/DHHS	of PA-24- 185	07-Jan-2026	Not Specified



			5							
SPIN ID	Program Title		Spor	sor Name	Sponsor Number	Deadline Date	Funding Amount			
		Contact Name	I							
		Contact Name								
		Contact Telephone	grantinfo@nih.gov							
		Sponsor Website								
		·								
		Program okt	Link to program URL 07-Jan-2026, 12-Feb-2026, 07-May-2026, 12-Jun-2026, 07-Sep-2026, 12-Oct-2026, 07-Jan-2027							
		Deadline Dates (ALL)	, 12-Feb-2027 , 07-May		un-2026 , 07-5ep-20	/20 , 12-UCL-2U20 ,	, U7-Jan-2027			
		Synopsis	to support the career of commitment to focus t Funding Opportunity (N not involve leading an i clinical trial. Under this clinical trial led by a me	H Mentored Patient-Orie evelopment of individua heir research endeavors IOFO) is designed specifindependent clinical trial NOFO applicants are peentor or co-mentor. Those puld apply to the compa	Is with a clinical doc on patient-oriented cally for applicants p , a clinical trial feasik rmitted to propose a e proposing a clinica	toral degree who research. This No proposing research bility study, or an a research experient trial or an ancilla	have made a tice of n that does ancillary nce in a			
		Mentored Patient-Orien 125227 Development Award (Patient Clinical Trial Required)		National Institutes of Health/DHHS	of PA-24- 184	77-Jan-2026	Not Specified			
			<u> </u>							
		Contact Name								
		Contact Telephone								
			grantinfo@nih.gov							
		Sponsor Website								
		Program URL	Link to program URL	026 07 May 2026 42 1	2026 07 60= 20	26 42 0-+ 2026	07 lan 2027			
		Deadline Dates (ALL)	, 12-Feb-2027 , 07-May	026 , 07-May-2026 , 12-J -2027	un-2026 , 07-Sep-20	126 , 12-UCT-2U26 ;	, U7-Jan-2U27			
		Synopsis	The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead							



Investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, a proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PA-24-185). Not								
study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposoing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PA-24-185). NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00 Clinical Trial Not Allowed)	SPIN ID	Program Title		Sponso	r Name	Sponsor Number	Deadline Date	
Allowed) Contact Name Shoba Thirumangalathu, PhD Contact Telephone Specified Contact Email Shoba Thirumangalathu, PhD Contact Email Shoba Thirumangalathu, PhD Contact Email Shoba Thirumangalathu, PhD Sponsor Website Program URL O7-Jan-2026, 12-Feb-2026, 07-May-2026, 12-Jun-2026, 07-Sep-2026, 12-Oct-2026, 07-Jan-2027 Deadline Dates (ALL) 7.2-Feb-2027, 07-May-2027, 12-Jun-2027, 07-Sep-2027, 12-Oct-2027, 07-Jan-2028, 12-Feb-2028, 07-May-2028 The purpose of the NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00) program is to develop and maintain a strong cohort of independently funded dentist scientists dedicated to improving dental, oral and craniofacial health. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent Synopsis research. An option for five years of independent (R00) support is available to accommodate clinical training in a dental specialty program at no more than 3 person-months (25% full-time professional effort) in anyear of the R00 phase. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO, candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor.				study to an existing trial, an independent clinical tr	as part of their researd ial, or proposing to gai	ch and career develo in research experien	pment. Applicant	s not planning
Contact Telephone Contact Email Sponsor Website Program URL O-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 Deadline Dates (ALL) Deadline Dates (ALL) The purpose of the NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00) program is to develop and maintain a strong cohort of independently funded dentist scientists dedicated to improving dental, oral and cranifocaia health. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. An option for five years of independent (R00) support is available to accommodate clinical training in a dental specialty program at no more than 3 person-months (25% full-time professional effort) in any year of the R00 phase. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO, candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor.			131740 Independence Award (KS			1)7-Jan-2026	
Sponsor Website Program URL Deadline Dates (ALL) Deadline Dates (Contact Name	Shoba Thirumangalathu, I	PhD			
Sponsor Website Program URL Or-Jan-2026, 12-Feb-2026, 07-May-2026, 12-Jun-2026, 07-Sep-2026, 12-Oct-2026, 07-Jan-2027 Deadline Dates (ALL) Deadline Dates (ALL) Deadline Dates (ALL) The purpose of the NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00) program is to develop and maintain a strong cohort of independently funded dentist scientists dedicated to improving dental, oral and craniofacial health. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. An option for five years of independent (R00) support is available to accommodate clinical training in a dental specialty program at no more than 3 person-months (25% full-time professional effort) in any year of the R00 phase. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent Clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO, candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor.			Contact Telephone	301-594-0652				
Program URL O7-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027 , 12-Jun-2027 , 07-Sep-2027 , 12-Oct-2027 , 07-Jan-2028 , 12-Feb-2028 , 07-May-2028 The purpose of the NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00) program is to develop and maintain a strong cohort of independently funded dentist scientists dedicated to improving dental, oral and craniofacial health. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. An option for five years of independent (R00) support is available to accommodate clinical training in a dental specialty program at no more than 3 person-months (25% full-time professional effort) in any year of the R00 phase. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO, candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. REA-MH-23-331 BRAIN Initiative Advanced National Institutes of REA-13-Eeh-2026			Contact Email	shoba.thirumangalathu@	nih.gov			
Deadline Dates (ALL) O7-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027 , 12-Jun-2027 , 07-Sep-2027 , 12-Oct-2027 , 07-Jan-2028 , 12-Feb-2028 , 07-May-2028 The purpose of the NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00) program is to develop and maintain a strong cohort of independently funded dentist scientists dedicated to improving dental, oral and craniofacial health. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent Synopsis Synopsi			Sponsor Website					
Deadline Dates (ALL) , 12-Feb-2027 , 07-May-2027 , 12-Jun-2027 , 07-Sep-2027 , 12-Oct-2027 , 07-Jan-2028 , 12-Feb-2028 , 07-May-2028 The purpose of the NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00) program is to develop and maintain a strong cohort of independently funded dentist scientists dedicated to improving dental, oral and craniofacial health. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. An option for five years of independent (R00) support is available to accommodate clinical training in a dental specialty program at no more than 3 person-months (25% full-time professional effort) in any year of the R00 phase. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO, candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. RFA-MH-23-331 — BRAIN Initiative Advanced National Institutes of RFA-13-Feb-2026			Program URL	Link to program URL				
(K99/R00) program is to develop and maintain a strong cohort of independently funded dentist scientists dedicated to improving dental, oral and craniofacial health. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent Synopsis research. An option for five years of independent (R00) support is available to accommodate clinical training in a dental specialty program at no more than 3 person-months (25% full-time professional effort) in any year of the R00 phase. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO, candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor.			Deadline Dates (ALL)	, 12-Feb-2027 , 07-May-2	•	•		
11/64/			Synopsis	(K99/R00) program is to discientists dedicated to imfacilitate a timely transition postdoctoral research postportion of the providing support for two research. An option for fix clinical training in a dental professional effort) in any designed specifically for clindependent clinical trial, NOFO, candidates are per	evelop and maintain a proving dental, oral ar on of outstanding dual sitions to independent years of mentored tra ve years of independer I specialty program at year of the R00 phase andidates proposing re a clinical trial feasibili	a strong cohort of ind and craniofacial healt degree dentist scient, tenure-track or equaining and three to fint (R00) support is a no more than 3 perce. This Notice of Funcesearch that does not ty study, or an ancill	dependently fund h. This program is ntists from mento uivalent faculty police years of indep vailable to accomponents (25% ding Opportunity ot involve leading ary clinical trial.	ed dentist designed to red, esitions by endent modate full-time (NOFO) is an nder this
POCTUDE TOTAL I STORY I PROCITION WAS TO DECEMBE HESTER ALL HER WAS ALL HER AL			11/64/			1	13-Feb-2026	



			5				
SPIN ID	Program Title		Sponso	r Name	Sponsor Number	Deadline Date	Funding Amount
		Diversity (K99/R00 Indep	endent Clinical Trial Not		331		
		Contact Name	James Churchill, Ph.D.				
		Contact Telephone	301-326-8800				
		Contact Email	BRAINDIVERSITYK99R00@	nih.gov			
		Sponsor Website					
		Program URL	Link to program URL				
		Deadline Dates (ALL)	13-Feb-2026				
		Synopsis	The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to enhance diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds, including those from underrepresented groups in the biomedical and behavioral sciences, in BRAIN Initiative research areas. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivale faculty positions. The program will provide independent NIH research support during this transition to assist awardees in launching independent research careers. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to clinical trial. Applicants to this Notice of Funding Opportunity (NOFO) are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (RFA-MH-22 330).				
		117690 RFA-MH-23-330 BRAIN Postdoctoral Career Tran Diversity (K99/R00 Indep Required)	sition Award to Promote	National Institutes o Health/DHHS	f RFA- MH-23- 1 330	3-Feb-2026	Not Specified
		Contact Name	James Churchill, Ph.D.				



Contact Email <u>BRAINDIVERSITYK99R00@nih.gov</u>

Contact Telephone 301-326-8800

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding
31 114 12	Trogram ritic	Sponsor Name	Sponsor Number	Deadinic Date	Amount

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 13-Feb-2026

The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to enhance diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds, including those from underrepresented groups in the biomedical and behavioral sciences, in BRAIN Initiative research areas. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to assist awardees in launching independent research careers. This Notice of Funding Opportunity is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (RFA-MH-22-331).

Synopsis

Notice of Special Interest (NOSI): Explainable 114061 Artificial Intelligence for Decoding and Modulating Neural Circuit Activity Linked to Behavior

National Institutes of Health/DHHS

NOT-MH-23- 07-Jan-2026 110

Not Specified

SPIN ID	Program Title		Spo	nsor Name	Sponsor Number	Deadline Date	Funding Amount			
			l	-1 -						
			Mauricio Rangel-Gome	ez, Ph.D.						
		Contact Telephone								
			mauricio.rangel-gome	<u>z@nih.gov</u>						
		Sponsor Website								
		Program URL	<u>Link to program URL</u>							
		Deadline Dates (ALL)	07-Jan-2026 , 05-Feb-2	.026						
		Synopsis	This Notice of Special Interest (NOSI) solicits applications in the area of XAI applied to neuroscientific questions of encoding, decoding, and modulation of neural circuits links behavior. This NOSI encourages collaborations between computationally and experime focused investigators. This NOSI seeks the development of machine learning algorithms able to mechanistically explain how experimental manipulations affect cognitive, affect processing in humans or animals. Proof-of-concept applications aimed at improving the state of the technology that uses XAI to provide unbiased, hierarchical explanations of relationships between complex neural and behavioral data are also appropriate.							
		120102 Social disconnection and (R21 Clinical Trial Option		National Institutes of Health/DHHS	of PAR-25- 066	16-Feb-2026	275,000 USD			
		Contact Name	Jovier Evans, Ph.D.							
		Contact Telephone	301-443-6328							
		Contact Email	jevans1@mail.nih.gov							
		Sponsor Website								
		·	Link to program URL							
		-	16-Feb-2026 , 16-Jun-2	2026						
			The purpose of this Notice of Funding Opportunity (NOFO) is to encourage research that addresse the link between social disconnection in late-life and late-life suicidal thoughts and behaviors. Of specific interest is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. Mechanism to be considered exist at multiple levels of analysis, including but not limited to neurobiological, behavioral, and environmental. This NOFO solicits R21 applications, while the companion							



announcement PAR-25-067 solicits R01 applications. High risk/high payoff projects that lack

SPIN ID	Program Title		Sponso	r Name	Sponsor Number	Deadline Date	Funding Amount
		preliminary data may be most appropriate for this R21 mechanism, while applications with preliminary data should apply to the R01 mechanism.					
		Secondary Analysis and 120393 to Elucidate Cancer Ris (R21 Clinical Trials Not		National Institutes o Health/DHHS	f PAR-25- 096	16-Feb-2026	400,000 USD
		Contact Nam Contact Telephor	ne Melissa Rotunno, Ph.D. ne 240-276-7245				
		Contact Ema Sponsor Websi	ail rotunnom@mail.nih.gov te				
			RL <u>Link to program URL</u> L) 16-Feb-2026, 16-Jun-202				
		Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) along wi other participating Institutes encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. Applicants are encouraged to leverage and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in cancer research.					
		121564 Developing Novel Theo Understanding the Ger Complex Human Traits Allowed)	netic Architecture of	National Institutes of Health/DHHS	f PAR-25- 256	16-Feb-2026	275,000 USD
		Contact Telephor	ne Alexander Arguello, Ph.D. ne 240-731-3753 ail <u>alexander.arguello@nih.g</u>	rov			



SPIN ID	Program Title		Sponso	r Name	Sponsor Number	Deadline Date	Funding Amount
		Deadline Dates (ALL)	Link to program URL 16-Feb-2026, 16-Jun-202 The goal of this NOFO is to enable better understand variation across individua interdependencies across use of theory, modeling, a interdisciplinary drawing	o support applications ing of how genetic and ls, families, and popula scales of biological, so	d non-genetic factor ations. Approaches social, and ecological ailable large-scale da	s contribute to con should account for organization, mak	mplex trait - e extensive
		115307 Notice of Special Interest Sudden Death in the You	_	National Institutes o Health/DHHS	f NOT-HL- 22-040	7-Jan-2026	Not Specified
		Contact Telephone Contact Email Sponsor Website	kristin.burns@nih.gov				
		•	Link to program URL 07-Jan-2026 , 05-Feb-202 , 05-Feb-2027 , 07-May-20	•			
		Synopsis	This Notice of Special Intermechanistic, genetic, and for sudden death in the yes samples and/or associate Registry as foundations for and/or samples and/or setudies are required to adwidely and provides an exSDY.	other studies to evaluoung (SDY). Studies are disequence data from their research. Studies quence data alone or ithere to the NIH Data Studies.	ate causes and conse required to use ph the NIH/CDC Sudde es may use SDY Case in combination with Sharing Policy so tha	equences of, and enotypic data and n Death in the You Registry phenoty other cohorts. Ret the data is disse	risk factors /or DNA ung (SDY) Case pic data sults of such minated
		120101 Social Disconnection and (R01 Clinical Trial Option)	· · · · · · · · · · · · · · · · · · ·	National Institutes o Health/DHHS	f PAR-25- 067	05-Feb-2026	Not Specified



SPIN ID	Program Title			Sı	ponsoi	r Name	Sponsor Number	Deadline Date	Funding Amount	
				l .						
				Jovier Evans, Ph.D.						
			Contact Telephone							
				jevans1@mail.nih.go	OV					
			Sponsor Website							
			Program URL	Link to program URI	<u>L</u>					
			Deadline Dates (ALL)	05-Feb-2026 , 05-Ju	ın-2026	5				
			Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to encourage research that addresses the link between social disconnection in late-life and late-life suicidal thoughts and behaviors. Of specific interest is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. Mechanism to be considered exist at multiple levels of analysis, including but not limited to neurobiological, behavioral, and environmental. This NOFO solicits R01 applications, while the companion announcement PAR-25-066 solicits R21 applications. High risk/high payoff projects that lack preliminary data may be most appropriate for the R21 mechanism.						
		117793	Interventions to Expand Preventive Services to Al Populations that Experie (R01, Clinical Trial Requir	DVANCE Health in nce Health Disparitie		National Institutes of Health/DHHS	f PAR-25- 098	07-Jan-2026	Not Specified	
			Contact Name	JoyAnn Courtney, Pl	h.D.					
			Contact Telephone	301-402-3911						
				joyann.courtney@n	ih.gov					
			Sponsor Website							
			Program URL	Link to program URI	L					
			_			5 , 07-May-2026 , 05-Ji	un-2026 , 07-Sep-20	, 05-Oct-2026	07-Jan-2027	
			Deadline Dates (ALL) 07-Jan-2026, 05-Feb-2026, 07-May-2026, 05-Jun-2026, 07-Sep-2026, 05-Oct-2026, 07-Jan-2027 The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICs) are issuing this R01 to solicit applications to address barriers Synopsis and facilitators that impede use or uptake of cancer screening and preventive services in populations that experience health disparities. Interventions should include screening, preventive							



services, or other healthcare processes, including timely follow-up of abnormal findings, and

SPIN ID	Program Title		Spons	or Name	Sponsor Number	Deadline Date	Funding Amount	
			referral to accessible care partners and service promore of the following leverage collaborations we existing interventions and should address barriers and healthcare setting, and near the service of t	viders. Interventions she wels: patient, clinician, he ts of participating NIH IO with community partnered/or adapt new combinand facilitators at two o	ould address barrie lealthcare setting, a Cs are detailed with rs and service provinations of evidence- r more of the follow	rs and facilitators a nd neighborhood/o in. Projects are er ders to promote or based strategies. I	t two or community. couraged to enhance nterventions	
		Addressing Health and H 122756 among Sexual and Gende (R01 - Clinical Trials Option	er Minority Populations	National Institutes o Health/DHHS	f PAR-24- 077	07-Jan-2026	2,500,000 USD	
		Contact Telephone	Rada K. Dagher, Ph.D., M 301-451-2187 ada.dagher@nih.gov	I.P.H.				
		Sponsor Website	Link to program URL					
		_		26 , 07-May-2026 , 05-J	un-2026 , 07-Sep-20)26 , 05-Oct-2026 ,	07-Jan-2027	
		Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to support innovative observation and intervention-based research to identify and characterize the pathways and mechanism through which health and health care disparities occur among sexual and gender minority populations of minoritized racial/ethnic and socio-economic statuses. Per Notice Number: MH-24-170: Research Priorities The National Institute of Mental Health (NIMH) will only accomposed to monclinical trials applications that reflect the mission and scientific priorities as identified in strategic plan NIMH » The National Institute of Mental Health Strategic Plan (nih.gov) and also NIMH's Approach to Mental Health Disparities Research. Clinical trial applications will accepted under this notice. Per NOT-MH-20-067, NIMH expects that grant applications involutions in the number of the pathways and mechanism through which health and health Disparities Research. Clinical trial applications will accepted under this notice. Per NOT-MH-20-067, NIMH expects that grant applications involutions are provided in the purpose of this Notice of Service and Institute of Mental Health Strategic Plan (nih.gov) and also NIMH's Approach to Mental Health Disparities Research. Clinical trial applications involutions are provided in the purpose of this Notice of Service NIMH expects that grant applications in the purpose of this Notice of Service NIMH expects that grant applications in the purpose of this Notice of Service NIMH expects that grant applications in the purpose of the					
		128630 Natural History of Disord Newborn Period (R01 Cli		National Institutes o Health/DHHS	t PAR-25- 227	06-Jan-2026 [Optional][LOI/Pre- App]	Not Specified	



SPIN ID	Program Title		s	ponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Contact Telephone Contact Email Sponsor Website Program URL	Link to program URI 06-Jan-2026 [Option 2026, 06-Sep-2026 05-Feb-2027, 06-M	<mark>gov</mark> L nal][LOI/Pre-App], 05-Feb-: [Optional][LOI/Pre-App], 0 lay-2027 [Optional][LOI/Pre	5-Oct-2026 , 06-Jan-2	2027 [Optional][LC	
		Synopsis	[Optional][LOI/Pre-App], 05-Oct-2027 This Notice of Funding Opportunity (NOFO) encourages applications that will expand knowledge the natural history of disorders that currently are, or may become, part of statewide newborn screening programs. A comprehensive understanding of the natural history of a condition is necessary to facilitate appropriate interventions for infants identified by newborn screening. Characterization of the sequence and timing of symptom development provides information crufor developing targeted, age-appropriate treatments and for establishing a baseline against white to assess novel interventions. In addition, for some conditions, establishment of genotype-phenotype correlations may facilitate prediction of the clinical course; for others, identification modifying genetic, epigenetic, or environmental factors may enhance understanding of clinical outcomes. Comprehensive data on the natural history of a condition will facilitate the field's abto: 1) identify the underlying biological mechanisms; 2) understand the genetic and clinical heterogeneity and phenotypic expression of the condition; 3) improve diagnostic accuracy; 4) facilitate clinical trials by providing comprehensive natural history data; 5) prevent, manage, antreat symptoms and complications of the condition; 6) furnish physicians and families with need support and predictive information about the condition; and 7) establish data collection system patient registries to collect longitudinal data (e.g., child/family outcomes following newborn				
		121565 <u>Health and Health Care Description of the Living with Disabilities (Roptional)</u>		National Institutes Health/DHHS	of PAR-23- 309	05-Feb-2026	Not Specified



Contact Name Sundania J. W. Wonnum, PhD, LCSW

SPIN ID	Program Title		Spon	sor Name	Sponsor Number	Deadline Date	Funding Amount	
		Contact Telephone						
		Contact Email	sundania.wonnum@nil	n.gov				
		Sponsor Website						
		Program URL	Link to program URL					
		Deadline Dates (ALL)	05-Feb-2026 , 05-Jun-2	026 , 05-Oct-2026				
		Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to support novel and innovative research that examines and/or intervenes on the underlying and multilevel causes, pathways, and factors adversely impacting the health and well-being of persons with disabilities at the intersections of race and ethnicity, and socioeconomic status.					
		Screening, Brief Interven Treatment or Prevention 120869 Tobacco, and Other Drug in Adult Populations That Disparities (R01, Clinical	(SBIRT/P) for Alcohol, s (ATOD) Use and Misus t Experience Health	National Institutes of Health/DHHS	of PAR-26- 001	07-Jan-2026	Not Specified	
		Contact Name	Denise Stredrick, Ph.D.					
		Contact Telephone	301-402-9749					
		Contact Email	denise.stredrick@nih.g	<u>ov</u>				
		Sponsor Website						
		Program URL	Link to program URL					
		Deadline Dates (ALL)	07-Jan-2026 , 05-Feb-20 , 05-Feb-2027 , 07-May		Jun-2026 , 07-Sep-20	026 , 05-Oct-2026	, 07-Jan-2027	
		Synopsis	The Office of Disease P Institutes, Centers, and approaches to impleme in adult populations the funding announcement intervening with a conv treatment or preventive of SBIRT/P and should I	Offices (ICOs) are issuirenting SBIRT/P for alcohole experience health displayment, involves screening incersation about harmfule services, as needed.	ng this NOFO seeking ol, tobacco, and othe parities. SBIRT/P, (a dividuals for risk of A substance use, and Proposed research sh	gapplications to te er drugs (ATOD) us term used for purp TOD use and misu referring individua nould include prosp	st innovative se and misuse coses of this se, briefly Is for pective tests	



SPIN ID	Program Title		Sponso	r Name	Sponsor Number	Deadline Date	Funding Amount
			research interests of parti	cipating NIH ICOs are o	detailed within.		
		on Non-Communicable a	Health Outcomes Across	National Institutes o Health/DHHS	f PAR-25- 342	07-Jan-2026	Not Specified
		Contact Name Contact Telephone	Larissa Avilés-Santa, MD, I 301-827-6924	MPH, Director			
		Contact Email Sponsor Website	avilessantal@nih.gov				
		-	Link to program URL				
		Deadline Dates (ALL)	07-Jan-2026 , 05-Feb-2026 , 07-May-2027	5 , 07-May-2026 , 05-Ji	un-2026 , 07-Sep-20	026 , 05-Oct-2026	, 07-Jan-2027
			The purpose of this Notice interdisciplinary team rese interventions that address chronic diseases (NCDs) w U.S. Hispanics/Latinos.	earch focused on clinic health and healthcar	cal, health services, e disparities related	and/or communit to non-communic	y-based cable and
		129396 NIH Research Project Gra Experimental Studies wit		National Institutes of Health/DHHS	f PA-25- 303	07-Jan-2026	Not Specified
		Contact Name Contact Telephone					
		Contact Email Sponsor Website	grantsinfo@nih.gov				
		·	Link to program URL				
		Deadline Dates (ALL)	07-Jan-2026 , 05-Feb-2026 , 05-Feb-2027 , 07-May-20	•	•		
		Synopsis	This Parent Notice of Fundamens, referred to in NC		-		-



SPIN ID	Program Title		Sponso	or Name	Sponsor Number	Deadline Date	Funding Amount
			participants." These stud definition of basic research that prospectively assign independent variables) a purpose of understanding towards processes or pro processes or products in 'Clinical Trial Optional' No	ch. Types of studies that human participants to one of that assess biomedicate from the fundamental aspendents in mind. Studies of mind should submit under the control of the fundamental aspendents in mind.	t should submit un conditions (i.e., exp cal or behavioral ou ects of phenomena conducted with spe	ider this NOFO incloserimentally maniputcomes in human without specific a ecific applications	ude studies oulate s for the pplication toward
		129398 NIH Research Project Grant Trial Required)	rant (Parent R01 Clinical	National Institutes of Health/DHHS	f PA-25- 305	07-Jan-2026	Not Specified
		Contact Name Contact Telephone	2				
			grantsinfo@nih.gov				
		Sponsor Website					
		Program UR Deadline Dates (ALL	L <u>Link to program URL</u> 07-Jan-2026 , 05-Feb-202) , 05-Feb-2027 , 07-May-2	•	•	-	•
		Synopsi	The NIH Research Project representing the specific Funding Opportunity required by related to the program Centers (ICs) based on the applications proposing multing opportunity annotations.	interests and competer uires that at least 1 clin nmatic interests of one eir scientific missions. A techanistic studies that	ncies of the investig ical trial be propos or more of the par Applicants should n	gator(s). This Pareled. The proposed ticipating NIH Instacted that some ICs	nt Notice of project must itutes and only accept
		129395 NIH Research Project Grant Not Allowed)	rant (Parent R01 Clinical	National Institutes of Health/DHHS	f PA-25- 301	07-Jan-2026	Not Specified
		Contact Name Contact Telephone Contact Emai					



					•					
SPIN ID	Program Title				Sponso	r Name	Sponsor Number	Deadline Date	Funding Amount	
			Sponsor Website							
			•	Link to program U	RL					
			Deadline Dates (ALL)	07-Jan-2026 , 05-F	eb-2026	5 , 07-May-2026 , 05-J 027 , 05-Jun-2027 , 07-	•			
			Synopsis	The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed promust be related to the programmatic interests of one or more of the participating NIH Institution and Centers (ICs) based on their scientific missions. This Funding Opportunity Announcement not accept applications proposing clinical trial(s).						
		129589	Academic-Industrial Part Technologies for Diagnos Clinical Trial Not Allowed	sis and Treatment (National Institutes o Health/DHHS	f PAR-25- 338	95-Feb-2026	2,495,000 USD	
			Contact Name	Miguel Ossandon	MS					
			Contact Telephone	240-276-5714						
			Contact Email	ossandom@mail.r	nih.gov					
			Sponsor Website							
			Program URL	Link to program U	RL					
			Deadline Dates (ALL)	05-Feb-2026 , 05-J	Jun-2026	5 , 05-Oct-2026 , 05-Fe	eb-2027 , 05-Jun-202	27 , 05-Oct-2027		
			Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to						



implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount

partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status. This FOA defines "innovation" as likelihood to deliver a new capability to end users.

NIH Brain Development Cohorts (NBDC) National Institutes of Not PAR-23-120775 06-Feb-2026 Biospecimen Access (X01 Clinical Trial Not Allowed) Health/DHHS 229 Specified

Contact Name Kimberly LeBlanc, Ph.D.

Contact Telephone 301-827-4102

Contact Email kimberly.leblanc@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 06-Feb-2026, 05-May-2026

The Adolescent Brain Cognitive DevelopmentSM (ABCD) Study is the largest longitudinal study of brain development and child health in the U.S., collecting data from more than 11,000 children across the country beginning when they were 9-10 years old and continuing for a decade. In addition to behavioral assessments, youth undergo neuroimaging and provide biospecimens, including oral fluids for hormone analysis, urine and hair for substance use and exposure, deciduous teeth for environmental exposures, and blood for genetic analysis and metabolic and hematologic assays. This initiative allows investigators to apply for access to biological samples

Synopsis from the ABCD Study[®]. More information about the ABCD Study can be found on the NIDA ABCD Study web page. Additional information about this resource is available on the NIDA funding opportunities page, under Supplemental Information for NOFOs. ABCD Study biospecimens are managed through the NIH Brain Development Cohorts (NBDC) Biorepository and Analysis Center, which offers a web portal with services related to biospecimen access. Visit the NBDC portal to query available samples using the Biospecimen Explorer, submit a Biospecimen Availability Inquiry to determine the resource availability and impact on existing samples, and learn more about this resource.

115920 NIH SIREN Neurologic Clinical Trials (UG3/UH3 -National Institutes of PAR-25- 07-Jan-2026 Not

	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<u>Clinical Trial Required)</u>	Health/DHHS		[Optional][LOI/Pre-App]	- Specified
	-			
_		·Feb-2026		
Synopsi	focused on neurological emergencies. Su within the NIH SIREN Network. The NIH S successful applicants to implement the process of the conter (DCC) will provide statistical and dot affiliated clinical sites will provide on-site not need to be part of the existing SIREN Network will also be uniquely poised to conecessary to conduct larger, definitive triemergencies. Multi-center clinical trials in	Iccessful applicants will colling and the coll	ollaborate and cond g Center (CCC) will we not the SIREN Data Co t. The NIH SIREN ha linical protocols. Ap noder this NOFO. The and international ctions for neurologic ery, or prevention s	uct the trial work with the coordinating ubs and their plicants do NIH SIREN consortia
128338 Efforts (IGNITE): Assay I Neurotherapeutic Agen	Development and National Instit t Identification (R61/R33 Health/DHHS		18-Feb-2026	750,000 USD
Contact Telephon Contact Ema	301-496-1779 I <u>rebecca.roof@nih.gov</u>			
	Contact Name Contact Telephone Contact Emai Sponsor Website Program URI Deadline Dates (ALL Synopsis Synopsis Innovation Grants to Nu Efforts (IGNITE): Assay E Neurotherapeutic Agent Clinical Trial Not Allowe Contact Name Contact Telephone Contact Emai	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) O7-Jan-2026 [Optional][LOI/Pre-App], 06- This Notice of Funding Opportunity (NOF focused on neurological emergencies. Su within the NIH SIREN Network. The NIH S successful applicants to implement the pi Center (DCC) will provide statistical and d affiliated clinical sites will provide on-site not need to be part of the existing SIREN Network will also be uniquely poised to o necessary to conduct larger, definitive tri emergencies. Multi-center clinical trials in NINDS will be conducted in the NIH Strok Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and National Instit	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) O7-Jan-2026 [Optional][LOI/Pre-App], 06-Feb-2026 This Notice of Funding Opportunity (NOFO) encourages application focused on neurological emergencies. Successful applicants will cut within the NIH SIREN Network. The NIH SIREN Clinical Coordinating successful applicants to implement the proposed trial efficiently at Center (DCC) will provide on-site implementation of the continued to be part of the existing SIREN infrastructure to apply un Network will also be uniquely poised to collaborate with other U.S necessary to conduct larger, definitive trials of promising intervent emergencies. Multi-center clinical trials in stroke treatment, recov NINDS will be conducted in the NIH StrokeNet, and not within SIRE firsts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed) Contact Name Contact Telephone Contact Telephone Contact Telephone Contact Telephone Contact Telephone Contact Email	Contact Name Contact Telephone Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Deadline Dates (ALL) Synopsis Contact Sign program URL Deadline Dates (ALL) Deadline Dates (ALL) This Notice of Funding Opportunity (NOFO) encourages applications for multi-center focused on neurological emergencies. Successful applicants will collaborate and cond within the NIH SIREN Network. The NIH SIREN Clinical Coordinating Center (CCC) will volume successful applicants to implement the proposed trial efficiently and the SIREN Data Center (DCC) will provide on-site implementation of the clinical protocols. Ap not need to be part of the existing SIREN infrastructure to apply under this NOFO. The Network will also be uniquely poised to collaborate with other U.S. and international necessary to conduct larger, definitive trials of promising interventions for neurologic emergencies. Multi-center clinical trials in stroke treatment, recovery, or preventions NINDS will be conducted in the NIH StrokeNet, and not within SIREN. Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed) Contact Name Contact Name Contact Telephone Contact Email



SPIN ID	Program Title		Spons	or Name	Sponsor Number	Deadline Date	Funding Amount
		Synopsis	This Notice of Funding O vitro, ex vivo or in vivo a potential therapeutic ago suite of Innovation Gran Opportunity (NOFO) req	ssays and conduct itera ents for neurological or ts to Nurture Initial Trar	tive screening effort neuromuscular disc nslational Efforts (IG	s to identify and corders.This NOFO in NITE). This Notice	haracterize s part of a
		Development of Interver 132878 Substance Use Disorders Clinical Trial Optional)	ations to Prevent and Trea and Overdose (UG3/UH3		f PAR-25- 446	2-Dec-2025	15,000,000 USD
		Contact Name	Ivan D. Montoya, M.D., N	И. Р.Н.			
		Contact Telephone	301-827-5936				
		Contact Email	imontoya@mail.nih.gov				
		Sponsor Website					
		Program URL	Link to program URL				
		Deadline Dates (ALL)	22-Dec-2025 , 20-Feb-20 , 22-Feb-2027 , 20-Apr-2 2028 , 20-Apr-2028 , 20-	027 , 21-Jun-2027 , 20- <i>l</i>	Aug-2027 , 20-Oct-2		
		Synopsis	The purpose of this noti research on the discover disorders (SUDs) and over preclinical and clinical reresults to advance candid NOFO will utilize the UG:	y and development of iterdose, including intervented in search studies that will date interventions close	nterventions to preventions to treat co-rehave high impact ar	vent and/or treat s norbid SUDs. This nd quickly yield the	substance use includes e necessary
		129391 NIH Small Research Gran Clinical Trial Not Allowed		National Institutes of Health/DHHS	f PA-25- 302	7-Jan-2026	100,000 USD
		Contact Name Contact Telephone Contact Email Sponsor Website	301-480-7075 grantsinfo@nih.gov				
		·	Link to program URL				



						_	
SPIN ID	Program Title		Sponso	r Name	Sponsor Number	Deadline Date	Funding Amount
		Synopsis	07-Jan-2026, 16-Feb-202, 16-Feb-2027, 07-May-2 The NIH Small Research G a short period of time wit including pilot and feasible research projects; develo technology. This Funding clinical trial(s).	027 , 16-Jun-2027 , 07- rant Program supports h limited resources. Th lity studies; secondary pment of research met	Sep-2027, 16-Oct-2 s small research pro- lis program support analysis of existing chodology; and deve	:027 , 07-Jan-2028 jects that can be c s different types o data; small, self-co elopment of new r	arried out in of projects ontained esearch
		NIH Exploratory/Develop 129394 Grant Program (Parent R Studies with Humans Rec	21 Basic Experimental	National Institutes o Health/DHHS	f PA-25- 307	7-Jan-2026	275,000 USD
		Sponsor Website Program URL	301-496-4000 grantsinfo@od.nih.gov Link to program URL 07-Jan-2026, 16-Feb-202	•	•		
		Deadline Dates (ALL) O7-Jan-2026, 16-Feb-2026, 07-May-2026, 16-Jun-2026, 07-Sep-2026, 16-Oct-2026, 07-Jan-2028, 16-Feb-2027, 07-May-2027, 16-Jun-2027, 07-Sep-2027, 16-Oct-2027, 07-Jan-2028 This Parent Notice of Funding Opportunity is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate 'Clinical Trials Required' or 'Clinical Trial Optional' NOFO.					
		129392 NIH Exploratory/Develop Program (Parent R21 Clin		National Institutes o Health/DHHS	f PA-25- 304	7-Jan-2026	275,000 USD



			0 1	•							
SPIN ID	Program Title			Sponsor	Name	Sponsor Number	Deadline Date	Funding Amount			
			I								
		Contact Name									
		Contact Telephone									
			grantsinfo@nih.go	<u> </u>							
		Sponsor Website									
		Program URL	<u>Link to program URL</u>								
		Deadline Dates (ALL)	07-Jan-2026, 16-Feb-2026, 07-May-2026, 16-Jun-2026, 07-Sep-2026, 16-Oct-2026, 07-Jan-2027, 16-Feb-2027, 07-May-2027, 16-Jun-2027, 07-Sep-2027, 16-Oct-2027, 07-Jan-2028								
The NIH Exploratory/Developmental Grant supports exploratory and developmental projects by providing support for the early and conceptual stages of these projects. The NIH Exploratory/Developmental Grant supports exploratory and developmental projects by providing support for the early and conceptual stages of these projects. The Notice of the early and conceptual stages of these projects. The NIH Exploratory/Developmental Grant supports exploratory and developmental projects by providing support for the early and conceptual stages of these projects. The NIH Exploratory/Developmental Grant supports exploratory and developmental projects by providing support for the early and conceptual stages of these projects. The NIH Exploratory/Developmental Grant supports exploratory and developmental projects. The NIH Exploratory/Developmental Grant supports exploratory and developmental Grant supports exploratory and developmental projects. The NIH Exploratory/Development of the early and conceptual stages of these projects. The NIH Exploratory/Development for the early and conceptual stages of these projects. The NIH Exploratory/Development of the early and conceptual stages of these projects. The NIH Exploratory/Development for the early and conceptual stages of these projects. The NIH Exploratory/Development for the early and conceptual stages of these projects. The NIH Exploratory/Development for the early and conceptual stages of these projects. The NIH Exploratory/Development for the early and conceptual stages of these projects. The NIH Exploratory/Development for the early and conceptual stages of these projects. The NIH Exploratory/Development for the early and conceptual stages of these projects. The NIH Exploratory/Development for the early and conceptual stages of the early							these projects. The articular area, or to or applications tha	nese studies to the at could have			
		129393 NIH Exploratory/Develop	mental Research G	<u>Grant</u>	National Institutes o	f PA-25-	7-Jan-2026	275,000			
		Program (Parent R21 Clin	nical Trial Required	1	Health/DHHS	306	77 3411 2020	USD			
		Contact Name									
		Contact Telephone									
		Contact Email	grantsinfo@nih.go	<u>v</u>							
		Sponsor Website									
		Program URL	Link to program U	RL							
		Deadline Dates (ALL)			, 07-May-2026 , 16-J 27 , 16-Jun-2027 , 07-	· ·					
		Synopsis	projects by provid may involve considevelopment of no a major impact on Opportunity Anno	ling suppo derable r ovel tech a a field o ouncemer	opmental Grant support for the early and of isk but may lead to a niques, agents, methof biomedical, behaviont requires that at leagrammatic interests of	conceptual stages of breakthrough in a p odologies, models, o oral, or clinical resea st 1 clinical trial be p	these projects. The articular area, or to are applications the rch. This Parent Fuoroposed. The pro	nese studies to the at could have unding posed project			

SPIN ID	Program Title		Sponse	or Name	Sponsor Number	Deadline Date	Funding Amount		
			and Centers (ICs) based of (seeRelated Notices) only definition of a clinical trial	accept applications p	roposing mechanist	ic studies that mee			
		129270 Limited Competition: Clin Science Award (CTSA) Pro Innovative Acceleration A Trial Optional)	ogram: Collaborative and	National Institutes of Health/DHHS	of PAR-25- 296	18-Feb-2026	3,250,000 USD		
		Contact Telephone Contact Email	kristopher.bough@nih.go	<u>ov</u>					
		_	Link to program URL						
		Deadline Dates (ALL) Synopsis	The CTSA Collaborative and Innovative Acceleration Award (CCIA) aims to accelerate the pace of translational research by supporting the collaborative development, dissemination, and sustainabl implementation of innovative solutions across the CTSA Program Consortium and beyond. This limited competition Notice of Funding Opportunity (NOFO) invites investigator-initiated applications to develop, demonstrate, and disseminate innovative new approaches, technologies, resources, or models that increase the impact of research across diseases, transform the field of translational science, and bring more treatments for all people more quickly.						
		122207 Ethical, Legal and Social I Research (R01 Clinical Tr		National Institutes of Health/DHHS	of PAR-25- 371	19-Feb-2026	Not Specified		
		Contact Telephone Contact Email Sponsor Website Program URL	dave.kaufman@nih.gov	26 . 20-Oct-2026					
		(' ·)	l	,					



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding
51 114 115	Trogram rice	Sponsor Hame	Sponsor Number	Deadinic Date	Amount

Synopsis

propose to study the ethical, legal and social implications (ELSI) of human genetic or genomic research. Applications may propose studies using either single or mixed methods. Approaches may include but are not limited to empirical qualitative and quantitative methods, and conceptual, legal, and normative analyses. Applied research designed to address ELSI issues in genetics and genomics will also be considered responsive. Direct engagement with communities and other interested groups is encouraged, but not required. Plan for Enhancing Diverse Perspectives The NIH recognizes that diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogeneous teams. There are many benefits that flow from a diverse scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved populations participate in, and benefit from research, and enhancing public trust. To support the best science, the NIH encourages inclusivity in research. Examples of structures that promote diverse perspectives include but are not limited to: Transdisciplinary research projects and collaborations among researchers from fields such as computational biology, physics, engineering, mathematics, computer and data sciences, as well as bioethics. Engagement from different types of institutions and organizations (e.g., researchintensive, undergraduate-focused, minority-serving, community-based). Individual applications and partnerships that enhance geographic and regional heterogeneity. Investigators and teams composed of researchers at different career stages. Participation of individuals from diverse backgrounds, including groups traditionally underrepresented in the biomedical, behavioral, and clinical research workforce (see NOT-OD-20-031), such as underrepresented racial and ethnic groups, those with disabilities, those from disadvantaged backgrounds, and women. Opportunities to enhance the research environment to benefit early- and mid-career investigators. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the

This Notice of Funding Opportunity (NOFO) invites Research Project Grant (R01) applications that

Ethical, Legal and Social Implications (ELSI)

122256 Exploratory/Developmental Research Grant (R21
Clinical Trial Optional)

National Institutes of Health/DHHS

NOFO instructions carefully and view the available PEDP guidance material.

PAR-25-369 19-Feb-2026 275,000 USD

Contact Name Dave Kaufman

CDIN ID	Due sus as Title		Constant	Nama	Constant Name have	Dan diina Data	Funding
SPIN ID	Program Title		Spons	sor Name	Sponsor Number	Deadline Date	Amount
		Contact Telephone	301-402-4997				
		Contact Email	dave.kaufman@nih.gov				
		Sponsor Website					
		Program URL	Link to program URL				
		Deadline Dates (ALL)	19-Feb-2026 , 18-Jun-20	26 , 20-Oct-2026			
		Synopsis	This Notice of Funding C (R21) applications that properties or genomic resemethods, that break new preliminary data in prepempirical qualitative and Applied research design responsive. Direct engagnequired.	propose to study the ether arch. Applications may by ground, extend previous aration for larger studied quantitative methods, ed to address ELSI issue	nical, legal and social propose studies using ous discoveries in neces. Approaches may and conceptual, legos in genetics and genetics and genetics	implications (ELS ig either single or w directions, or do include but are notal, and normative nomics will also be	ol) of human mixed evelop of limited to e analyses. e considered
		122258 Ethical, Legal and Social I		National Institutes o	of PAR-25-	.7-Feb-2026	100,000
		Research Grant (R03 Clin	ical Trial Optional)	Health/DHHS	370	17-1 60-2020	USD
		Contact Name	Dave Kaufman				
		Contact Telephone	301-402-4997				
		Contact Email	dave.kaufman@nih.gov				
		Sponsor Website					
		Program URL	Link to program URL				
		Deadline Dates (ALL)	17-Feb-2026 , 18-Jun-20	26 , 16-Oct-2026			
	Deadline Dates (ALL) This Notice of Funding Opportunity (NOFO) invites Small Research Grant (R03) applications that propose to study the ethical, legal and social implications (ELSI) of human genetic or genomic research. These applications should be for small, self-contained research projects, such as those that involve single investigators. Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues. This mechanism can also be used for the collection of preliminary data and the secondary analysis of existing data. Applications may propose studies						



SPIN ID	Program Title		Sponso	r Name	Sponsor Number	Deadline Date	Funding Amount
		December February	using either single or mixe and genomics will also be stakeholders is encourage	considered responsive	_		-
		129182 Health Professional Scho (R15 Clinical Trial Not Al		National Institutes of Health/DHHS	f PAR-25- 298	97-Jan-2026	375,000 USD
		Contact Telephone Contact Emai Sponsor Website	lynn.king@nih.gov				
		Program URI Deadline Dates (ALL)	Link to program URL 07-Jan-2026, 25-Feb-2026, 25-Feb-2027, 07-May-20	•	· · · · · · · · · · · · · · · · · · ·		
		Synopsis	The purpose of the Resear and Graduate Schools is to substantial funding from the primarily for health professing research environment at a sadvanced science degrees support (in both direct and composed of multiple school NIH funding received by a determining the Organization found here or https://gram	b support small scale re he NIH, with an emph- isional, undergraduate applicant institutions. I and have received no d F&A/indirect costs) it bols and colleges, the ll the schools and collection Funding Level can	esearch grants at in asis on providing bid and graduate stude Eligible institutions in more than \$6 million 4 of the last 7 fisc \$6 million funding lieges within the institute	stitutions that do nomedical research ents and enhancin must award baccal on dollars per year al years. For institumit is based on th	not receive experiences g the laureate or of NIH utions e amount of
		Treatment of Mental Dis	Groups (NCDDG) for the sorders (U19 Clinical Trial	National Institutes of Health/DHHS	f PAR-25- 353	25-Feb-2026	Not Specified
		Contact Name	Yael Mandelblat-Cerf, Ph.I	D.			



SPIN ID Pro	rogram Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
-------------	--------------	--------------	----------------	---------------	-------------------

Contact Telephone 301-793-7563

Contact Email yael.mandelblat-cerf@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 25-Feb-2026, 25-Jun-2026, 25-Oct-2026, 25-Feb-2027, 25-Jun-2027, 25-Oct-2027

The purpose of this notice of funding opportunity (NOFO) is to: accelerate innovative drug and device discovery; develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health, develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative new candidates for mental disorders, and support early-stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)ready agents or Investigational Device Exemption (IDE)-ready devices for the treatment of mental disorders. This NOFO encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders and to develop novel ligands and circuit-engagement devices Synopsis as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. This NOFO supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary, and often long-term approach. Projects seeking support for a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies should consider the companion NOFO (PAR-25-352). This NOFO will also support applications proposing preclinical discovery of biotechnology products and biologics with potential as candidate therapeutics including, but not limited to, large biologic macromolecules, (e.g., proteins,

antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral vector-based), cell

NIDCD Clinical Research Center Grant (P50 Clinical 132926 Trial Optional)

National Institutes of Health/DHHS

therapies, and novel emerging therapies (e.g., microbial and microbiome therapies).

PAR-25-445

02-Feb-2026

7,500,000 USD

Contact Name Holly L. Storkel, Ph.D.

Contact Telephone 301-496-5061



SPIN ID	Program Title	Sponso	r Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Websit	The National Institute on I applications for Clinical Retreatment, and amelioration announcement, Clinical Recommunication disorder, disorder. Examples of such pathogenesis, pathophysic disorder of hearing, balance the research will involve in	Deafness and Other Co search Center Grants on of human sensory esearch is defined as re- or data/tissues from in research include but ology, diagnosis, treat ce, smell, taste, voice, adividuals with sensor ory and/or communication di are possible with appretaff. Applications may neresponsive applications di	ommunication Disor designed to advance and communication esearch involving including with a seriare not limited to, sment, management speech, or language y and/or communication disorders, who liternatives (e.g., no sorder, human at ristopriate and strong strong seriare and strong strong seriare and strong strong seriare and strong strong seriare and seriare and strong seriare and strong seriare and strong seriare and seriare and strong seriare and seriare an	ders (NIDCD) invite the diagnosis, prodisorders. For this dividuals with a sensory and/or communitudies of the prevention disorders or epidemiology of the clinical research sk for a sensory are scientific justificat clinical trial but are wed. Prospective communicate with	es revention, s revention, s rensory and/or munication rention, of a disease or rent is that all data/tissues rearch goal(s) a, human ad/or ion and in renot applicants are a the
	NHLBI TOPMed: Omics 133023 and Blood Disorders (XO Allowed)	Phenotypes of Heart, Lung, 01 - Clinical Trial Not	National Institutes o Health/DHHS	f PAR-25- 447	08-Jan-2026	Not Specified
	Contact Telephon	il <u>ye.yan@nih.gov</u>				



SPIN ID	Program Title			Spo	nsor Name	Sponsor Number	Deadline Date	Funding Amount
				1				
			Program URL	Link to program URL				
			Deadline Dates (ALL)		2026 , 08-May-2026 , 08-J y-2027 , 08-Jun-2027 , 08			
			Synopsis	for Precision Medicine of integrated genetic a Heart, Lung, Blood, an genomic data and rela access database such access database such Catalyst (BDC). The ovunderstanding how ge This transformation wapplications of Al and	Opportunity (NOFO) invi- (TOPMed) program to ac- and multi-omics data to fa- d Sleep (HLBS) disorders. ted phenotypic data will leas the database for Geno- erall goal is to move from netic factors contribute to ill help move TOPMed from ML tool sets where possil to personalized medicine.	ccess TOPMed capace capace capace capace capace capace and put types and Phenotype a simply cataloging good HLBS diseases at the genetic Map to Market capace capac	ity to generate a lathe molecular me provided under this blic NIH-designate es (dbGaP) and NH enetic associations he molecular and offechanism with po	arge volume chanisms of s NOFO. The ed controlled- ILBI's BioData s to cellular levels.
		133058	Mind and Body Intervent Person Health via Emotio Mechanisms (R61/R33 C	onal Well-Being	National Institutes of Health/DHHS	of PAR-25- 449	09-Feb-2026	2,375,000 USD
			Contact Name	Erin Burke Quinlan, Ph	.D.			
			Contact Telephone	301-451-0636				
			Contact Email	erin.quinlan@nih.gov				
			Sponsor Website					
			Program URL	Link to program URL				
			Deadline Dates (ALL)	09-Feb-2026 , 08-Jun-: 07-Jun-2028	2026 , 07-Oct-2026 , 08-F	eb-2027 , 08-Jun-202	27 , 07-Oct-2027 ,	08-Feb-2028 ,
			Synopsis	Funding Opportunity (interventions through acupuncture, massage	or Complementary and Int NOFO) to solicit application psychological and/or phy , and other brain- and/or EWB) and their association	ons for research on lastical practices (e.g., body-based interve	now mind and bod mindfulness medi ntions) impact me	ly tation, yoga, chanisms of



SPIN ID Program Title Sponsor Name Sponsor Number Deadline Date Amount	SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
--	-----------------------	--------------	----------------	---------------	-------------------

with the NIH priority to address the health needs of the American people and improve their wellbeing. The NOFO will support rigorous and well-powered human mechanistic research studies that are supported by strong preliminary data. The studies should examine the effects of mind and body interventions on innovative mechanisms of EWB (as the primary outcome), as well as the associated relationship with the Whole Person Health Index (WPHI, as a secondary outcome). To enhance research safety, rigor, and efficiency of NIH-funded mechanistic clinical trials, this initiative will use a two-phased award funding mechanism (R61/R33). The funding will support an initial phase (R61) to establish feasibility benchmarks for a subsequent proposed second phase (R33) mechanistic clinical trial, which will be contingent upon successful achievement of R61 benchmarks ("Go/No-Go Criteria"). Applications should provide preliminary data that are comparable in quality and quantity to those expected for an R01 application.

NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored Clinical 126793 Scientist Development Awards (K08 - Basic Experimental Studies with Humans (BESH)

National Institutes of Health/DHHS

PAR-24- 12-Feb- Not 218 2026 Specified

Contact Name Laura D. Wandner

Contact Telephone

Contact Email Laura. Wandner@nih.gov

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL)

12-Feb-2026, 12-Mar-2026, 12-Jun-2026, 12-Jul-2026, 12-Oct-2026, 12-Nov-2026, 12-Feb-2027, 12-Mar-2027, 12-Jun-

2027, 12-Jul-2027

Synopsis

The purpose of this NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored Clinical Scientist Development Awards (K08) (BESH) is to support the career development of individuals with clinical doctoral degrees to create a group of new and well-trained, independent investigators. This supervised career development program will provide independent NIH research support during the early-career phase to help awardees establish independent research programs in areas supported by the NIH HEAL Initiative's Clinical Research in Pain Management program. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human

Required)

SPIN ID	Program Title	s	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	1					

participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial basic experimental study with humans led by another investigator, must apply to the Independent Clinical Trial Not Allowed companion NOFO.

123977 NIA Career Transition Award (K22 Independent Clinical Trial Not Allowed)

National Institutes of Health/DHHS

PAR-24- 12-Feb- Not 120 2026 Specified

Contact Name Jamie Lahvic, Ph.D.

Contact Telephone

Contact Email NIATraining@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 12-Feb-2026, 12-Mar-2026, 12-Jun-2026, 12-Jul-2026

line Dates (ALL) 12-Feb-2026 , 12-Mar-2026 , 12-Jun-2026 , 12-Jul-2026

Synopsis

The purpose of the NIA Career Transition Award (CTA) is to facilitate the transition of mentored, postdoctoral researchers to tenure-track or equivalent faculty positions conducting research that advances the mission of NIA. This award does not provide postdoctoral phase funding; therefore, candidates should be prepared to transition to tenure-track or equivalent faculty positions within 12 months after confirmation of a positive funding decision. After transition to an approved faculty position at an extramural institution/organization, the award will provide three years of protected research time through salary and research support. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial.

114250 Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)

National Institutes of Health/DHHS

PA-25- 07-Jan-169 2026

400,000 USD

							Funding
SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline	I Date I	Amount
					•		
	Contact Name	Randy King, Ph.D.					
	Contact Telephone	301-451-0707					
	Contact Email	Randy.King@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	07-Jan-2026 , 16-Feb-2026 , 16-Mar-2026 ,	07-May-2026				
(https://grants.nih.gov/policy/early-investigators/index.htm) to pursue research programs of high interest to the integrate engineering and the physical sciences with the life and/or biomedical sciences. A Trailblazer project mexploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed driven, or hypothesis-driven. Importantly, applicants must propose research approaches for which there are mix preliminary data. A distinct feature for this FOA is that no preliminary data are required, expected, or encourage if available, minimal preliminary data are allowed. Preliminary data are defined as material which the applicant independently produced and not yet published in a peer-reviewed journal.All preliminary data should be clearly limited to one-half page, which may include one figure. Applications including data more than one-half page or one figure will be considered noncompliant with the FOA instructions and will not go forward to review.							, discovery- nimal or no ed. However, has v marked and
118583	NLM Grants for Scholarly Works i Allowed)	in Biomedicine and Health (G13 Clinical Tria	National Library Medicine/NIH/		PAR-23- 183	26-Feb- 2026	160,000 US
	Contact Name	Yanli Wang, Ph.D.					
	Contact Telephone	301-827-7092					
	Contact Email	yanli.wang@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	26-Feb-2026					
This Notice of Funding Opportunity (NOFO) solicits grant applications for the preparation of book-length manuscripts and Synopsis other works of academic and/or public health policy value to U.S. health professionals, public health officials, biomedical researchers and historians of the health sciences.							
113609	NLM Research Grants in Biomedi Optional)	cal Informatics and Data Science (R01 Clinic	al Trial National Librar Medicine/NIH/		PAR-25- 238	07-Jan- 2026	1,000,000 USD

		5 .	•					
SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadlin	e Date	Funding Amount
	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	sufianm@mail.nih.gov	on biomedical disc can be translated erest in these resectiven discovery in the oducible approaches	overy and c into scientif arch domain he biomedio	ata-powered health ic insights, clinical c ns is broad, with em cal and clinical healt	n, integrat are, publi phasis on th science	ting strear c health p new and s as well a	ms of comple oractices, and innovative as domain-
128780	Development of Animal Models a Clinical Trial Not Allowed)	and Related Biological Materials for Researd		of Researc ams/NIH/DI	h Infrastructure HHS	PAR-25- 273	- 07-Jan- 2026	275,000 US
	Contact Name	Sige Zou, Ph.D.						
	Contact Telephone							
	Contact Email	sige.zou@nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-Jan-2026 , 16-Feb-2026 , 07-May-2026 2027 , 16-Jun-2027 , 07-Sep-2027 , 16-Oct			16-Oct-2026 , 07-Ja	n-2027 <i>,</i> 1	.6-Feb-20	27 , 07-May-
	Synopsis	This notice of funding opportunity (NOFO) animal models as well as animal model rel for studies relevant to human health and control of diseases that could confound or broad applicability to multiple NIH Institut	ated biological mad disease. This NOFO rinterfere with anim	terials, tech also seeks mal use in b	nologies, and new a projects aimed at in iomedical research	approach aproving t . The prop	methodol the diagno oosed proj	logies (NAMs osis and ject must hav



Infrastructure Programs (ORIP). The proposed studies must include animal models and explore multiple body systems or multiple categories of diseases. Applications that develop models focused on a specific disease or area of research, or only

SPIN ID	Program Title		Sponsor N	ame	Sponsor Number	Deadline	e pate	Funding Amount
		propose studies primarily relevant to a sin	gle NIH IC,	will be considered	not acceptable to th	is NOFO a	nd will b	e withdrawn.
128808	<u>Limited Competition: Small Gran</u> <u>Award (SERCA) K01 Recipients (R</u>	t Program for ORIP Special Emphasis Resea 03 Clinical Trials Not Allowed)	irch Career	Office of Research Programs/NIH/DI		PAR-25- 176	07-Jan- 2026	150,000 USI
	Contact Name	Stephanie Murphy, VMD, PhD						
	Contact Telephone	301-451-7818						
	Contact Email	stephanie.murphy@nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	07-Jan-2026 , 16-Feb-2026 , 07-May-2026						
	Synopsis	The Office of Research Infrastructure Prog Initiatives announces an opportunity to ap Award (SERCA) K01 recipients who have co- enhance the ability of ORIP SERCA K01 rec- status. The R03 mechanism supports projects small, self-contained research projects; de technology. The R03 is intended to suppor require limited levels of funding. This Funda-	oply for sma ompleted the cipients to c ects includir evelopment rt research	Il grant support for ne first two years (2 onduct research as ng pilot and feasibil of research metho projects that can re	ORIP-supported Sp 24 months) of the SE they transition to fu ity studies; seconda dology; and develop ealistically be comple	ecial Emp RCA K01 a ally indepory analysis oment of r eted in tw	hasis Resaward. O endent ir s of existinew resea	search Career RIP seeks to evestigator ing data; arch nd that

trial(s).

			. ,			
SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
122369	Designing Synthetic Cells Beyo	and the Bounds of Evolution	National Science Founda	tion 24-505 02	-Feb-2026 6.0	 000.000 USD
122303		Anthony G. Garza		21303 02	100 2020 0)	
	Contact Telephone					
	•	aggarza@nsf.gov				
		Link to sponsor website				
	•	Link to program URL				
	Deadline Dates (ALL)					
		cell-like systems for a variety of basic at (1) develops cell-like systems to identificells to address fundamental questions exists in nature, and (3) leverages basic innovative biotechnology applications and broader impacts, while proposals incremental impact) will not be competissues associated with designing and be	ces in synthetic biology and bioengineer and applied research purposes. The goal fy the minimal requirements for the process in the evolution of life or to explore bic research in cell design to build novel sy Highest funding priority is given to propositive. Proposals submitted to this solicituilding synthetically modified cells as an	of this solicitation cesses of life, (2) dological diversity by the thetic cell-like syposals that have out hose that are percentation should addrintegrated compositions.	is to support resigns synthet eyond that whe estems and cell atstanding interived as likely ess social, ethiconent of the pressure.	research that tically-modified nich currently is for ellectual merit to have an ical, and safety roject.
124484		Methods, and Mathematical Reasoning	National Science Founda	tion 24-554 05	-Feb-2026 1,2	200,000 USD
		Tomek Bartoszynski				
	Contact Telephone					
		tbartosz@nsf.gov				
	•	<u>Link to sponsor website</u>				
	· ·	Link to program URL				
	Deadline Dates (ALL) Synopsis	The Artificial Intelligence, Formal Meth interface of innovative computational mathematical reasoning to automate that plays an important role in knowle	nods, and Mathematical Reasoning (AIM and artificial intelligence (AI) technologic knowledge discovery. Mathematical reasing dge discovery. In the last decades, both arch in machine-assisted mathematical reasing the mathematical reasoning (AIM) and the mathematical re	es and new strates coning is a central the mathematics a	gies/technolog ability of huma and computer	gies in an intelligence science

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		techniques from artificial intelligence.	orm of both formal methods and interact Recent technological advances have led nematical sciences, formal methods, and I.	to a surge of inte	erest in machine	e-assisted
117040	A Science of Science Approach Research Enterprise	to Analyzing and Innovating the Biome	dical National Science Founda	ation 23-569 0	9-Feb-2026 1,0)00,000 USD
	Contact Name	Mary Feeney				
	Contact Telephone	703-292-7197				
	Contact Email	mfeeney@nsf.gov				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	09-Feb-2026				
	Synopsis	our understanding of the biomedical repolicy research community. NSF promoducation across all fields of science and NSF supports basic research on people social, economic, political, cultural and in turn shape those forces. SBE's Science research designed to advance the science with supporting biomedical research in supports basic biomedical research that in disease diagnosis, treatment and programmatic goals are compatitive.	and the National Institutes of Health (Nesearch enterprise by drawing from the otes the progress of science by maintain and engineering. The Social, Behavioral a and society. The SBE sciences focus on environmental forces affect the lives of ce of Science: Discovery, Communication pointific basis of science and innovation point the U.S. The National Institute of General increases understanding of biological evention. Both NSF and NIH believe that a focus on the scientific research enterpole, coordinated management and function of research and can leverage the investigation.	scientific expertishing the general had Economic Scientime human behavior for people from birth and Impact Proposition. The NIH is the eral Medical Scientime processes and lay there are opportorise. The two ageding of a research	se of the science ealth of research ces (SBE) Direct and social organish to old age; and gram (SoS:DCI) see U.S. federal agoes (NIGMS) with the foundation tunities and need program can harms.	e of science ch and ctorate within nizations; how nd how people supports gency charged thin the NIH on for advances eds for building gnize that ave a positive

scientific leaders will emerge.

and SBE are partnering to enable collaboration in research between the SoS:DCI program and NIGMS. This partnership will result in a portfolio of high-quality research to provide scientific analysis of important aspects of the biomedical research enterprise and efforts to foster a diverse, innovative, productive and efficient scientific workforce, from which future

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
109075	Algorithms for Modern Power	<u>Systems</u>	National Science Fou	indation 22-569 0	9-Feb-2026 2	,000,000 USD
	Contact Name	Tomek Bartoszynski				
	Contact Telephone	703-292-4885				
	Contact Email	tbartosz@nsf.gov				
	Sponsor Website	<u>Link to sponsor website</u>				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	09-Feb-2026				
	Synopsis	The Algorithms for Modern Power Syst mathematical and statistical algorithm The program is a partnership between and the Office of Electricity Delivery &	s for improvement of the security, r the Division of Mathematical Science	eliability, and efficiences (DMS) at the Natio	cy of the mod	ern power grid.
123546	Growing Convergence Research	th (GCR)	National Science Fou	indation 24-527 0	9-Feb-2026 1	,200,000 USD
	Contact Name					
	Contact Telephone	1-800-518-4726				
	Contact Email	support@grants.gov				
	Sponsor Website	<u>Link to sponsor website</u>				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	09-Feb-2026				
	Synopsis	This GCR solicitation targets multidiscipling highly innovative solutions to complex technical challenges and bottlenecks wexing problems. Successful GCR projeestablishment of new scientific commultiplication of the scientific or societal impact. The for addressing a specific and compelling novel avenues not previously investigated must make a convincing case that the division boundaries, and is currently not scientific to the scientific transfer of	research problems. GCR proposals a which if resolved have the potential to cts are anticipated to lead to paradi unities, or development of transform aim of GCR is to cultivate and grow ag problem. As such, proposals submated that are at the forefront of advances	are expected to be be to transform scientific gm shifting approach native technologies th the earliest foundati nitted to this solicitati ancing science throug NSF's purview, integra	old and addres and and addres and and address within discinat have the poons of convergon are expected the deep integral ates across NSF	s scientific or g and solve plines, otential for gent approaches ed to explore stion. Proposers

CDINIID	Drogram Title	Snancar Nama	Sponsor	Deadline	Funding
SPIN ID	Program Title	Sponsor Name	Number	Date	Amount

year research plan delineated in two phases, Phase I: years 1-2, and Phase II: years 3-5. The total budget for Phase I may not exceed \$1,200,000, and the total for Phase II may not exceed \$2,400,000. Successful proposals will be funded initially for two years. Each team's progress will be evaluated at a reverse site visit near the end of year 2; this will involve preparing a progress report and making a team presentation to a panel of reviewers/site visitors.

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	e	Sponsor Number	Deadline Da	te F	unding Amount
123850	AHRQ Small Health Services Rese	earch Grant Program (R03)	Agency for Healthcare Re Quality/DHHS	esearch and P	A-24-155	16-Feb- 2026	100,000 USD
	Contact Name						
	Contact Telephone	301-427-1025					
	Contact Email	kathryn.woolridge@ahrq.hhs.go	<u>ov</u>				
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	16-Feb-2026 , 16-Jun-2026 , 16- 2028 , 16-Feb-2029 , 16-Jun-202		.6-Jun-2027 , 16-Oct-2027	7 , 16-Feb-2028 <i>,</i>	16-Jun-2	028 , 16-Oct-
	Synopsis	AHRQ research priorities, included practice improvement, and enhance including the hospital, long-term Research may involve many part policymakers, payers, healthcar Government, and others.	ancing whole-person healt n care, ambulatory care, ho tners and other groups, in	hcare delivery. AHRQ sup ome healthcare, pharmac cluding patients, families,	pports research in cy, and care trans clinicians, non-c	n all healt sitions be clinical he	thcare settings, tween settings. althcare staff,
115139	Special Emphasis Notice (SEN):Re Healthcare	esearch on Climate Change and	Agency for Healthcare Re Quality/DHHS	esearch and	IOT-HS-23-006	12-Dec- 2025	Not Specified
	Contact Name	Brent Sandmeyer, MPH					
	Contact Telephone	301-427-1441					
	Contact Email	Brent.sandmeyer@ahrq.hhs.gov	<u>v</u>				
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	12-Dec-2025 , 12-Feb-2026 , 12-	-Jun-2026 , 12-Oct-2026 , 1	l2-Feb-2027			
	Synopsis	This Special Emphasis Notice (Standards the intersection of climaters)			ervices research	grant ap	plications that
114270	Special Emphasis Notice (SEN): In Infections and Combating Antibio		Agency for Healthcare Re Quality/DHHS	esearch and	NOT-HS-23-003	25-Jan- 2026	Not Specified



Other Federal Funding Opportunities

CDINI ID	Due sure Title	C	and Name	Consumer Name have	Dandling Dat		
SPIN ID	Program Title	Spons	sor Name	Sponsor Number	Deadline Date	е Е	Funding Amount
	Contact Name Contact Telephone	1 ' '					
	•						
		leyi.lin@ahrq.hhs.gov					
	Sponsor Website						
	_	Link to program URL	026 25 May 2026 05 ly 2026	25 Car 202C 05 Oct 20	26 05 0-+ 2026		
		The purpose of this Spe Research and Quality (A reduce the burden of he resistant organisms. HA consequences for healt observed increases of s	026, 25-May-2026, 05-Jun-2026 ecial Emphasis Notice (SEN) is to in AHRQ) continued interest in, and ealthcare-associated infections (IAIs continue to cause significant pathorare facilities and for patients. Useveral types of HAIs as well as income resilient and adaptable countered.	nform the research comm available funding for, supp HAIs) and to address the gratient harm and are also a Unfortunately, the COVID- creases in antimicrobial re	unity of the Agency porting innovative in rowing threat pose associated with con 19 pandemic has b	research ed by an nsiderab een ass	h seeking to itimicrobial ble financial ociated with
123849	AHRQ Health Services Research F	Projects (R01)	Agency for Healthcare Quality/DHHS	Research and	ΡΔ-24-154	05-Feb- 2026	2,000,000 USD
	Contact Name						
	Contact Telephone	301-427-1025					
	Contact Email	kathryn.woolridge@ahi	rq.hhs.gov				
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	05-Feb-2026 , 05-Jun-20 2028 , 05-Feb-2029 , 05	026 , 05-Oct-2026 , 05-Feb-2027 5-Jun-2029	, 05-Jun-2027 , 05-Oct-202	:7 , 05-Feb-2028 , 0)5-Jun-2	1028 , 05-Oct-
	Synopsis	AHRQ research prioritie practice improvement, including the hospital, I Research may involve n	otice of Funding Opportunity (NOI es, including improving healthcard and enhancing whole-person healthcard care, ambulatory care, many partners and other groups, nealthcare organizations, providens.	e quality and patient safet althcare delivery. AHRQ su home healthcare, pharma including patients, families	y, improving health pports research in cy, and care transi s, clinicians, non-cli	ncare de all heali tions be inical he	elivery and thcare settings, etween settings. ealthcare staff,



Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	e	Sponsor Number	Deadline Da	ate F	unding Amount
107009	Large Research Projects for Comb Bacteria (CARB) (R01)	bating Antibiotic-Resistant	Agency for Healthcare Ro Quality/DHHS	esearch and	PA-22-047	05-Feb- 2026	2,500,000 USD
	Contact Name	James Cleeman, MD					
	Contact Telephone	301-427-1330					
	Contact Email	james.cleeman@ahrq.hhs.gov					
	Sponsor Website	<u>Link to sponsor website</u>					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	05-Feb-2026 , 05-Jun-2026 , 05-	Oct-2026				
	Synopsis	Agency for Healthcare Research Demonstration and Disseminati use the R01 Research Project Gr	on Projects (R18) focused		-		
133060	FY 2025 Regional Technology and	d Innovation Hub Program	Economic Development		EDA-TECHHUBS-	18-Feb-	220,000,000
133000	Notice of Funding Opportunity (N	NOFO)	Administration/Departm	ent of Commerce	2025	2026	USD
	Contact Name						
	Contact Telephone						
	Contact Email	techhubs@eda.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	18-Feb-2026					
	Synopsis	The Tech Hubs Program seeks to investments in regions with the and industries of the future with start, grow, and remain in the U	assets, resources, capacity nin approximately 10 years	y, and potential to beco	me globally comp	etitive in	the technologies



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID Program Title		Sponsor Name	Sponsor Numl	ber Deadline Date	Fundi	ng Amount	
080401 <u>Travel Grants</u>			Alpha-1 Foundation	06-Feb-	-2026	1,000 USD	
Contact Name	Vanessa Valenci	a, Grants Administration	Vlanager				
Contact Telephone	305-567-9888 ex	x.242					
Contact Emai	vvalencia@alph	a1.org					
Sponsor Website	Link to sponsor	<u>website</u>					
Program URI	Link to program	<u>URL</u>					
Deadline Dates (ALL	06-Feb-2026						
Alpha-1 Foundation provides grants to support travel to attend national and international scientific conferences meetings to present AAT-related abstracts and to support cross-training at an established Alpha-1 laboratory by established Alpha-1 investigator. Grants are generally funded at a level of \$1,000.							
067833 Postdoctoral Research Fellows	hip Grant		Alpha-1 Foundation	06-Feb-	-2026	150,000 USD	
Contact Name	Vanessa Valenci	a, Grants Administration	Manager				
Contact Telephone	305-567-9888						
Contact Emai	vvalencia@alph	a1.org					
Sponsor Website	Link to sponsor	<u>website</u>					
Program URI	Link to program	URL					
Deadline Dates (ALL	06-Feb-2026						
Synopsis	Alpha-1 Foundar fellows who are	tion offers Postdoctoral R starting their research ca	esearch Fellowship Grants to reers and are working in the	o provide support for postdoct laboratories of established re	oral re	search ers or	



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	unding Amount
		_	arch with the mentorship of two year period.	establishe	d researchers. The fellow	ship provides a maxin	num of \$75,000
126242	John W. Walsh Career Develop	ment Grant		Alpha-1	Foundation	06-Feb-2	026 300,000 USD
	Contact Name						
	Contact Telephone	1-877-228-7321	,ext.242				
	Contact Email	vvalencia@alpha	a1.org				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	06-Feb-2026					
	Synopsis	The Alpha-1 Fou period to encou	undation offers the John W. rage the development/testi	Walsh Care ng of new h	er Development Grant of hypotheses/new methods	up to \$100,000 for a in AATD relevant res	three-year earch.
067831 <u>I</u>	Research Grants			Alpha-1	Foundation	06-Feb-2	026 100,000 USD
	Contact Name	Vanessa Valenci	a, Grants Administration Ma	nager			
	Contact Telephone	305-567-9888 ex	xt. 242				
	Contact Email	vvalencia@alpha	a1.org				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	URL				



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date Fun	ding Amount			
Deadline Dates (ALL)	06-Feb-2026						
The objective of this grant is to provide funds to encourage the development of new information that contribute the understanding of the basic biology of alpha-1 antitrypsin expression, and the pathogenesis/management of Deficiency. Consideration will be given to those projects that provide insight into the development of information that may contribute to new therapies for AAT Deficiency. All proposals must be hypothesis generating or hypothesis and provide sufficient preliminary data to justify the Alpha-1 Foundation's support. In addition, this grant category can provide funding to 2 investigators from 2 different institutions who wish to collaborate on research requires a team science approach to develop new information that contributes to the understanding of the basic biology of Alpha-1 Antitrypsin Deficiency, and the pathogenesis/management of AAT Deficiency. Research grant provide up to \$100,000 over a two-year period, or for 2 PI proposals, a maximum of \$100,000 per year may be requested per institution.							
067828 Pilot and Feasibility Grants		Alpha-1 Foundation	06-Feb-2026	75,000 USD			
Contact Name	Vanessa Valencia, Grants Administration	Manager					
Contact Telephone	877-228-7321, ext. 242						
Contact Email	vvalencia@alpha1.org						
Sponsor Website	Link to sponsor website						
Program URL	Link to program URL						
Deadline Dates (ALL)	06-Feb-2026						



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Fund	ng Amount
	Synopsis	Alpha-1 Foundation offers Pilot and Feas new hypotheses and/or new methods in requested.			•		-
126290 <u>C</u>	Clinical Pilot Grants		Alpha-1	Foundation	06-Fe	b-2026	75,000 USD
	Contact Name	Vanessa Valencia, Grants Administration	Manager				
	Contact Telephone	877-228-7321, ext. 242					
	Contact Email	vvalencia@alpha1.org					
	Sponsor Website	<u>Link to sponsor website</u>					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	06-Feb-2026					
	Synopsis	Alpha-1 Foundation offers Clinical Pilot g new hypotheses and/or new methods (o support promising new investigators as t	r those being a	applied to the problem	s of Alpha-1 for the	first time	•
059477 <u>N</u>	Neuroimaging and CSF Biomarl	ker Development Program	Alzheim Discove Foundat	,		eb-2026 Pre-App]	600,000 USD
	Contact Name						
	Contact Telephone						
	Contact Email	grants@alzdiscovery.org					



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date Fu	nding Amount	
	Sponsor Website Program URL	Link to sponsor					
	Deadline Dates (ALL)	23-Feb-2026 [LC	OI/Pre-App], 01-Jun-2026 , 14-Sep-	2026 [LOI/Pre-App]			
The Alzheimer's Drug Discovery Foundation provides funding to academic centers and biotechs from around the world that are advancing therapeutic and biomarker development for Alzheimer's and related dementias. The Neuroimaging and CSF Biomarker Program RFP aims to further develop and validate established biomarkers for whither is a clear clinical need in Alzheimer's disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.							
071751 <u>C</u>	Competitive Research Grants		Ass End	nerican sociation of dodontists undation	07-Feb-202	Not 6 Specified	
	Contact Name						
	Contact Telephone	312-872-0452					
	Contact Email	grants.foundation	on@aae.org				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	07-Feb-2026					



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title	Spoi	nsor Name	9	Sponsor Number	Deadline Date	Fundi	ng Amount
	Synopsis	The goal for the Com	ndodontics inspires and s petitive Research Grants ant to the practice of end	program i	s to support rigorous, i			
114585	Glenn Foundation for Medical	Research (GFMR) Disc	overy Award	American Federation Aging Res	on for		-2026 re-App]	555,000 USD
	Contact Name							
	Contact Telephone	212-703-9977						
	Contact Email	grants@afar.org						
	Sponsor Website	Link to sponsor webs	<u>ite</u>					
	Program URL	Link to program URL						
	Deadline Dates (ALL)	18-Feb-2026 [LOI/Pre	e-App]					
	Synopsis	\$555,000 to support underlying biological this award are expect Biology of Aging in th	n for Medical Research (G projects with strong pote mechanisms that govern ted to attend the combina ie second and third year c among recent AFAR and G	ntial to de normal ho ed AFAR G of the awa	evelop pioneering discouman aging and its relationships and its re	overies for understar ated physiological de d Glenn Foundation meetings is to prom	iding th cline. Ro Worksh ote scie	e ecipients of op on entific and
089670	Fellow Abstract Award			American Gastroen Association	terological	19-Feb	-2026	Not Specified



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Nun	nber	Deadline Date	Fundi	ng Amount
	Contact Name							
	Contact Telephone	301-654-2055						
	Contact Email	awards@gastro	.org					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	19-Feb-2026						
	Synopsis	are MD, PhD or	astroenterological Association (A equivalent fellows giving abstrac scoring abstract will be designat	t-based oral or post	er presentat	ions at Digestive Dis	sease V	Veek
106409 <u>A</u>	AMS Congressional Fellowship		N	merican athematical ociety		01-Feb-:	2026	108,162 USD
	Contact Name							
	Contact Telephone	401-455-4000						
	Contact Email							
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	01-Feb-2026						
	Synopsis		lathematical Society (AMS), in co sponsors this fellowship. It inclu					



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Fund	ing Amount
		Fellow spends a year working on	n issues involving science, technology and p the staff of either a member of Congress or ring scientific and technical input.		-	
003442 <u>F</u>	Physicians of Tomorrow Schola	nrship Program	American Medical Association Foundation	09-Feb-	2026	10,000 USD
	Contact Name	Allison Wesel, Program Manager				
	Contact Telephone					
	Contact Email	allison.wesel@ama-assn.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	09-Feb-2026				
	Synopsis	final year of training. With more underrepresented in medicine ar	10,000 tuition assistance scholarships to exthan 17 scholarship categories, including that those pursuing specific areas of interest resilience, and a deep commitment to serv	ose dedicated to studer or leadership, the progra	its	_
043086 <u>\$</u>	Student Educational Scholarsh	<u>q</u> i	American Phytopathological Society	28-Feb-	2026	1,000 USD
	Contact Name					



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date F	unding Amount
	Contact Telephone	651-454-7250				
	Contact Email	apsfoundation@	Oscisoc.org			
	Sponsor Website	Link to sponsor	<u>website</u>			
	Program URL	Link to program	URL			
	Deadline Dates (ALL)	28-Feb-2026				
	Synopsis	for students pur	ucation Scholarship fund provides suppressing a variety of projects and experient network with other scientists.			
043874 <u>F</u>	French-Monar Latin American <i>i</i>	Awar <u>d</u>	Americ Phytop Society	athological	28-Feb-20	26 2,000 USD
	Contact Name					
	Contact Telephone					
	Contact Email	apsfoundation@	Oscisoc.org			
	Sponsor Website	Link to sponsor	<u>website</u>			
	Program URL	Link to program	URL			
	Deadline Dates (ALL)	28-Feb-2026				
	Synopsis	The French-Mor graduate studer	nar Latin American Award provides finants or early career plant pathologists in	ancial support to APS mem a variety of ways.	bers that are Latin An	nerican



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date F	unding Amount
043878 <u>I</u>	Books for the World Award		American Phytopathological Society	28-Feb-20	O26 Not Specified
	Contact Name				
	Contact Telephone	651-454-7250			
	Contact Email	apsfoundation@scisoc.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	28-Feb-2026			
	Synopsis	The Books for the World (BFTW) fund is a agriculturalists in developing countries addistribution of books, electronic media, a tools and pest management.	cquire educational materials from A	APS PRESS and to promote	international
1/3/41	Henry P. David Grant for Intern Behavior and Population Studio	national Travel in Human Reproductive	American Psychological Foundation	13-Feb-20	026 1,000 USE
	Contact Name				
	Contact Telephone	202-336-5843			
	Contact Email	programs@ampsychfdn.org			
	Sponsor Website	Link to sponsor website			
	·	·			



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL Deadline Dates (ALL)	Link to program 13-Feb-2026	URL			
	Synopsis	demonstrated in concerns. This is	nterest in the behavioral asp	enry David Fund was established ects of human reproductive beha ntended to cover expenses assoc	avior or an area relate	ed to population
059738 <u>C</u>	ilinical Grants			American Society for Surgery of the Hand		b-2026 60,000 Pre-App] USD
	Contact Name					
	Contact Telephone	312-880-1900				
	Contact Email	afsh@assh.org				
	Sponsor Website	Link to sponsor	<u>website</u>			
	Program URL	Link to program	URL			
	Deadline Dates (ALL)	16-Feb-2026 [LC	OI/Pre-App], 06-Apr-2026			
	Synopsis	have established investigators to Institutes of Hea	d grant funding to encourage initiate pilot projects that w alth (NIH). The AFSH is comm ity and fiscal responsibility.	nd (ASSH) and the American Foun e investigators to perform clinica ill lead to subsequent funding fro nitted to excellence in clinical res The award amount is up to \$30,0	research studies. Th om other sources sucl earch while maintain	e goal is to enable n as the National ing the highest



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title	9	Sponsor Name	Sponsor Number	Deadline Date Fu	nding Amount					
116862 <u>H</u>	Hematology Inclusion Pathway	(HIP) - Resident A	<u>ward</u>	American Society of Hematology	02-Feb-202	6 7,000 USD					
	Contact Name										
	Contact Telephone	202-776-0544									
	Contact Email	awards@hemato	ology.org								
	Sponsor Website	Link to sponsor w	<u>vebsite</u>								
	Program URL	Link to program l	<u>URL</u>								
	Deadline Dates (ALL)	02-Feb-2026	2-Feb-2026								
	Synopsis	and second-year across the U.S., C participants with receive career de complimentary A their research. Th	medical residents from a wo canada, and Mexico. As part funds to conduct blood scie evelopment mentorship from SH membership. Recipients	fers the Hematology Inclusion Parkforce that reflects the patient point the Hematology Inclusion Pathoce research under the mentorshows ASH members, gain valuable helalso receive a honorarium to attend recognizes the highest-scoring ase.	population it serves in he way, the HIP Resident Av hip of an ASH member. Re matology knowledge, and end the ASH annual meeti	matology vard provides sidents also I benefit from ng to present					
021033 <u>F</u>	Hematology Inclusion Pathway	(HIP) Medical Stu	dent Award	American Society of Hematology	02-Feb-202	Not Specified					
	Contact Name										
	Contact Telephone										
	Contact Email	awards@hemato	ology.org								



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID Prog	ram Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Sponsor Website	Link to sponsor	website				
	·	Link to program					
	Deadline Dates (ALL)		<u></u>				
The ASH Hematology Inclusion Pathway (HIP) Medical Student Award provides medical students from communities underrepresented in hematology in the US and Canada with a stipend to conduct hematologic research under the mentorship of an ASH member. Recipients of this award will also receive a stipend to attend the ASH annual meeting to present their research. As part of the ASH Hematology Inclusion Pathway program, the Medical Student Award aims to create inclusivity and expand the program's reach to the next generation of hematologists.							
058655 <u>Chronic</u>	Pain Medicine Researc	h Grant	Re	nerican Society of gional Anesthesia d Pain Medicine	01-Feb-2	026 200,000 USD	
	Contact Name						
	Contact Telephone	412-471-2718					
	Contact Email	asraassistant@a	<u>sra.com</u>				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	01-Feb-2026					
	Synopsis	ASRA Pain Medi pain medicine. F	cine's Chronic Pain Medicine Rese Results of such research will guide	earch Grant aims to promot clinical practice for pain ph	e and facilitate high qual ysicians and improve pa	ity research in tient health care.	



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Fundi	ng Amount
058656 <u>(</u>	Carl Koller Memorial Research	<u>Grant</u>		Regiona	n Society of I Anesthesia I Medicine	01-Feb-2	2026	75,000 USD
	Contact Name							
	Contact Telephone	412-471-2718						
	Contact Email	asramembership	@asra.com					
	Sponsor Website	Link to sponsor v	<u>website</u>					
	Program URL	Link to program	<u>URL</u>					
	Deadline Dates (ALL)	01-Feb-2026						
	Synopsis	The Carl Koller Nanesthesia and a	Memorial Research Grar analgesia and their appl	nt supports clinic ication to surge	cal and laboratory stud ry. The amount of the	dies related to any aspe award will not exceed \$	ct of r \$75,00	egional 10.
110441 <u>F</u>	Hoffman ALS Clinical Trial Awai	rds Program		Amyotro Lateral S (ALS) As		17-Feb-2	2026	1,000,000 USD
	Contact Name							
	Contact Telephone							
	Contact Email	researchgrants@	alsa-national.org					
	Sponsor Website	Link to sponsor v	website					
	Program URL	Link to program	<u>URL</u>					
	Deadline Dates (ALL)	17-Feb-2026						



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	repurposed app mid-stage (phas studies testing in aggregation. Fur strategy, and wh investigators. Su proposed treatn methods for inc for funding. Lon	tion's Hoffman ALS Clinical Trial Awaroaches for ALS by providing up to se 1 or phase 2a) trials. Both disease maging tracers. We are particularly nding will be prioritized for trials where outcomes are aligned with the accessful applicants will provide strent/tracer and a clear plan for clinication the probability that trials digeterm development plans should in funding if results are positive.	\$1,000,000 in total funding of the conditying and symptomatic interested in funding prograth a clear biological rationals trial phase. These awards arong preclinical data supporticial development. Biomarke efinitively answer relevant so	over 2 or 3 years to such treatments are in some targeting TDP-43 erand an integrated bigger open to industry arong the biological rations, will entific questions, will	pport early- to cope, as are early and/or protein omarkers and academic enale for the along with other lbe prioritized
063104 <u>lr</u>	nnovation Grants		Wor Obs	ociation of men's Health, tetric and natal Nurses	01-Feb-2	2026 5,000 USD
	Contact Name					
	Contact Telephone					
	Contact Email	research@awho	onn.org			
	Sponsor Website	Link to sponsor	<u>website</u>			
	Program URL	Link to program	URL			
	Deadline Dates (ALL)	01-Feb-2026				



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title	Spo	onsor Name	Sponsor Number	Deadline Date Fund	ding Amount
	Synopsis	innovation and tech implements novel te	g this competitive research go nology. This grant seeks to so echnological solutions and/oo nd healthcare system perforn plemental funding.	upport high-impact nursing innovative practices to enh	research that explores, evalu nance patient care, nursing w	ates, or orkflows,
098919	Postdoctoral Fellowships			anting and Best abetes Centre	24-Feb-2026	35,000 USD
	Contact Name	Rose LaBarbera				
	Contact Telephone	416-978-4656				
	Contact Email	diabetes.bbdc@utor	ronto.ca			
	Sponsor Website	Link to sponsor web	<u>site</u>			
	Program URL	Link to program URL	=			
	Deadline Dates (ALL)	24-Feb-2026				
	Synopsis	(or are expecting to awards is to attract a	red by the Banting & Best Di complete) a doctoral degree and foster young investigato ear fellowships are to be use ed institutions.	(PhD) or medical degree (Nrs to initiate and/or continu	1D or equivalent). The object e research training in the fiel	ive of these d of
133089	Discovery Research Grants Req	uest for Applications	III VCIE 41	D2: Breakthrough scoveries for	20-Feb-2026	4,500,000 USD



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date Fu	nding Amount			
		Thriving with Bipolar Disorder						
	Contact Name							
	Contact Telephone							
	Contact Email	DiscoveryGrants@BipolarDiscoveries.org						
	Sponsor Website	<u>Link to sponsor website</u>						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	20-Feb-2026						
	Synopsis	The BD2 Discovery Research program aims t allowing the development of effective intervorse scientists and clinicians who generate new mechanisms of bipolar disorder with an eye	rentions. They are making this a v hypotheses and drive innovation	reality by funding multidisc	plinary teams			
096577 \$	Strategic Longer and Larger (sL	oLa) Grants	Biotechnology and Biological Sciences Research Council (BBSRC)	05-Feb-202	2,620,000 6 USD			
	Contact Name							
	Contact Telephone							
	Contact Email	bbsrc.lolagrants@bbsrc.ac.uk						
	Sponsor Website	Link to sponsor website						



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount			
	Program URL Deadline Dates (ALL)	<u>Link to program URL</u> 05-Feb-2026						
	UK researchers can apply for funding to undertake large team-based fundamental bioscience research projects which push the frontiers of human knowledge. Projecst should demonstrate: the potential for major breakthroughs in our fundamental understanding of living systems a fully integrated team science approach the need for longer and larger scale funding enhancing the capability and capacity of UK biosciences The full economic cost of a project must be over £2 million. Biotechnology and Biological Sciences Research Council (BBSRC) will fund 80% of the full economic cost. Projects can be up to five years in duration.							
132957 <u>B</u>	BBSRC Pioneer Awards 2025 to	26: Bioscience Discovery Research	Biotechnology and Biological Sciences Research Council (BBSRC)	25-Fel	o-2026 USD			
	Contact Name							
	Contact Telephone							
	Contact Email	pioneerawards@bbsrc.ukri.org						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	25-Feb-2026						
	Synopsis	BBSRC is accepting applications for funding to open novel adventurous research avenues wi						



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date F	unding Amount
		systems. Projects must: be early-stage fur untested ideas have the potential to oper		<u> </u>	·	ary and
028540 <u>F</u>	Project Grants		Bloodw	ise	05-Feb-20	366,800 USD
	Contact Name					
	Contact Telephone					
	Contact Email	research@bloodcancer.org.uk				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Feb-2026				
	Synopsis	Blood Cancer UK provides funding for labor of blood cancer. Proposals are invited that awarded for up to £280,000 for up to three Blood Cancer UK's treatment topics.	t focus on de	veloping better and less t	oxic treatments. Proje	ct grants are
064817 <u>I</u>	nvestigator Initiated Research	<u>Program</u>		oss and Blue of Michigan tion	07-Jan-20	75,000 USD
	Contact Name					
	Contact Telephone	313-225-8706				
	Contact Email	foundation@bcbsm.com				



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Fundi	ing Amount
	Sponsor Website	Link to sponsor	website					
	·	Link to program						
	_			Apr-2026	5 , 27-May-2026 [LOI/Pre-/	App], 05-Aug-2026		
Synopsis The Investigator Initiated Research Program supports primary investigators with medical or doctoral-level credentia interested in finding ways to improve health and health care in Michigan. The award offers up to \$75,000 per grant.								
122280 <u>F</u>	Future Leaders in Canadian Bra	in Research Prog	<u>ram</u>	Brain Ca	anada	20-Feb	-2026	70,000 USD
	Contact Name							
	Contact Telephone	514-989-2989						
	Contact Email	futureleaders@l	oraincanada.ca					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	<u>URL</u>					
	Deadline Dates (ALL)	20-Feb-2026						
	Synopsis	research that wi	Fers the Future Leaders in Car Il fundamentally change our un n. There is an overall funding o	nderstar	nding of nervous system fu	unction and dysfun	ction ar	nd their
1 4 4 / 1 X	Request for Applications: Development of the Communication of the Commun	opment of Conti	nuous C-Peptide Monitoring	Breakth	rough T1D	04-Dec [LOI/Pr	:-2025 re-App]	900,000 USD
	Contact Name	Asja Guzman, Ph	ı.D.					



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor No	umber	Deadline Date	Funding Amo	ount
	Contact Telephone							
	Contact Email	aguzman@Brea	kthroughT1D.org					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	04-Dec-2025 [LC	OI/Pre-App], 12-Feb-2026					
	Synopsis	technologies. Ap and early-stage in total funding	1D invites Letters of Intent (Lo oplications focused on early-s clinical evaluation of CCPM to over a maximum period of th re there is a strong justification	tage development of chnologies will be co ree years. Application	sensor techno nsidered. App	logies, preclinical/f lications may reque	easibility studiest up to \$900,0	ies 000
133761	Request for Applications: Estab Replacement Therapy for Type			Breakthrough T1D		07-Jan- [LOI/Pr	2026 900,00 e-App] USD)0
	Contact Name	Dr. Nicholas Ma	mrak					
	Contact Telephone	800-533-2873						
	Contact Email	nmamrak@brea	kthroughT1D.org					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	<u>URL</u>					
	Deadline Dates (ALL)	07-Jan-2026 [LO	I/Pre-App], 24-Feb-2026					
	Synopsis		ID is soliciting Letters of Inter es that induce specific tolera					



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Fundi	ng Amount
	pathways and must be compatible verified this funding opportunity is open to be given to projects closer to clinical te	and cancer surveillance. LOIs may address of with scalable manufactured islet cells (i.e., hoighly innovative projects at early stages of sting with a well-articulated plan for translatry partners of up to \$900,000.00 over 3 yeartners.	numan stem cell-deri development, priori ation. This initiative v	ved isle tizatior	ets). While n will be
038334 <u>Four Directions Summer Resea</u>	rch Program	Brigham and Women's Hospital	01-Feb	-2026	5,000 USD
Contact Name					
Contact Telephone					
Contact Email	fourdirections@mgb.org				
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	01-Feb-2026				
Synopsis	for undergraduate rising sophomore health of Native American communifaculty mentor. Additional activities networking events and more. Upon	ch Program is a unique summer research or es, juniors and seniors and first-year medicalities. Students engage in a basic science restinctude clinical shadowing, career developed completion of the program, students leaved to empower themselves, their coons.	al students, with a co earch project under ment seminars, talkii Mass General Brigh	mmitm the dire ng circle am with	nent to the ection of a es, new skills,



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date Fu	nding Amount
040142	Clinical Study Grants			British H Foundat		14-Jan-202	655,000 USD
	Contact Name						
	Contact Telephone						
	Contact Email	research@bhf.o	org.uk				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	14-Jan-2026 , 05 Oct-2026 [LOI/P	5-Feb-2026 [LOI/Pre-A re-App]	pp], 23-Apr-2026	[LOI/Pre-App], 01-Jul-2	026 , 27-Aug-2026 [LOI/P	re-App], 22-
	Synopsis	The Clinical Stud larger clinical tri	dy Grant scheme will b als, usually late phase	e for clinical stud (phase III/IV) and	ies that cost more than I for large observational	£500,000. Clinical Study studies of specific patier	Grants are for at groups.
064546	Innovation Research Grants			British S Haemat	ociety for ology	03-Feb-202	6 52,400 USD
	Contact Name						
	Contact Telephone						
	Contact Email	grants@b-s-h.or	rg.uk				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	03-Feb-2026					
	·	•					



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

 $\label{lem:consider} \mbox{Additional GCO Policies to consider when prior to applying.}$

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date F	unding Amount			
		The BSH Innovation Research Grant is a puprojects with a clear plan for sustainability data-driven, or community-focused.						
106089 \$	Semi-Annual Competitive Gran	<u>ts</u>	Cabell Foundation	15-Feb-20 [LOI/Pre-A	26 Not App] Specified			
	Contact Name	Sarah Williams, Executive Director						
	Contact Telephone	804-780-2050						
	Contact Email	Executive.Director@thecabellfoundation.c	org					
	Sponsor Website	<u>Link to sponsor website</u>						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	15-Feb-2026 [LOI/Pre-App], 01-Mar-2026	, 15-Aug-2026 [LOI/Pre-App], 01	-Sep-2026				
	Synopsis	The Cabell Foundation's competitive grants program provides support for permanent, capital projects. Generally, awards are made on a challenge or match basis in order to help stimulate broad community support.						
085377 <u>C</u>	Community-Led Conference Av	vards	California Breast Cancer Research Program	19-Feb-20	25,000 USD			
	Contact Name							
	Contact Telephone	888-313-2277						
	Contact Email	conferenceaward@cabreastcancer.org						
	Sponsor Website	<u>Link to sponsor website</u>						



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title	Sponsor Name	Sponso	or Number	Deadline Date	Fundi	ng Amount
	Program URL Deadline Dates (ALL)	<u>Link to program URL</u> 19-Feb-2026					
	Synopsis	The Community-Led Conference Award is c time or resources to develop and execute a cancer research, education and/or policy d	successful event.	Γhe event must de	liver a product that		
131337 <u>C</u>	Operating Grant: Leadership Av	ward for Vaccine Research	Canadian Instit of Health Resea		18-Feb-	2026	210,000 USD
•	Contact Name						
	Contact Telephone	613-954-1968					
	Contact Email	support-soutien@cihr-irsc.gc.ca					
	Sponsor Website	<u>Link to sponsor website</u>					
	Program URL						
	Deadline Dates (ALL)	18-Feb-2026					
	Synopsis	This funding opportunity builds upon previteration of this award was launched in 202 for Infectious Diseases of Epidemic Potentiresearchers who, at the time of the funding ago) and aimed to contribute to national at threats and position Canada as a leader in the mid-career vaccine researchers in Canada was technologies and facilities, and Expanded as	1 as the CIHR-CEPI al. It supported the start date, assume ad international eff his research area. To with: Exposure to na	Leadership Award career developmed their first indeports to prevent an This funding opporational and global	for Excellence in Valent of mid-career research post of prepare for future tunity will build cap expertise, Access to	searchesition 5 global acity a	Research ers (i.e., 5-15 years I health nd provide g-edge



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		innovations in the vaccine space. Ultimate accelerate progress in vaccine research, st and pandemic preparedness.	•		•
133268 (Operating Grant: Advancing 2S	/LGBTQI+ Health Through Research	Canadian Institutes of Health Research		o-2026 490,000 re-App] USD
	Contact Name				
	Contact Telephone	613-954-1968			
	Contact Email	support-soutien@cihr-irsc.gc.ca			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	11-Feb-2026 [LOI/Pre-App], 19-Mar-2026			
	Synopsis	The overall purpose of this funding opport impact, and community-engaged health recommunities in Canada.	,	•	,
065525 <u>F</u>	Project Grant: Fall 2025 and Sp	ring 2026	Canadian Institutes of Health Research	04-Feb [LOI/P	o-2026 Not re-App] Specified
	Contact Name				
	Contact Telephone	613-954-1968			
	Contact Email	support-soutien@cihr-irsc.gc.ca			
	Sponsor Website				



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Fundi	ing Amount
	Program URL	Link to program	<u>URL</u>					
	Deadline Dates (ALL)	04-Feb-2026 [LC	0I/Pre-App], 04-Mar-2026					
	The Project Grant program is designed to capture ideas with the greatest potential for important advances in fundamental or applied health-related knowledge, the health care system, and/or health outcomes, by supporting Synopsis projects of research proposed and conducted by individual researchers or groups of researchers in all areas of heal The best ideas may stem from new, incremental, innovative, and/or high-risk lines of inquiry or knowledge translat approaches.							
095860	Other: Health System Impact E	mbedded Early C	areer Researcher Award		in Institutes th Research	04-Fel	o-2026	Not Specified
	Contact Name							
	Contact Telephone	613-954-1968						
	Contact Email	support-soutien	@cihr-irsc.gc.ca					
	Sponsor Website							
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	04-Feb-2026						
	Synopsis	and is launched embedded resea priority challeng improvement, a	em Impact (HSI) Embedded biennially. The award providarch roles and programs; apges, contribute to evidence-ind advance the Quintuple Aealth system communities; a	des early ca ply their re nformed d im; build tl	areer researchers (ECRs) search skills to help hea ecision-making, strengtl heir collaborations and I	the opportunity to: Ilth system organizat nen cultures of learn partnerships within a	develor ions tac ing and and acro	o their ckle high oss the



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Fundi	ing Amount
131100	Геат Grant: Pan-Canadian Net Health	work: Emerging LHS in Perinatal Mental		n Institutes h Research	05-Feb	-2026	4,200,000 USD
	Contact Name						
	Contact Telephone	613-954-1968					
	Contact Email	support-soutien@cihr-irsc.gc.ca					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	05-Feb-2026					
	Synopsis	This funding opportunity will support the health. The LHS approach integrates resuments that the most effective treatment approach would also enable the rapid transchanism for evaluating program impage.	earch, data, an its are consiste anslation of re	d knowledge for continently updated and imple search findings into clin	uous improvement in mented equitably acr ical and care practice	care to	o help nada. This
			Canadia	n Society of			
054775 <u>C</u>	CSHP Foundation Pharmacy Le	adership Academy Scholarship	Hospita Pharma		01-Feb	-2026	3,500 USD
	Contact Name						
	Contact Telephone						
	Contact Email	cshpfoundation@cshp.ca					
	Sponsor Website	<u>Link to sponsor website</u>					
		1					



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date F	unding Amount
		<u>Link to program URL</u> 01-Feb-2026, 15-Feb-2026, 31-Mar-2026				
	Synopsis	The CSHP Foundation is pleased to provide a System Pharmacists (ASHP) Foundation Phar	n annual s macy Lead	cholarship to participate in Iership Academy (PLA) pro	n the American Socie gram.	ty of Health-
131571 <u>I</u>	Increasing Equity, Diversity and	I Inclusion in the Canadian Space Sector	Canadia Agency	n Space	06-Feb-20	Not Specified
	Contact Name					
	Contact Telephone	450-926-6749				
	Contact Email	stedia-dstemu@asc-csa.gc.ca				
	Sponsor Website	<u>Link to sponsor website</u>				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	06-Feb-2026				
	Synopsis	This AO aims to offer under-represented groscience and technology and promote their p inclusion (EDI) in Canada's space workforce.				
095984	Career Establishment Awards		Cancer F	Research UK	19-Feb-20	Not Specified
	Contact Name					
	Contact Telephone	0300 123 1022				
	Contact Email	fellowships@cancer.org.uk				



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date Fu	nding Amount
	Sponsor Website	Link to chancer	vohsito			
	•					
	_	Link to program	URL			
	Deadline Dates (ALL)					
			olishment Award supports new grou endent research group. Funding sup ng.		·	
035945 <u>S</u>	enior Cancer Research Fellows	ship	Cance	r Research UK	19-Feb-202	6 Not Specified
	Contact Name					
	Contact Telephone	0300 1231022				
	Contact Email	fellowships@car	ncer.ok.uk			
	Sponsor Website	Link to sponsor v	<u>website</u>			
	Program URL	Link to program	URL			
	Deadline Dates (ALL)	19-Feb-2026				
	Synopsis	The Senior Cance build their reput	er Research Fellowship supports gro ation as a world-leader in their canc	up leaders to further develo er research field.	p their own research pi	rogramme and
074272 <u>C</u>	areer Development Fellowship	<u>o</u>	Cance	r Research UK	19-Feb-202	6 Not Specified
	Contact Name					
	Contact Telephone	0300 1231022				



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date F	unding Amount
	Contact Email	fellowships@ca	ncer.org.uk			
	Sponsor Website	Link to sponsor	<u>website</u>			
	Program URL	Link to program	URL			
	Deadline Dates (ALL)	19-Feb-2026				
	Synopsis		elopment Fellowship supports new gr own independent research group. Fun ng part-time.	·	· ·	•
014652	Grants Program - Higher Educa	<u>tion</u>		(Roy J.) able Trust	15-Feb-20	Not Specified
	Contact Name					
	Contact Telephone	563-263-4010				
	Contact Email	info@carvertrus	st.org			
	Sponsor Website	Link to sponsor	<u>website</u>			
	Program URL	Link to program	URL			
	Deadline Dates (ALL)	15-Feb-2026 , 1	5-May-2026 , 15-Aug-2026			
	Synopsis	projects to be co Mr. Carver had a strengthen insti	er Charitable Trust awards grants to I.I onducted within, the state of Iowa an an interest during his lifetime. The Trututions and offer innovative learning ams throughout the grant-making regions.	d portions of Illinois, as wel ust's program in higher edu opportunities to students e	l as to other organiza cation extends projec nrolled in baccalaurea	tions in which ts that



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Fund	ing Amount
078842]	Travel Awards			CASS Fo	undation	20-Feb	o-2026	3,200 USD
	Contact Name	David Abraham	AM					
	Contact Telephone	0418 335 642						
	Contact Email	travel@cassfour	ndation.org					
	Sponsor Website	Link to sponsor	website_					
	Program URL	Link to program	<u>URL</u>					
	Deadline Dates (ALL)	20-Feb-2026 , 28	3-Aug-2026					
	Synopsis	Each year CASS of international col	offers two rounds of Trave inferences relevant to their	el Awards to e r current rese	enable early career reso earch.	earchers to attend an	d partio	cipate in
030571 <u>(</u>	CART Grants Program			Coins fo Alzheim Researc Fund (C	er's h Trust		c-2025 re-App]	,
	Contact Name	Dr. Gary Goforth	, MD, Vice President of Gi	rants				
	Contact Telephone	828-243-5870						
	Contact Email	gagoforth@eart	hlink.net					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	<u>URL</u>					
	Deadline Dates (ALL)	05-Dec-2025 [LC	0I/Pre-App], 13-Feb-2026					



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date F	unding Amount			
	Synopsis	The Coins for Alzheimer's Research T Disease (AD) research projects within those projects that may not yet be su advance biomedical research.	the United States	s by providing support for	the early and concep	tual plans of			
027490 <u>1</u>	<u> ravelling Fellowships - Disease</u>	Models and Mechanisms	Compar Biologis	·	27-Feb-20	Not Specified			
	Contact Name								
	Contact Telephone	+44 (0) 1223 632850							
	Contact Email	tf@biologists.com							
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	27-Feb-2026 , 29-May-2026 , 28-Aug-2026 , 30-Oct-2026							
	Synopsis	DMM Conference Travel Grants are a conferences, workshops and training				etings,			
101227 <u>F</u>	Research Grants Program			Marijuana Outcomes	04-Feb-20 [LOI/Pre-	026 Not App] Specified			
	Contact Name								



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount			
	Contact Telephone	352-273-6984							
	•	mmj.outcomes@	@cop.ufl.edu						
	Sponsor Website	Link to sponsor	website						
	•	Link to program							
	Deadline Dates (ALL)	04-Feb-2026 [LOI/Pre-App], 03-Apr-2026							
		member institut	for Medical Marijuana Clinical Outo tions within Florida. The Consortium to investigators within member inst	provides awards to suppor					
019497	Support for Ongoing Clinical Re	search in Thalass	semia	ey's Anemia dation, Inc.		c-2025 100,000 re-App] USD			
	Contact Name								
	Contact Telephone								
	Contact Email	grants@thalasse	emia.org						
	Sponsor Website	Link to sponsor	<u>website</u>						
	Program URL	Link to program	URL						
	Deadline Dates (ALL)	15-Dec-2025 [LC	OI/Pre-App], 09-Feb-2026						
	Synopsis	Clinical Research backgrounds (M	emia Foundation invites national ar h projects in Thalassemia. The goal o ID, RN, PhD, MPH, MSW or other dis owing areas impacting patients with	of this initiative is to suppor ciplines) with their ongoing	t investigators from clinical projects to	all disciplines and address one or			



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title	Sponsor Name	Sponsor	Number	Deadline Date F	unding Amount
		overload; fertility, pregnancy and family disease.	planning; bone health, o	quality of life, ps	sychosocial impact and	d/or burden of
019493	Support for Trials in Thalassem	ia Cell and Gene Therapy Grant	Cooley's Anemia Foundation, Inc.		15-Dec-20 [LOI/Pre- <i>i</i>	025 75,000 App] USD
		grants@thalassemia.org				
	·	Link to sponsor website				
	_	Link to program URL 15-Dec-2025 [LOI/Pre-App], 09-Feb-2020	c			
		The Cooley's Anemia Foundation invites trials in Cell and Gene Therapy to advantage eligible for support.	national and internation			
009507	Fulbright ProgramsEurope an International Education Admin	d EurasiaGermanyU.SGermany istrators Award	Council for International Exchange of Scholars	261180-DE	02-Feb-20	Not Specified
	Contact Telephone	Julia Lieber, Outreach and Recruitment (646-768-8319 EuropeEurasia@iie.org	Officer			



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date Fu	ınding Amount
	Sponsor Website	Link to sponsor	<u>website</u>			
	Program URL	Link to program	URL			
	Deadline Dates (ALL)	02-Feb-2026				
	Synopsis	community colle workshops, and opportunities fo	nar is designed to familiarize U.S. higher eges in the U.S. with the latest trends in campus visits in Berlin and other region or academic exchanges in Germany and bout higher education mobility trends i	n Germany's higher educa ns of Germany, participan the challenges to be over	tion system. Through I ts will explore the mar come in times of crisis	ectures, nifold
007676 <u>R</u>	Research Grants		Crafoor Founda		05-Feb-20	100,000 USD
	Contact Name					
	Contact Telephone	+46 (0) 46 38 58	3 80			
	Contact Email	crafoord@crafo	ord.se			
	Sponsor Website	Link to sponsor	<u>website</u>			
	Program URL	Link to program	URL			
	Deadline Dates (ALL)	05-Feb-2026				
	Synopsis	Foundation invit	far-reaching scientific foundation that tes applications for grants primarily for at its disposal may be awarded a 2-yea	one-year research projec	ts (A). Some of the fun	



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date Fu	nding Amount
033065 Clinical Pilot and Feasibility Aw	<u>vards</u>	Cystic Fibrosis Foundation	16-Feb-202	Not Specified
Contact Name	Angela Minucci			
Contact Telephone				
Contact Emai	aminucci@cff.org			
Sponsor Website	Link to sponsor website			
Program URI	Link to program URL			
Deadline Dates (ALL)	16-Feb-2026 , 02-Apr-2026 [LOI/Pre-A	App], 16-Aug-2026		
	IClinical Pilot and Feasibility Awards as	re affered to support projects involvin	ng human suhjects that will d	evelon and
Synopsis	Clinical Pilot and Feasibility Awards and test new hypotheses and/or new met and to support promising new investi	thods (or those being applied to the p	roblems of cystic fibrosis for	the first time)
Synopsis 005450 <u>Clinical Research Award</u>	test new hypotheses and/or new met	thods (or those being applied to the p	roblems of cystic fibrosis for	ystic fibrosis.
	test new hypotheses and/or new met and to support promising new investi	thods (or those being applied to the pagators as they establish themselves in Cystic Fibrosis	problems of cystic fibrosis for n research areas relevant to o	the first time; ystic fibrosis.
005450 Clinical Research Award	test new hypotheses and/or new met and to support promising new investi	thods (or those being applied to the pagators as they establish themselves in Cystic Fibrosis	problems of cystic fibrosis for n research areas relevant to o	the first time ystic fibrosis.
205450 Clinical Research Award Contact Name Contact Telephone	test new hypotheses and/or new met and to support promising new investi	thods (or those being applied to the pagators as they establish themselves in Cystic Fibrosis	problems of cystic fibrosis for n research areas relevant to o	the first time ystic fibrosis.
Contact Name Contact Telephone Contact Email	test new hypotheses and/or new met and to support promising new investi Dara Riva 301-841-2637	thods (or those being applied to the pagators as they establish themselves in Cystic Fibrosis	problems of cystic fibrosis for n research areas relevant to o	the first time ystic fibrosis.
Contact Name Contact Telephone Contact Email	test new hypotheses and/or new met and to support promising new investi Dara Riva 301-841-2637 driva@cff.org	thods (or those being applied to the pagators as they establish themselves in Cystic Fibrosis	problems of cystic fibrosis for n research areas relevant to o	the first time ystic fibrosis.



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date Fu	nding Amount
	Synopsis	Clinical Research Awards are offered to prothe potential to make an important contribution diagnosis, treatment, management of disea (observational/interventional), translational	ution to the CF Foundation's misase or symptom, or the pathophy	ssion. Research projects may siology of CF using clinical	
080852	Oraper Scholar Program		Draper Laboratory	01-Feb-20.	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	education@draper.com			
	Sponsor Website	<u>Link to sponsor website</u>			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Feb-2026			
	Synopsis	At Draper, academic research is integrated student's field through graduate thesis researcess to state-of-the-art facilities, expertisemerge as the next wave of innovators.	earch while addressing crucial ch	allenges in national security	. Scholars gain
132500 <u>I</u>	ravel and Training Awards		Epilepsy Research Institute UK	01-Dec-20	25 1,310 USD
	Contact Name	Lucy Brooks			
	Contact Telephone	020 3882 9438			



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Fundi	ing Amount	
	Contact Email	l.brooks@epilep	sy-institute.org.uk						
	Sponsor Website	Link to sponsor	<u>website</u>						
	Program URL	Link to program	<u>URL</u>						
	Deadline Dates (ALL)	01-Dec-2025 , 23-Feb-2026 , 18-May-2026							
The Epilepsy Research Institute is piloting a scheme to help UK-based early career researchers and PhD students working in epilepsy research to attend important meetings or training opportunities when no other funding is available.									
057603 <u>Y</u>	oung Investigator Awards for	the Year's Outsta	nding Publications	Europea Atheros Society	sclerosis	02-Feb	-2026	2,300 USD	
	Contact Name								
	Contact Telephone								
	Contact Email	office@eas-soci	ety.org						
	Sponsor Website	Link to sponsor	<u>website</u>						
	Program URL	Link to program	<u>URL</u>						
	Deadline Dates (ALL)	02-Feb-2026							
	Synopsis	recognize distino metabolic distur	therosclerosis Society (EAS ction that contributes to the bances. Two recipients (ba ning Ceremony of the EAS	ie advancem isic & clinica	nent of knowledge in the fi	eld of atherosclero	sis and	linked	



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

European Union Sponsored Projects

CDIN ID	Dragram Title	Spansor Nan	-	Chancar Number	Deadlin	o Doto	unding Amou
SPIN ID	Program Title	Sponsor Nan	ne	Sponsor Number	Deadiin	e Date F	unding Amou
	Cluster 6: Food, Bioeconomy, N Environment Emerging and F		and Europea Commis	n 02-FARI	N-CL6-2025- M2FORK-01- ge	18-Feb-20	026 6,900,00 USD
	Contact Name						
	Contact Telephone						
	Contact Email						
	Sponsor Website	<u>Link to sponsor website</u>					
	Program URL	Link to program URL					

Deadline Dates (ALL) 18-Feb-2026

Proposals are invited against the following topic: HORIZON-CL6-2025-02-FARM2FORK-01-two-stage: Emerging and future risks to plant health Successful proposals should contribute to the objectives of the common agricultural policy, as well as to the European Green Deal's goals for resilient and sustainable agri-food systems, the EU biodiversity strategy for 2030, and support Regulation 2016/2031[1] on protective measures against pests of plants. Successful proposals will deliver on the expected impacts of the destination by enabling agri-food systems to enhance the EU's strategic autonomy through promoting food security and long-term sustainability with multidisciplinary approaches, including One Health. They will also empower farmers and key actors in the agricultural sector to manage sustainable, efficient, profitable, and circular farming systems with low greenhouse gas emissions, contributing to climate-neutrality and resilience. Project results are expected to contribute to all of the following expected outcomes: the understanding of drivers of plant pest emergence, including the influence of climate change, ecosystem degradation and globalisation, is increased; cost-effective preventive and/or curative measures to new and/or emerging plant pests are developed; economic, social, and environmentally sound solutions for effective pest

Synopsis



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID P	rogram Title	Sponsor Name	Sponsor N	Number De	eadline Date	Fundi	ing Amount
		management in farming and/or forestry in lin scientific support, recommendations, and pol			_		eloped;
137035	Mission: A Soil Deal for Euro tinental, Boreal and Alpine	ope Living Labs To Enhance Soil Health in Biogeographical Regions	European Commission	HORIZON-MISS- 05-SOIL-01-two	1X-Feh.	-2026	13,800,000 USD
	Contact Name						
	Contact Telephone						
	Contact Email	EU-HORIZON-MISSION-SOIL@ec.europa.eu					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	18-Feb-2026					
Deadline Dates (ALL) 18-Feb-2026 Proposals are invited against the following topic: HORIZON-MISS-2025-05-SOIL-01-two-stage: Living labs to enhall soil health in Continental, Boreal and Alpine biogeographical regions This topic is part of the EU Mission 2025 can Soil Deal for Europe. Activities under this topic respond directly to the goal of the Mission 'A Soil Deal for Europe (Mission Soil) to set up 100 living labs and lighthouses to lead the transition to healthy soils by 2030. They suppose specific objectives 1 to 8 of the Mission Soil (see the Mission implementation plan). Activities should also contribute to meeting the European Green Deal ambitions and targets and more specifically those of the EU Biodiversity Strategy for 2030, the EU soil strategy for 2030 and theproposal for a Soil Monitoring and Resilience Directive, to Sustainable Development Goals 15 on Life on land and 3 on Good health and well-being. Project results are expected to contribute to all of the following outcomes: Increased capacities for participatory, interdisciplinary R&I to co-create, and co-implement economically viable soil health solutions. Improved soil health solutions.							



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor N	umber	Deadline D	Date Fund	ing Amount
		oriented knowle consideration ar health including	increased availability of high- edge and tools are more easily nd uptake of effective soil hea the economic sustainability of s to enhance soil health.	available to land ma lth solutions. Policy	anagers and la makers are mo	nd users res ore aware of	ulting in an er local needs re	hanced egarding soil
	EU Mission: A Soil Deal for Euro Soil Health in Africa and Latin A			European Commission	HORIZON-M 05-SOIL-02-t		18-Feb-2026	6,900,000 USD
	Contact Name							_
	Contact Telephone							
	Contact Email	EU-HORIZON-M	ISSION-SOIL@ec.europa.eu					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	18-Feb-2026						
	Synopsis	labs approach for 2025 call: A Soil Soil Deal for Euron Sustainable Agri Communication commitments su	vited against the following topor soil health in Africa and Lati Deal for Europe. Activities un ope'. Activities will also contri iculture (FNSSA), African Unio [2], as well as other initiatives uch as the United Nations Susculture, food and nutrition sec	n America and the C der this topic contrib bute to the EU-Afric n strategies, the 'Dec and action plans rel tainable Developme	aribbean (LAC) oute to the eigle a Partnership of the claration of the evant for soil had Goals (SDGs) This topic is nt specific ol on Food and e EU-CELAC S nealth and th), in particul	s part of the E ojectives of th Nutrition Sec Summit 2023' ne support of ar in the areas	U Mission e Mission 'A urity and 1], the LAC global s of



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title	Sponsor Name	Sponsor Nu	ımber	Deadline Date	Funding Amount				
		contribute to all of the following expected ou enhanced in rural, urban and peri-urban area and small land managers and land users in Af learning mechanisms for soil health, including recognised mechanism for exchange of soil h replicated and that can attract additional fina health. Policy makers can put in place an effe knowledge-based, context-specific solutions	s of Africa or Latin Am rica or LAC have incre g monitoring, based of ealth knowledge, of le ince to support human ctive framework to su	nerica and the Ca ased access to s in participatory rearning experien in-centred design ipport continuou	aribbean (LAC). Lo ccalable practice-o esearch. Establish nces and tools that n and testing of so us generation and	cal communities riented tools and ment of a can be lutions for soil adoption of				
132098 <u>E</u>		Natural Resources, Agriculture and esilience: Enhancing Multi-Stress Tolerance in	European Commission	HORIZON-CL6- 01-BIODIV-02- stage		2026 8,050,000 USD				
	Contact Name									
	Contact Telephone									
	Contact Email									
	Sponsor Website	<u>Link to sponsor website</u>								
	Program URL	Link to program URL								
	Deadline Dates (ALL)	18-Feb-2026								
	Synopsis	Proposals are invited against the following topic: HORIZON-CL6-2025-01-BIODIV-02-two-stage: Breeding for resilience: enhancing multi-stress tolerance in crops In line with the objectives of the European Green Deal, the								



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title	Sponsor Name	Sponsor I	Number	Deadline Da	te Fund	ing Amount		
effects of climate change, increasing biodiversity in agroecosystems, and promoting low-input practices, the enhancing the resilience of agricultural systems and safeguarding food security. Projects are expected to cot to all of the following expected outcomes: deeper knowledge and characterisation of relevant traits for tole resistance to multiple stresses, whether occurring simultaneously or sequentially, are more accessible to residude and breeders; the identification of local varieties with high plasticity to cope with multi-stress conditions is along with the development of agro-ecological practices that improve stress tolerance while supporting biodification of the capacities to evaluate the effects of multiple stresses in crops by researchers breeders are strengthened; information and recommendations on variety performance and practices to copmulti-stress are available to advisors and farmers.									
132134 <u>E</u>		Natural Resources, Agriculture and ystems More Resilient to Food Safety Risks chnological Solutions	European Commission	HORIZON-CI 02-FARM2F0 two-stage		8-Feb-2026	6,900,000 USD		
	Contact Name								
	Contact Telephone								
	Contact Email								
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	18-Feb-2026							
	Proposals are invited against the following topic: HORIZON-CL6-2025-02-FARM2FORK-03-two-stage: Making food systems more resilient to food safety risks through the deployment of technological solutions The successful proposition will be in line with the European Green Deal priorities and the farm to fork strategy for a fair healthy and								



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

Contact Telephone

Contact Email

European Union Sponsored Projects

6011110						
SPIN ID	Program Title	Sponsor Name	Sponsor Nu	umber	Deadline Date	Funding Amount
	For wa following for the following f	avironmentally friendly food system. This to lood 2030 pathways for action 2.0 report, pages published in December 2023 by the Euro Illowing expected outcomes: a new level of shancing the deployment of solutions in the railable technologies (such as molecular measults achieved by European framework prograrketable results addressing the "innovation arketable products and services); food system and close to the market impactful application of available knowledge and technologies, farming, raw materials and ingredients so take in the field of food safety and/or food and synergies with programmes and their asset European Innovation Council (EIC); contridustry, to boost food manufacturing efficients	rticularly on the food pean Commission. Properties of food safety a thods, genomic strates grammes projects. The paradox" (i.e. the factorial become more respected in the factorial become more from the paradox of the factorial will beneficularly fraud with past and expected project result bute to EU climate actorial commissions.	safety systems oject results are ty is implement nd/or food fraugies, photonics e EU's strong kind that knowled silient to food shod chain and fot and connect stry, etc.); increasexisting Europe is from the Europic tion: deployme	of the future particle expected to consider to tackle innoted using existing and using existing and using existing and using existing and the second systems complements an framework propean Research (thway, this report ntribute to all the ovation creation, knowledge, etc.) and the stranslated into ays translate to gh the use and petitiveness I systems actors arities and results ogrammes projects, Council (ERC) and
132639	Cluster 6: Food, Bioeconomy, Natu Environment Substances of Cond Based Industries and Products: Ma	cern and Emerging Pollutants From Bio-	European Commission	HORIZON-CL6 01-ZEROPOLL 01-two-stage		5,750,000 USD
	Contact Name					



Non Federal Funding Opportunities: Feb 2026

The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title	9	Sponsor Name	Spo	onsor Number	Deadline Date	Funding Amount		
	•	Link to sponsor w Link to program L 18-Feb-2026							
	Synopsis	Proposals are invited against the following topic: HORIZON-CL6-2025-01-ZEROPOLLUTION-01-two-stage: Substances of concern and emerging pollutants from bio-based industries and products: mapping and replacement In line with the chemical strategy for sustainability and the revision of the Industrial Emissions Directive, successful proposals wi support the deployment of safe and sustainable by design bio-based industries and products, contributing to the defossilization and to the climate neutrality of EU industrial systems in a sustainable way. Project results are expected to contribute to all of the following expected outcomes: stakeholders of bio-based value chains, including in public procurement, researcher centres, industries, public administrations, final consumers, etc., gain awareness on the releases of hazardous substances, emerging pollutants and substances which are persistent and liable to bio-accumulate in ecosystems from bio-based industrial processes and from bio-based products; bio-based industries operators and customers improve their knowledge and use of safe and sustainable bio-based alternatives replacing hazardous substances, to achieve healthier air, water and soil.							
132097	Cluster 6: Food, Bioeconomy, Natural Resources, Agriculture and 132097 Environment Living Labs Co-Creating Innovative Solutions for Forests and Freshwater Ecosystems Restoration			European Commission	HORIZON-CL6 01-BIODIV-01 n stage		2026 8,050,000 USD		
	Contact Name Contact Telephone Contact Email Sponsor Website		vebsite_						



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor N	lumber	Deadline Date	Funding	g Amount	
	_	Link to program 18-Feb-2026	<u>URL</u>						
Deadline Dates (ALL) Proposals are invited against the following topic: HORIZON-CL6-2025-01-BIODIV-01-two-stage: Living labs co- innovative solutions for forests and freshwater ecosystems restoration Successful proposals will contribute to impacts of this destination by improving knowledge and developing innovations, methods, pathways and tool restore degraded ecosystems ensuring the provision of ecosystem services, including for adaptation and/or mitigation to climate change. Project results are expected to contribute to all the following expected outcome capacities of researchers, policymakers, practitioners and other stakeholders are enhanced, facilitating effect collaboration among research, practice, and policy to co-develop, test, refine and scale up solutions, methods tools for ecosystem restoration and for their non-deterioration; Practice-oriented knowledge and tools are av to stakeholders having to restore ecosystems and to ensure their non-deterioration, and to provide advice, su public and private land managers, foresters or environmental NGOs; Competent authorities in charge of prep and updating national restoration plans to implement the EU Nature Restoration Law and of national climate adaptation strategies and plans are aware of effective solutions, methods and tools for ecosystem restoration they are able to propose appropriate restoration measures; Collaborations between actors across territories a sectors are strengthened and consideration of effective solutions for ecosystem restoration and for their non-						to the cols to the citive ds and color as to paring e color and co			
		deterioration in regions where living labs are operating is increased, and business models to finance them are developed; Social, economic and environmental co-benefits and trade-offs of nature restoration activities are demonstrated, including for climate mitigation and adaptation.							
132656	Cluster 6: Food, Bioeconomy, N Environment Strengthening to Sector to Climate and Global So	the Resilience of '	Water Systems and Water	uropean ommission	HORIZON-CL 02-CLIMATE- stage		-ノロノカ	5,900,000 JSD	



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID Program Title	Spon	sor Name	Sponsor Number	Deadline Date	Funding Amount
Contact Name Contact Telephone					
Contact Email					
Sponsor Website	Link to sponsor websit	<u>te</u>			
Program URL	Link to program URL				
Deadline Dates (ALL)	18-Feb-2026				
	resilience of water systeuropean Green Deal, legislation and the upon this Destination on ad biodiversity protection outcomes: assessing a risks amplified by climobserving systems to management and plar protection/restoration water use sectors and at basin level, balancing governance of water;	against the following topic: HOR tems and water sector to climate notably the EU climate adaptate coming European water resilience aptation and mitigation of watern and restoration. Project results and managing better the changing ate change, including floods and monitor trends in the atmospheming and natural water cycle resiliency and by enhancing cross-sector complementarity between watern getter water demand and suphelping policy makers to prepares fair access to drinking water are	te and global socio-economion strategy, the Nature Resce strategy, successful proper systems in the context of estare expected to contribute and hydrological cycle, also and droughts, by fostering furtic hydrological cycle; by fostoration, also contributing ral and transboundary catcher related policies; increasing ply, helping to transform the for better water infrastructer.	ic change impacts listoration Regulation sosals will contribute climate change, supe to all of the follow t fine spatial scales, ther development castering water resilies to support biodiver himent cooperationing water use efficie he economics and resource is to support biodiver himent cooperationing water use efficie he economics and resource is to support biodiver himent cooperationing water use efficie he economics and resource is support biodiver himent cooperationing water use efficie he economics and resource is support biodiver himent cooperation and resource is support biodiver him and resource is support	n line with the n, EU water e to the impact of oporting also ving expected to reduce water of innovative ent land use, rsity between various ency in all sectors restructuring the



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID Progran	n Title	Sponsor N	ame	Sponsor Number	Deadline Date	Fundi	ng Amount
)22329 <u>Education</u>	and Scientific Bursar	y Programme	Fed	opean eration for nunogenetics	01-Fel	o-2026	1,725 USD
	Contact Name						
	Contact Telephone	+31(0) 71 - 526 51 11					
	Contact Email	efioffice@lumc.nl					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
1	Deadline Dates (ALL)	01-Feb-2026 , 01-May-2026	5				
	Synopsis	To promote training in the allocated a fixed number of to develop research collaboratory of up to a maximur	f bursaries to EFI memb prations. The duration o	ers wishing to visit another f the stay should be between	er laboratory to learn r	new tech	niques an
.33298 Joint Trans Protocols	snational Call 2026 -	Treatments and Adherence	Par <u>to Treatment</u> Hea Ant Res	opean tnership on One Ilth imicrobial istance (EUP AMR)		o-2026 re-App]	Not Specified



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amou		
	Contact Email	EUPOHAMR cal	lls@agencerecherche.fr					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	02-Feb-2026 [LOI/Pre-App], 17-Jun-2026						
This first EUP OHAMR joint transnational call for projects will explore new treatments to tackle AMR. The call Synopsis "Treatments and adherence to treatment protocols", involves 37 funding organisations from 28 different countries with an estimated total call budget of over 31 million Euro.								
098183 <u>S</u>	cientific Research Grants			rida Breast ncer Foundation	12-Dec [LOI/Pr	-2025 10,000 re-App] USD		
	Contact Name	Jessica Parker-K	err					
	Contact Telephone							
	Contact Email	Jessica@Floridal	BreastCancer.org					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	12-Dec-2025 [LC	OI/Pre-App], 13-Feb-2026					
The Florida Breast Cancer Foundation supports unique research projects or ideas (from small- to large-scale) that specifically focus on scientific and clinical breast cancer issues, which, if successfully addressed, could ultimately revolutionize the understanding and/or treatment of breast cancer and move us closer to the goal of eradicating disease.						ld ultimately		



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date Fund	ding Amount
004604 <u>I</u>	International Networks of Exce	<u>llence</u>	Fond	ation Leducq	13-Feb-2026	9,000,000 USD
	Contact Name					
	Contact Telephone	+33 (0)1 45 00 59	9 65			
	Contact Email	contact@flcq.org	g			
	Sponsor Website	Link to sponsor w	<u>website</u>			
	Program URL	Link to program	<u>URL</u>			
	Deadline Dates (ALL)	13-Feb-2026				
	Synopsis	Research Program cardiovascular ar scientific researc	ndation has created the Internationally on which promotes internationally on the prince of the princ	ollaborative basic, translatic ipal aim of this program is to I teams of researchers with	onal, and clinical research o foster outstanding and i	in nnovative
019073 <u>/</u>	ATTRACT Programme		la Re	s National de cherche mbourg - FNR	12-Feb-2026	2,300,000 USD
	Contact Name	Marie-Claude Ma	arx, PhD, ATTRACT Programme Coo	rdinator		
	Contact Telephone	+352 691 36 28 2	21			
	Contact Email	marie-claude.ma	arx@fnr.lu			
	Sponsor Website	Link to sponsor v	<u>website</u>			
		1				



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date F	unding Amount		
	Program URL	Link to program	<u>URL</u>					
	Deadline Dates (ALL)	12-Feb-2026						
	Synopsis	by FNR can be up to EUR 1.5M€ or 2M€ for 'Starting Investigators' or 'Consolidating Investigators', respectively. Institutional co-funding is required.						
040153 <u>S</u>	imall Grants		Ford B	ritain Trust	28-Feb-20	26 328 USD		
	Contact Name							
	Contact Telephone							
	Contact Email	fbtrust@ford.co	<u>om</u>					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	28-Feb-2026						
	Ford Britain Trust offers Small grants for amounts up to £250 to support projects focusing on education, environment Synopsis children, the disabled, youth activities and projects that provide clear benefits to the local communities close to UK locations.							
030560 <u>P</u>	Parkinson's Disease Therapeuti	cs Pipeline Progr	ram '	ichael J.) ation for	11-Dec-20	2,000,000 USD		



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount					
	Parkinson's Research										
	Contact Name										
	Contact Telephone	212-509-0995									
	Contact Email	grants@michaeljfox.org									
	Sponsor Website	Link to sponsor website									
	Program URL	Link to program URL									
	Deadline Dates (ALL)	Dates (ALL) 11-Dec-2025 , 22-Feb-2026 , 23-Apr-2026 , 25-Jun-2026									
	Synopsis	The Pre-clinical Therapeutics Pipelin clinical testing of approaches addre to benefit therapeutics with clear p daily symptoms.	ssing unmet needs	of people with Parkins	on's disease (PD). The pr	ogram is set up					
036254 <u>k</u>	Keith Michael Andrus Cardiac A	Award		ch's Ataxia h Alliance	15-Feb-2	026 250,000 USD					
	Contact Name										
	Contact Telephone	484-879-6160									
	Contact Email	grants@curefa.org									
	Sponsor Website	Link to sponsor website									
	Program URL	Link to program URL									
	Deadline Dates (ALL)	15-Feb-2026 , 15-Apr-2026									



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount	
	Synopsis	The Keith Michael Andrus Cardiac and to help advanced our unders award should focus on advancing may request a budget of up to \$1	tanding and treatmen understanding and/o	t of the cardiomyopath r treatment of the card	y associated with FA.	Proposals for this	
036255 <u>K</u>	(yle Bryant Translational Resea	arch Award				Feb-2026 400,000 I/Pre-App] USD	
	Contact Name						
	Contact Telephone	484-879-6160					
	Contact Email	grants@curefa.org					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	15-Feb-2026 [LOI/Pre-App], 15-A	pr-2026				
Friedreich's Ataxia Research Alliance (FARA) accepts applications for the Kyle Bryant Translational Research Alliance (FARA) accepts applications for the Kyle Bryant Translational Research Alliance (FARA) accepts applications for the Kyle Bryant Translational Research Alliance (FARA) accepts applications for the Kyle Bryant Translational Research Alliance (FARA) accepts applications for the Kyle Bryant Translational Research Alliance (FARA) accepts applications for the Kyle Bryant Translational Research Alliance (FARA) accepts applications for the Kyle Bryant Translational Research Alliance (FARA) accepts applications for the Kyle Bryant Translational Research Alliance (FARA) accepts applications for the Kyle Bryant Translational Research Alliance (FARA) accepts applications for the Kyle Bryant Translational Research Alliance (FARA) accepts applications for the Kyle Bryant Translational Research Alliance (FARA) accepts applications for the Kyle Bryant Translational Research Alliance (FARA) accepts applications for the Kyle Bryant Translational Research Alliance (FARA) accepts applications for the Kyle Bryant Translational Research Alliance (FARA) accepts applications for the Kyle Bryant Translational Research Alliance (FARA) accepts applications for the Kyle Bryant Translational Research Alliance (FARA) accepts applications for the Kyle Bryant Translational Research Alliance (FARA) accepts applications for the Kyle Bryant Translational Research Alliance (FARA) accepts applications for the Kyle Bryant Translational Research Alliance (FARA) accepts applications for the Kyle Bryant Translational Research Alliance (FARA) accepts applications for the Kyle Bryant Translational Research Alliance (FARA) accepts applications for the Kyle Bryant Translational Research Alliance (FARA) accepts accepts a constant accepts accepts a consta							
006873 <u>B</u>	Bronya J. Keats Research Collab	poration Award		ch's Ataxia h Alliance	15-Feb [LOI/Pı	-2026 350,000 re-App] USD	
	Contact Name						
	Contact Telephone	484-879-6160					



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	S	Sponsor Number	Deadline Date	Fundi	ng Amount
	Contact Email	grants@curefa.c	org					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	15-Feb-2026 [LC	OI/Pre-App], 15-Apr-2026					
	Synopsis	The Bronya J. Ke that relies on co	eats Research Collaboration Aw Illaboration among investigator	rard suppors from at	orts proposals that focus least two different Instit	on Friedreich's ata ations.	axia (FA) research
093950	SeneSolve Program			Genome Columbia		28-Nov [LOI/Pr	/-2025 re-App]	175,000 USD
	Contact Name							
	Contact Telephone							
	Contact Email	genesolve@gen	omebc.ca					
	Sponsor Website	Link to sponsor	website_					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	28-Nov-2025 [L0	OI/Pre-App], 05-Feb-2026					
			orts projects providing solution ue in that it encourages a colla a.		~	•		
129515 <u>J</u>	eremy Ingham Fund			Geologica of Londor	•	09-Feb	-2026	2,620 USD
	Contact Name	Awards Secretar	ſy					



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date Fu	nding Amount				
	Contact Telephone	+44 (0)20 7434 9	9944							
	Contact Email	grants@geolsoc	<u>.org.uk</u>							
	Sponsor Website	Link to sponsor	<u>website</u>							
	Program URL	Link to program	URL							
	Deadline Dates (ALL)	09-Feb-2026	eb-2026							
	Synopsis		d of up to £2,000 will be made for the eggiven to the study of construction ma	~						
073959 <u>F</u>	Research Grants		Gerber	Foundation	15-Feb-202	Not Specified				
	Contact Name									
	Contact Telephone	231-924-3175								
	Contact Email	tgf@gerberfoun	dation.org							
	Sponsor Website	Link to sponsor	<u>website</u>							
	Program URL	Link to program	<u>URL</u>							
	Deadline Dates (ALL)	15-Feb-2026								
	Synopsis	The Foundation	ndation provides support for studies to 's mission focuses on infants and young rition, care and development of infants	g children. Accordingly, pr	iority is given to projec	s that				



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID Program Title	Sponsor Name		Sponsor Number	Deadline Date Fu	nding Amount
012781 Research Grants in Germany		Exchang	Academic ge Service - London	16-Feb-202	Not Specified
Contact Name					
Contact Telephone	+44 (20)/7831-9511				
Contact Emai	scholarships.london@daad.de				
Sponsor Website	Link to sponsor website				
Program URI	Link to program URL				
Deadline Dates (ALL)	16-Feb-2026				
Synopsis	DAAD United Kingdom's Researd years after completing their doc university of applied sciences, n	ctorate) the opportunity	to realise a research pro	ject at any German uni	• •
069801 Guts UK/Falk Foundation Dieti	tian Recognition Prize	Guts UK		02-Feb-202	26 1,310 USD
Contact Name					
Contact Telephone					
Contact Emai	research@gutscharity.org.uk				
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	02-Feb-2026				



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

	Program Title	Sponsor Nan	ne	Sponsor Number	Deadline Date	Fundi	ng Amount
	Synopsis	The Falk Foundation and Guts dietitians working in primary improvement in patient care.					
035801	Guts UK/Falk Foundation Nurse	Recognition Prize	Guts UK		02-Feb	-2026	1,310 USD
	Contact Name						
	Contact Telephone	020 7486 0341					
	Contact Email	research@gutscharity.org.uk					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	02-Feb-2026					
	Synopsis	The Falk Foundation and Guts		om gastroenterology (in 00 prize in recognition o		-	creatology)
	57.15651	improvement in patient care.	secondary care for a £1,0		or arr minovation that	nas led	to an
103232 <u>I</u>	Health Services Research Grant	improvement in patient care.	HCF Res	earch	03-Dec	:-2025	Not Specified
103232]		improvement in patient care.	HCF Res	earch	03-Dec	:-2025	Not
103232 <u>I</u>	Health Services Research Grant	improvement in patient care.	HCF Res	earch	03-Dec	:-2025	Not
103232]	Health Services Research Grant Contact Name Contact Telephone	improvement in patient care.	HCF Res	earch	03-Dec	:-2025	Not
103232]	Health Services Research Grant Contact Name Contact Telephone Contact Email	improvement in patient care.	HCF Res	earch	03-Dec	:-2025	Not



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID Program Title	Sponsor Nan	ne	Sponsor Number	Deadline Date	Fundi	ng Amount		
Deadline Dates (ALL)	03-Dec-2025 [LOI/Pre-App], 2	5-Feb-2026						
	The HCF Research Foundation Translational Research Grants (TRG) scheme is focused on responding to health is identified within health care provider communities, and the translation of research findings into practice by heal service delivery stakeholders. Through this scheme, the Foundation aims to facilitate the implementation of cost effective evidence-based innovation into health care delivery to improve outcomes and the experience of patier carers and health care workers.							
128560 Doctoral Personnel Awards for	Black Scholars	Heart a Founda Canada		12-Feb	-2026	84,000 USD		
Contact Name								
Contact Telephone	1-888-473-4636							
Contact Email	research@heartandstroke.ca							
Sponsor Website	Link to sponsor website							
Program URL	Link to program URL							
Deadline Dates (ALL)	12-Feb-2026							
Synopsis	The Doctoral Personnel Awards for Black Scholars (BSA-PhD) will support Black scholars of African or Caribbean deritage and/or ancestry in Canada. These awards aim to promote strategic growth in heart and brain health science with Black communities by supporting Black students pursue their post graduate studies. The stipends awarded will be up to \$120,000 CAD (\$40,000 per year for up to 3 years) enabling Black trainees to focus on their Doctoral esearch studies and engage with mentors as part of their training.							



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Fundi	ng Amount
128562	Doctoral Personnel Awards for	Indigenous Scho	lar <u>s</u>	Heart ar Foundat Canada	nd Stroke tion of	12-Feb-2	2026	252,000 USD
	Contact Name							
	Contact Telephone	1-888-473-4636						
	Contact Email	research@heart	tandstroke.ca					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	12-Feb-2026						
		Métis peoples) i with Indigenous awarded will be	rsonnel Awards for Indigenous n Canada. These awards aim to communities by supporting Ir up to \$120,000 CAD (\$40,000 esearch studies and engage wi	o promo digenou per year	te strategic growth in hear s students pursue their po for up to 3 years) enablin	rt and brain health so est graduate studies. g Indigenous trainee	cience The s	tipends
089513 <u>C</u>	Complex Joint Reconstruction (Center Clinical Fe	llowship	Hospital Surgery	l for Special	02-Feb-2	2026	Not Specified
	Contact Name							
	Contact Telephone	1-212-774-2572						
	Contact Email	complexjoint@h	nss.edu					
	Sponsor Website	Link to sponsor	<u>website</u>					
		•						



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	ID Program Title		Sponsor Name	S	Sponsor Number	Deadline Date	Funding Amount	
	Program URL Deadline Dates (ALL)	Link to program 02-Feb-2026	<u>URL</u>					
	Synopsis	The Complex Joint Reconstruction Center (CJRC) Fellowship in the Department of Orthopaedic Surgery of the for Special Surgery (HSS) is a program to train clinicians in the evaluation and management of patients in the musculoskeletal specialty of hip and knee arthroplasty. The one-year clinical fellowship is designed to provide fellow with an ongoing, in-depth experience in the management of patients undergoing complex primary join replacement and revision surgery. Emphasis is placed on the preoperative evaluation and operative management these problems. The fellowship will accomplish these objectives through didactic clinical lectures, academic conferences, supervised patient care, in-depth surgical exposure, and research projects that support the concand skills learned in the clinical arena.						
069446 <u>A</u>	Addressing Evidence-Based He	alth Benefits of H	luman-Animal Interaction	Human A Bond Res Institute		26-Feb-2	50,000 USD	
	Contact Name	Matt Cryer						
	Contact Telephone							
	Contact Email	MCryer@HABRI	.org					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	26-Feb-2026						
Synopsis The Human Animal Bond Research Institute (HAB organizations across the globe to investigate the					suing a call for research poutcomes of pet owners	proposals from instit hip and/or animal-as	utions and sisted	



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

 $\label{lem:consider} \mbox{Additional GCO Policies to consider when prior to applying.}$

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date Fund	ing Amount
		interventions (AAI), both for the peop framework and focus on innovative aphealth.	•	_	
128669	Metrex CaviWipes Canada Sch	olarshi <u>p</u>	Infection Prevention and Control Canada	13-Feb-2026	1,750 USD
	Contact Name				
	Contact Telephone	1-866-999-7111			
	Contact Email	info@ipac-canada.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	13-Feb-2026			
	Synopsis	Infection Prevention and Control (IPAG attend the 2026 National Education Co attendance only.	•	•	
114538	Jerzy Giedroyc Fellowship		Institute for Human Sciences	10-Feb-2026	Not Specified
	Contact Name	Kasper Nowak			
	Contact Telephone	+43-1-313-58-0			
	Contact Email	fellowships@iwm.at			



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name		Sponsor Nu	mber	Deadline Date	Funding Amount
	•	The Institute fo				Giedroyc Junio	r Visiting Fellowshi	ps which are open
SPIN ID	Program Title		Sponsor Name	Sponsor	· Number	Deadline Dat	e Funding	
113487	Equipment, Professional Dev Patient Care Grants	Jim Pattison Children's Hospital Foundation			15-Feb-2026	Not Spe	ecified	
	Contact Name							
	Contact Telephone	306-655-3050						
	Contact Email	info@pattisonchilo	drens.ca					
	Sponsor Website	Link to sponsor we	<u>bsite</u>					
	Program URL	Link to program UI	<u>RL</u>					
	Deadline Dates (ALL)	15-Feb-2026						
Through the Jim Pattison Children's Hospital Foundation Grant Program, the sponsor seeks to promote excellence in maternal and pediatric health care. They grant professional development, equipment and technology, and patient care requests that have potential for an enhancement of care based on scientific excellence and relevance to children's and maternal health.								d
021422	Grant Programs - Medical Re	<u>esearch</u>	Keck (W. M.) Foundation			16-Feb-2026	Not Spe	ecified



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
	Contact Name							
	Contact Telephone	213-612-2000						
	·	research@wmkeck	org					
		Link to sponsor web						
	Program URL	Link to program UR	<u>L</u>					
	Deadline Dates (ALL) 16-Feb-2026 , 16-Feb-2026 [Optional][LOI/Pre-App], 01-May-2026 [LOI/Pre-App], 17-Aug-2026 , 17-Aug-2026 [Optional][LOI/Pre-App], 02-Nov-2026							
			earch Program seeks to benefit humar novel in their approach, question the p in their field.					
002712	Klingenstein Fellowship Awa Neuroscience	ards in	Klingenstein (Esther A. & Joseph) Fund	01-Feb-2026	450,000	0 USD		
	Contact Name							
	Contact Telephone							
	Contact Email	info@klingenstein.d	org					
	Sponsor Website	Link to sponsor web	<u>osite</u>					
	Program URL	Link to program UR	<u>L</u>					
	Deadline Dates (ALL)	01-Feb-2026						
	Synopsis	The Klingenstein Fe investigators. The r	llowship Awards in Neuroscience suppessearch should have relevance for und	orts innovative research by erstanding the mechanism	y early career ns underlying			



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		these disorders. The disease cures can d	ehavioral disorders, that may lead to in ne sponsor recognizes, however, that so come from basic research, without an in so support basic research.	ome of the most important	contributions tow	ard
071136 <u>A</u>	lbert Lasker Basic Medical	Research Award	Lasker Foundation	02-Feb-2026	Not Sp	ecified
	Contact Name					
	Contact Telephone Contact Email	dkeegan@laskerfo	undation.org			
		Link to sponsor we				
		Link to program UI	<u>RL</u>			
	Deadline Dates (ALL)					
	Synopsis		Basic Medical Research Award honors in warea of biomedical science.	ndividuals who have made a	a fundamental dis	covery
055958 <u>N</u>	lew Investigator Research (Grant Program	Leukemia Research Foundation	06-Feb-2026 App]	[LOI/Pre- 150,00	0 USD
	Contact Name					
	Contact Telephone	847-424-0600				
	Contact Email	grants@leukemiar	f.org			
	Sponsor Website	Link to sponsor we	<u>bsite</u>			
	Program URL	Link to program UF	<u>RL</u>			



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title	S	ponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)		Research Grant Program supports ea			vity
	Synopsis	leukemia research. Fo	nnovative research projects with the or the program to support the best and lect the full diversity of the research graphic locations.	nd brightest minds, applica	ations are sought fr	
070305 <u>E</u>	arly Career Fellowships	Le	everhulme Trust	19-Feb-2026	Not Spe	ecified
	Contact Name	Andreas Heiner				
	Contact Telephone	020 7042 9863				
	Contact Email	grants@leverhulme.a	<u>nc.uk</u>			
	Sponsor Website	Link to sponsor websi	<u>ite</u>			
	Program URL	Link to program URL				
	Deadline Dates (ALL)	19-Feb-2026				
	Synopsis		t offers Early Career Fellowships for e d a full-time permanent academic po			
126529 <u>S</u>	itart-Up Programme	Lı	undbeck Foundation	02-Feb-2026	Not Spe	ecified
	Contact Name	Peter Thostrup				
	Contact Telephone	+45 3059 4943				
	Contact Email	pth@lundbeckfonder	n.com			



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
	•	Link to sponsor we						
	•	Link to program UR						
	Deadline Dates (ALL)		pr-2026 , 13-Aug-2026 , 22-Oct-2026					
	Synopsis	neuroscience by far abroad or from ind the field of neurosc brain and better pr help to ensure that biomedical, clinical strengthens science	ne purpose of the Lundbeck Foundation Start-Up programme is to support the development of Danish euroscience by facilitating the process for recruiting researchers to Danish Universities or hospitals from broad or from industry. The Lundbeck Foundation has a strategic goal to make Denmark a frontrunner in e field of neuroscience by funding Danish-based research that promotes a better understanding of the rain and better prevention, diagnosis, and treatment of brain disorders. At the same time, the grants must elp to ensure that Denmark has the best graduates and scientists at all career levels in the fields of omedical, clinical and health sciences in Denmark. Lundbeck Foundation believes that diversity rengthens science and for this reason diversity, including, but not limited to, gender and ethnic origin, is incouraged. It is therefore important that we receive applications for recruitment from all backgrounds.					
126531	Science Engagement and Co	mmunication	Lundbeck Foundation	03-Feb-2026	Not Sp	ecified		
	Contact Name	Anette Høye						
	Contact Telephone							
	Contact Email	ah@lundbeckfonde	en.com					
	Sponsor Website	Link to sponsor we	<u>bsite</u>					
	Program URL	Link to program UR	<u>:L</u>					
	Deadline Dates (ALL)	03-Feb-2026 , 09-A	pr-2026 , 13-Aug-2026 , 22-Oct-2026					
	Synopsis		ndation wishes to strengthen the disse society, with focus on neuroscience, th					



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

 $\label{lem:consider} \mbox{Additional GCO Policies to consider when prior to applying.}$

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		the Science Engagement and Communication Ca engage young people to focus on science, partic knowledge about the brain and brain disorders	ularly neuroscience, as a career; and		
006968 <u>C</u>	Cancer Research Grant Prog	ram Mary Kay Ash Foundation	01-Feb-2026	100,000) USD
	Contact Name				
	Contact Telephone				
	Contact Email	info@marykayashfoundation.org			
	Sponsor Website	<u>Link to sponsor website</u>			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Feb-2026			
	Synopsis	The Mary Kay Foundation's grant program funds cancers affecting women (ovarian, uterine, brea awarded up to \$100,000 (combined direct and i	st, endometrial or cervical cancer ar		
021854 <u>S</u>	Summer Fellowship Progran	Masonic Medical Research Institute	06-Feb-2026	Not Spe	ecified
	Contact Name				
	Contact Telephone	315-735-2217			
	Contact Email	sf@mmri.edu			
	Sponsor Website	<u>Link to sponsor website</u>			
	Program URL	<u>Link to program URL</u>			



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount			
	Deadline Dates (ALL) Synopsis	The Summer Fellov graduate and medi	e Summer Fellowship Program at MMRI provides a scientific research experience for undergraduate, aduate and medical students. To be eligible, students must have completed at least one year of dergraduate coursework.						
III /Xh/I	Neurosurgery - Peripheral N Fellowship (Minnesota)	lerve Surgery	Mayo Clinic College of Medicine and Science	01-Feb-2026	Not Sp	ecified			
	Contact Name								
	Contact Telephone	507-538-5851							
	Contact Email	rstnseduc@mayo.e	<u>edu</u>						
	Sponsor Website	Link to sponsor we	<u>bsite</u>						
	Program URL	Link to program UF	<u>RL</u>						
	Deadline Dates (ALL)	01-Feb-2026							
	The Peripheral Nerve Surgery Fellowship Mayo Clinic's campus in Rochester, Minnesota offers trainees the rare opportunity to specialize in a growing area of neurosurgery and reconstructive surgery. The one-year fellowship is divided between the core training (six months) and elective rotations (six months). At the beginning of the fellowship, fellows are expected to complete a one-week microvascular training course.								
133174	MRC Centre of Research Exc CoRE): Round Four	cellence (MRC	Medical Research Council (MRC)	08-Dec-2025 [Optional][L0 App]	3/1 327	,500			
	Contact Name								



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
	Contact Telephone							
	Contact Email	core@mrc.ukri.org						
	Sponsor Website	Link to sponsor web	<u>osite</u>					
	Program URL	Link to program UR	<u>L</u>					
	Deadline Dates (ALL)	08-Dec-2025 [Option	onal][LOI/Pre-App], 04-Feb-2026 [LOI/I	Pre-App], 10-Sep-2026				
	Synopsis Applications are invited for MRC Centre of Research Excellence (MRC CoRE) funding to tackle complex and interdisciplinary health challenges.							
132967	Special Opportunity: RTFCC Science Awards on Improvir Detection, Diagnosis, and Ri Melanoma	ng the Early	Melanoma Research Alliance	02-Feb-2026	Not Spe	ecified		
	Contact Name							
	Contact Telephone							
	Contact Email	science@curemelar	noma.org					
	Sponsor Website	Link to sponsor web	<u>osite</u>					
	Program URL	Link to program UR	<u>L</u>					
	Deadline Dates (ALL)	02-Feb-2026						
	Synopsis	I) clinical trials aime	CR will jointly support a Team Science ed at improving melanoma early detec be actively demonstrated throughout t	tion, diagnosis, and risk str	atification. Patient			



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	dissemination. The sponsor defines patient involvement as meaningful engagement of patient partners in the development of therapeutic, detection, or prevention approaches to cancer care. It encompasses the active and collaborative interaction between patient partners and researchers across all stages of the research process from conception to results distribution, where research decision making is supported by patient partners' contributions, recognizing their specific experiences, values, and expertise. These awards will support innovative approaches with preliminary data, where funding is required to advance the validation of tests, technologies, or devices. The sponsor welcomes applications from all research groups with a track record in melanoma. Grant applicants should actively involve patient partners in the protocol design.					
038045 Research Grants		Ménière's Society	01-Feb-2026	Not Spe	cified	
Contact Nar	ne					
Contact Telepho	ne +44 0 1306 876883					
Contact Em	ail <u>research@meniere</u>	s.org.uk				
Sponsor Webs	te Link to sponsor we	<u>bsite</u>				
Program U	RL Link to program UF	<u>RL</u>				
Deadline Dates (A	L) 01-Feb-2026					
Synop	The Ménière's Society is the only registered charity in the UK dedicated solely to supporting people with vestibular disorders causing dizziness and imbalance. The overall aims of research funded by the Ménière's Society are therefore: to improve the diagnosis and treatment of Ménière's disease and other vestibular disorders. The ultimate aim is to contribute towards finding a cure.					
046429 <u>Catalyst Awards</u>		Multiple Sclerosis Society UK	10-Feb-2026	78,600	USD	



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount				
	Contact Name									
	Contact Telephone	020 8438 0700								
	Contact Email	research@mssocie	ty.org.uk							
	Sponsor Website	Link to sponsor wel	<u>bsite</u>							
	Program URL	Link to program UR	<u>L</u>							
	Deadline Dates (ALL)	10-Feb-2026	eb-2026							
	Synopsis	These may be "high researchers from w	Catalyst Awards provide support for short-term, small-scale pilot or proof-of-concept research projects. These may be "high risk, high reward" type projects and must be hypothesis-driven. The sponsor intends for researchers from within and outside the MS field to use these Awards to explore innovative ideas in MS research. If merited, ideas may lead to further support through the larger grant schemes or other funding sources.							
029133 <u>P</u>	roject Awards		Multiple Sclerosis Society UK	10-Feb-2026	Not Spe	ecified				
	Contact Name									
	Contact Telephone	020-8438-0822								
	Contact Email	research@mssocie	ty.org.uk							
	Sponsor Website	Link to sponsor wel	<u>bsite</u>							
	Program URL	Link to program UR	<u>L</u>							
	Deadline Dates (ALL)	10-Feb-2026								



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

 $\label{lem:consider} \mbox{Additional GCO Policies to consider when prior to applying.}$

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Synopsis		ites applications for projects that w ts or prevention strategies for MS a MS.				
037398	Research Associateship Prog	gram (RAP)	National Academies	02-Feb-2026	Not Sp	ecified	
	Contact Name Contact Telephone					<u></u>	
	Contact Email	RAP@nas.edu					
	Sponsor Website	Link to sponsor we	<u>bsite</u>				
	Program URL	Link to program UF	<u>RL</u>				
	Deadline Dates (ALL)	02-Feb-2026					
	The NRC Research Associateship Programs (RAP) are prestigious postdoctoral and senior research awards designed to provide promising scientists and engineers with high-quality research opportunities at federal laboratories and affiliated institutions. These programs offer a comprehensive experience, including mentorship, access to state-of-the-art facilities, and opportunities to influence government policy, all geared toward enhancing the research career development of the Research Associates.						
128551	Medical Research Future Fu Health Futures Mission - 20 Health Futures Grant		National Health and Medical Research Council	21-Jan-2026 App]	[LOI/Pre-Not Sp	ecified	
	Contact Name Contact Telephone						



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

European Union Sponsored Projects

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email	help@nhmrc.gov.a	<u>u</u>			
	Sponsor Website	Link to sponsor wel	<u>osite</u>			
	Program URL	Link to program UR	<u>L</u>			
	Deadline Dates (ALL)	21-Jan-2026 [LOI/P	re-App], 04-Feb-2026			

The Genomics Health Futures Mission (the Mission) aims to support research to improve testing, diagnosis and treatment for genetic diseases, guide prevention and help personalise treatment options to better target and improve health outcomes and reduce unnecessary interventions and health costs. Under the 3rd MRFF 10-Year Investment Plan, the Mission is allocated \$191.2 million over 4 years from 2024-25 to 2027-28, with further investment from 2028-29 to 2033-34 subject to evaluation. Genomics is already transforming our ability to diagnose conditions and provide targeted interventions, especially for people with rare genetic diseases and cancer. Genomics is also improving the prevention and control of infectious disease. Continually improving genomics technologies and their applications offers an opportunity to

Synopsis

disease. Continually improving genomics technologies and their applications offers an opportunity to generate individual, public health, social and economic benefits in Australia and globally. To maximise these benefits, new ways of thinking and working are required to develop and disseminate advances in genomics technologies, and to support their timely adoption and implementation into health care and disease prevention and treatment. The scope of the Mission is to fund research to integrate genomics knowledge and technology into clinical practice and public health impact. It aims to: - ensure Australians live longer and healthier lives through access to genomics knowledge and technology - deliver improved diagnostics and targeted treatments, including precision medicine - avoid unnecessary health costs improve patient experience and outcomes - position Australia as a global leader in genomics research The objectives and outcomes of this grant opportunity align with the Roadmap and Implementation Plan for the Mission. The objectives and intended outcomes of this grant opportunity are aligned with the following Australian



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Spoi	nsor Number	Deadline D	ate	unding Amount
			and Innovation Priorities 2024- lander Health and Wellbeing -				- Aborigin	al
108015	Medical Research Future Fu Brain Cancer Mission - 2025 Research Grant Opportunity	Brain Cancer	National Health and Medical Research Council	G07827	21-Jan-2026 App]	[LOI/Pre-	Not Specif	ied
	Contact Name							
	Contact Telephone	1800 500 983						
	Contact Email	help@nhmrc.gov.a	<u>u</u>					
	Sponsor Website	Link to sponsor we	<u>bsite</u>					
	Program URL	Link to program UR	<u>RL</u>					
	Deadline Dates (ALL)	21-Jan-2026 [LOI/P	re-App], 04-Feb-2026					
The Medical Research Future Fund (MRFF) Australian Brain Cancer Mission aims to support transformative improvement to the quality and length of life of people with brain cancer, with the longer-term aim of defeating brain cancer. The objective of this grant opportunity is to provide grants of financial assistance to support medical research and medical innovation projects that develop novel approaches to reduce treatment toxicity and adverse effects of brain cancer treatment for patients, to minimise the short- and/or long-term negative impacts for patients and carers.						to		
121866	Medical Research Future Fu Priorities and Consumer Dri InitiativeChildhood Menta Grant Opportunity	ven Research	National Health and Medical Research Council	GO7968	25-Feb-2026 App]	[LOI/Pre-	Not Specif	ied



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Contact Name						
	Contact Telephone	1800 500 983					
	Contact Email	help@nhmrc.gov.a	<u>ıu</u>				
	Sponsor Website	Link to sponsor we	<u>bsite</u>				
	Program URL Link to program URL						
	Deadline Dates (ALL) 25-Feb-2026 [LOI/Pre-App], 25-Mar-2026						
	Synopsis	to enable or suppo collaboration betw	rch Future Fund (MRFF) Emergiont research that improves patient research that improves patient researchers and researchers with diagnoses, treatments and cu	nt care a s. Fundir	and translation of new disc ng from this Initiative will s	coveries, and encor support the	urage
174610	Application Development Amend Care Professionals	ward for Health	National Institute for Health and Care Research (NIHR)	2025/41	.5 04-Feb-2026	196,50	0 USD
	Contact Name						
	Contact Telephone						
	Contact Email	crossprogramme@	nihr.ac.uk				
	Sponsor Website						
	Program URL	Link to program UF	<u>RL</u>				
	Deadline Dates (ALL)	04-Feb-2026					



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Synopsis	work prior to resea Professionals (HCP opportunities for H	commission up to ten Application Deve arch applications, with a requirement fo). Through these ADAs and other HCP ICPs to develop as highly skilled researd sional approach to addressing the healt	or applicant teams to invo specific initiatives, NIHR is chers and research leaders	lve Health and Care s offering more s, and to move tow	e ards a	
U/I3hI	Revolutionary Aerospace Sy Academic Linkage (RASC-AL		National Institute of Aerospace	23-Feb-2026	6 Not Sp	ecified	
	Contact Name						
	Contact Telephone	757-218-8313					
	Contact Email	rascal@nianet.org					
	Sponsor Website	Link to sponsor we	<u>bsite</u>				
	Program URL	Link to program UF	<u>RL</u>				
	Deadline Dates (ALL)	23-Feb-2026					
	The NASA Revolutionary Aerospace Systems Concepts - Academic Linkage (RASC-AL) Competition fuels innovation for aerospace systems concepts, analogs, and technology prototyping by bridging gaps through university and college engagement. RASC-AL is open to undergraduate and graduate university-level students studying fields with applications to space exploration (i.e., aerospace, bio-medical, electrical, and Synopsis mechanical engineering; and life, physical, and computer sciences). RASC-AL projects allow students to incorporate their coursework into real aerospace design concepts and work together in a team environment. Interdisciplinary teams are encouraged. In 2026, up to 14 Finalist Teams may be chosen to compete at the RASC-AL Competition Forum in Cocoa Beach, Florida. Each finalist team will receive a \$7,000 stipend to facilitate full participation in the RASC-AL Competition. The top 2 overall winning teams will receive an						



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		additional stipend 2026.	and an invitation to showcase their wi	nning concepts at a major a	aerospace conferer	nce in
107632	Kidney Health Equity Comm Award	unity Engagement	National Kidney Foundation	09-Feb-2026	75,000	USD
	Contact Name					
	Contact Telephone	855-653-2273				
	Contact Email	research@kidney.d	org			
	Sponsor Website	Link to sponsor we	<u>bsite</u>			
	Program URL	Link to program UF	<u>RL</u>			
	Deadline Dates (ALL)	09-Feb-2026				
	Synopsis	kidney health at a	ey Foundation (NKF) seeks proposals the community level. The application musters, and patient outcomes.	•		
112144	Research Associateship Prop Warfare Center Weapons D		National Research Council	02-Feb-2026	Not Sp	ecified
	Contact Name	Dr. Stephen Fallis				
	Contact Telephone	760-939-1602				
	Contact Email	stephen.fallis@nav	vy.mil			
	Sponsor Website	Link to sponsor we	<u>bsite</u>			
	Program URL	Link to program UF	<u>RL</u>			



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)		Лау-2026 , 03-Aug-2026 , 02-Nov-2026			
	The NRC Research Associateship Programs (RAP) are prestigious postdoctoral and senior research awards designed to provide promising scientists and engineers with high-quality research opportunities at federal laboratories and affiliated institutions. The Naval Air Warfare Center Weapons Division (NAWCWD) offers a research opportunity for Postdoctoral applicants.					
058592	Research Associateship Prog Aviation and Missile Researd and Engineering Center (AM	ch, Development,	National Research Council	02-Feb-2026	5 Not Sp	ecified
	Contact Name	Jennifer Griffiths, N	NRC RAP Program Administrator			
	Contact Telephone	202-334-2974				
	Contact Email	jgriffiths@nas.edu				
	Sponsor Website	Link to sponsor we	<u>bsite</u>			
	Program URL	Link to program UF	<u>RL</u>			
	Deadline Dates (ALL)	02-Feb-2026 , 01-N	лау-2026 , 03-Aug-2026 , 02-Nov-2026	5		
	Synopsis	designed to provid laboratories and af mentorship, access toward enhancing	Associateship Programs (RAP) are pre e promising scientists and engineers vifiliated institutions. These programs casto state-of-the-art facilities, and opposite research career development of the ciateship Program at the Army Aviation (AMRDEC).	with high-quality research confer a comprehensive expendention of the comprehensive expendence governers. The Research Associates. The	opportunities at fed erience, including ernment policy, all is opportunity is fo	deral geared



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount			
II5XhII7	Research Associateship Prog Medical Research and Mate		National Research Council	02-Feb-2026	Not Sp	ecified			
	Contact Name	Jennifer Griffiths, I	NRC RAP Program Administrator						
	Contact Telephone	202-334-2974							
	Contact Email jgriffiths@nas.edu								
	Sponsor Website Link to sponsor website								
	Program URL Link to program URL								
	Deadline Dates (ALL)	Deadline Dates (ALL) 02-Feb-2026 , 01-May-2026 , 03-Aug-2026 , 02-Nov-2026							
	The NRC Research Associateship Programs (RAP) are prestigious postdoctoral and senior research awards designed to provide promising scientists and engineers with high-quality research opportunities at federal laboratories and affiliated institutions. These programs offer a comprehensive experience, including mentorship, access to state-of-the-art facilities, and opportunities to influence government policy, all geared toward enhancing the research career development of the Research Associates. This opportunity is for the U.S. Army Medical Research and Materiel Command.								
115X544	Research Associateship Prognstitute of Standards and T		National Research Council	02-Feb-2026	Not Sp	ecified			
	Contact Name	Jennifer Griffiths, I	NRC RAP Program Administrator						
	Contact Telephone	202-334-2974							
	Contact Email	jgriffiths@nas.edu							
	Chancar Wahaita	Link to sponsor we	hsita						



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Program URL	Link to program UI	R <u>L</u>				
	Deadline Dates (ALL) 02-Feb-2026 , 03-Aug-2026 The NRC Research Associateship Programs (RAP) are prestigious postdoctoral and senior research awards designed to provide promising scientists and engineers with high-quality research opportunities at federal laboratories and affiliated institutions. These programs offer a comprehensive experience, including mentorship, access to state-of-the-art facilities, and opportunities to influence government policy, all geared toward enhancing the research career development of the Research Associates. This opportunity is for the NRC Research Associateship Program at the National Institute of Standards and Technology (NIST).						
058601	Research Associateship Prog CCDC Chemical Biological Co		National Research Council	02-Feb-2026	Not Spe	ecified	
	Contact Name	Jennifer Griffiths, N	NRC RAP Program Administrator				
	Contact Telephone	202-334-2974					
	Contact Email	jgriffiths@nas.edu					
	Sponsor Website	Link to sponsor we	<u>ebsite</u>				
	Program URL	Link to program UI	<u>RL</u>				
	Deadline Dates (ALL)	02-Feb-2026 , 01-N	May-2026 , 03-Aug-2026 , 02-Nov-2026				
	Synopsis	designed to provid laboratories and at	Associateship Programs (RAP) are prest le promising scientists and engineers wi ffiliated institutions. These programs off s to state-of-the-art facilities, and oppor	th high-quality research of fer a comprehensive expe	pportunities at federience, including	eral	



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

 $\label{lem:consider} \mbox{Additional GCO Policies to consider when prior to applying.}$

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		_	-	t of the Research Associates. Thi my CCDC Chemical Biological Cer		the
USXS47	Research Associateship Prog Science and Technology	grams Air Force	National Research Council	02-Feb-2026	Not Spe	ecified
	Contact Name	Jennifer Griffiths, N	IRC RAP Program Administrator			
	Contact Telephone	202-334-2974				
	Contact Email	jgriffiths@nas.edu				
	Sponsor Website	Link to sponsor we	<u>bsite</u>			
	Program URL	Link to program UR	<u>L</u>			
	Deadline Dates (ALL)	02-Feb-2026 , 01-N	1ay-2026 , 03-Aug-2026 , 02-Nov	<i>y</i> -2026		
The NRC Research Associateship Programs (RAP) are prestigious postdoctoral and senior research awards designed to provide promising scientists and engineers with high-quality research opportunities at federal laboratories and affiliated institutions. These programs offer a comprehensive experience, including mentorship, access to state-of-the-art facilities, and opportunities to influence government policy, all geared toward enhancing the research career development of the Research Associates. This opportunity is for the NRC Research Associateship Program with the Air Force.					eral	
058545	Research Associateship Prop Oceanic and Atmospheric A NOAA)		National Research Council	02-Feb-2026	Not Spe	ecified
	Contact Name	Jennifer Griffiths, N	IRC RAP Program Administrator			



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
	Contact Telephone	202-334-2974						
	•	jgriffiths@nas.edu						
		Link to sponsor wel	osite					
	•	Link to program UR						
	Deadline Dates (ALL) 02-Feb-2026 , 01-May-2026 , 03-Aug-2026 , 02-Nov-2026							
	Synopsis	The NRC Research Associateship Programs (RAP) are prestigious postdoctoral and senior research awards designed to provide promising scientists and engineers with high-quality research opportunities at federal laboratories and affiliated institutions. These programs offer a comprehensive experience, including mentorship, access to state-of-the-art facilities, and opportunities to influence government policy, all geared toward enhancing the research career development of the Research Associates. This opportunity is for the NRC Research Associateship Program at the National Oceanic and Atmospheric Administration (NOAA).						
HSXBHX	Research Associateship Prog CCDC Soldier Center (CCDC)		National Research Council	02-Feb-2026	6 Not Spe	ecified		
	Contact Name	Jennifer Griffiths, N	RC RAP Program Administrator					
	Contact Telephone	202-334-2974						
	Contact Email	jgriffiths@nas.edu						
	Sponsor Website	Link to sponsor wel	<u>osite</u>					
	Program URL	Link to program UR	<u>L</u>					
	Deadline Dates (ALL)	02-Feb-2026 , 01-N	lay-2026 , 03-Aug-2026 , 02-Nov-2026					



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	designed to provide laboratories and af- mentorship, access toward enhancing t	Associateship Programs (RAP) are prest e promising scientists and engineers wifiliated institutions. These programs off to state-of-the-art facilities, and oppor the research career development of the ciateship Program at the U.S. Army CC	th high-quality research of fer a comprehensive exper rtunities to influence gove e Research Associates. This	pportunities at fede rience, including rnment policy, all g s opportunity is for	eral
USABUS	Research Associateship Prog Research Office (ARO)	grams U.S. Army	National Research Council	02-Feb-2026	Not Spe	cified
	Contact Name	Jennifer Griffiths, N	IRC RAP Program Administrator			
	Contact Telephone	202-334-2974				
	Contact Email	jgriffiths@nas.edu				
	Sponsor Website	Link to sponsor wel	<u>osite</u>			
	Program URL	Link to program UR	<u>L</u>			
	Deadline Dates (ALL)	02-Feb-2026 , 01-M	lay-2026 , 03-Aug-2026 , 02-Nov-2026			
	Synopsis	designed to provide laboratories and af- mentorship, access toward enhancing t	Associateship Programs (RAP) are prest e promising scientists and engineers wifiliated institutions. These programs off to state-of-the-art facilities, and opporties the research career development of the ciateship Program at the U.S. Army Res	th high-quality research of fer a comprehensive exper rtunities to influence gove e Research Associates. This	pportunities at fede rience, including rnment policy, all g	eral



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
119646 James Lathrop And Wayne Internship	Capurro Memorial	Nevada Department of Wildlife	06-Feb-2026	Not Spo	ecified
Contact Name					
Contact Telephone	775-688-1529				
Contact Emai	russellw@ndow.or	g			
Sponsor Website	Link to sponsor we	<u>bsite</u>			
Program URL	Link to program UF	<u>RL</u>			
Deadline Dates (ALL)	06-Feb-2026				
Synopsis	graduating Nevada in pursuing a caree education. Selected (NDOW). They will	and Wayne Capurro Memorial Interns high school seniors or current college or in wildlife management an opportunite interns will become paid seasonal em receive 'on-the-job' training to provide ge studies and future career. Applicant seasonal position.	or university students that ty to earn funds to help su ployees of the Nevada De them with practical know	have a sincere into apport his/her colle partment of Wildlif aledge and experier	ge e nce to
116098 Special Projects Fund		New York Health Foundation	12-Feb-2026	200,00	0 USD
Contact Name					
Contact Telephone	212-664-7656				
Contact Email	specialprojectsfund	d@nyhealthfoundation.org			
Sponsor Website	Link to sponsor we	<u>bsite</u>			



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL Deadline Dates (ALL)	Link to program UR	RL			
	Synopsis	The New York Heal especially people of grantmaking through organizations implesspecial Projects Fund address important priority areas (Primesspecial Projects (Primesspecial Projects)	th Foundation (NYHealth) has a broad of color and others who have been histogh the Special Projects Fund, the Foundamenting projects that can improve health awards are one-time, nonrenewable and emerging health care and public heary Care; Healthy Food, Healthy Lives; anaximum of \$200,000.	orically marginalized. With dation seeks to partner wit alth at the local, regional, e funding opportunities su ealth issues that fall outsic	its responsive th a wide range of or statewide levels. pporting projects the de the Foundation's	nat s three
012522 <u>B</u>	Biotechnology Meeting Gran	nt (BMG)	North Carolina Biotechnology Center	25-Feb-2026	10,000	USD
	Contact Name	Michelle Collins				
	Contact Telephone	919-549-8845				
	Contact Email	michelle_collins@r	ncbiotech.org			
	Sponsor Website	Link to sponsor we	<u>bsite</u>			
	Program URL	Link to program UR	<u>:L</u>			
	Deadline Dates (ALL)	25-Feb-2026				
	Synopsis	Biotechnology Mee in North Carolina a	eting Grants (BMG) support national and offer up to \$10,000. Funds can be re	d international life science equested for in-person, vir	es-focused meeting tual, or hybrid ever	s held nts.



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

 $\label{lem:consider} \mbox{Additional GCO Policies to consider when prior to applying.}$

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Any North Carolina apply.	university or non-profit organization	(with an independent tax II	O number or EIN) m	nay
012520 <u>B</u>	siotechnology Event Sponso	orship (BES)	North Carolina Biotechnology Center	25-Feb-2026	3,000 L	JSD
	Contact Name	Michelle Collins				
	Contact Telephone	919-549-8845				
	Contact Email	michelle_collins@r	ncbiotech.org			
	Sponsor Website	Link to sponsor we	<u>bsite</u>			
	Program URL	Link to program UF	<u>RL</u>			
	Deadline Dates (ALL)	25-Feb-2026				
	Biotechnology Event Sponsorships (BES) provide up to \$3,000 for events to support life science-focused synopsis events held primarily for a North Carolina audience. BES funds can be requested for in-person, virtual or hybrid events.					
071230 <u>R</u>	071230 Research and Education Grants		Northeast Region Sustainable Agriculture Research and Education Program	02-Feb-2026	250,000	0 USD
	Contact Name	Heather Omand, A	ssociate Director			
	Contact Telephone	802-656-7654				
	Contact Email	northeast-re@sare	ong			



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID Program Title	Program Title		Sponsor Number	Deadline Date	Funding Amount			
Sponsor Website	Link to sponsor we	<u>bsite</u>						
Program URL	Link to program UF	o program URL						
Deadline Dates (ALL)	02-Feb-2026							
Synopsis	farmers, educators key issues affecting regional SARE prog projects that North Maintain and enha resources, and fish Protect the health	he Northeast Sustainable Agriculture Research and Education (SARE) Program offers competitive grants to armers, educators, service providers, researchers, nonprofit staff, graduate students and others to address ey issues affecting the sustainability of agriculture throughout our region. Northeast SARE is one of four egional SARE programs funded by the USDA National Institute of Food and Agriculture (NIFA). By law, rojects that Northeast SARE funds must help improve farming in at least one of the following ways: 1. Maintain and enhance the quality and productivity of the soil; 2. Conserve soil, water, energy, natural esources, and fish and wildlife habitat; 3. Maintain and enhance the quality of surface and ground water; 4. rotect the health and safety of persons involved in the food and farm system; 5. Promote the well being of nimals; and 6. Increase employment opportunities in agriculture.						
093031 Start Package Grant - For Fa	culty Recruitment	Novo Nordisk Fonden	03-Feb-2026	6 Not Sp	ecified			
Contact Name Contact Telephone	Rikke Stefansen, G	rant Manager						
Contact Email Sponsor Website	Contact Email Sponsor Website Program URL Link to program URL							
Deadline Dates (ALL)		_						



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount			
	Synopsis	The primary purpose of the Start Package grant is to make more competitive when recruiting top researchers of any r mobility across borders, among Danish universities and fro	nationality. The aim is also					
125756 <u>C</u>	Challenge Programme	Novo Nordisk Fonden	04-Feb-2026	Not Sp	ecified			
	Contact Name							
	Contact Telephone							
	Contact Email	challenge@novo.dk						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	04-Feb-2026						
	The Challenge Programme aims to contribute substantially to the development of Danish and European research ecosystems within research areas of strategic priority to the Novo Nordisk Foundation. The goal is Synopsis to develop innovative solutions to major scientific challenges, supporting leading researchers to form a consortium united by a clear vision and mission. The Programme provides funding to enable scientific depth and focus and facilitate synergy between the research partners.							
133159 _	NNF Laureate Research Gra	nt - Novo Nordisk Novo Nordisk Fonden	05-Feb-2026	Not Sp	ecified			
	Contact Name	Eugenia Krasnopjorova						
	Contact Telephone							
	Contact Email	ekr@novo.dk						



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	S	Sponsor Number	Deadline Date	Funding Amount		
	Sponsor Website	Link to sponsor we	<u>bsite</u>						
	Program URL	Link to program UF	<u>RL</u>						
	Deadline Dates (ALL)	ne Dates (ALL) 05-Feb-2026							
	NNF Laureate Research Grant is for recruitment or retainment of an outstanding established biomedical researcher to come to Denmark from abroad or stay in Denmark to further expand their research. The grant should also facilitate collaboration across scientific and geographic borders, thereby strengthening the Danish biomedical research environment to meet societal challenges.								
107862	National Intelligence Postdo	Office of National Intelligence (Australia)	GO8053	13-Feb-2026	Not Spe	ecified			
	Contact Name								
	Contact Telephone								
	Contact Email	nipg@oni.gov.au							
	Sponsor Website	Link to sponsor we	<u>bsite</u>						
	Program URL	Link to program UF	<u>RL</u>						
	Deadline Dates (ALL)	13-Feb-2026							
	Synopsis	designed to achiev and security. The p researchers to und relevance to the Na	The National Intelligence Postdoctoral Grant (NIPG) program sponsors unclassified academic research esigned to achieve Australian Government objectives for research and innovation in national intelligence and security. The program offers funding for Postdoctoral Research Fellow positions for early-mid career esearchers to undertake academic research in relation to Research Topics - specific areas of interest and elevance to the National Intelligence Community (NIC). This round of the program has 18 Research Topics see documents). Each fellowship is funded full time for a period of two (2) years or part time where						



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

 $\label{lem:consider} \mbox{Additional GCO Policies to consider when prior to applying.}$

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
			or a period of up to four (4) years. The usive) by ONI before the end of the 202	-	e instalment (up t	0
021864	Fleming Scholar Program		Oklahoma Medical Research Foundation (OMRF)	01-Feb-2026	5,000	USD
	Contact Name					
	Contact Telephone	405-271-7435				
	Contact Email	SummerScholars@	omrf.org			
	Sponsor Website	Link to sponsor we	<u>bsite</u>			
	Program URL	Link to program UF	<u>RL</u>			
	Deadline Dates (ALL)	01-Feb-2026				
	Synopsis	biomedical researc	r Program gives Oklahoma's high scho h experience. Fleming Scholars are pai ummer program will be paid \$5,000.	_	~	
120814	Ono Pharma Breakthrough S Awards Program	Science Initiative	Ono Pharma Foundation	13-Feb-2026 App]	[LOI/Pre-Not Sp	ecified
	Contact Name					
	Contact Telephone					
	Contact Email					
	Sponsor Website	Link to sponsor we	<u>bsite</u>			
	Program URL	Link to program UF	RL			



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
	Deadline Dates (ALL) Synopsis	Annually, the Ono	Pre-App], 15-May-2026 Pharma Foundation considers proposal	s from PIs for research tha	t could ultimately			
	-, -,	transform human h	nealth.					
001901	Graduate Research Grant Pr	<u>rogram</u>	Organization for Autism Research	02-Feb-2026	Not Spe	ecified		
	Contact Name							
	Contact Telephone	571-977-5391						
	Contact Email	ct Email programs@researchautism.org						
	Sponsor Website	Link to sponsor we	<u>bsite</u>					
	Program URL	Link to program UF	<u>RL</u>					
	Deadline Dates (ALL)	02-Feb-2026						
	The Organization for Autism Research (OAR) offers the Graduate Research Competition with awards of \$1,000 for students conducting autism research as a requirement in pursuit of a master's degree and \$2,000 for students who are doctoral candidates or post-doctoral students. The grant is intended to encourage and support students conducting research pursuant to graduate and post-graduate studies in disciplines related to assessment, intervention and support of autistic learners and their families.							
144144	OREF/Musculoskeletal Tran Research Grant	splant Foundation	Orthopaedic Research & Education Foundation (OREF)	16-Feb-2026	100,000) USD		
	Contact Name							



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Da	ete Funding Amount			
Contact Telephone								
Contact Email	grants@oref.org							
Sponsor Website	Link to sponsor wel	<u>bsite</u>						
Program URL	ogram URL Link to program URL							
Deadline Dates (ALL) 16-Feb-2026								
Synopsis	The Orthopaedic Research & Education Foundation/Musculoskeletal Transplant Foundation Research Grant is soliciting investigator-initiated proposals focusing on research in the science of biologic - reconstruction, bone regeneration, transplantation - allografts, and including stem cells for graft transplantation. Maximum funding will be a total of \$100,000 over a two-year grant period, conditional upon periodic progress reports and annual review.							
024601 Resident Research Project C	024601 Resident Research Project Grant		15-Dec-2025 App]	[LOI/Pre- 5	,000 USD			
Contact Name								
Contact Telephone	847-430-5109							
Contact Email	grants@oref.org							
Sponsor Website	Link to sponsor wel	<u>bsite</u>						
Program URL	Link to program UR	<u>:L</u>						
Deadline Dates (ALL)	15-Dec-2025 [LOI/F	Pre-App], 16-Feb-2026						



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline [Date	Funding Amount	
	Synopsis	provide funding to	esearch & Education Foundation (OREF residents who are interested in researc gery residents in approved orthopaedic	ch. Grants of \$5,000 for on	e year will l	be consid	ered	
132190	Osteoarthritis Research Gra	<u>nt</u>	Orthopaedic Research & Education Foundation (OREF)	15-Dec-2025 App]	[LOI/Pre-	50,000 U	SD	
	Contact Name						_	
	Contact Telephone	847-698-9980						
	Contact Email	grants@oref.org						
	Sponsor Website	Link to sponsor wel	<u>osite</u>					
	Program URL	Link to program UR	<u>L</u>					
	Deadline Dates (ALL)	15-Dec-2025 [LOI/P	Pre-App], 16-Feb-2026					
The Orthopaedic Research & Education Foundation offers research grants for proposals that aim to help us better understand how to prevent and treat osteoarthritis, one of the most common causes of disability in adults. This Funding Announcement solicits investigator-initiated clinical and translational research proposals. Successful applicants will have demonstrated experience in their fields. Maximum funding will be a total of \$50,000 over a one-year grant period.								
087892	Impact Awards		Parkinson's Foundation	23-Feb-2026		200,000	USD	
	Contact Name							



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount				
	Contact Telephone	<u></u>								
	·	grants@parkinson.	Org							
	Sponsor Website Link to sponsor website									
	Program URL Link to program URL									
	Deadline Dates (ALL) 23-Feb-2026									
	Synopsis	The Parkinson's Foundation offers Impact Awards for projects that are "outside the box" with the goal of bringing new light to the biology of Parkinson's disease (PD), a new approach to PD research, or testing a truly novel therapeutic idea. Projects should be based on groundbreaking or unconventional ideas that are unlikely to be funded through more traditional funding mechanisms.								
040709 <u>E</u>	nvironment Research Gran	its .	Pierce Cedar Creek Institute	12-Jan-2026 App]	[LOI/Pre-Not Sp	ecified				
	Contact Name	Ellen Holste – Resea	arch and Community Engagement Man	nager						
	Contact Telephone	269-721-4170								
	Contact Email	eholste@cedarcree	ekinstitute.org							
	Sponsor Website	Link to sponsor wel	<u>bsite</u>							
	Program URL	Link to program UR	<u>L</u>							
	Deadline Dates (ALL)	12-Jan-2026 [LOI/P	re-App], 02-Feb-2026							
	Synopsis	critical species and	Institute's Environment Research Gran ecosystems, as well as the improveme vironment Research Grant program fu	nt of land management to	ols to support eco					



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
			er institutions in natural areas manage k takes place at Pierce Cedar Creek Inst			oring
008303 <u>J</u>	ames Gear International Fe	ellowship	Poliomyelitis Research Foundation	28-Feb-2026	5 17,500	USD
	Contact Name					
	Contact Telephone	+27 11 555-0395				
	Contact Email	prf@nicd.ac.za				
	Sponsor Website	Link to sponsor we	<u>bsite</u>			
	Program URL	Link to program UF	<u>RL</u>			
	Deadline Dates (ALL)	28-Feb-2026				
	Synopsis	The award which is develop their resea	s at present R 350,000 + flight (one yea arch careers in overseas academic insti	r), is for outstanding candi tutions.	dates to enable the	em to
114174h	oung Investigator Student or Female Scholars in Vision		Prevent Blindness Ohio	15-Feb-2026	5,000 L	JSD
	Contact Name	Laura Schwartz				
	Contact Telephone	1-800-301-2020 x1	12			
	Contact Email	lauras@pbohio.org	K			
	Sponsor Website	Link to sponsor we	<u>bsite</u>			
	Program URL	Link to program UF	<u>RL</u>			



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
Deadline Dates (ALL		ess Young Investigator Student Fellows	hip Awards for Female Sc	holars in Vision	Research		
Synopsi	biomedical, behavi	ovides training support for future generations of outstanding female scientists committed to pursuing smedical, behavioral or clinical research careers relevant to the mission of Prevent Blindness – to prevent andness and preserve sight.					
058301 Research Grants		PSC Partners Seeking a Cure	01-Dec-2025 App]	5 [LOI/Pre- Not	Specified		
Contact Nam	е						
Contact Telephon	303-771-5227						
Contact Ema	grants@pscpartner	s.org					
Sponsor Websit	Link to sponsor we	<u>bsite</u>					
Program UR	Link to program UR	<u>L</u>					
Deadline Dates (ALL) 01-Dec-2025 [LOI/F	Pre-App], 01-Feb-2026					
Synopsi	PSC Partners and affiliate PSC Partners Canada offer grants to conduct research that addresses an important and novel, basic or clinical research question related to PSC and closely associated diseases (such as Synopsis inflammatory bowel diseases (IBD) and cholangiocarcinoma). The Research Grants Program seeks to encourage investigators to conduct research in promising new areas, with the goal that data generated will lead to federal (NIH) or external international funding.						
022929 Research Medical Student	<u>Grant</u>	Radiological Society of North America	06-Feb-2026	3,00	DO USD		



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount			
	Contact Name								
	Contact Telephone	630-571-2670							
	Contact Email	grants@rsna.org							
	Sponsor Website	Link to sponsor wel	ink to sponsor website						
	Program URL	ram URL Link to program URL							
	Deadline Dates (ALL)	Pates (ALL) 06-Feb-2026							
	Synopsis	The Medical Student Research Grant gives medical students the opportunity to gain research experience in medical imaging while they're still in school. Recipients will define objectives, develop research skills and test hypotheses, all before choosing a residency program. Ultimately, this experience gives students a chance to consider academic radiology as a future career option. In order to attract the brightest young researchers to radiology, the R&E Foundation will award up to 10 additional grants for medical students who identify as minorities underrepresented in medicine (UIM). Grant recipients receive \$3,000, which is matched by the sponsoring department, equaling \$6,000 total. It is to be used as a stipend for the medical student. Funds are intended to secure time for the recipient and may not be used for non-personal research expenses.							
001884 <u>lr</u>	nnovator Awards		Rainin (Kenneth) Foundation	02-Feb-2026	300,000	0 USD			
	Contact Name								
	Contact Telephone	510-625-5200							
	Contact Email								
	Sponsor Website	Link to sponsor wel	<u>osite</u>						
	Program URL	Link to program UR	<u>L</u>						



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
	Deadline Dates (ALL)	02-Feb-2026						
	Synopsis	support individual i multiple investigato	the Kenneth Rainin Foundation offers Innovator Awards in the field of Inflammatory Bowel Disease (IBD) to apport individual research projects with grants of up to \$150,000 and collaborative projects involving aultiple investigators with grants of up to \$300,000. Grantees who demonstrate significant progress are ligible for up to two years of additional support.					
133103 <u>R</u>	esearch Ireland Pathway P	rogramme 2026	Research Ireland (Taighde Éireann)	20-Feb-2026 App]	[LOI/Pre- 615,25	0 USD		
	Contact Name							
	Contact Telephone							
	Contact Email	pathway@research	<u>iireland.ie</u>					
	Sponsor Website	Link to sponsor wel	<u>osite</u>					
	Program URL	Link to program UR	<u>L</u>					
	Deadline Dates (ALL)	20-Feb-2026 [LOI/P	re-App], 07-May-2026					
	The Pathway Programme call supports talented postdoctoral researchers from all research disciplines to develop their track record and transition to become independent research leaders. These grants will enable postdoctoral researchers to conduct independent research for a four-year period and will provide funding for a postgraduate student who will be primarily supervised by the Applicant.							
010661 <u>R</u>	esident Research Precepto	rship	Rheumatology Research Foundation	02-Feb-2026	15,000	USD		
	Contact Name							



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount			
	Contact Telephone	404-365-1373							
	Contact Email	Contact Email foundation@rheumatology.org							
	Sponsor Website	ite Link to sponsor website							
	Program URL	am URL Link to program URL							
	Deadline Dates (ALL) 02-Feb-2026								
	The purpose of this Resident Research Preceptorship is to introduce residents to the specialty of rheumatology by supporting a full-time research experience, with the goal of attracting promising physician scientists to the field of rheumatology. The award amount is \$15,000 for a three-month research preceptorship, to be completed within 12 months of the award's start date.								
071713 <u>N</u>	Medical and Graduate Stud	ent Preceptorship	Rheumatology Research Foundation	02-Feb-2026	5 4,000 l	JSD			
	Contact Name								
	Contact Telephone	404-365-1373							
	Contact Email	Foundation@rheur	matology.org						
	Sponsor Website	Link to sponsor we	<u>bsite</u>						
	Program URL	Link to program UR	<u>RL</u>						
	Deadline Dates (ALL)	02-Feb-2026							
	The Medical and Graduate Student Preceptorship program introduces medical and graduate students to Synopsis rheumatology-related health care by supporting a 4-Week or 8-Week, full-time clinical or research experience in the broad area of rheumatic disease.								



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

 $\label{lem:consider} \mbox{Additional GCO Policies to consider when prior to applying.}$

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
128114	Resident Research Precepto	orship	Rheumatology Research Foundation	02-Feb-2026	15,000	USD		
	Contact Name							
	Contact Telephone							
	Contact Email Foundation@rheumatology.org							
	Sponsor Website	Link to sponsor wel	<u>osite</u>					
	Program URL	Link to program UR	<u>L</u>					
	Deadline Dates (ALL) 02-Feb-2026							
	Synopsis	The mission of the Rheumatology Research Foundation is to advance research and training to improve the health of people with rheumatic diseases. The purpose of this Resident Research Preceptorship is to introduce residents to the specialty of rheumatology by supporting a full-time research experience, with the goal of attracting promising physicians to develop an investigative career in the field of rheumatology.						
040657	PhD Plus Program		Rosetrees Trust	16-Feb-2026	Not Spe	cified		
	Contact Name	Richard Miller						
	Contact Telephone							
	Contact Email	rmiller@rosetreest	<u>rust.co.uk</u>					
	Sponsor Website	Link to sponsor wel	<u>osite</u>					
	Program URL	Link to program UR	<u>L</u>					
	Deadline Dates (ALL)	16-Feb-2026						
		•						



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	N ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	these awards is to	PhD Plus awards are intended to extend allow students who have already made eatly add to the value of their research	outstanding progress to c	arry out additional	
095861	One-Year Surgical Research	<u>Fellowships</u>	Royal College of Surgeons of England	25-Feb-2026	Not Spe	ecified
	Contact Name					
	Contact Telephone					
	Contact Email	research@rcseng.a	ac.uk			
	Sponsor Website	Link to sponsor we	<u>bsite</u>			
	Program URL	Link to program UF	<u>RL</u>			
	Deadline Dates (ALL)	25-Feb-2026				
	Synopsis		wship provides 12 months of funding to or a higher degree and want to comple earch project.		_	
127941	Faraday Discovery Fellowsh	i <u>ps</u>	Royal Society	05-Feb-2026	10,480, USD	000
	Contact Name					
	Contact Telephone					
	Contact Email	faraday@royalsoci	ety.org			



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	Link to sponsor wel	osite			
	•	Link to program UR				
	Deadline Dates (ALL)	·	_			
	Synopsis	Investigator (PI) to research questions grants of up to £8m	ery Fellowships are large, investigator- enable them to establish an outstandin The programme is aimed at outstand over a ten-year period to support the Research Institutes.	ng team of researchers to ing mid-career STEM rese	address challenging archers and will pro	ovide
060295	Research Trainee Program		Smith (Michael) Health Research BC	27-Nov-2025 App]	5 [LOI/Pre- 135,450	0 USD
	Contact Name	Asta Jureliaviciute,	Research Competitions Coordinator			
	Contact Telephone	604-714-6609				
	Contact Email	trainee@healthrese	earchbc.ca			
	Sponsor Website	Link to sponsor wel	<u>osite</u>			
	Program URL	Link to program UR	<u>L</u>			
	Deadline Dates (ALL)	27-Nov-2025 [LOI/F	re-App], 29-Jan-2026 , 05-Feb-2026			
		early career researd eligible for a resear	's Research Trainee Program is designe chers from across BC who have recently ch fellowship (or equivalent) program. health research activities during post-o	y completed a PhD, and he The Research Trainee awa	ealth professionals ard protects award	



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		•	e awards support health research nd contribute to the success of B		ear and long-term he	ealth
109166	SPR Research and Education Education Project Award	Foundation	Society for Pediatric Radiology	09-Feb-2026	50,000	USD
	Contact Name Contact Telephone					
	Contact Email	info@spr.org				
	Sponsor Website	Link to sponsor we	<u>bsite</u>			
	Program URL	Link to program UR	<u>.L</u>			
	Deadline Dates (ALL)	09-Feb-2026				
The SPR Research and Education Foundation Education Project Grant is intended to encourage innovation and improvement in health sciences education by providing research opportunities to individuals in pursu of advancing the science of radiology education. In addition, this program will help build a critical mass of radiology education researchers and promote the careers of persons advancing the science of radiology education.					rsuit of	
109167	SPR Research and Education Institutional Pilot Award	Foundation Multi-	Society for Pediatric Radiology	09-Feb-2026	5 100,000	O USD
	Contact Name Contact Telephone Contact Email	517-893-5191				



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Sponsor Website	Link to sponsor wel	<u>bsite</u>				
	Program URL	Link to program UR	<u>L</u>				
	Deadline Dates (ALL)	09-Feb-2026					
	The SPR Research and Education Foundation Multi-Institutional Pilot Grant is intended to provide a higher level of support for pediatric radiology-related research projects conducted across multiple institutions. The goal of this award is to fund collaborative projects across multiple institutions to increase the sample size of synopsis rare pediatric diseases to allow for more rigorous, reproducible research in the pediatric population. The Grant is provided to facilitate projects that require (1) recruitment of patients from multiple institutions to achieve a necessary study population and/or (2) equipment and physical resources from multiple institutions.						
020497	Distinguished Career Award		Society for the Study of Ingestive Behavior	27-Feb-2020	6 1,500	USD	
	Contact Name						
	Contact Telephone	847-807-4924					
	Contact Email	info@ssib.org					
	Sponsor Website	Link to sponsor wel	<u>bsite</u>				
	Program URL	Link to program UR	<u>L</u>				
	Deadline Dates (ALL)	27-Feb-2026					
	Synopsis	The award honors a ingestive behavior.	an individual for his or her accomplishr	nents in and contribution	s to the understand	ling of	



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
020728 Alan N. Epstein Research Awa	Society for the Study of Ingestive Behavior	27-Feb-2026	750 US	D
Contact Name				
Contact Telephone 8	847-807-4924			
Contact Email <u>i</u>	nfo@ssib.org			
Sponsor Website <u>I</u>	<u> Link to sponsor website</u>			
Program URL <u>I</u>	Link to program URL			
Deadline Dates (ALL)	27-Feb-2026			
Synopsis i	This award honors an individual for a specific research ngestive behavior. The Award consists of a plaque, a cathe Awards Symposium at the SSIB Annual Meeting.	•	_	
020729 New Investigator Travel Awar	Society for the Study of Ingestive Behavior	27-Feb-2026	Not Spe	ecified
Contact Name				
Contact Telephone 8	347-807-4924			
Contact Email <u>i</u>	nfo@ssib.org			
Sponsor Website <u>I</u>	<u> ink to sponsor website</u>			
Program URL <u>I</u>	Link to program URL			



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	degree). These aw	available for students and postdoctora ards are competitive, and are made ba TA selection committee.		_	
034944 <u>F</u>	Racial/Ethnic Minority Grad	uate Scholarship	Society for the Study of Social Problems	01-Feb-2026	15,000	USD
	Contact Name	Dr. Onwubiko Ago	zino, Chair			
	Contact Telephone					
	Contact Email	agozino@vt.edu				
	Sponsor Website	Link to sponsor we	<u>ebsite</u>			
	Program URL	Link to program U	<u>RL</u>			
	Deadline Dates (ALL)	01-Feb-2026				
The Society for the Study of Social Problems (SSSP), in keeping with its philosophy of active engagement with social problems, participation in social problem solutions, and advancement of knowledge through study, service and critical analysis, established the Racial/Ethnic Minority Graduate Scholarship. A 15,000 fellowship will be awarded to two students.						
056760 <u>J</u>	oyce Wahr Starter Grant		Society of Cardiovascular Anesthesiologists	09-Feb-2026	75,000	USD
	Contact Name	Dr. Anne Cherry				
	Contact Telephone	855-658-2828				
	Contact Email	anne.cherry@duk	<u>e.edu</u>			



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
	Sponsor Website	Link to sponsor wel	<u>osite</u>					
	Program URL	Link to program UR	<u>L</u>					
	Deadline Dates (ALL)	09-Feb-2026						
	Synopsis	SCA supports cardio to \$37,500 per year	othoracic and vascular research project for two years.	s. The SCA Joyce Wahr Sta	rter Grant provi	des up		
001413	Research Grants		St. Baldrick's Foundation	08-Dec-2025 App]	[LOI/Pre- 200,0	000 USD		
	Contact Name	Laura Chung						
	Contact Telephone	626-792-8247						
	Contact Email	Grants@Stbaldricks	s.org					
	Sponsor Website	Link to sponsor wel	<u>osite</u>					
	Program URL	Link to program UR	Link to program URL					
	Deadline Dates (ALL)	08-Dec-2025 [LOI/F	re-App], 27-Feb-2026					
These grants are for specific research projects which are hypothesis driven and may be either laboratory, clinical, or epidemiological in nature. Grant will be \$100,000/year for two years. Research Grant applicants should hold at least an M.D./D.O. or Ph.D. degree by the date the award becomes effective. Applicants mube employed by an academic or non-profit research institution or laboratory.						licants		
044861	St. Baldrick's International S	<u>cholars</u>	St. Baldrick's Foundation	28-Dec-2025 App]	[LOI/Pre-Not S	Specified		
	Contact Name	Laura Chung, Direct	or of Grants Administration					



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Contact Telephone	626-792-8247 x236	;				
	Contact Email	Laura@StBaldricks.	org				
	Sponsor Website	Link to sponsor wel	<u>bsite</u>				
	Program URL	Link to program UR	<u> </u>				
	Deadline Dates (ALL)	28-Dec-2025 [LOI/F	Pre-App], 27-Feb-2026				
	This three (3) year award, with an option for two (2) additional years based on progress, is to train researchers from low- and middle- income countries (as classified by the World Bank) to prepare them to fill specific stated needs in an area of childhood cancer research upon returning to their country of origin. Proposals should detail a realistic impact of the award on pediatric cancer research in their country of origin. Recipients are called St. Baldrick's International Scholars. Grants will be up to \$110,000/year, for three years.						
026001	St. Baldrick's Summer Fellov	<u>ws</u>	St. Baldrick's Foundation	20-Feb-2026	5,000 L	JSD	
	Contact Name						
	Contact Telephone	626-792-8247					
	Contact Email	Grants@StBaldricks	s.org				
	Sponsor Website	Link to sponsor wel	<u>bsite</u>				
	Program URL	Link to program UR	<u>:L</u>				
	Deadline Dates (ALL)	20-Feb-2026					
	Synopsis	St. Baldrick's Summ pediatric oncology	ner Fellows awards offer a \$5,000 stipe research.	nd (one per institution) fo	r a student to work	on	



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
UTTHEX	Swedish Institute Scholarshi Professionals	ps for Global	Swedish Institute	25-Feb-2026	Not Sp	ecified
	Contact Name					
	Contact Telephone	+46-8-453 7800				
	Contact Email	si@si.se				
	Sponsor Website	Link to sponsor we	<u>osite</u>			
	Program URL	Link to program UR	<u>L</u>			
	Deadline Dates (ALL)	25-Feb-2026				
	Synopsis	The SI Scholarship to master's studies at	or Global Professionals is an academic Swedish universities, across a wide rar	scholarship supporting ful age of English-taught progr	l-time, one- or two ammes.	o-year
044513	Postdoc.Mobility Fellowship	<u>os</u>	Swiss National Science Foundation	03-Feb-2026	Not Sp	ecified
	Contact Name					
	Contact Telephone	+41 31 308 22 22				
	Contact Email	pm@snf.ch				
	Sponsor Website	Link to sponsor we	<u>osite</u>			
	Program URL	Link to program UR	<u>L</u>			
	Deadline Dates (ALL)	03-Feb-2026				
	Synopsis		ellowships are aimed at researchers wh demic career in Switzerland. A research			



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

 $\label{lem:consider} \mbox{Additional GCO Policies to consider when prior to applying.}$

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		fellowships include to research and cor initial period of rese	wledge, increases their scientific indep a grant for subsistence costs, a flat-ra nference costs. In addition, fellowship earch after returning to Switzerland. T funding period is in principle 24 montl	te for travel expenses and holders can apply for a re he return grant includes a	d a possible contril turn grant to finar a salary and social	oution nce their security
090503	Grants Program		Taper (S. Mark) Foundation	02-Feb-202 App]	6 [LOI/Pre-Not S	pecified
	Contact Name					
	Contact Telephone	310-476-5413				
	Contact Email	grants@smtfounda	tion.org			
	Sponsor Website	Link to sponsor web	<u>osite</u>			
	Program URL	Link to program UR	<u>L</u>			
	Deadline Dates (ALL)	02-Feb-2026 [LOI/P	re-App]			
	Synopsis	The S. Mark Taper Forganizations and t	Foundation is dedicated to enhancing heir work in southern California comn	the quality of people's livenuments.	es by supporting n	onprofit
029964	Support of Projects		Thyssen (Fritz) Foundation	01-Feb-202	6 Not S	pecified
	Contact Name					
	Contact Telephone					
	Contact Email	fts@fritz-thyssen-st	tiftung.de			
	Sponsor Website	Link to sponsor web	<u>osite</u>			



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Program URL Deadline Dates (ALL)	Link to program UR 01-Feb-2026	<u>RL</u>			
Synopsis	biomedicine fields.	by the Fritz Thyssen Foundation focus An application can be filed in the follow d Society Medicine and the Natural Scie	wing areas of support: Hist		
059390 Summer Research Training Veterinary Medicine	Program	University of Illinois at Urbana-Champaign	01-Feb-2026	5,997 U	SD
Contact Name					
Contact Telephone	217-333-2760				
Contact Email	SRTP@vetmed.illin	<u>ois.edu</u>			
Sponsor Website	Link to sponsor we	<u>bsite</u>			
Program URL	Link to program UR	R <u>L</u>			
Deadline Dates (ALL)	01-Feb-2026				
Synopsis	See more at: http:/opportunities-dvm-Research Training Fhttp://vetmed.illingstudents/summer-	rich Training Program helps veterinary street //vetmed.illinois.edu/education/doctor-students/summer-research-training-program helps veterinary students explois.edu/education/doctor-veterinary-mresearch-training-program/#sthash.lu5 of Veterinary Medicine's Summer Research-	-veterinary-medicine-degr rogram/#sthash.Iu5VPaDN ore research-focused care nedicine-degree/research-o VPaDM.dpuf The Universit	ee/research- 1.dpuf The Summer er paths See more opportunities-dvm- ty of Illinois at Urba	e at: na-



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		explore research-focused career paths. Students week program.	will receive a stipend of \$5,997 for	participation in the	e 10-
074759 <u>K</u>	<u> (night-Wallace Fellowships</u>	University of Michigan	01-Dec-2025	85,000	USD
	Contact Name				
	Contact Telephone	734-998-7666			
	Contact Email	apply2kwf@umich.edu			
	Sponsor Website	<u>Link to sponsor website</u>			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Dec-2025 , 01-Feb-2026			
	Synopsis	Knight-Wallace Fellowships offer accomplished jo Journalists eager for growth and deeply committee the University of Michigan to access the resource project. Areas of focus can include but are not limic challenge facing your newsroom, digging into data developing a journalism venture.	ed to the future of journalism spend s of a world-class university and div ited to sharpening professional ski	d an academic year ve into a journalisn Ils, addressing a	
117827 <u>V</u>	/irchow Prize for Global Hea	Virchow Foundation for Global Health	28-Feb-2026	Not Spe	ecified
	Contact Name				
	Contact Telephone	+49 30 2063 0613			
	Contact Email	nominations@virchow.foundation			



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
	Sponsor Website Link to sponsor web		<u>bsite</u>					
	Program URL	Link to program UF	<u>RL</u>					
	Deadline Dates (ALL)	28-Feb-2026						
	Synopsis	The Virchow Prize honours significant contributions towards "health for all" in the entire breadth of global health through groundbreaking research, innovations, achievements and long-standing engagement.						
054894	Alzheimer's and Related Dis Award Fund	eases Research	Virginia Commonwealth University	01-Dec-2025 App]	[LOI/Pre- 75,000) USD		
	Contact Name							
	Contact Telephone	804-828-1525						
	Contact Email	ardraf@vcu.edu						
	Sponsor Website	Link to sponsor we	<u>bsite</u>					
	Program URL	Link to program URL 01-Dec-2025 [LOI/Pre-App], 01-Feb-2026						
	Deadline Dates (ALL)							
The Alzheimer's and Related Diseases Research Award Fund (ARDRAF) provides seed funds for research in Alzheimer's and other dementias at institutions around the state. These funds are used to stimulate synopsis innovative research into biomedical and psychosocial aspects of dementia, including cell biology, caregive and animal modeling. Four awards will be made on a competitive basis to scientists in Virginia and are limited to \$75,000 each.						giving,		
114413	Master of Science in Food To	echnology	VLIR-UOS	01-Feb-2026	Not Sp	pecified		
	Contact Name							



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Tolonhone	22 2 280 05 50				
Contact Telephone 32-2-289.05.50						
		info@vliruos.be				
	Sponsor Website	Link to sponsor web	<u>osite</u>			
	Program URL	Link to program UR	<u>L</u>			
	Deadline Dates (ALL)	01-Feb-2026				
	The Interuniversity Programme in Food Technology (IUPFOOD) is an academic master of science programme that intends to equip its alumni with the scientific, technical and managerial knowledge, skills and attitudes which they require to contribute successfully to solving problems related to food security through the production of safe foods of high quality.					
122063 <u>N</u>	Master of Epidemiology Sch	<u>olarship</u>	VLIR-UOS	28-Feb-2026	Not Spe	ecified
	Contact Name					
	Contact Telephone					
	Contact Email	scholarships@vlirud	os.be			
	Sponsor Website	Link to sponsor web	<u>osite</u>			
	Program URL Link to program URL					
	Deadline Dates (ALL)	28-Feb-2026				
	Synopsis	attend one of the 1 of Epidemiology at	cholarships to applicants from 29 eligib 5 master's programmes taught in Engl University of Antwerp provides knowled demiological research on questions co	ish at one or more Flemish edge, skills and competenc	universities. The Nees related to design	Naster



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
			nt or prognosis of disease (illness) ific research and learn to translate tions.		-	
112096 <u>E</u>	arly-Career Awards		Wellcome Trust	17-Feb-2026	524,00	0 USD
	Contact Name					
	Contact Telephone	0 20 7611 5757				
	Contact Email					
	Sponsor Website	Link to sponsor well	<u>osite</u>			
	Program URL	Link to program UR	<u>L</u>			
Deadline Dates (ALL) 17-Feb-2026						
	Synopsis	their research iden	es funding for early-career resear tity. Through innovative projects, and wellbeing. By the end of the a ne.	they will deliver shifts in under	standing related to	
058680 <u>R</u>	lesearch Infrastructure Sup	port (RIS) Program	Western Australian Future Health Research and Innovation Fund	24-Feb-2026	Not Sp	ecified
	Contact Name					
	Contact Telephone					
	Contact Email	DOH.OMRI@health	ı.wa.gov.au			



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

 $\label{lem:consider} \mbox{Additional GCO Policies to consider when prior to applying.}$

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL Deadline Dates (ALL) Synopsis	The Research Infras research environme will provide suppor the indirect costs of services and equipor research, where the such as laboratory of Stream 1 eligible m to support their indirections institutes. Stream 1 previous three-year institutes, universit with running shared accessible to the he		h and medical research in all research institutes, universe operating shared research resources essential for survey research grants. Example staff, research services and hospitals will receive a dedicated allocation for elearch excellence demonstome. Under Stream 2 eligible \$7.5 million for the operation.	Western Australia. ersities, and hospita ch-dedicated facilities porting quality les include indirect of equipment. Under a share of \$17.5 mil ligible medical researched through the ble medical researched through the ational costs associatem more broadly	als' for es, costs er lion arch
008556 /	Aerospace Outreach Progra	<u>m</u>	Wisconsin Space Grant Consortium	02-Feb-2026	5,000 U	ISD
	Contact Name Contact Telephone					



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Additional GCO Policies to consider when prior to applying.

Non-Profit Indirect Cost (IC) Waiver Policy Implementation Guidance

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email	amy.prevost@btci.o	org			
		Link to sponsor web				
	Program URL	Link to program UR	<u>L</u>			
	Deadline Dates (ALL)	02-Feb-2026				
	Synopsis	The Wisconsin Spac projects that advan	ce Grant Consortium (WSGC) Aerospace ce STEM engagement and outreach ali	e Outreach Program suppo gned with NASA Mission D	orts new or ongoing irectorates.	,

